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 Abstract 
 
Breast cancer is the most prevalent malignancy in the Portuguese population and it 
is expected that about 1 in 9 women will suffer from this disease at some time in their 
lifetime. Basal-like breast cancers are particularly aggressive, representing 15-20% of all 
breast cancer cases, especially affecting young women, frequently in a reproductive age. 
Except for a few agents still undergoing clinical trials, novel and improved anticancer 
agents are urgently needed to target this specific molecular subtype. Notably, basal-like 
breast carcinomas show increased expression of the basal marker P-cadherin. This is a 
type-I classical cadherin molecule that mediates important tumour promoting effects in 
breast carcinomas, being an indicator of poor differentiated carcinomas, high histological 
grade and decreased patient survival.  
The Cancer Stem Cell (CSC) Hypothesis, states that the recurrence of breast 
cancer and the lack of therapy effectiveness is due to a small population of cells with 
stem-like characteristics present within the tumour mass. This population of cells is 
responsible for intratumoural heterogeneity, owing to the establishment of a cellular 
hierarchy. Although the cell surface phenotype CD44+CD24-/low is the most successfully 
employed in the literature to describe CSCs, this is not a universal phenotype and it is 
urgent to better define these very important population of cells, as well as to characterize 
the distribution of different CSC markers within the distinct breast cancer molecular 
subtypes. 
Herewith, we report the analysis of the expression of the CSC markers CD44, 
CD24, CD49f and Aldehyde Dehydrogenase (ALDH)-1 in breast cancer cells, as well as in 
a large series of invasive human primary tumours comprising a total of 466 breast cancer 
cases. Our data revealed that several markers are needed, as different phenotypes are 
able to detect cells with distinct levels of differentiation. The CSC phenotype CD44+CD24-
/low and ALDH1 were significantly increased in the basal-like molecular subtype of human 
breast carcinomas. Using flow cytometry analysis in a panel of breast cancer cell lines, we 
showed that basal cells with a mesenchymal phenotype are enriched in the CSC 
phenotype CD44+CD24-/low whereas basal cells with an epithelial phenotype are mainly 
CD44+CD24+; and luminal and HER-2 overexpressing (HER-2 OE) cell lines are enriched 
for the CD44-/lowCD24+ phenotype. Furthermore, we found that the phenotype 
CD49f+CD24+ was associated with the basal epithelial cell lines, whereas the phenotype 
CD49f-CD24+ was associated with luminal and HER-2 OE cells. The activity of ALDH1 
was mainly found in HER-2 OE and basal/epithelial breast cancer cell lines.  
- 18 - 
We report that P-cadherin is directly associated with the expression of the breast 
stem cell markers CD44, CD49f and the activity of ALDH1 in the series of breast cancer 
cell lines. The expression of these stem cell markers was also found to be associated with 
P-cadherin and with the basal-like subtype. Moreover, cell populations enriched for P-
cadherin expression by Fluorescence Activated Cell Sorting (FACS) comprised increased 
in vitro self-renewal capacity (measured by the mammosphere assay), increased ability to 
grow colonies in tridimensional matrigel cultures, as well as greater tumourigenicity in 
immune compromised mice (athymic nude). Using genetically manipulated breast cells, 
we showed that the over-expression of P-cadherin increased the mammosphere forming 
efficiency. Conversely, when we inhibited P-cadherin using siRNA transient knock-down a 
decrease in the capacity to form mammospheres was observed (Vs. control cells). 
Additionally, P-cadherin expression was shown to confer resistance to X-ray induced cell 
death, sustaining a role for this molecule in another stem cell property. An association was 
found between P-cadherin and the stem/progenitor-like phenotype: CD44+CD24+, as well 
as with the luminal progenitor phenotype of the normal breast differentiation hierarchy: 
CD49f+CD24+. 
In this work, we have also focused our attention in the extracellular matrix (ECM) 
components and their receptors, integrins, that constitute major players in the 
maintenance of the stem cell niche. Given the highly aggressive behaviour of P-cadherin 
in breast cancer, it is important to clarify the downstream pathways that are triggered by 
this adhesion molecule and which mechanisms can be targeted for cancer therapy. Thus, 
using breast cancer cell lines we showed that P-cadherin is essential for the adhesion of 
cells to extracellular matrix substrates, such as laminin, vitronectin and fibronectin. The 
α6β4 integrin heterodimer was implicated in the downstream signalling of P-cadherin in 
response to laminin, as well as in the stem cell activity of cancer cells (measured by the 
mammosphere assay). Importantly, the activation of FAK and Src signalling was 
dependent on P-cadherin expression. We showed for the first time that P-cadherin and 
integrin receptors do not signal alone and they have a central role in the oncogenic 
response.  
In summary, the results generated in this research work indicated that in human 
breast cancer tissue, the basal-like subtype is enriched in the CSC phenotype 
CD44+CD24-/low and ALDH1 expression, whereas in human cell lines the basal-like 
subtype is associated with ALDH1 activity and the luminal progenitor phenotype 
CD44+CD49f+. We demonstrated for the first time that the basal marker P-cadherin 
mediates stem cell properties in basal-like breast cancer, uncovering a novel oncogenic 
signalling pathway in which P-cadherin cross-talks with α6β4 integrin. Therefore, P-
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cadherin could be explored as a marker to better define the CSC phenotype of basal-like 
breast carcinomas, as well as the cell-of-origin for this malignancy. 
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 Resumo 
 
O cancro de mama representa a doença maligna mais prevalente na população 
portuguesa, prevendo-se que 1 em cada 9 mulheres irá sofrer desta doença no decurso 
da sua vida. O carcinoma de mama do tipo basal é particularmente agressivo, 
representando 15-20% dos cancros de mama, afectando em especial mulheres jovens, 
frequentemente em idade reprodutiva. Com exceção de alguns agentes ainda em 
ensaios clínicos, a pesquisa de novos e melhores agentes anti-tumorais dirigidos a este 
subtipo particular de cancro de mama torna-se essencial. Os carcinomas do subtipo basal 
apresentam um aumento de expressão do marcador basal P-caderina. Esta é uma 
molécula de adesão clássica do tipo-I, implicada em características agressivas no cancro 
de mama, sendo um importante indicador de indiferenciação, elevado grau histológico, e 
mau prognóstico. 
Segundo o Modelo das Células Estaminais Tumorais, a recidiva de cancro de 
mama e a resistência aos agentes anti-tumorais devem-se à presença de uma pequena 
população de células com propriedades semelhantes às células estaminais normais, que 
se encontram na massa tumoral. Esta população de células é responsável pela 
heterogeneidade intratumoral devido ao estabelecimento de uma hierarquia de 
diferenciação, semelhante à hierarquia que se encontra no tecido normal. Apesar do 
fenótipo caracterizado pelos marcadores de superfície CD44+CD24-/low ser o mais usado 
para descrever a população de células tumorais estaminais, este não se trata de um 
fenótipo universal e torna-se urgente definir especificamente esta população de células 
tumorais, assim como caracterizar a distribuição dos diferentes marcadores de células 
estaminais tumorais nos diferentes subtipos moleculares de cancro de mama. 
Neste trabalho, reportamos a análise da expressão dos marcadores de células 
estaminais CD44, CD24, CD49f e Aldeído Desidrogenase (ALDH)-1 em linhas celulares 
de cancro de mama e numa série de carcinomas primários invasivos, contendo um total 
de 466 casos. Os nosso dados indicam que vários marcadores estaminais são 
necessários, pois os diferentes fenótipos são capazes de detetar células com diferentes 
níveis de diferenciação. O fenótipo das células estaminais tumorais CD44+CD24-/low e o 
marcador ALDH1 encontram-se significativamente aumentados no subtipo molecular 
basal. Aplicando a técnica de citometria de fluxo numa série de linhas celulares de mama, 
mostramos que as células basais com um fenótipo mesenquimal se encontram 
enriquecidas no fenótipo CD44+CD24-/low, enquanto que as células basais com um 
fenótipo epithelial são CD44+CD24+, e as céluas luminais e com sobre-expressão de 
HER-2 estão enriquecidas no fenótipo CD44-/lowCD24+. Adicionalmente, descobrimos que 
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o fenótipo CD49f+CD24+ está associado às linhas basais epiteliais, enquanto que o 
fenótipo CD49f-CD24+ se encontra relacionado com as células luminais e com sobre-
expressão de HER-2. 
Mostramos que a P-caderina está diretamente associada com a expressão dos 
marcadores estaminais CD44, CD49f e com a atividade da enzima ALDH em linhas 
celulares de cancro de mama. A expressão destes marcadores estaminais também 
surgiu associada à P-caderina e ao subtipo molecular basal na série de carcinomas de 
mama invasivos. Além disso, populações celulares enriquecidas para a expressão de P-
caderina, por citometria de fluxo, apresentam maior capacidade de auto-renovação in 
vitro (medida pelo ensaio das mamosferas), maior capacidade clonogénica em culturas 
tridimensionais contendo matrigel, assim como maior tumorigenicidade em ratinhos 
imunocomprometidos (atímicos, modelo nude). Usando células geneticamente 
manipuladas, mostramos que a sobre-expressão de P-caderina aumenta a eficiência de 
formação de mamosferas. Por outro lado, a inibição transiente de P-caderina (usando 
small interfering RNA) leva a uma diminuição da atividade estaminal das células. 
Adicionalmente, a expressão da P-caderina confere resistência à morte celular induzida 
por raio-X, apoiando assim mais uma característica estaminal. Encontramos ainda uma 
associação marcante entre a P-caderina e o fenótipo estaminal/progenitor CD44+CD24+, 
assim como com o fenótipo progenitor luminal CD49f+CD24+. 
Neste trabalho, focamos a nossa atenção no estudo dos componentes da matriz 
extracelular (ECM) e nos seus recetores, as integrinas, que constituem peças 
fundamentais na manutenção do nicho das células estaminais. Dada a importância da P-
caderina no comportamento agressivo do cancro de mama, torna-se importante 
esclarecer as vias de sinalização desencadeadas por esta molécula de adesão e quais 
os mecanismos que poderão funcionar com alvo terapêutico. Usando linhas celulares de 
cancro de mama do tipo basal, mostramos que a P-caderina é essencial para a adesão 
das células aos substratos da ECM laminina, vitronectina e fibronectina. A integrina α6β4 
está implicada na via de sinalização desencadeada pela P-caderina em reposta à 
laminina, assim como na atividade estaminal das células tumorais. A ativação das 
tirosinas cinases FAK e Src em resposta à laminina é dependente da expressão de P-
caderina.  
Em suma, os resultados gerados neste estudo mostram que em carcinomas de 
mama primários, o subtipo basal está enriquecido no fenótipo da célula estaminal tumoral 
CD44+CD24-/low e na expressão do marcador ALDH1. Nas linhas celulares, o fenótipo 
basal surge associado à atividade da enzima ALDH1 e ao fenótipo da célula progenitora 
luminal CD44+CD49f+. Demonstramos ainda, pela primeira vez, que a P-caderina medeia 
propriedades estaminais nos carcinomas de mama do subtipo basal, descobrindo uma 
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nova via de sinalização oncogénica, em que a P-caderina e a integrina α6β4 interatuam. 
A P-caderina poderá ser explorada como um marcador que permitirá definir/otimizar o 
fenótipo da célula estaminal tumoral de carcinomas de mama basais, assim como a 
célula-de-origem para este subtipo de cancro de mama. 
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 Thesis Outline 
 
In Chapter I, a general introduction presents the state of the art in the field of breast 
development and cancer, with a special focus in the aggressive basal-like subtype of 
breast carcinoma. The hierarchical model of tumour progression, based in the Cancer 
Stem Cell hypothesis is presented. The relevance of cadherin molecules, particularly P-
cadherin, in the cancer context, as well as its significance in stem cell biology is also 
described. A brief depiction of the importance of the tumour microenvironment is 
portrayed, with a particular focus in integrin signalling. This introduction section focuses 
the main topics related with the research data presented in the following chapters. 
In Chapter II, the aims of the thesis are defined, in accordance with the state of the 
art. 
In Chapter III, a description of the materials and the detailed methodology applied to 
perform the work leading to this thesis dissertation is specified.  
Chapters IV, V and VI describe all the experimental work that gave rise to the 
original data presented in this thesis, already accepted or submitted to publication in 
international peer reviewed journals. 
A general analysis and an integrated view of the results is presented in the General 
Discussion section of this thesis, with the conclusion remarks (Chapter VII) followed by 
Future Perspectives (Chapter VIII). 
The Appendix 1 section describes the establishment of a human basal-like cell 
model stably expressing shRNA for the CDH3/P-cadherin gene, inducible with doxycycline 
(DOX). The publications that resulted from this thesis are included in the Appendix 2 
section. 
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 1. Breast Cancer 
 1.1 Epidemiology, risk factors and molecular classification  
  
In western countries, breast cancer is the most frequent malignancy in women. Not 
surprisingly, this type of cancer is the most prevalent in the adult Portuguese female 
population. The latest Globocan estimates (in reference to the year 2008) indicate that in 
Portugal 5333 new cases emerge every year, with an incidence rate of 49.9 cases per 
100.000 people. Mortality rates are in the order of 14.4 cases per 100.000 people, 
corresponding to 4.2 deaths daily in the whole Portuguese population (1537 deaths/ year) 
(Figure 1) (Ferlay et al., 2010 and Liga Portuguesa contra o Cancro). This reality has 
turned breast cancer into one of the main research interests in the national cancer 
research community. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - GLOBOCAN estimates presented for 2008 regarding the annual numbers of incidence and 
mortality of the most common types of cancer for both sexes in Portugal (GLOBOCAN 2008 v1.2, Cancer 
Incidence and Mortality Worldwide: IARC Cancer Base No. 10, (Ferlay et al., 2010)). 
 
This malignancy has a multifactorial etiology, since a single causative agent is not 
sufficient to induce breast cancer development. The interaction between environmental 
factors and the individual genetic profile dictate the susceptibility for the development of 
this disease. Notably, breast cancer is more common among Caucasians living in the 
colder climates and the more highly industrialized countries of the western hemisphere 
(Macdonald et al., 2004). One of the most relevant risk factors for breast cancer is age: 
older women are more likely to develop this type of malignancy. Certain breast alterations, 
such as atypical mammary hyperplasia or preneoplastic lesions can represent important 
risk factors. The previous history of developing a neoplastic breast lesion, as well as the 
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family history, such as inherited germline mutations in the breast cancer susceptibility 
genes BRCA1 and BRCA2 are also major predetermining factors. The earlier age at 
menarche (before 12 years of age), the late menopause (after the age of 55 years) and 
postmenopausal obesity are significant risk factors, since they increase the breast 
exposure to elevated levels of oestrogen. Other factors such as a late pregnancy, 
sedentary life style, alcohol consumption, the use of oral contraceptives and hormonal 
replacement therapy also contribute to increased breast cancer risk (Kufe et al., 2010). 
Breast cancers vary greatly in clinical behavior, outcome, morphology, and biologic 
characteristics. Histologically, invasive breast cancers are categorized into at least 18 
different subtypes, based on growth patterns and cytological characteristics (Tavassoli & 
Devilee, 2003). This heterogeneity led to the development of a new classification system 
that more accurately relates the molecular characteristics, prognosis, and treatment 
options for this malignancy. Based in gene expression profiles, four main molecular 
subtypes of breast cancers were described: Luminal A, Luminal B, human epidermal 
growth factor receptor (HER)-2 overexpressing cancers and triple negative carcinomas 
(that comprise mainly basal-like, normal breast-like and claudin-low carcinomas) (Figure 
2) (Perou et al., 1999, Perou et al., 2000, Sorlie et al., 2001, Sorlie et al., 2003, 
Herschkowitz et al., 2007, Hennessy et al., 2009). 
Luminal breast cancers represent the bulk of breast cancers (60-75%); these 
express estrogen receptor (ER)-α and are generally of good prognosis, because directed 
therapy may be applied to inhibit the mitogenic paracrine effects of this receptor. Current 
therapies are based on the administration of tamoxifen or fulvestrant (ER antagonists) or 
aromatase inhibitors (oestrogen synthesis inhibitors), such as anastrazole or letrozole. 
Within this molecular group, Luminal A carcinomas are distinguished from Luminal B, 
since the latter cancer subtype usually expresses lower levels of ER-related genes, high 
levels of Ki-67 (proliferation), may present HER-2 overexpression and show a worse 
prognosis. 
HER-2 overexpressing breast carcinomas represent 18-20% of breast cancers 
(Rakha & Reis-Filho, 2009) and present high levels of a member of the epidermal growth 
factor receptor family, the HER-2 receptor, and the neighboring genes found in the 
chromosome region 17q, frequently amplified in these cancers. Though of poor prognosis, 
therapeutic strategies are used in an attempt to target HER-2 receptor, either with the 
monoclonal antibody trastuzumab (Herceptin), or tyrosine kinase receptor inhibitors (e.g., 
lapatinib). 
Triple negative carcinomas denote 10-17% of all breast carcinomas (Reis-Filho & 
Tutt, 2008). They represent a heterogeneous group of malignancies that are ER-negative, 
progesterone receptor (PgR)-negative and HER-2-negative. For this reason, this type of 
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breast cancer is usually insensitive to endocrine and anti-HER-2 therapies. The triple 
negative normal breast-like subgroup is typified by the high expression of genes 
characteristic of basal epithelial cells and adipose cells, and the low expression of genes 
characteristic of luminal epithelial cells. These breast cancers have usually a better 
prognosis and cluster together with benign lesions of the breast (Sorlie et al., 2003). On 
the other hand, basal-like breast cancer is a triple negative carcinoma that includes 
tumors characterized by an expression signature similar to that of the basal cells of the 
breast, such as cytokeratins (CK) 5, 14 and 17, laminin-5, α6β4-integrin, caveolin-1 and 2, 
P-cadherin, and calponin (Lakhani et al., 1998, Lakhani et al., 2005, Lakhani et al., 2002). 
Finally, Claudin-low tumors are a recently described molecular subgroup within the triple 
negative tumors, defined by loss of a cluster of genes involved in cell-cell adhesion, 
namely claudins 3, 4, and 7, occludin and E-cadherin. The gene set used also describes 
low expression of luminal genes, inconsistent expression of basal-like genes, and high 
expression of lymphocyte and endothelial cell markers (Hennessy et al., 2009, 
Herschkowitz et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Hierarchical clustering of 205 breast tissue samples into five subgroups according to the intrinsic 
gene set defined by Sorlie et al., 2003 and Herschkowitz et al., 2007. Dark blue – luminal A subtype, light blue 
– Luminal B subtype, pink – HER-2 overexpressing subtype, red – basal subtype, orange – claudin low 
subtype, green – normal breast like subtype. Branches corresponding to tumours with low correlation to any 
subtype are shown in black. Adapted from Hennessy BT, Cancer Research, 2009 (Hennessy et al., 2009). 
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 1.2. The breast cancer basal-like molecular subtype  
 
Basal-like breast tumors account for 15% of all breast cancer cases, occur at a 
slightly younger age and have an extremely bad prognosis, presenting the shortest 
survival of all breast-cancer subtypes. This observation is in part due to early relapses 
within the first five years after diagnosis (Da Silva et al., 2007, Korsching et al., 2008, 
Sorlie et al., 2001, Yehiely et al., 2006). It mainly affects african-american, hispanic and 
obese women (Rakha & Reis-Filho, 2009). In addition, the basal tumour phenotype 
generates therapeutic dilemmas, since anti-oestrogens and trastuzumab are not adequate 
options for such patients.  
Basal-like breast cancers encompass grade III invasive ductal carcinomas of no 
special type, (atypical) medullary carcinomas, metaplastic breast cancers and other rare 
histological subtypes, such as adenoid cystic, acinic cell carcinoma, pleomorphic lobular 
and secretory breast cancers (Rakha & Reis-Filho, 2009, Weigelt et al., 2010). Pushing 
and non-infiltrative borders of invasion are observed, with large zones of geographic or 
comedo-type necrosis, stromal lymphocytic infiltrates, scant stromal content, lack of tubule 
formations, marked cellular pleomorphism, high nuclear–cytoplasmic ratios, vesicular 
chromatin, prominent nucleoli, high mitotic indices, and frequent apoptotic cells (Rakha & 
Reis-Filho, 2009). Basal-like cancer is associated with an aggressive clinical history, 
development of recurrence, shorter survival, and a specific pattern of hematogenous 
distant metastasis (Patanaphan et al., 1988). 
Using immunohystochemistry, basal-like cancers can be identified by a panel that 
comprises 4 markers (lack of ER and HER-2, and expression of EGFR and/or CK5/6) with 
100% specificity and 76% sensitivity (Nielsen et al., 2004). Basal-like cancers are also 
usually PgR-negative and may present a CK14-positive staining. P-cadherin is also used 
as an adjunct marker to identify this type of carcinomas (Matos et al., 2005, Paredes et 
al., 2007b, Sousa et al., 2010), since its expression is highly associated with this 
molecular subgroup. Cyclin E, Ki-67, fascin, Sox-2, moesin, vimentin, nestin and laminin 
are also frequently expressed (Rakha & Reis-Filho, 2009). Basal-like tumors are 
predominantly negative for BRCA1, cyclin D1, p27 and MUC1 (Foulkes, 2004, Nielsen et 
al., 2004, Potemski et al., 2005), and may express luminal keratins (CK8/18), albeit at 
lower levels than those found in luminal cancers (Honrado et al., 2007). 
Familial breast tumors account for 5-10% of all breast tumors and about half of 
these cases are related to BRCA1 gene mutations (Hwang-Verslues et al., 2008). Breast 
tumors arising in BRCA1 germline mutation carriers often exhibit a basal-like phenotype 
and frequently these tumors also harbor p53 mutations (Foulkes et al., 2003, Lakhani et 
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al., 2005, Turner & Reis-Filho, 2006). Although somatic BRCA1 gene mutations are rare 
in sporadic basal-like cancers, there is evidence to suggest that BRCA1 mRNA (Turner et 
al., 2007) and protein levels (Lambie et al., 2003, Rakha et al., 2008) are downregulated, 
either by epigenetic silencing of the BRCA1 gene promoter (i.e., BRCA1 gene promoter 
methylation) (Turner et al., 2007) or by up-regulation of ID4, a BRCA1-negative regulator 
(Beger et al., 2001). BRCA1 protein is involved in the DNA repair mechanism by 
homologous recombination and several lines of evidence suggest that cancer cells 
harboring this defective DNA repair mechanism show an exquisite sensitivity to cross-
linking agents, such as carboplatin, and to inhibitors of the PARP enzyme (Edwards et al., 
2008, Farmer et al., 2005). However, agents that effectively target basal-like breast 
cancers are needed.  
Currently, chemotherapy and radiotherapy for systemic and local control remains 
the mainstay to treat basal-like cancer, although a high proportion of patients die in a 
shorter time frame due to metastatic disease to the lungs and brain (Da Silva et al., 2007, 
Fulford et al., 2007, Rakha et al., 2006, Reis-Filho & Tutt, 2008, Yehiely et al., 2006). The 
mechanisms involved in this aggressive behavior are under study. Based on the strong 
association with poor relapse-free and overall survival, numerous studies, including ours, 
attempt to further define the pathology, biology, clinical features and, essentially, 
therapeutic options for basal-like tumors. This is particularly challenging, since not much is 
known about the genes or the cells that are responsible for the aggressive phenotype of 
these tumors, which is a major barrier to develop target therapies. Additionally, data in the 
literature supports the idea that the poor outcome phenotype of basal-like breast cancers 
may reflect its cellular origin and a cancer stem cell component. One of the findings 
supporting this hypothesis is that BRCA1 regulates breast stem cell function and fate 
(Foulkes, 2004), as well as transcriptionally regulates genes associated with basal-like 
phenotype in breast cancer, namely P-cadherin, CK5 and CK17 (Gorski, 2009).  
 
 2. Normal breast development and mammary stem cells 
 
The mammary gland in humans and other mammals is a dynamic organ that 
undergoes significant developmental changes during embryonic development, puberty, 
pregnancy, lactation and involution. The mature gland consists of a branching ductal-
lobular system. The lobules of the human breast are organized into 15-20 lobes, which 
are drained by collecting ducts that converge at the nipple in a radial arrangement 
(Osborne, 2000) (Figure 3A). Each lobule in turn is made up of acini (also called alveoli) 
that form the functional secretory units of the mammary gland, the terminal duct lobular 
- 34 - 
units (TDLUs). The acini and ducts have a central lumen and are lined by two cell layers, 
an inner layer of epithelial cells and an outer layer of myoepithelial cells. Surrounding this 
structure is a basement membrane separating the epithelium from the stroma (Osborne, 
2000) (Figure 3B and 3C). The mammary gland is embedded in stroma, which is 
composed of mesenchymal cells, such as fibroblasts, adipocytes, endothelial cells, 
immune cells, and extracellular matrix components.  
 
 
Figure 3 – Schematic representation of the human mammary gland (comprising 15-20 lobes) (A); 
Representation of the mammary duct (B) and a terminal end bud (C). A suprabasal region contains cells 
(represented in red) that sit on the myoepithelial layer, but do not reach the lumen. This is most likely the 
region where the mammary stem cells are located. Adapted from Visvader JE, Genes and Development, 2009 
(Visvader, 2009). 
 
The mammary epithelial tissue develops from the embryonic ectoderm, forming a 
primitive branched ductal system (Hennighausen & Robinson, 2001, Robinson et al., 
1999). The rudiments of the mammary gland remain quiescent until puberty. At this time, 
the increase in steroid hormones, oestrogen (Robinson et al., 1999) and progesterone, 
stimulate significant ductal growth, which is driven by specialized structures at the tips of 
the elongating ducts, the terminal end buds (TEB) (Figure 3C). This region is enriched in 
stem cell activity and consists of two morphologically distinct cell types, an inner layer of 
body cells and an outer layer of cap cells, which give rise to luminal and basal cell layers 
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respectively (Ball, 1998, Sapino et al., 1993). Once the mammary fat pad has been filled 
with glandular tissue, the TEBs regress and are converted to terminal ducts. During 
pregnancy, a surge of hormones results in major structural changes in the mammary 
gland. Proliferation and maturation of the side branches occurs to form alveoli, which 
contain the alveolar cells of TDLUs, responsible for milk production (Hennighausen & 
Robinson, 2001). In humans, at least some TDLUs are already present prior to 
pregnancy, although they are probably not as complex as during pregnancy (Molyneux et 
al., 2007). The termination of breast-feeding initiates significant structural remodelling 
known as involution, resulting in apoptotic cell death and collapse of the alveoli. The 
mammary gland returns to a predominantly ductal structure resembling the mature virgin 
gland. The cycles of proliferation, differentiation and involution that occur with every 
pregnancy suggest that these development changes are supported by adult multipotent 
mammary stem cells. 
 
In the last decade, it has been firmly established that, like most tissues, if not all, the 
mammary gland has also a hierarchical organization, similar to the hematopoietic system 
(Visvader & Lindeman, 2006) (Figure 4). At the top of this cell-hierarchy there is a small 
population of cells with self-renewal capability, named stem cells, responsible for 
generating and maintaining the tissue architecture and permitting tissue remodeling and 
repairing.  
Stem cells in the breast are scarce and although they have been purified and 
isolated using different techniques, they have not yet been fully characterized. A number 
of different cell surface markers have been described to define stem and progenitor 
mammary cells from both human and mice origin. It is important to say that some 
biomarkers that are useful for human stem cell characterization are not effective in the 
mouse model. In 2001, using Fluorescence Activated Cell Sorting (FACS), Stingl et al 
fractionated the human mammary epithelial gland using the markers EpCAM and CD49f 
and the isolated subpopulations were characterized for lineage restricted in vitro colony 
forming ability (Stingl et al., 2001). Since then several groups have used several markers 
to isolate and characterize in vitro colony forming ability as well as in vivo mammary 
repopulating capacity. Using FACS sorting of cell populations, Stingl et al., Eirew et al. 
and Lim et al. showed that mammary stem cells of the human breast were enriched in the 
subpopulation EpCAM-/lowCD49f+, whereas the phenotype EpCAM+CD49f+ was 
considered to have luminal progenitor features (Eirew et al., 2008, Lim et al., 2009, Stingl 
et al., 2001). Villadsen et al. and Raouf et al. propose that EpCAM+CD49f+ (CD10+Thy1+) 
cells preferentially have a bipotent differentiation capacity (Raouf et al., 2008, Villadsen et 
al., 2007). Recently, Keller et al. fractionated the human breast tissue using the same 
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markers and demonstrated that, within the CD49f+ fraction, both EpCAMhigh (CD10-) and 
EpCAMlow (CD10+) appear to have bipotent differentiation capacity, although the later 
phenotype was more associated with basal-like characteristics (Keller et al., 2011). Other 
subsets of cells were also found to be enriched in mammary stem cells, expressing the 
following sets of markers: SSEA-4+/K5+/K6a+/K15+/Bcl-2+ (Villadsen et al., 2007), 
K19+/K14+ (Villadsen et al., 2007), ALDH1+ (Ginestier et al., 2007), CD44+/CD24-
/PROCR+/ER-/MUC1-/HER-2- (Mani et al., 2008, Shipitsin et al., 2007).  
 It has also been shown that putative mammary stem cells in the mouse typically 
show the expression of EGFR and high molecular weight cytokeratins, weak or almost 
absent expression of CK18 and lack the expression of ER and HER-2 (Korsching et al., 
2008, Asselin-Labat et al., 2006). Human breast stem cells are also likely negative for ER 
expression (O'Brien et al., 2011, Raouf et al., 2008, Shipitsin et al., 2007).  
All these studies are consistent with the idea that mammary stem cells reside within 
the basal compartment of the mammary gland. However, no definitive phenotype is 
described for the stem cell at the top of the hierarchy or the multipotent early and late 
progenitor cells. It is important to refer that increasing data show that the breast hierarchy 
is not static. This means that progenitor cells or even mature cells can dedifferentiate and 
spontaneously move up the hierarchy (Chaffer et al., 2011, Gupta et al., 2011). In this 
scenario, stem cells can originate non-stem cells and vice-versa. 
 
 
Figure 4 – Model of the differentiation hierarchy within human mammary epithelium. Primary cell surface 
markers used in the isolation of human epithelial cell subsets are shown. The common progenitor is also 
referred to as bipotent progenitor cell. Adapted from Visvader JE, Genes and Development, 2009 (Visvader, 
2009). 
 
Nothing is known about the location of mammary stem cells and their niche in the 
mature gland. A significant proportion of the total cells present in the mammary epithelium 
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of the rat, approximately 3%, were proposed to be stem/early progenitor cells. These 
small cells reside in a suprabasal position, between luminal and myoepithelial cell layers, 
lacking organelles and with a pale cytoplasm (Chepko & Dickson, 2003). Terminal end 
buds within the pubertal gland and the ductal branch points in the adult gland may be 
sites of residence of stem cells (Visvader & Lindeman, 2006). It is possible that adhesion 
molecules, which allow the interaction between these stem cells and neighboring cells, as 
well as with the extracellular matrix, may play an important role in maintaining the stem 
cell niche. 
 
 3. The Cancer Stem Cell Hypothesis 
  
The cellular origin of most solid tumors is largely unknown, but it has been 
speculated that different subtypes of cancer reflect distinct cells of origin at the time of 
tumor initiation. Alternatively, the tumor phenotype may reflect the acquisition of specific 
genetic mutations and epigenetic alterations, that influence the intercation between tumor 
cells and their microenvironment (stroma, inflammatory cells and recruited vasculature) 
and have a profound influence on the tumorigenic process (Visvader, 2011). Although the 
definition of a cell of origin or a driver mutation for the different subtypes of breast cancer 
has been proven very difficult, there is evidence that tumors contain a minority of cells 
with normal stem cell-like characteristics that may be responsible for their propagation. 
Normal adult stem cells have self-renewal and differentiation capacity into several 
lineages; tumor cells have high proliferative capacity, phenotypic plasticity and aberrant 
differentiation (Reya et al., 2001). These similarities between stem cells and tumor cells 
have given rise to the hypothesis that breast tumors should arise from undifferentiated 
stem or progenitor cells. On the other hand, alternatively, it is believed that cancer cells 
may result from progressive de-differentiation during tumor development (Beachy et al., 
2004, Reya et al., 2001, Stingl & Caldas, 2007). 
In this way, whatever the cell of origin for breast tumors may be, two hypothesis 
attempt to explain the observed heterogeneity in solid tumors, namely in breast cancer.  
In the traditional hypothesis, or the clonal evolution model (Figure 5) (Campbell & Polyak, 
2007, Nowell, 1976), any cell in the mammary gland can receive an oncogenic hit and 
mutant tumor cells with growth advantage are selected and expanded. The cells in the 
dominant population have a similar potential for regenerating tumor growth. In this model, 
most cancer cells can proliferate extensively and have tumuorigenic potential. Intratumoral 
heterogeneity is due to the accumulation of additional mutations during tumor growth. The 
acquisition of genetic events underpins this model, but epigenetic differences and 
microenvironmental changes are also likely to have an important role. 
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Figure 5 - The clonal evolution model of tumor progression. All undifferentiated cells have similar tumorigenic 
capacity (most cells can proliferate extensively and form new tumors). Cellular phenotypes are not stable and 
can change as the tumor evolves. Existing therapeutic approaches have been based largely in this model. 
 
The most recent model, known as cancer stem cell hypothesis or hierarchical model 
(Figure 6) (Bonnet & Dick, 1997, Reya et al., 2001), proposes that only a small 
subpopulation of cancer cells is tumourigenic and has the ability to self renew and 
generate the diverse cells that comprise the tumor. These cells, named cancer stem cells 
(CSC), share important properties with normal tissue stem cells, including self-renewal (by 
symmetric and asymmetric division) and differentiation capacity, albeit aberrant. Markers 
have been identified that distinguish the tumourigenic from the non-toumourigenic cells 
and the difference between these cells is epigenetic. Importantly, CSCs do not necessarily 
originate from the transformation of normal stem cells. The intratumural heterogeneity of 
human breast cancers is due to the establishment of a hierarchy with the CSC lying at the 
apex.  
Importantly, the CSC model of tumor progression is consistent with the behaviour of 
some leukemias  (Bonnet & Dick, 1997) and certain solid tumors, such as breast cancer 
(Al-Hajj et al., 2003), brain cancers (Singh et al., 2004), colon cancers (O'Brien et al., 
2007) and germ cell cancers (Illmensee & Mintz, 1976) in which cancer cells seem to be 
clearly organized in a hierarchical manner. However, some other tumors such as 
melanoma (Quintana et al., 2008) and B-cell lymphoblastic leukaemia (Williams et al., 
2007) have a much more high frequency of cancer cells with tumourigenic ability and the 
clonal evolution model is a better description for these malignancies.  
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Figure 6 – The cancer stem cell hypothesis or hierarchical model of tumor progression. Only the cancer stem 
cell (CSC) can propagate a tumor, based on its extensive self-renewal and differentiation capacity. Most 
cancer cells have limited proliferative potential. 
 
Although the CSC model offers a tempting explanation for the aggressive behaviour 
of certain tumours, several aspects are not clearly addressed. The unknown origin of the 
CSC, and the lack of a universal CSC phenotype for solid cancers complicate the 
establishment of this model. Furthermore, not a single CSC was able to reconstitute the 
whole solid tumour, only subpopulations of cells. Also, technical issues, like the 
unfeasibility of testing this model in humans, and the bias of in vitro stem cell assays, are 
major caveats of this model. In fact, the hierarchical model of tumour progression seems 
to be imperfect and probably cancer stem cells also evolve according to a clonal evolution 
model (Shackleton et al., 2009). This would mean that the previous two models proposed 
do not have to be mutually exclusive, and their combination is also plausible. 
 
 3.1. The clinical relevance of Cancer Stem Cells  
 
Classical antineoplastic treatments, such as chemotherapy or radiation, can 
efficiently eradicate the majority of proliferating and genetically unstable malignant cells 
within neoplastic lesions. However, these regimens frequently fail to eliminate the minor 
subpopulation of resistant CSCs. Therefore, the concept of the CSC leads to an important 
consequence in the clinical setting: more effective treatments are needed for cancers and 
clinicians probably need to focus therapy on the most malignant cells. The cancer stem 
cell model offers a good explanation for recurrence and metastasis, as well as the 
resistance of certain tumors to current therapy, indicating that targeting CSCs, in 
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combination with current therapies is goal to achieve in cancer treatment (Ablett et al., 
2012). 
The recurrence of breast cancer, often in a secondary site, may reflect the inherent 
ability of CSCs to survive as circulating tumor cells and to form micrometastasis, 
remaining quiescent in distant sites for a long period. In this setting the pre-metastatic 
niche has a major role, since it gathers all the necessary conditions to the survival of the 
metastatic cells. Importantly, the metastatic behaviour of cancer cells may be associated 
to the acquisition of a more mesenchymal phenotype, which enables certain stem-like 
characteristics (Mani et al., 2008, Morel et al., 2008). 
Concerning patient’s resistance to current therapy, it is important to mention that 
CSCs possess innate resistance mechanisms against radiation- and chemotherapy-
induced cell death, allowing them to survive and cause tumor recurrence.  
 
The mechanisms of intrinsic therapy resistance in normal and malignant mammary 
stem cells involve enhanced DNA repair mechanisms, which confer resistance of stem 
cells to DNA-damaging agents (Cairns, 1975, Cairns, 2002, Park & Gerson, 2005, Potten 
et al., 2002) and increased stem-cell maintenance signalling pathways, such as Wnt/β-ctn 
and Notch signalling (Wang et al., 2010, Chen et al., 2007). Novel targeted therapies 
against the DNA damage checkpoint or stem-cell maintenance pathways may sensitize 
cancer stem cells to radiation or other therapies. Additionally, it was found that many 
cancer stem cells are not cycling and are in G0 and, thus, are resistant to cell cycle–
specific chemotherapy agents (Venezia et al., 2004). Furthermore, it was postulated that 
during DNA replication, the parental ‘‘immortal’’ DNA strand always segregates with the 
stem cell and not with the differentiating progeny. This prevents the stem cell 
compartment from accumulating mutations associated with replication (Rambhatla et al., 
2005). Stem cells also express higher levels of anti-apoptotic proteins, such as members 
of the Bcl-2 family and inhibitors of apoptosis, than do the differentiated cells (Wang et al., 
2003). Stem cells still express high levels of transporter proteins, such as ABCG2 
(BCRP1), ABCB1 (P-glycoprotein 1) and ABCC1 (MRP1), which represent the three 
principal multidrug resistance genes (Wicha et al., 2006). Although certain regulators of 
stem cell function have been implicated in cancer pathogenesis (Beachy et al., 2004), a 
broad characterization of stem cell-associated regulatory networks in tumors, as well as in 
normal and cancerous stem cells is still lacking. 
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 3.2. Cancer Stem Cells in basal-like breast cancer 
 
In 2003, Michael Clarke´s group described for the first time the phenotype of the 
breast CSCs. The cancer initiating cells were identified and isolated using cell surface 
markers as Lineage- ESA+CD44+CD24-/low in eight out of nine patients. As few as 200 cells 
with this phenotype were able to form tumours in NOD/SCID immunocompromised mice, 
whereas 20000 cells with alternate phenotypes failed to form a tumour. The tumourigenic 
cells gave rise to non-tumourigenic cells and could be serially passaged, proving the 
differentiation ability and self-renewal potential of these cells (Al-Hajj et al., 2003). 
Basal breast tumors are mainly composed of cells expressing the cancer stem cell 
marker CD44 (Fulford et al., 2007, Polyak, 2007, Shipitsin et al., 2007) and an association 
between the CD44+/CD24- phenotype and basal-like breast cancer subtype has been 
reported (Ali et al., 2011, Honeth et al., 2008, Park et al., 2010), indicating possible stem 
cell features for this cancer. Moreover, other cell markers associated with stem cell 
properties were identified in basal-like breast cancers, such as the enzyme aldehyde 
dehydrogenase-1 (ALDH1), which was correlated with poor prognosis cancers (Ginestier 
et al., 2007, Park et al., 2010). Notably, the CSC phenotype CD44+CD24-/low is not 
universal and other phenotypes have been proposed to better describe CSCs present in 
basal-like mammary tumors. Thus, for mice breast tumors harbouring BRCA1 deletion, 
additionally to the CD44+CD24-/low subpopulation, the population defined as CD133+ 
(Prominin+) correlated with stem cell activity, producing increased spheroids, being 
significantly more resistant to DNA damaging drugs, and having increased tumourigenic 
ability (Wright et al., 2008). Furthermore, for the human basal-like breast cancer cell line 
MDA-MB-231 (which is mainly CD44+CD24-/low), the phenotype ESA+PROCR+ could be 
used to highly enrich for stem/progenitor properties, including increased colony forming 
ability, in vitro regenerative capacity, and increased mesenchymal markers (Hwang-
Verslues et al., 2009). Also, in human ER-negative breast cancers, the phenotype 
CD44+CD49fhighCD133/2high defined a population of tumor initiating cells with self-renewal 
capacity (Meyer et al., 2010). 
From an immunohystochemical point of view, basal-like breast cancers share a 
profile similar to the physiological stem/progenitor cells of the normal female breast, 
including c-kit, α6-integrin, K5, K14 and prion protein. It is believed that the stem cell at 
the top of the hierarchy is, like the basal cell of the breast, triple negative (ER-/PgR-/HER2-
), EGFR+, p63+ and p21-. Actually, basal-like cancers show a mixed basal/luminal 
phenotype: they are positive for basal K5 and K14, and luminal K8 and K18. This 
suggests that a stem cell or a putative bi-potential progenitor cell, that gives rise to both 
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luminal and myoepithelial cells, may be in the origin of these cancers (Korsching et al., 
2008, Yehiely et al., 2006). In fact, recent data from several groups indicate that the cell of 
origin for basal-like breast cancers may be the luminal progenitor cell (Lim et al., 2009, 
Molyneux et al., 2010, Proia et al., 2011). In fact, human BRCA1 gene inactivation, which 
is often associated with this phenotype of breast cancer, causes a defect in progenitor cell 
lineage commitment, with an increase in the immature K14+/19+ cells (Proia et al., 2011), 
as well as an increase in ALDH1 activity with loss of mature luminal differentiation 
markers (Liu et al., 2008). Furthermore, although the studies performed are not 
completely clear, BRCA1 mutation carriers seem to possess an expansion of the luminal 
progenitor cell population (Lim et al., 2009, Proia et al., 2011) and this cell population is 
most likely the target of oncogenic transformation in basal-like breast tumours (Molyneux 
et al., 2010, Proia et al., 2011). 
 
 4. Cadherin molecules in normal and malignant tissues 
 
Cadherins are a large family of molecules that mediate cell-cell adhesion. Cadherins 
can be subdivided into six subfamilies: the type I and type II classical cadherins, the 
desmosomal cadherins, the seven-pass transmembrane cadherins, the large cadherins of 
the fat and dachsous group, and the group of protocadherins (Nollet et al., 2000, 
Stemmler, 2008). The type I classical cadherins, which include CDH1/E-cadherin 
(epithelial), CDH2/N-cadherin (neuronal), CDH3/P-cadherin (placental) and CDH4/R-
cadherin (retinal), constitutes the best characterized subgroup (Nollet et al., 2000). These 
cadherins are composed of three components: 1) an extracellular portion responsible for 
calcium-dependent homotypic cadherin-cadherin interaction (which has 5 repeated 
cadherin domains); 2) a single pass transmembrane domain; and 3) a highly conserved 
cytoplasmic domain that binds to the intracellular catenins p120-catenin (p120ctn) and β-
catenin (β-ctn). Catenins have a dual role, acting as signalling mediators or as adaptor 
molecules that stabilize the cadherin complex at the membrane and link the cadherin 
molecule to the actin filaments of the cytoskeleton (Wheelock et al., 2001) (Figure 7). 
Cadherin mediated cell-cell adhesion is accomplished by homophilic interactions between 
two cadherin molecules at the surface of the respective cells (Cavallaro & Dejana, 2011) 
and the cadherin-catenin complex constitutes the main building block of the adherens-
type junctions. These complexes, not only regulate cell shape and polarity, but also 
represent a major regulatory mechanism that guides cell fate decisions, influencing cell 
growth, differentiation, cell motility and survival (Cavallaro & Dejana, 2011). 
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Figure 7 – Representation of the structural components of a classical cadherin adhesive structure. In the 
figure, P-cadherin (placental) is represented. P-cadherin extracellular domain interacts with the extracellular 
domain of an adjacent cell. Intracellular catenins bind to the cytoplasmic tail of P-cadherin: p120-catenin binds 
at the juxtamembrane domain (JMD), whereas β-catenin to the distal catenin binding domain (CBD). α-catenin 
associates with β-catenin and is directly linked to the actin cytoskeleton. The lower panel shows the genomic 
structure of the CDH3/P-cadherin gene, which is constituted by 16 exons: the extracellular part of P-cadherin 
is encoded by 10 exons (exons 4-13), whereas the transmembrane and the intracellular domains are 
determined by the information coded by the last 3 exons (exons 14-16). Adapted from Albergaria A, et al., 
International Journal of Development Biology, 2011 (Albergaria et al., 2011). 
 
The maintenance of normal epithelial cellular architecture is frequently altered 
during tumour progression. For example, lobular breast carcinoma, in which cells actively 
invade the mammary stroma, is characterized by E-cadherin loss (De Leeuw et al., 1997). 
In fact, it is well known that E-cadherin acts as a tumour suppressor, negatively regulating 
the invasion and metastasis of tumour cells in most, if not all, cancers of epithelial origin 
(Yilmaz & Christofori, Cavallaro & Christofori, 2004).  The loss of E-cadherin function 
during tumour progression can be caused by various genetic or epigenetic mechanisms. 
In patients with lobular breast cancer and diffuse gastric cancer, the E-cadherin gene is 
mutated leading to the expression of a non-functional protein (Guilford et al., 1998). E-
cadherin expression can also be downregulated at the transcriptional level, by the 
repressors Snail (Snai1), Slug (Snai2), Sip1 (Zeb2) and Twist that bind to E2 boxes in the 
promoter of the CDH1/E-cadherin gene (Batlle et al., 2000, Comijn et al., 2001, Hajra et 
al., 2002). The E-cadherin gene locus can also be epigenetically silenced by 
hypermethylation (Di Croce & Pelicci, 2003) and proteolytic cleavage of E-cadherin by 
matrix metalloproteases (MMPs) is another mechanism by which E-cadherin-mediated 
tumour cell-cell adhesion can be ablated (Nawrocki-Raby et al., 2003). The mechanisms 
of E-cadherin mediated signalling involve a crosstalk with receptor tyrosine kinases, such 
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as EGFR, c-Met and IGF1R, the activation of the Wnt signalling pathway and modulation 
of the available pool of β-ctn, and the signalling through RHO GTPases (Cavallaro & 
Christofori, 2004). 
However, not all classical cadherins have a tumour suppressor function. In a 
process termed epithelial to mesenchymal transition (EMT), which is normally present in 
embryonic development and tissue repair, tumour cells progressively down-regulate E-
cadherin and express de novo N-cadherin and other mesenchymal molecules (Thiery, 
2002). This cadherin switch leads to the inhibition of cell-cell contacts and elicits signals 
that support tumour cell migration, invasion and metastasis (Frixen et al., 1991). This type 
of transition is found in several human cancer types, including melanoma, prostate and 
breast cancer (Cavallaro & Christofori, 2004).  
Importantly, P-cadherin molecule was also shown to promote cell motility, migration 
and cell invasion. The aggressive properties mediated by P-cadherin will be addressed in 
detail in the following section.  
 
Described for the first time in 1986, as “a novel class of cadherin that appeared in 
developing mouse embryos”, this adhesion molecule was found in the structures that 
gave rise to its name, the placenta (Nose & Takeichi, 1986). P-cadherin is a calcium-
dependent cell-cell adhesion glycoprotein, which plays a role in many cellular processes 
such as embryonic development, differentiation, cell polarity, growth and migration (Larue 
et al., 1996). In the adult, it is only expressed certain tissues, usually co-expressed with E-
cadherin, such as the basal layer of the epidermis and breast, the mesothelium, the ovary, 
the prostate, the hair follicle, and the corneal endothelium (Nose & Takeichi, 1986, Imai et 
al., 2008). Sharing about 67% of homology with the CDH1/E-cadherin gene, P-cadherin 
differs mainly in the extracellular portion; it is far less characterized, and it has a 
considerably opposing effect regarding mammary cancer biology (Albergaria et al., 2011, 
Hulpiau & van Roy, 2009). In normal breast tissue, P-cadherin expression is restricted to 
myoepithelial cells as a linear cell membrane staining, whereas E-cadherin is expressed 
in both myoepithelial and epithelial cell layers of the breast (Paredes et al., 2002a).  
The CDH3/P-cadherin gene harbours 16 exons (Figure 7) and maps to 
chromosome 16q22.1, a region that contains a cluster of several cadherin genes, just 32 
kilobases upstream of the gene encoding E-cadherin (Bussemakers et al., 1994).  
Concerning CDH3/P-cadherin gene regulation, the literature is not as extensive as 
regarding CDH1/E-cadherin gene. The main transcriptional activators described for the  
CDH3/P-cadherin gene promoter are β-catenin (Faraldo et al., 2007), p63 (Shimomura et 
al., 2008) and C/EBPβ (Albergaria et al., 2010). In contrast, BRCA1/c-Myc/Sp1 complex 
acts as transcriptional repressor of the CDH3 promoter (Gorski et al., 2009). It was also 
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demonstrated that ER can indirectly repress P-cadherin expression by controlling 
epigenetic changes in CDH3 gene promoter (Albergaria et al., 2010) (Figure 8). 
 
 
Figure 8 – Transcriptional regulators of CDH3/P-cadherin gene promoter. It has been shown that β-catenin, 
p63 and C/EBPβ are transcriptional activators of the CDH3 promoter. In contrast, BRCA-1/c-Myc/Sp1 complex 
acts as transcriptional repressor of the CDH3 promoter. It was also demonstrated that oestrogen receptor 
(ER) can indirectly repress P-cadherin expression by controlling epigenetic changes in CDH3 gene promoter. 
Adapted from Albergaria A, et al., International Journal of Development Biology, 2011 (Albergaria et al., 2011). 
 
 4.1. P-cadherin promoting effects in breast cancer 
 
P-cadherin aberrant expression is found in 20% to 40% of invasive breast 
carcinomas, as well as in 25% of pre-invasive (in situ) ductal carcinomas. Aberrant P-
cadherin expression was shown to be associated with tumours of high histological grade, 
as well as with well established markers of poor prognosis, like Ki-67, EGFR, CK5, 
vimentin, p53 and HER-2 expression, and negatively associated with age at prognosis 
and hormonal receptors (ER and PgR) expression. Interestingly, none of these reports 
showed a significant association with tumour size and lymph node metastasis (Paredes et 
al., 2005, Paredes et al., 2002b, Gamallo et al., 2001, Peralta Soler et al., 1999, Turashvili 
et al.).  
P-cadherin up-regulation is predominantly found in the basal-like subgroup of breast 
cancers (Matos et al., 2005, Paredes et al., 2007a, Paredes et al., 2007b) and it is 
strongly associated with the presence of BRCA1 mutation (Arnes et al., 2005) and poor 
clinical outcome (Paredes et al., 2005, Turashvili et al., 2011).  
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P-cadherin is altered in various human tumours, but its effective role in the 
carcinogenesis process remains object of debate, since it can behave differently 
depending on the studied tumour cell model and context. For example, in melanoma, P-
cadherin seems to have a tumor suppressive function, exactly as E-cadherin (Van Marck 
et al., 2005). In breast and several other models, P-cadherin is often reported to exhibit 
tumour promoting effects. 
Using breast cancer cell lines, we found that overexpression of P-cadherin promotes 
cell motility, cell migration, as well as invasion capacity in matrigel matrix (Ribeiro et al., 
2010). A similar aggressive phenotype was also observed in bladder and pancreatic 
cancer cell lines (Mandeville et al., 2008, Taniuchi et al., 2005, Van Marck et al., 2011). 
Curiously, we have noticed that P-cadherin is able to induce invasion only in cell systems 
which already express an endogenous and functional E-cadherin in breast cancer cells 
(Paredes et al., 2004, Ribeiro et al., 2010, Taniuchi et al., 2005). In fact, breast 
carcinomas that co-express E- and P-cadherin actually show a patient survival that is 
even worse than carcinomas that express only one of the cadherins or that do not express 
any of these adhesion molecules (Paredes et al., 2008). These tumors have a decrease in 
membrane staining of p120ctn and an increase in the cytoplasmic localization for this 
catenin. In pancreatic and ovarian cancer, it was shown that p120ctn, once in the 
cytoplasm can activate Rho-GTPases, Rac1 and Cdc42, altering the actin cytoskeleton 
polymerization and promoting cell motility (Taniuchi et al., 2005, Cheung et al., 2010). 
Based on this, we have recently proved that P-cadherin is able to interact with E-cadherin 
in breast tumours and cancer cells, promoting cancer cell invasion by disrupting the 
interaction between E-cadherin and both p120ctn and β-ctn. In the absence of E-cadherin 
expression, in the same cancer model, P-cadherin is able to suppress invasion by its 
strong interaction with catenins, surrogating the role of E-cadherin in cell-cell adhesion 
(Ribeiro et al., unpublished data). It is also possible that signaling pathways, such as 
Wnt/β-ctn, may play an important role in mediating the oncogenic effects derived from P- 
and E-cadherin aberrant expression. Notably, this signaling pathway is responsible for the 
self-renewal and pluripotency of mammary stem cells (Beachy et al., 2004). Transient or 
irreversible inactivation of the cadherin-catenins complexes by factors secreted by tumor 
cells and/or stromal cells cannot be ruled out. An example of such factors could be 
metalloproteases. These post-translational mechanisms could also be related to 
accumulation of catenins in the cytoplasm. In vitro studies from our laboratory have shown 
that, in E-cadherin positive breast cancer cell lines, P-cadherin overexpression promotes 
cell invasion, migration and motility accompanied by the secretion of MMP-1 and MMP-2, 
which lead to P-cadherin ectodomain cleavage. This soluble P-cadherin fragment is able 
to induce in vitro invasion of breast cancer cells (Ribeiro et al., 2010). 
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Importantly, in addition to breast cancer, P-cadherin upregulation is also found in 
other malignancies such as gastric, endometrial, colorectal and pancreatic carcinomas 
(Hardy et al., 2002, Imai et al., 2008, Stefansson et al., 2004, Taniuchi et al., 2005). 
Targeting P-cadherin in cancer may be a good therapeutical approach, since normal 
tissues usually express very low levels of this cadherin (Imai et al., 2008). In fact, a novel 
and highly selective human monoclonal antibody against P-cadherin (PF-03732010) 
demonstrated anti-tumour and anti-metastatic activity in a panel of P-cadherin 
overexpressing tumour models, without significant secondary effects in mice (Park et al., 
2011, Zhang et al., 2010). PF-03732010 has just completed a Phase I clinical trial. 
 
 4.2. P-cadherin role in breast cell differentiation, development 
and stem cell biology 
 
P-cadherin deficient female mice present abnormal mammary gland morphology 
and development. Although no tumors were detected, these animals exhibit precocious 
mammary gland differentiation in the virgin state, and breast hyperplasia and dysplasia 
with age (Radice et al., 1997). These observations implicate P-cadherin cell-cell 
interactions and signaling as regulatory determinants of the negative growth of the luminal 
epithelium, being important for the maintenance of an undifferentiated state of the normal 
mammary gland. Noteworthy, this mouse model was never thoroughly studied regarding 
cancer, namely upon oncogenic transformation of breast cells.  
In humans, the loss of P-cadherin induces characteristic genetic syndromes. CDH3 
gene mutations have been shown to cause P-cadherin functional inactivation, leading to 
developmental defects associated with two inherited diseases in humans: 1) hypotrichosis 
with juvenile macular dystrophy (HJMD) and 2) ectodermal dysplasia, ectrodactyly, and 
macular dystrophy (EEM syndrome). The common features of both diseases are sparse 
hair and macular dystrophy of the retina, while only EEM syndrome shows the additional 
finding of split hand/foot malformation (SHFM) (Kjaer et al., 2005, Sprecher et al., 2001). 
No defects were described for these conditions, concerning the human mammary 
development, or other epithelial bud structures.  
The role of P-cadherin in development and differentiation is clear during embryonic 
histogenesis, as this cadherin molecule is specifically found in extra-embryonic ectoderm 
and visceral endoderm, originating the placenta in mice (Hirai et al., 1989b). Also in 
humans, this protein is detected in the placental tissue and its embryonic precursors, but 
with a lower expression level (Aplin et al., 2009, Shimoyama et al., 1989). 
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In a recent study, it has been shown that CDH3 is one of the genes that encode a 
surface protein that identifies the pluripotent population of human embryonic stem cells. 
This expression is concomitant with E-cadherin (Kolle et al., 2009). Interestingly, stem cell 
transcription factors, namely β-catenin and p63, were found to induce P-cadherin 
expression in (Faraldo et al., 2007, Shimomura et al., 2008). Additionally, in the growing 
hair follicle, the early hair progenitor cells from hair germs and small hair placodes, were 
isolated as P-cadhein+ (and K14+/α6-integrin+) cells (Rhee et al., 2006). In fact, P-
cadherin expression is mainly found in the basal and proliferating regions of the tissues, 
such as of the epidermis and hair follicles, where stem cells are known to be located 
(Fujita et al., 1992). Like hair follicles, sweat glands and mammary glands develop also 
from the same discrete accumulation of stem cells resting in the primitive epidermis, the 
outermost cell layer of an embryo, and there is strong evidence that dynamic changes in 
the composition of adherens junctions are important for the development of skin 
appendages (Fujita et al., 1992). 
P-cadherin is extremely important for the establishment of the correct architecture of 
the mammary epithelial tissue, as recently demonstrated by Chanson et al.. P-cadherin 
contributes specifically to the organization of the myoepithelial cell layer of the breast, 
since when an antibody that blocks P-cadherin function was used in an in vitro self-
organizing assay of the human mammary bilayer, the migration of mammary epithelial 
cells, occurring during normal sorting of both layers, was compromised (Chanson et al., 
2011).  
Interestingly, the expression of this adhesion molecule is activated in human 
mammary luminal cells during late pregnancy and lactation. In human milk a soluble 
fragment of P-cadherin (sP-cad) with 80KDa was found to be present, corresponding to 
the extracellular domain of the molecule (Figure 9) (Soler et al., 2002). Recently, 
Mannello and collaborators showed that the highest concentration of sP-cad is detected in 
milk collected during the first trimester of lactation (Mannello et al., 2008). Still, it is not 
clear the biological and physiological role attributed to this fragment in the normal function 
of the breast. Some authors suggest a role for sP-cad in alveolar differentiation during 
lactation, or in the immune response of the mother or the baby, or as a signalling protein 
between epithelial and myoepithelial cells (Albergaria et al., 2011). 
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Figure 9 – Representation of cadherins expression during mammary gland development. During 
embryoniogensis and puberty, the growth of the ductal tree in the developing mammary gland is sustained by 
the terminal end bud (TEB), where cells with stem cell activity are located. Cap cells at the tip of the TEB are 
P-cadherin+ and E-cadherin+ and generate cells of the basal lineage, namely myoepithelial cells (MECs). The 
cells in the central TEB mass are known as body cells and will differentiate into the luminal epithelial lineage, 
producing the luminal epithelial cells (ECs) (E-cadherin+). Although it is still unclear how the TEB progresses 
through the fat pad, proteases and extracellular matrix remodeling enzymes are involved in the process. 
During lactation, luminal secretory cells present in the breast lobules express P-cadherin and secrete a 
soluble form of this protein (sP-cad). Adapted from Albergaria A, et al., International Journal of Development 
Biology, 2011 (Albergaria et al., 2011). 
 
 5. Integrins and the extracellular matrix in breast cancer 
 
During the past few years, results from the cellular and molecular dissection of 
tumour progression have led to the idea that, besides the cellular processes and 
molecular pathways that exist in tumor cells themselves, an equally important contribution 
to malignant tumor progression comes from components of the tumor microenvironment. 
These include endothelial cells, tumour fibroblasts, infiltrating cells of the immune system 
and the tumor ECM (Christofori, 2006, Bissell & Labarge, 2005). Many tumors can lie 
dormant or develop slowly for decades before manifesting as a clinical outcome and it is 
believed that the tumor microenvironment has a fundamental role in the putative niche 
where CSCs are located (Bissell & Labarge, 2005). Importantly, the microenvironment can 
function both as a tumor promoter for precancerous or even apparently normal cells and 
as a powerful tumor suppressor (Bissell & Labarge, 2005). 
Both stromal and epithelial cells are responsible for producing many of the 
connective tissue ECM and the ECM degrading enzymes. Regarding ECM components, 
laminin is a major constituent of the basement membrane (basal lamina or lamina propria) 
of the breast. This is a 100 nm thick sheet of glycoproteins and proteoglycans, which is 
constructed around an assembled polymer of laminins and a cross-linked network of 
collagen IV fibrils (Yurchenco & Patton, 2009). The basement membrane has a gate-
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keeper function, since it maintains tissue polarity in the normal epithelium and it retains 
nascent in situ carcinomas within its boundaries, as a benign lesion (Allred et al., 2008, 
Chin et al., 2004, Hwang et al., 2004). In cancer, tumor cells increase the production of 
proteases, occurring basement membrane remodeling at the invasive front (Rowe & 
Weiss, 2008) and, simultaneously, cancer associated myoepithelial cells loose the 
production of laminin production (Allinen et al., 2004, Gudjonsson et al., 2002). Upon 
stromal invasion, the tumor cell becomes exposed to a distinct array of matrix molecules, 
such as collagen type-I and hyaluronan, which influence cell invasion and metastasis 
(Itano & Kimata, 2008, Provenzano et al., 2008). Importantly, increases in collagen 
synthesis and cross-linking produce a stiffer matrix, which can foster malignancy. Notably, 
breast density is a significant risk factor for cancer progression.  
In the metastatic setting, ECM molecules have also a central role, namely in the 
preparation of the pre-metastatic niche and in the quiescence, survival and growth of 
metastasis (Kaplan et al., 2006, Psaila & Lyden, 2009). In fact, changes in cell-ECM 
interactions are present in the progression of cancers at every stage, from premalignancy 
to invasion, and the survival and growth of metastasis (Bissell & Radisky, 2001, Muschler 
& Streuli, 2011). The dynamics of cell-ECM interactions and ECM turnover remain to be 
studied in detail. However, efficient therapies aimed at reverting the ECM of the tumor 
stroma, or disrupting the metastatic niche could improve cancer therapy (Muschler & 
Streuli, 2011). The manipulation of the ECM receptors (integrins) and their signalling 
(Pontier & Muller, 2009), the manipulation of ECM modifying enzymes (Overall & Kleifeld, 
2006), or specific ECM antagonists (Tsuruta et al., 2008) are possible targets for the 
tumour microenvironment. 
Integrins are the major ECM receptors, which can also serve for some cell-cell 
interactions. Their ability to promote cell anchorage, proliferation, survival, migration and 
the induction of active ECM-degrading enzymes suggests that they play an essential role 
in normal mammary morphogenesis, as well as in promoting tumour progression. 
Integrins are heterodimers composed of two transmembrane proteins, the α-subunit and 
the β-subunit. The binding of ECM ligands to integrins is followed by recruitment of 
several signalling and adaptor proteins to the β-integrin cytoplasmic domain and the 
initiation of signalling cascades (Figure 10). 
Immunohistochemical studies in human and mouse mammary gland revealed that 
most integrins are on sites of cell-ECM interaction, with the presence of α2, α3, α6, β1 
and β4 subunits in the luminal and myoepithelial cells, and of α1, α5 and αv chains 
exclusively in the myoepithelial cells. Some integrins have also been found on the lateral 
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surface of luminal cells at sites of cell-cell interaction, where ECM proteins are not 
detected (Taddei et al., 2003). 
 
 
Figure 10 – (A) Schematic representation of the structure of the mammary epithelium and the different 
integrin heterodimers expressed in luminal and myoepithelial cells (adapted from Pontier et al., Journal of Cell 
Science, 2009 (Pontier & Muller, 2009)); (B) 19 α-subunits and 8 β-subunits have been reported in 
vertebrates. They form at least 25 αβ heterodimers that bind to different ligands present in the ECM (adapted 
from Taddei et al., Journal of Mammary Gland Biology and Neoplasia, 2003 (Taddei et al., 2003)). (C) Integrin 
downstream signalling is often coupled to signals triggered by soluble growth factors (GF) and growth factor 
receptors (GFR) (adapted from Comoglio et al., Current Opinion in Cell Biology, 2003 (Comoglio et al., 2003)). 
 
Implicated in signal transduction by integrins, as well as other cell surface receptors, 
is a cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK). Upon its activation and 
auto-phosphorylation at Tyr-397, eg., by integrin mediated cell adhesion to the ECM, FAK 
associates to a number of other kinases and adaptor molecules, including Src family 
kinases, PI3K,  Grb7, Shc, paxilin and p130CAS.  FAK is recruited as a participant in focal 
adhesion dynamics between cells, and the interaction with these signalling molecules has 
been shown to regulate cell spreading, migration, cell survival and cell cycle progression 
(Parsons, 2003). FAK expression plays an important role in mammary gland development: 
although the complete deletion of FAK is embryonic lethal, mammary epithelial cell-
specific FAK conditional knock-out leads to reduced cyclin D1, as well as reduced Erk and 
STAT-5 signalling. As consequence, FAK knock-out females have severe lobulo-alveolar 
hypoplasia and secretory immaturity during pregnancy and lactation (Nagy et al., 2007). 
This conditional knock-out model also proved that FAK expression in the mammary 
epithelium has important oncogenic effects (Luo et al., 2009). Ablation of FAK leads to the 
depletion of cancer stem/progenitor cells and impaired self-renewal and migration in vitro, 
as well as the tumourigenic capacity in vivo. Analysis of human tumour samples and cell 
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lines derived from tumors reveals elevated expression of FAK, compared to normal 
tissues (Owens et al., 1995). In such cells, increased FAK expression has been correlated 
with increased cancer cell motility, invasiveness and proliferation (Owens et al., 1995, 
Slack et al., 2001, Wang et al., 2000).  
An important kinase with the ability to phosphorylate FAK, which is also found in the 
focal adhesion structures, is Src. This is a non-receptor tyrosine kinase with several 
substrates that was found to be over-expressed and highly activated in a wide variety of 
human cancers (Irby & Yeatman, 2000). In human mammary carcinomas and in breast 
cancer cell lines, Src kinase activity was increased compared with normal tissues or 
normal cells (Egan et al., 1999, Jacobs & Rubsamen, 1983). Similarly to FAK, the effect of 
Src over-expression and activation appears to be pleiotropic, regulating cell spreading, 
migration and cell survival. The essential role of Src in the breast in seen in the src-null 
mice, which displayed a dramatic mammary developmental delay characterized by the 
inability of mammary epithelial cells to activate a number of signalling pathways in 
response to exogenous oestrogen stimulation (Kim et al., 2005). 
Src has also been shown to play a significant role in cancer progression and the 
metastatic phenotype, regulating angiogenesis, tumour cell invasion and tumour growth 
(Irby & Yeatman, 2000). The specific activity of Src protein kinase is not only dependent in 
integrin receptor signaling, but it may also be increased by direct or indirect interaction 
with receptor tyrosine kinases, such as EGFR, platelet derived growth factor receptor, 
fibroblast growth factor receptor, colony simulating factor-1 receptor, HER2, and 
hepatocyte growth factor receptor (c-Met) (Irby & Yeatman, 2000). The extensive 
presence of activated Src in human cancers and its potential role in their development 
and progression, makes Src an appealing target for drug discovery efforts. 
 
 5.1. The α6β4 and α6β1 integrins in the breast  
 
Integrins have been implicated in several aspects of tumor progression. One of the 
most studied integrin dimmer in breast is the laminin receptor, the α6β4 integrin, which 
has been implicated in tumor cell survival, migration and invasive potential (Mercurio et 
al., 2001, O'Connor & Mercurio, 2001, Shaw, 1999). In normal cells, α6β4 forms a 
hemidesmosomal integrin, which is linked to the cytokeratin intermediate filament network, 
forming strong adhesive structures to the laminin substratum. In tumor cells, α6β4-integrin 
is associated with actin microfilaments and does not form hemidesmosomes. In this way, 
α6β4 activates PI3K, the small GTP-ases Rho and Rac, and the protein kinase A, which 
are molecules essential for cell migration and invasion (Mercurio et al., 2001, O'Connor & 
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Mercurio, 2001), and tumor cell survival (Mercurio et al., 2001). α6β4 also cooperates with 
other molecules such as HER-2 or tetraspanin, in order to induce migration (Mercurio et 
al., 2001).  
The role of α6β4 in stem/progenitor cell activity has been partly addressed. Normal 
breast architecture is not particularly affected by perturbation of either α6 or β4 integrin 
subunits (Gardner et al., 1996, Klinowska et al., 2001). α6 integrin (also known as CD49f) 
has been recently used as a marker to purify mouse and human mammary stem cells 
(Eirew et al., 2008, Raouf et al., 2008, Stingl et al., 2001, Stingl et al., 2006, Villadsen et 
al., 2007) and characterize a population of human cancer cells with aggressive behavior 
(Cariati et al., 2008). Another example where integrins were described as stem cell 
markers is β1 integrin (also known as CD29), which was used by Shackleton and 
collaborators to purify mouse mammary stem cells (Shackleton et al., 2006). Interestingly, 
however, deletion of β1 integrin clearly affected mammary morphogenesis and the ability 
of stem cells to self-renew (Taddei et al., 2008), causing a reduction in the TEB number, 
growth defects in pregnancy and lactation, and precocious dedifferentiation in involution 
(Taddei et al., 2008). β1 integrin is able to form a heterodimer with α6 integrin, constituting 
another laminin receptor, the α6β1 heterodimer. It is thought that the attachment of 
stem/progenitor cells through α6β1, or even α6β4, to interstitial matrix components, 
namely laminins, might support their stem cell activity, or contribute to a cancer stem cell 
phenotype. The actual molecular role of integrins in these cells and the signals released 
from the normal and the cancer stem cell niche remain to be determined (Pontier & Muller, 
2009). 
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Breast cancer is a type of solid carcinoma for which tumour initiating cells exhibiting 
stem-like properties have already been isolated and described. However, the cellular 
origin of these cancer stem cells, as well as their phenotype is not completely clear among 
all the molecular subtypes described for this disease.  
The general goal of this work is to characterize the stem cell features in the basal-
like subtype of breast carcinomas with a focus in P-cadherin, a classical adhesion 
molecule with a poor prognostic signature and whose oncogenic signalling pathways 
could potentially be targeted for therapy. 
Thus, comprising a series of human breast cancer cell lines and invasive breast 
carcinoma samples, studies were performed in order to assess the following specific aims: 
 
i. TO EVALUATE THE EXPRESSION DISTRIBUTION OF BREAST CANCER STEM CELL 
MARKERS WITHIN THE DIFFERENT MOLECULAR SUBTYPES OF BREAST CANCER 
 
Despite several methods have been described for the characterization of 
stem cell properties, further studies are needed in order to support the 
characterization of the cancer stem model in both human tissue cases and 
in human breast cell lines, with a comparison between both models. 
Furthermore, it is imperative to improve CSCs identification into routine 
formalin-fixed and paraffin-embedded tissue samples. Moreover, there is 
often inconsistency in the published literature. Therefore, the aim of this 
work is to characterize stem cell properties in our series of human breast 
cell lines and compare it with our series of human breast cancer tissues and 
the published work from other groups.  
 
ii. TO EVALUATE IF P-CADHERIN EXPRESSION CAN MEDIATE STEM CELL 
PROPERTIES IN BASAL-LIKE BREAST CANCER 
 
The role of the adhesion molecule P-cadherin in breast cancer 
aggressiveness is well described by our group and others, especially in the 
basal-like subtype, for which this adhesion molecule was found to be 
overexpressed and correlated with poor survival. This adhesion molecule 
has also a role in different contexts of stem cell biology. Thus, considering 
the Cancer Stem Cell hypothesis of tumour progression, the second aim of 
this work was to explore the potential role of P-cadherin in mediating cancer 
stem cell phenotype/activity in this special group of human breast 
carcinomas.  
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iii. TO EVALUATE IF P-CADHERIN SIGNALLING IS DEPENDENT ON INTEGRIN 
ACTIVATION TO INDUCE BREAST CANCER STEM CELL AND INVASIVE PROPERTIES 
 
The specific signalling pathways mediated by P-cadherin are only recently 
being clarified, namely in the context of cell-cell adhesion. Importantly, 
studies addressing the role of this adhesion molecule in the context of 
cancer cell-extracellular matrix (ECM) adhesion and signalling are lacking. 
Thus, clarifying the importance of P-cadherin in the tumour 
microenvironment is crucial, as this would potentially provide new insights 
on the ‘cancer stem cell niche’ signalling. Hence, the third aim of this work 
was to test weather P-cadherin affects the adhesion of cancer cells to 
different ECM substrates, as well as to clarify the signalling pathways 
mediated by this adhesion molecule in response to microenvironmental 
stimuli, namely integrin activation.  
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This chapter describes the materials and the methods that were used to generate all 
the data presented in Chapters IV, V and VI. 
 
Human breast cell lines and cell culture 
 
Different human breast cancer cell lines were used during the work, as stated in the 
different chapters. The breast cancer cell lines T47D, SkBr3, BT-474, MDA-MB-468, BT-
20, MDA-MB-231, BT-549 and were obtained from ATCC (American Type Culture 
Collection, Manassas, VA). The human breast cancer cell line MCF-7/AZ was obtained 
from a collection developed in the laboratory of Prof. Marc Mareel (Ghent University 
Hospital, Belgium), which was genetically manipulated to overexpress P-cadherin (MCF-
7/AZ.Pcad). The control cell line (MCF-7/AZ.mock) shows low P-cadherin levels, identical 
to the parental cell line (Paredes et al., 2004).  
All these cell lines were grown in DMEM supplemented with 10% FBS (Invitrogen, 
Carlsbad, CA) and with 1% antibiotic solution (penicillin–streptomycin, Invitrogen).  
The normal human MCF10A cells was also obtained from ATCC and cultured in 
DMEM:F12, supplemented with 5% heat inactivated horse serum (Invitrogen), 10 µg/ml 
insulin (Sigma-Aldrich, St Louis, MO), 0.5 µg/ml hydrocortisone (Sigma-Aldrich), 20 ng/ml 
EGF (Sigma-Aldrich), 100 ng/ml cholera toxin (Sigma-Aldrich).  
All cell lines were routinely cultured in a humidified atmosphere with 5% CO2 and at 
37ºC. Cells were used in experiments when reached 70–80% confluence. 
 
 
Flow cytometry analysis 
 
This technique was used to investigate the cell surface expression of the stem cell 
markers CD44, CD49/α6-integrin and CD24 in a series of breast cancer cell lines (in 
Chapter IV). Moreover, P-cadherin cell surface expression was also evaluated, in Chapter 
V. Finally, the expression of the markers CD49f/α6-integrin and CD104/β4-integrin, 
CD29/β1-integrin was investigated in Chapter VI. 
Cells were washed twice with PBS and then harvested with versene/0.48mM EDTA 
(Invitrogen). Detached cells were washed with PBS supplemented with 0.5% FBS (stain 
buffer), and re-suspended in the stain buffer (1x106 cells/100µl). Cells were passed 
through a 25G needle in order to obtain a single cell suspension. This cell suspension was 
labeled by fluorescence-conjugated antibodies at a concentration of 1 to 10 in stain buffer: 
FITC-conjugated CD44, PE-conjugated CD24, FITC-conjugated CD49f/α6-integrin, PE-
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conjugated CD104/β4-integrin and PE-Cy5-conjugated CD29/β1-integrin. These 
antibodies were obtained from BD Biosciences (San Diego, CA). P-cadherin monoclonal 
antibody APC-conjugated was obtained from R&D (Minneapolis, MN) and used at the 
same concentration as above.  
Primary antibodies or the respective isotype controls (BD Biosciences) were 
incubated at 4°C in the dark for 20 min. A cell viability marker was included (violet 
fluorescent reactive dye, Invitrogen) in order to remove dead cells. The labeled cells were 
washed in the stain buffer and then analysed on a FACS Calibur (BD Biosciences) or 
LSR-II (BD Biosciences).  
In multicolor experiments, fluorescent minus one samples were used to determine 
the gating strategy. 
 
 
ALDEFLUOR assay  
 
ALDH activity was assessed in several breast cancer cell lines representing the 
main molecular subtypes of human breast cancer (Chapter IV and V). The ALDEFLUOR 
kit (Stem Cell Technologies) was used to characterize the population with high ALDH 
enzymatic activity using a FACS Calibur (BD Biosciences) or LSR-II (BD Biosciences), 
according to the manufacturer instructions. Briefly, cells were incubated in ALDEFLUOR 
assay buffer containing the ALDH substrate, BAAA (1 µmol/L per 1 x 106 cells). In each 
experiment, a sample of cells was stained, under identical conditions, with 50 mmol/L of 
diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as a negative control. A cell 
viability marker was included (violet fluorescent reactive dye, Invitrogen) in order to 
remove dead cells. Cells were washed in assay buffer and left at 4ºC, until measurements 
and sorting had been performed. 
In the experiments performed in Chapter V, P-cadherin monoclonal antibody (APC-
conjugated, R&D) was incubated after the reaction of ALDEFLUOR cells, in assay buffer, 
for 20 minutes on ice. Incubation with the isotype antibody (BD Biosciences) was used as 
a control. Cells were washed in assay buffer and analyzed in the FACS analyzer LSR-II 
(BD Biosciences). 
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Immunoblot analysis 
 
Used to monitor protein expression levels, as shown in Chapters V and VI.  
Cells grown in monolayer were lysed with phosphate-buffered saline (PBS) 
containing 1% Nonidet-P40 (Sigma-Aldrich), 1% Triton X100 (Sigma-Aldrich) and 
protease inhibitors cocktail (Roche Diagnostics Gmbh, Mannheim, Germany) and 
phosphatase inhibitors cocktail (Sigma-Aldrich).  
In some experiments, the cell lysis was done after performing the adhesion assay 
over a laminin coated surface (6 wells plate, BD Biosciences) as described below. 
Protein concentration was determined by Bio-Rad protein assay (Bio-Rad, 
Richmond, CA) and equal amounts were resolved on a denaturating polyacrylamide gel 
(Bio-Rad) and transferred onto a nitrocellulose membrane (Amersham Pharmacia 
Biotech, Piscataway, NJ). After blocking nonspecific binding with 5% non-fat dry milk (for 
non-phosphorylated protein detection) or 5% BSA (for phosphorylated protein detection) 
in PBS containing 0.5% Tween 20, each membrane was incubated for 1 hour at room 
temperature with each of the following primary antibodies: anti-P-cadherin (1:500, BD 
Transduction), anti-CD49f/α6-integrin (1:000, HPA012696, Sigma-Aldrich), anti-CD44 
(1:500, Cell Signalling Technology, Danvers, MA), anti-CD44v6 (1:500, VFF-7, Abcam, 
Cambridge, UK), and anti-CD104/β4-integrin (1:2000, Santa Cruz Biotechnologies). The 
primary antibodies used to study signalling activation were: anti-pSrc Tyr416 (1:1000, Cell 
Signalling, Danver, MA), anti-total Src (1:1000, Cell Signalling), anti-pFAK Tyr397 (1:1000, 
Cell Signalling), anti-total FAK (1:500, BD Transduction), anti-pAKT Ser473 (1:2000, Cell 
Signalling) and anti-AKT1/2 (1:500, Santa Cruz Biotechnology). 
β-actin (1:1000, Santa Cruz Biotechnology, Inc., Heidelberg, Germany) or α-tubulin 
(1:10 000, DM1A, Sigma-Aldrich) were detected as loading controls.  
After washing four times with PBS for 5 minutes, the membranes were incubated 
with peroxidase-conjugated secondary antibodies from Santa Cruz Biotechnology 
(1:2000) for 45 minutes and washed six times for 5 minutes. Detection was detection was 
performed using the Amersham Hyperfilm and Amersham ECL Detection substrate (GE 
Healthcare, Chalfont St. Giles, UK). 
 
 
Mammosphere assay 
 
This assay was used as a measure of stem cell activity in Chapters IV, V and VI. 
Breast cancer cell lines were harvested with trypsin (Invitrogen) or versene/0.48mM 
EDTA, neutralized with 10% FBS containing medium, centrifuged 1200 rpm for 2 min at 
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room temperature and re-suspended in cold PBS. This solution was passed three times 
through a 25-gauge needle, using a syringe, to separate cells into a single cell 
suspension. Cells were plated at 500 cells/ml in low attachment plates coated with 1.2% 
poly(2-hydroxyethylmethacrylate)/95%ethanol (Sigma-Aldrich). Cells were grown for 5 
days, in DMEM/F12 containing B27 supplement (Invitrogen), and 500 ng/ml 
hydrochortisone (Sigma-Aldrich), 40 ng/ml insulin (Sigma-Aldrich), 20 ng/ml EGF (Sigma-
Aldrich) and maintained in a humidified incubator at 37°C and 5% (v/v) CO2. 
Mammosphere forming efficiency (MFE) was calculated as the number of mammospheres 
formed (≥50 µm, determined by using an eyepiece graticule with crossed scales), divided 
by the cell number plated, being expressed as a percentage. 
 
 
Patient selection and TMA construction 
 
A series of 466 primary invasive breast carcinomas was retrieved from the 
Pathology Department, Hospital Xeral- Cíes, Vigo, Spain, diagnosed in 1978 - 1992.  
Representative tumor areas were carefully selected and at least two tissue cores 
(0.6 mm in diameter) were deposited into a tissue microarray. Non-neoplastic tissue cores 
were included as controls. Patient ages ranged from 28 to 92 years old. The formalin-fixed 
paraffin-embedded histological sections were reviewed and the diagnosis confirmed by a 
pathologist. The tumours were characterised for clinical and pathological features, namely 
age, tumour size, lymph nodes status and histological grade. Patient follow-up information 
was available for 455 cases, ranging from a minimum of one to a maximum of 120 months 
after the diagnosis. The disease-free survival (DFS) interval was defined as the time from 
the diagnosis to the date of breast-cancer-derived relapse/metastasis, whereas overall 
survival (OS) was considered as the number of months from the diagnosis to the disease-
related death. This study was conducted under the national regulative law for the handling 
of biological specimens from tumour banks, being the samples exclusively available for 
research purposes in retrospective studies.  
 
 
Immunohistochemistry and Immunohistochemical evaluation  
 
This technique was used to characterize our series of human carcinomas into 
molecular subtypes and to investigate the expression and subcellular localization of the 
stem cell markers (CD44, CD49f, CD24 and ALDH1) presented in Chapters IV and V. 
In order to classify all breast cancer tumours molecularly, we evaluated the 
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expression of commonly used breast cancer biomarkers for this purpose, namely the 
hormonal receptors ER and PgR, the proliferation marker Ki67, the tyrosine kinase 
receptors HER-2 and EGFR, the basal cytokeratins CK5 and CK14, and P-cadherin and 
vimentin as basal markers. Immunohistochemistry (IHC) was performed in 3 mm sections. 
Table 1 presents the primary antibodies used to characterize this series of human breast 
carcinomas and the conditions used in the immunohistochemical reactions. High 
temperature (98ºC) antigenic retrieval with Tris-EDTA or Citrate buffer was performed 
before primary antibody incubation. 
 
Antigen 
Primary antibodies Antigen 
retrieval Detection method Clone Origin Incubation time dilution 
ER SP1 Neomarkers 30’ 1:200 Citrate HRP polymer 
PgR NCL-L-PgR-312 Novocastra 30’ 1:300 Citrate HRP polymer 
HER-2 CB11 Novocastra 30’ 1:400 Citrate HRP polymer 
Ki67 SP6 Neomarkers 30’ 1:300 Citrate HRP polymer 
K5 XM26 Neomarkers 60’ 1:50 Citrate HRP polymer 
K14 NCL-L-LL002 Novocastra 60’ 1:400 Tris-EDTA HRP polymer 
EGFR 31G7 Zymed 60’ 1:100 Pepsin HRP polymer 
P-cadherin C56 BD Transduction 60’ 1:50 Tris-EDTA HRP polymer 
Vimentin V9 Dako 30’ 1:150 Citrate HRP polymer 
CD44 156-3C11 Cell Signalling 30’ 1:100 Citrate 
Streptavidin-biotin 
peroxidase complex 
CD49f HPA012696 Sigma-Aldrich 120’ 1:10 Citrate HRP polymer 
CD24 SN3b Neomarkers 30’ 1:100 Citrate HRP polymer 
ALDH1 EP1933Y Abcam 60’ 1:100 Citrate HRP polymer 
 
Table 1 – Antibodies and immunohistochemical reaction conditions used to characterize se series of invasive 
breast carcinomas. 
 
The primary antibodies were detected using a secondary antibody with horseradish 
peroxidase polymer (Cytomation Envision System HRP; DAKO, Carpinteria, California, 
USA), or a biotinylated goat anti-polyvalent as secondary antibody, followed by the 
streptavidin-peroxidase complex (Thermo Fisher Scientific, Fremont, California, USA), 
according to the manufacturer’s instructions. Both methods used diaminobenzidine as 
chromogen.  
The expression of the breast cancer biomarkers ER, PgR, HER2, EGFR, CK5, 
CK14, P-cadherin and vimentin was evaluated according to the grading systems already 
described (Sousa et al., 2010). These immunohistochemical results were used to classify 
the tumours in the different molecular breast cancer subtypes, namely in luminal A, 
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luminal B, HER-2 OE, basal-like and unclassified group, according to the definition 
presented in Table 2. 
 
 
Luminal A Luminal B HER-2 OE 
Triple Negative 
 Basal-like Unclassified 
ER 
+ + 
- - - 
PgR - - - 
HER-2 - 
+ 
+ - - 
Ki67 - + or - + or - + or - 
K5 
+ or - + or - + or - + 
- 
K14 - 
EGFR - 
Vimentin - 
P-cadherin - 
 
Table 2 – Immunohistochemical classification of invasive breast carcinomas in distinct molecular subtypes. 
 
P-cadherin, CD44, CD24, CD49f staining were detected mainly at the membrane of 
tumor cells and the scoring was considered as follows: (0), 0-10% of positive tumor cells; 
(1+), 10-25% of positive tumor cells; (2+), 25-50% of positive tumor cells; (3+), >50% of 
positive tumor cells. For P-cadherin, CD44 and CD49f, the cases which were classified as 
(0) were considered negative, whereas (1+), (2+) and (3+) were established as positive 
cases. For CD24, the cases were divided in negative/low (-/low), when considered (0) or 
(1+), or in positive cases when classified as (2+) or (3+). Immunohistochemical staining of 
ALDH1 was classified as positive when more than 1% of tumor cells showed clear 
cytoplasmic positivity (Deng et al., 2010, Ginestier et al., 2007). Since the 
immunohistochemical result was not interpretable for some of these markers, the 
statistical analyses were performed using only the breast tumor cases with available data. 
The present study was conducted under the national regulative law for the usage of 
biological specimens from tumor banks, where the samples are exclusively available for 
research purposes in the case of retrospective studies. 
 
 
P-cadherin and stem cell markers knock-down  
 
Gene silencing presented in Chapters V and VI was conducted by siRNA, using 
sequences specifically targeting P-cadherin and the stem cell genes. 
P-cadherin (CDH3 gene) expression was silenced using the siRNA target sequence: 
AAGCCTCTTACCTGCCGTAAA. Inhibition of P-cadherin was maintained for at least 72h 
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after cell transfection, confirmed by western-blot. Inhibition of the expression of CD49f 
(ITGA6 gene), target sequence: CAGGGTAATAAACTTAGGTAA, β4-integrin (ITGB4 
gene) target sequence: GTGGATGAGTTCCGGAATAAA and CD44 (CD44 gene), target 
sequence AACTCCATCTGTGCAGCAAAC was also performed. 
All transfections were carried out using HiPerFect transfection reagent (Qiagen, 
Hilden, Germany) in a final concentration of 2 or 5 nM siRNA (Qiagen), according to 
manufacturer instructions. Optimal inhibition of the target genes was achieved at 48h, 
which was confirmed by immunoblot analysis (see protocol and antibodies above). A 
siRNA scrambled sequence was included as a control (Qiagen).  
Protein analysis was performed by western blot, as described above. 
 
 
Fluorescence activated cell sorting (FACS) for P-cadherin  
 
For the sorting experiments presented in Chapter V, two luminal cell lines (MCF7/AZ 
and T47D) and four basal cell lines (MDA-MB-468, BT-20, BT-549, MCF10A) were sorted 
according to P-cadherin expression (highest 20% expressing cells Vs. lowest 20% 
expressing cells). Briefly, cells were stained for APC-conjugated anti-P-cadherin (R&D) 
and a live-dead dye (Violet dye, Invitrogen) in stain buffer, as described above. Cells were 
then passed through a 50µm mesh to remove clumps and re-suspended in stain buffer 
prior to sorting. Cells were sorted using BD Influx (BD Biosciences) or FACS ARIA-II (BD 
Biosciences) and collected into 10% Hanks buffered solution (Invitrogen). The purity of 
sorted populations was checked and the sorted populations contained 80-95% purified 
cells. In addition, a sample of cells was also collected that passed through the laser under 
pressure, but not sorted, to act as a control for the effect of the pressure on the cells. No 
differences in cell behavior were detected. 
 
 
3D cultures 
 
This assay was used to measure the ability of selected populations of breast cancer 
cells to growth in differentiating conditions. The 3D on-top method was used. Briefly, 
single-cell suspensions were seeded at a density of 250 or 1000 cells per well into 8-well 
glass chamber slides containing 50 µL of 100% growth factor–reduced matrigel per well [a 
biologically active matrix material resembling the mammalian cellular basement 
membrane (BD Biosciences)]. Cells were plated in growth medium containing H14 
medium (DMEM/F12 with insulin 250 ng/ml, transferrin 10 µg/ml, sodium selenite 2.6 
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ng/ml, estradiol 10-10 M, hydrocortisone 1.4x10-6M, prolactin 5 µg/ml, EGF 10 ng/ml, 
according to Kenny PA, et al., 2007 (Kenny et al., 2007) with 5% growth factor–reduced 
matrigel and 1% FBS). 
Cells were incubated at 37 °C, with replacement of the growth medium containing 
2% growth factor–reduced matrigel every 2–3 days, to allow 3D structures to form. The 
size and number of the structures formed was assessed microscopically after 21 days. 
 
 
Cell Cycle  
 
To evaluate the cell cycle profile in the basal breast cancer cell lines presented in 
Chapter V, cells grown in monolayer were washed 2 times in PBS and detached using 
trypsin for 5 min, 37ºC (Invitrogen). Cells were counted and resuspended to 1-2x106 
cells/ml. 3 ml of cold absolute ethanol was added to 1 ml of cell suspension and the cells 
were fixed for at least 1h at 4ºC. After washing the cells with PBS, the Hoescht-33342 dye 
(Invitrogen) was added to a final concentration of 2 µg/ml and incubated for 15 min at 
37ºC. Cells were analysed for cell cycle fluorescence in BD LSR-II (BD Biosciences). 
 
 
Cell X-ray irradiation  
 
The role of P-cadherin in radioresistance was tested in Chapter V. Normal and 
cancer cells were plated in mammosphere culture conditions and immediately irradiated 
with 2Gy or 4Gy, respectively. Irradiations were performed using a 320 kV x-ray system 
(Gulmay Medical Ltd, Camberley, UK). The machine was operated at 300 kV, 10 mA, with 
filtration fitted in the x-ray beam to give a radiation quality of 2.3 mm Cu half-value layer. 
Samples were positioned at a distance of 500 mm from the x-ray focus, where the dose 
rate was determined to be 1.37 Gy/min.  
 
 
In vivo assessment of P-cadherin tumourigenic capacity 
 
In Chapter V, the basal-like cell line MDA-MB-468 was sorted according to P-
cadherin expression into two subpopulations: P-cadhigh and P-cadlow fractions, as 
described above. The sorted cells were xeno-transplanted at varying dilutions (106, 105, or 
5x104 cells in 100 µl DMEM cell suspension) into the subcutaneous region, under the left 
abdominal mammary fat pad of 4-5 weeks old female N:NIH(s)II:nu/nu nude mice,  using 
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a 25-gauge needle. Mice were maintained and housed at IPATIMUP Animal House, sited 
at the Medical Faculty of the University of Porto, in a pathogen-free environment, under 
controlled conditions of light and humidity. Animal experiments were carried out in 
accordance with the European Guidelines for the Care and Use of Laboratory Animals, 
directive 2010/63/UE. Mice (4 per group) were weighted, and tumor width and length were 
measured with calipers every week. Tumor volume was estimated by using the equation, 
V = 0.5 × a × b2, where V is volume, a is the length of the major axis of the tumor, and b is 
the length of its minor axis. Mice were euthanized 3 months after tumor cell inoculation.  
 
 
Adhesion assay to ECM substrates  
 
Cell adhesion assay was performed (Chapter VI) in 96-well microtiter plates coated 
with laminin 332 (Sigma, St. Louis, MO), fibronectin (Sigma), vitronectin (BD Biosciences, 
San Diego, CA), type-I or -IV collagen (Sigma) (5µg/ml) overnight at 4ºC. Subsequently, 
plates were washed three times in PBS and non-specific-binding sites were blocked by 
adding 0.5% BSA (w/v) in PBS containing Pen/Strep (Invitrogen) for 2h at 37ºC. Once 
washed again with PBS, 100µl of cells (106 cells/ml) were seeded in serum-free medium 
for 20 min (for MDA-MB-468 cell line) or 30 min (for BT-20 cell line). Thereafter, the plates 
were washed with PBS to remove non-adherent cells, and the attached cells were fixed 
with acetone:methanol (1:1) for 10 minutes at 4ºC. Cell adhesion was determined 
following the colorimetric method described by Busk (Busk et al., 1992). The absorbance 
was measured at 570nm with a microplate reader. The attachment of cells to wells coated 
with 1mg/ml of poly-L-Lys (Sigma) and fixed with 4% paraformaldehyde before aspiration 
was defined as 100% of adhesion. 
 
 
Invasion assay 
 
Matrigel invasion assay was performed in Chapter VI according to manufacturer’s 
instructions (BD Biosciences). Briefly, transwell chambers with polycarbonate membrane 
filters (6.5 mm diameter, 8 µm pore size) were coated with 20 µL of a Matrigel solution. 
30,000 BT-20 cells or 50,000 MCF7/AZ cells were added to the upper compartment of the 
chamber. The lower compartment was filled with DMEM medium supplemented with 10% 
FBS and 1% antibiotic solution (penicillin–streptomycin) (Invitrogen). After 24 or 48 hours 
of incubation (BT20 or MCF7/AZ, respectively) at 37°C, 5% CO2, the upper surface of the 
filter was washed with serum-free DMEM and cleared from nonmigratory cells with a 
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cotton swab. The remaining (invasive) cells at the lower surface of the filter were fixed 
with cold methanol and stained with 4′, 6-diamidino-2-phenylindole (Sigma, 0.4 mg/mL). 
Invasive cells were scored by counting the whole filter with a fluorescence microscope, at 
200x magnification. 
 
 
Immunofluorescence microscopy 
 
In Chapter IV, double immunofluorescence staining with CD44 and CD24 antibodies 
was performed to evaluate the number of CSCs (CD44+CD24-/low) present in the human 
carcinoma cases. Using the same primary antibodies used in the IHC analysis (see 
above), we performed double immunofluorescence in 10% of all breast cancer cases 
present in the TMAs, as well as in whole tissues. Detection of the primary antibody anti-
CD44 was performed using the secondary antibody goat anti-mouse IgG (H+L) 
conjugated with Alexa Fluor 488 (Invitrogen) and the detection of the anti-CD24 was done 
using the secondary antibody goat anti-mouse IgM (µ chain) Alexa Fluor 594 (Invitrogen). 
 
The immunofluorescence technique was also used to evaluate integrins expression, 
focal contact formation and actin filaments distribution in the basal cell lines used in 
Chapter VI. Thus, the cell lines BT-20 and MDA-MB-468 were seeded on top of glass 
coverslips coated with laminin-332 (Sigma). Cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton X-100 and blocked with 2% BSA before staining. The 
following primary antibodies were used for immunofluorescence: FITC-conjugated α6 
integrin (CD49f) (1:10, BD Biosciences), PE-conjugated β4 integrin (1:10, CD104) (BD 
Biosciences) and p-FAK tyr397 (1:200 dilution, Cell Signalling). To visualize p-FAK, anti-
rabbit Alexa-488 (1:1000 dilution, invitrogen) was incubated on slides for 30 minutes. F-
actin was detected by staining with phalloidin conjugated to rhodamine (Invitrogen) at a 
dilution of 1:1000. Cells were visualized using a Zeiss Imager Z.1 microscope (Zeiss, 
Welwyn Garden City, UK). Representative photos were acquired using the associated 
software, and edited in Photoshop and Illustrator (both CS4; Adobe). 
 
 
Statistical analysis  
 
Immunohistochemical association between different categorical variables (IHC 
markers, clinicopathological parameters, or the different molecular subtypes) were 
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assessed by Pearson correlation and chi-squared tests. Survival analyses were estimated 
using the Kaplan-Meier method and compared using the log-rank test. A maximum cut-off 
value of 120 months (10 years) was considered. For multivariate survival analysis, Cox 
regression models were fitted to estimate hazard ratios (HR) and the corresponding 95% 
confidence interval.  
Mammosphere forming ability and growth in 3D cultures (size and number) was 
compared using two-tailed unpaired t-test. 
Statistical analyses were carried out using SPSS statistics 17.0 software (SPSS 
Inc., Chicago, IL, USA) or Prism GraphPad (La Jolla, CA) and a significant level of 5% 
was considered. 
Flow cytometry data was analysed with the Flowjo software package (TreeStar, 
Ashland, OR, USA). 
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 1. Introduction 
 
In breast cancer, CSCs have been identified in freshly dissociated cell preparations 
by means of certain cell-surface markers that are often related to adhesion processes. 
The first report identifying and isolating tumourigenic CSCs from non-tumourigenic breast 
cancer cells used the combined expression of two cell surface markers: CD44 and CD24 
(Al-Hajj et al., 2003). CD44 is a glicosylated type 1 transmembrane protein, constituting 
the receptor for hyaluronic acid being involved in cell-cell and cell-matrix interactions. The 
CD44 gene is highly polymorphic, possessing numerous alternative splice variants, with 
its protein undergoing extensive post-translational modifications. In addition to the 
standard isoform (CD44s), the isoform v6 (CD44v6) is expressed in various human 
carcinomas, including breast cancer (Snyder et al., 2009). The CD24 antigen (heat stable 
antigen) is a cell surface sialoglycoprotein, anchored via a glycosyl phosphatidylinositol 
(GPI) to the cell membrane. It is an adhesion molecule that binds P-selectin and L1. In the 
pioneering study by Al-Hajj and colleagues, CSCs were identified within the mammary cell 
population depleted from the hematopoietic and endothelial markers (Lin-), having the 
phenotype ESA+CD44+CD24-/low (Al-Hajj et al., 2003). Surface expression of CD44 and 
CD24 have also been used in normal breast tissue to fractionate epithelial subpopulations 
and to identify and characterize differentiation states and lineages (Shipitsin et al., 2007). 
CD24+ cells have luminal differentiation traits, whereas CD44+ cells were enriched in 
progenitor/stem cell features. 
Interestingly, in vitro studies revealed an enrichment of the cell populations defined 
as CD44+/CD24-/low (CSC phenotype) and as CD44-/CD24+ in basal and luminal breast 
cancer cell lines, respectively (Fillmore & Kuperwasser, 2008, Sheridan et al., 2006), 
being CD44 positively associated with stem cell-like characteristics and CD24 expression 
related with differentiated epithelial features (Park et al., 2010). Fillmore and collaborators, 
examined CD44+/CD24- cells in 8 breast cell lines (including normal breast epithelia and 
tumourigenic cell lines) and found that this subpopulation had certain stem-like features 
like self-renewal, pluripotency and chemotherapy resistance (Fillmore & Kuperwasser, 
2008). Furthermore, Mani and collaborators showed that normal human breast cells have 
a subpopulation with CD44+CD24-/low phenotype, with mesenchymal traits and increased 
stem cell activity (Mani et al., 2008). Taken together, there are accumulating studies 
supporting the notion that CD44+CD24- could be regarded as a stem-like marker in normal 
breast, breast cancer and cell lines. 
Later, an attempt has been made in order to translate this in vitro data into primary 
breast carcinomas (Honeth et al., 2008); however, the clinical and prognostic impact of 
these markers in breast cancer remains a controversial issue (Abraham et al., 2005, 
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Shipitsin et al., 2007), demanding additional efforts to better characterize the prognostic 
value of the CSC phenotype , as well as to find other CSC markers that could better 
predict breast cancer patient survival.  
Aldehyde dehydrogenase-1 (also known as RALDH1, ALDH1 or AHD2) is an 
enzyme involved in the oxidation of a wide variety of aliphatic aldehydes to the 
corresponding carboxylic acids, being highly expressed in undifferentiated cells of the 
hematopoietic system (Kastan et al., 1990). This enzyme converts retinol to retinoic acid 
during vertebrate embryogenesis and it is also involved in the detoxification of intracellular 
aldehydes. A flow cytometry method, using the detection of the enzymatic activity of 
ALDH1, has been successfully applied by Ginestier et al. to human breast cancer cell 
lines, as well as to human tissue samples, to isolate stem and progenitor cell populations 
(Ginestier et al., 2007). In this method, designated ALDEFLUOR assay, the ALDEFLUOR-
positive cells isolated from both normal and tumour human breast had the phenotypic and 
functional characteristics of mammary stem cells. Furthermore, in breast carcinomas, 
ALDH1 activity identified the tumorigenic cell fraction capable to self-renew and to 
differentiate, and serial passages of ALDEFLUOR-positive cells originated tumours 
recapitulating the phenotypical diversity of the initial tumour (Ginestier et al., 2007). In the 
same study, the expression of ALDH1, detected by immunostaining, correlated with poor 
prognosis (Ginestier et al., 2007). Additionally, ALDEFLUOR-positive tumour cells have 
increased mammosphere forming efficiency with visibly larger colonies, when compared 
with ALDEFLUOR-negative cells (Deng et al., 2010).  
Interestingly, CD44+CD24-/low cells and ALDH1+ cells are more frequently found in 
basal-like than in luminal tumours; however, ALDH1+ cells are also commonly found in the 
HER-2 OE subtype (Ginestier et al., 2007, Korkaya et al., 2008). It was recently shown 
that ALDH1 can further divide the CD44+CD24-/low cell population into fractions that are 
highly tumourigenic: ALDH1+CD44+CD24-/low cells were able to generate tumours from 
only 20 cells, whereas ALDH1-CD44+CD24-/low were not tumourigenic in this same cell 
density (Croker et al., 2009, Ginestier et al., 2007). Based on this current knowledge, 
there is evidence to support the idea that the use of CD44 and CD24 cell surface markers 
in combination with ALDH1 activity is the most accurate method to identify and isolate 
CSC-like cells within breast cancer populations. However, the overlap between 
CD44+CD24-/low and high ALDH1 expression in primary tumours is quite small (about 1%) 
(Ginestier et al., 2007). 
In addition to the previously described stem cell markers, integrin molecules have 
also been used to define cells in the mouse breast with colony-forming ability in vitro and 
mammary repopulating capacity in vivo.  In this way, α6 integrin (CD49f) and β1 integrin 
(CD29) have been used in combination with CD24 to define a single cell with the 
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phenotype CD24medCD49f+CD29+ that has stem cell capacity in the murine mammary 
gland (Shackleton et al., 2006, Stingl et al., 2006). Furthermore, the phenotype 
CD24+CD49f+ has also been associated with cancer stem cell features in BRCA1 deficient 
cells, exhibiting in vitro regeneration potential (Vassilopoulos et al., 2008). 
In the present study, we analysed the expression of the main established breast 
CSC markers - CD44, CD49f and CD24 and ALDH1 in breast cancer cell lines from 
distinct molecular subtypes, where the different cancer cell populations expressing these 
CSC markers were selected by flow cytometry. These features were compared with the 
results obtained in a large series of invasive breast carcinomas, in order to evaluate their 
distribution among the different molecular subtypes. In addition, we investigated the 
correlation between the presence of these markers and breast cancer patient survival. 
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 2. Results 
 
Breast cancer cell lines are representative of the biological heterogeneity found in 
human breast cancers 
 
In general, breast cancer cell lines exhibit the substantial genomic, transcriptional 
and biological heterogeneity found in primary tumours, and can also be divided in 
molecular subtypes. In fact, in most cases the various molecular classifications published 
for breast cell lines are fairly consistent and fall within the classifications derived for the 
tumour samples (Perou et al., 1999, Perou et al., 2000, Sorlie et al., 2001, Sorlie et al., 
2003).  
Table 1 summarizes the main molecular and phenotypic classifications attributed to 
the most commonly studied breast cancer lines.  
 
Cell line 
Neve  
et al., 
2006 
Charafe-
Jaufrett et al., 
2006 
Prat  
et al., 
2010 
Sieuwerts 
et al., 
2009 
Keller et al., 
2011 
Tissue 
source 
Tumour 
type 
MCF-7/AZ Luminal Luminal Luminal Luminal Luminal 1 Pleural effusion IDAC 
T47D Luminal Luminal Luminal - Luminal 2 Pleural effusion IDAC 
SkBr3 Luminal Luminal Luminal HER-2 - Pleural effusion AC 
BT-474 Luminal - Luminal - - Primary tumour IDAC 
MDA-MB 
468 Basal A - - Basal-like - 
Pleural 
effusion AC 
BT-20 Basal A Basal Basal Basal-like Luminal 2 Primary tumour AC 
BT-549 Basal B - Claudin-low 
Normal-
like - 
Primary 
tumour IDAC 
MDA-MB 
231 Basal B Mesenchymal 
Claudin-
low 
Normal-
like Mesenchymal 
Pleural 
effusion AC 
 
Table 1 – Classification of the panel of breast cancer cell lines selected for this study, according to their profile 
of gene expression defined by Neve et al., Charafe-Jaufrett et al., Prat et al. and Sieuwerts et al. (Charafe-
Jauffret et al., 2006, Neve et al., 2006, Prat et al., 2010, Sieuwerts et al., 2009).  In a recent study, Keller et al. 
provided a phenotypic classification according to the cell-surface differentiation state (Mesenchymal – 
EpCAM-CD49f+, Luminal 1 – EpCAM+CD49f-, Luminal 2 – EpCAM+CD49f+CD24+, Basal – 
EpCAM+CD49f+CD24-) (Keller et al., 2010). AC, adenocarcinoma; IADC – infiltrating ductal adenocarcinoma;  
 
Throughout this work, we have mainly adopted a classification based in the 
morphology of the cells and the Charafe-Jauffret et al. or Neve et al. classification for 
tumourigenic and normal cell lines. In the classification by Charafe-Jauffrett et al., cells 
are grouped according to their profile of gene expression into Luminal, Basal and 
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Mesenchymal, (Charafe-Jauffret et al., 2006), whereas in the Neve et al. classification cell 
lines are grouped as Luminal, Basal B and Basal A (Neve et al., 2006). In the latter 
classification, the Basal B subtype roughly corresponds to the Mesenchymal subtype 
attributed by Charaffe-Jaufret et al. 
Thus, in the present work, tumourigenic cell lines that express the steroid receptors 
- ER and PgR – and present a luminal phenotype were grouped into the luminal group 
(MCF-7/AZ and T47D). Cell lines in which the most significant genetic alteration is the 
amplification of the ERBB2 gene were included in the HER-2 OE group (SkBr3 and BT-
474). Most of the steroid receptor negative cell lines form the basal group. This group was 
further divided in a basal/epithelial subgroup (MDA-MB-468 and BT-20) and a 
basal/mesenchymal subgroup (BT-549 and MDA-MB-231), according to their morphology 
and E-cadherin expression (Table 2). 
 
Cell line 
Classification 
used in this 
work 
SR status E-cad Invasiveness Morphology 
MCF-7/AZ Luminal + ++ Low Epithelial 
T47D Luminal + ++ Low Epithelial 
SkBr3 HER-2 OE - - Low Epithelial 
BT-474 HER-2 OE + ++ Low Epithelial 
MDA-MB 
468 
Basal / 
Epithelial - ++ Moderate Epithelial 
BT-20 Basal / Epithelial - ++ Moderate Epithelial 
BT-549 Basal / Mesenchymal - - High Mesenchymal 
MDA-MB 
231 
Basal / 
Mesenchymal - - High Mesenchymal 
 
Table 2 – Cell lines selected in this study, classified according to our classification, based in the molecular 
and phenotypic profiles described in Table 1, invasiveness potential and morphology profile. MCF-7/AZ is a 
luminal cell line derived from the original MCF-7 cell line, retaining most of its molecular characteristics. The 
luminal cell lines BT-474 and SkBr3 have amplification of the oncogene Her-2. The basal A cell lines MDA-
MB-468 and BT-20 have amplification of the oncogene EGFR; SR - steroid receptor; Her-2 OE – HER-2 
overexpressing. 
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Human breast cancer cell lines have distinct expression of the cell surface 
biomarkers CD44, CD24 and CD49f 
 
To address if breast cancer cell lines representing the different molecular subtypes 
of breast cancer could be distinguished phenotypically by the cell surface expression of 
stem cell markers, we measured by flow cytometry the expression of three biomarkers 
commonly used to define stem cell and cancer stem cell populations, both in the normal 
breast and in breast carcinoma. The markers used were CD24, CD44 and CD49f    
(Figure 1).  
 
Figure 1 – Expression of commonly used cell surface biomarkers of normal/cancer stem cells of the breast. 
For each cell line, the % expression of CD44, CD24 or CD49f is represented ± SEM; ND – not determined. 
 
Expression of the marker CD24 was very high (>70%) in all epithelial cell lines, 
independently of the molecular subtype (luminal, HER2-OE and basal/epithelial). 
However, in mesenchymal cell lines (basal/mesenchymal) the expression of CD24 was 
reduced. Notably, CD24 is regarded as a marker of mature luminal cells.  
CD44 and CD49f were differentially expressed amongst the panel of cell lines 
analysed. Expression of CD44 was higher in the basal cell lines (epithelial and 
mesenchymal), compared to luminal cells. Similarly to the marker CD44, CD49f 
expression was mainly found in basal cells, particularly within the epithelial phenotype. 
This result is in accordance with the phenotype found in the normal human breast, in 
which CD49f is typically seen as a basal marker. 
We subsequently asked weather any of the subgroups of cell lines was enriched for 
the most commonly used CSC phenotype, the CD44+CD24-/low phenotype defined by Al-
Hajj and colleagues (Al-Hajj et al., 2003). Therefore, the combined expression of 
CD44/CD24 was determined by flow cytometry in the breast cancer cell lines. Results are 
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summarized in Figures 2 and 3. In fact, flow cytometry analysis allowed us to divide the 
populations according to different levels of CD24 and CD44 expression. The size of the 
subpopulations obtained were in agreement with previously published data (Sheridan et 
al., 2006). Luminal cells (MCF-7/AZ, T47D) and HER2-OE cells (SkBr3 and BT-474) are 
mainly constituted by a CD44-CD24+ population. Basal cell lines (MDA-MB-468 and BT-
20) are mainly double positive CD44+CD24+. The mesenchymal cell line MDA-MB-231 is 
essentially CD44+CD24-, which is the putative cancer stem cell phenotype (Figure 2).  
The CSC phenotype, CD44+CD24-/low, has been related to a higher invasion rate in 
human breast cancer cell lines (Sheridan et al., 2006). In our study, we defined a 
threshold for CD24 expression according to the levels of the unstained/isotype control and 
we did not define the “CD24 low” subpopulation. That said, MDA-MB-231 cells show the 
highest levels of CD44+/CD24- phenotype and this cell line is highly invasive. Basal cell 
lines (MDA-MB-468 and BT-20), which are moderately invasive, have a small 
subpopulation defined by the CSC phenotype. Finally, luminal cells (MCF-7/AZ, T47D) 
and HER-2 OE cell (BT474 and SkBr3) are negative for this phenotype and demonstrate 
the lowest invasiveness potential (Figure 2). Furthermore, there was a striking 
relationship between the proportion of CD44+CD24- cells and spindle cell morphology, 
corroborating previous studies (Fillmore & Kuperwasser, 2008, Keller et al., 2010, 
Sheridan et al., 2006).  
 
 
Figure 2 – Graphical representation of the expression of the subpopulations defined by the combination of 
CD44 / CD24 markers. There is as association of the CSC phenotype (i.e., CD44+CD24-/low) with the 
mesenchymal phenotype and the invasion potential. Basal epithelial cell lines (MDA-MB-468 and BT-20) are 
enriched for the phenotype CD44+CD24+. 
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Figure 3 - Identification of the subpopulations defined by CD44-FITC and CD24-PE expression in breast 
cancer cell lines by flow cytometry. Isotype controls for IgG2b-FITC and IgG2a-PE were performed (not 
shown). The percentages of the subpopulations defined by CD44 and CD24 are shown in the table.  Indicated 
is the mean ± SEM of up to three independent experiments 
Cell line CD44-CD24+ CD44+CD24+ CD44+CD24- CD44-CD24- 
Cell type 
classification 
MCF-7/AZ 49.93 ± 9.77 34.57 ± 12.64 0.14 ± 0.05 15.30 ± 3.33 Luminal 
T47D 85.50 ± 2.40 10.00 ± 1.22 0 4.42 Luminal 
SkBr3 79.03 ± 5.27 18.50 ± 6.07 0 2.50 ± 1.04 HER-2 OE 
BT-474 64.52 ± 2.32 23.31 ± 5.99 0 11.91 ± 0.75 HER-2 OE 
MDA MB 
468 6.92 ± 2.05 91.17 ± 1.88 0.56 ± 0.21 1.38 ± 0.14 Basal / Epithelial 
BT-20 15.41 ± 6.20 66.30 ± 2.10 11.45 ± 2.35 6.84 ± 1.77 Basal / Epithelial 
BT-549 0 64.3 ± 5.23 35.4 ± 1.99 0 Basal / Mesenchymal 
MDA MB 
231 0 1.60 ± 0.65 91.35 ± 3.47 7.04 ± 2.83 Basal / Mesenchymal 
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As described above, we characterized our panel of breast cell lines using an 
additional lineage marker, CD49f, also known as α6 integrin. This marker has been used 
previously with EpCAM in order to define and characterize cells within the luminal and 
basal lineages present in normal human breast tissue (Eirew et al., 2008, Keller et al., 
2011, Raouf et al., 2008, Stingl et al., 2001, Villadsen et al., 2007). Additionally, some 
studies have included CD24 to the previous markers to better fractionate the human 
stem/progenitor compartments (Keller et al., 2010, Lim et al., 2009). Also, in the mouse 
breast, the combination of CD24 with CD49f was used to define the cell surface 
phenotype of a single cell that exhibited mammary repopulating ability (Stingl et al., 2006). 
To determine which differentiation states were retained in our series of breast 
cancer cell lines, we analysed by flow cytometry the combined expression of the markers 
CD49f and CD24. EpCAM expression was not included in this study. Breast cell lines 
have high levels of EpCAM surface expression, except for MDA-MB-231 cells, which are 
classified in the basal mesenchymal subgroup (Keller et al., 2010).  
The results of flow cytometry analysis of the double staining with CD49f and CD24 
are represented in Figure 4 and 5. Luminal cell lines have mainly CD49f-CD24+ 
phenotype, basal mesenchymal cell lines have a CD49f-CD24- and basal epithelial cell 
lines show a prominent CD49f+CD24+ phenotype (Figure 4).  
 
 
Figure 4 - Graphical representation of the expression of the subpopulations defined by the combination of 
CD49f / CD24 markers. Basal epithelial cell lines (MDA-MB-468 and BT-20) have mainly the phenotype 
CD49f+CD24+. 
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Figure 5 – Identification of the subpopulations defined by CD49f-FITC and CD24-PE expression in breast 
cancer cell lines by flow cytometry. Isotype controls for IgG2b-FITC and IgG2a-PE were performed (not 
shown). The percentages of the subpopulations defined by CD44 and CD24 are shown in the table.  Indicated 
is the mean ± SEM of up to three independent experiments. 
Cell line CD49f-CD24+ CD49f+CD24+ CD49f+CD24- CD49f-CD24- 
Cell type 
classification 
MCF-7/AZ 72.00 ± 3,00 5.46 ± 2,27 0 22.53 ± 2.13 Luminal 
T47D 69.5 ± 2.99 8.8 ± 1.52 8.6 ± 1.23 13.1 ± 1.86 Luminal 
SkBr3 89.55 ± 4.85 1.09 ± 0.65 0 9.37 ± 4.24 HER-2 OE 
MDA MB 
468 41.90 ± 11.39 57.08 ± 11,88 0 1.00 ± 0.61 Basal / Epithelial 
BT-20 25.38 ± 8.62 47.20 ± 4.35 13.03 ± 7.31 14.39 ± 3.82 Basal / Epithelial 
BT-549 34.60 ± 1.20 11.59 ± 3.47 10.01 ± 2.55 43.8 ± 6.75 Mesenchymal 
MDA MB 
231 0.03 ± 0.01 0.65 ± 0.39 26.53 ± 4.93 72.73 ± 4.59 Mesenchymal 
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Aldehyde dehydrogenase (ALDH) activity is increased in HER-2 OE and basal 
epithelial cell lines 
 
In this study, the activity of the ALDH enzyme was evaluated by the ALDEFLUOR 
assay in a panel of breast cancer cell lines representative of the different molecular 
subtypes of breast cancer. A summary of the percentage of the putative stem cell fraction 
obtained by the ALDEFLUOR assay is presented in Figure 7. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
Figure 7 – (A) ALEDFLUOR assay principle and gating strategy to identify the ALDEFLUOR+ subpopulation 
in breast cancer cell lines (e.g., SkBr3). BAAA – ALDH1 substrate, DEAB – ALDH1 inhibitor; (B) Percentages 
of the ALDEFLUOR positive subpopulation defined by the ALDEFLUOR-assay (StemCell Technologies) in a 
panel of breast cancer cell lines representative of distinct molecular subtypes of the disease. Plotted is the 
mean ± SEM of three independent experiments. 
BAAA$+$DEAB$
(negative$control)$
BAAA$
SkBr3$
In:  ALDEFLUOR ® technical bulletin  
(StemCell Technologies) 
Prospective stem/ 
progenitor cells 
 - 86 - 
 
The mesenchymal cell line MDA-MB-231, as well as the luminal cell lines MCF-7/AZ 
and T47D have very low, nearly absent, levels of ADEFLUOR activity. In contrast, the 
highest levels of the ALDEFLUOR-positive fraction are present in the cell lines SkBr3 and 
BT-474, which present overexpression of the HER-2 receptor due to gene amplification. 
Interestingly, Korkaya et al. showed that HER-2 overexpression expands the 
ALDEFLUOR-positive cell population of normal mammary epithelial cells, as well as in 
tumorigenic breast cancer cell lines, in a mechanism involving the up-regulation of stem 
cell related genes (Korkaya et al., 2008). The basal epithelial breast cancer cell lines 
(MDA-MB-468 and BT-20) also exhibit a significant putative stem cell population, present 
in 18.5% and 22.5% respectively. Furthermore, the cell line BT-549 is classified as 
ALDEFLUOR-positive, despite being included into the basal mesenchymal subgroup and 
not having HER-2 amplification. In fact, the behaviour of this cell line regarding the 
ALDEFLUOR activity as well as the cell surface phenotype shown in the previous section 
indicated that BT-549 cells are probably in the transition between of the basal epithelial 
subtype and the basal mesenchymal state. 
 
 
The survival in anchorage-independent conditions measured by the mammosphere 
assay is not related to the molecular subtype of breast cancer cell lines 
 
The mammosphere technique has been used to isolate normal human mammary 
stem and progenitor cells (Dontu et al., 2003). Under non-adherent mammosphere culture 
conditions, mammary stem and progenitor cells proliferate in an undifferentiated state, 
whereas differentiated cells die by anoikis. The final stage is a multicellular structure 
formed by the stem/progenitor cell and the surrounding differentiated cells, which can be 
dissociated and passaged again. Thus, this technique provides a measure of the self-
renewal and differentiation capacity of cells with stem cell activity in vitro. 
We used this technique to determine the mammosphere forming efficiency (MFE) of 
our panel of 8 breast cancer cell lines (Figure 9). We observed that stem/progenitor cells 
in breast cell lines represent a small fraction of the whole population, with the MFE 
ranging from 0.3 to 3%. All cell lines have a variable MFE that does not correlate with the 
classification into groups considered for our panel of breast cancer cell lines (Figure 9). 
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Figure 9 – Percentage of mammosfere forming efficiency (MFE) of eight breast cell lines. Plotted is the % 
mean ± SEM of up to three independent experiments. 
 
Mammospheres derived from breast cancer cell lines had the capacity to form new 
generations of mammospheres when passaged as single cells and re-seeded in non-
adherent culture conditions. Although a small decrease in MFE was found in the 
secondary passage, this assay revealed that primary mammospheres contained 
stem/progenitor cells with capacity for self-renewal. 
Mammospheres are multicellular structures that can encompass different 
morphologies. An example of the mammospheres obtained is depicted in Figure 10. Our 
microscopical analysis showed that mammospheres could be roughly divided into two 
main groups: a compact spherical structure (MCF7/AZ, T47D, BT-474, BT-549, BT-20) 
that forms a sphere-like shape that contains in the inside the stem/progenitor cells. This 
central sphere can be surrounded by differentiated cells that either resisted death by 
anoikis or that derived from the central structure. On the other hand, some 
mammospheres have a loose grape-like structure and no central compact aggregate can 
be distinguished (SkBr3, MDA-MB-468 and MDA-MB-231). From this analysis, we 
concluded that mammosphere morphology does not correlate with the group classification 
used in our panel of breast cancer cell lines. 
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Figure 10 - Morphological characteristics of 2D (monolayer) and mammospheres formed in  a panel of breast 
cell lines. Scale bar=100µm. 
 
 
Expression of breast cancer cell markers in a series of invasive human carcinomas 
comprising different molecular subtypes  
 
A series of 466 invasive breast carcinomas were classified into molecular subtypes 
by immunohistochemical evaluation: 64.8% (302/466) were luminal A, 8.8% (41/466) 
luminal B, 7.1% (33/466) HER-2 OE, 14.6% (68/466) basal-like tumours and 4.7% 
(22/466) were unclassified tumours (for details, see Chapter III. Materials and Methods, 
and Ricardo S et al in the appendix section (Ricardo et al., 2011)). This series of human 
breast tumours has been completely characterized for clinical and pathological features, 
namely age, tumour size, lymph node status and histological grade and, as expected, the 
majority of basal-like and HER-2 OE tumours were grade III, highly proliferative and 
presented the worse patient survival, as seen in the Kaplan-Meier curves (Figure 11), 
demonstrating the validity and power provided by this series of invasive breast 
carcinomas. 
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Figure 11 - Patient and tumour parameters of the series of 466 primary invasive breast carcinomas used in 
this study. The breast tumour signature was determined by immunohistochemistry according to the definition 
described in Chapter III. Materials and Methods (A). The disease-free survival and overall-survival of the 
different breast subtypes is shown (B). 
 
This series was studied for the expression of the stem cell markers CD44, CD49f, 
CD24 and ALDH1 by immunohistochemistry. A representative positive stain for these 
markers is shown in Figure 12. 
Concerning CD44 membranous staining, 51.2% (237/463) of the cases were 
positive. CD49f membranous staining was positive in only 11.5% (49/427) of the invasive 
breast carcinomas. Regarding the marker CD24, the majority of the cases were classified 
as negative/low (88.6% - 410/463), and only 11.4% (53/463) of the tumours had clear 
membrane staining. For ALDH1, a minority of cases were classified as positive (7.1% - 
33/464), showing a clear cytoplasmic expression in tumour cells (Table 3).  
 
 
 
Variable 
(n=466) 
Data 
Frequency Percentage (%) 
Age at Diagnosis 
<50 years 
>=50 years 
Missing (n= 27) 
 
115 
324 
 
 
26.2 
73.8 
Tumour Size 
T1:<2cm 
T2: 2-5 cm 
T3: >5cm 
Missing (n=58) 
 
101 
244 
63 
 
 
24.8 
59.8 
15.4 
Lymph Nodes 
Positive 
Negative 
Missing(n=101) 
 
206 
159 
 
 
56.4 
43.6 
Histological 
Grade 
Grade I 
Grade II 
Grade III 
Missing (n=23) 
 
81 
135 
227 
 
 
18.3 
30.5 
51.2 
Molecular 
Subtype 
Luminal A 
Luminal B 
HER-2 OE 
Basal-like 
Unclassified 
 
 
302 
41 
33 
68 
22 
 
 
64.8 
8.8 
7.1 
14.6 
4.7 
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Figure 12 – The expression of the stem cell markers CD44, CD49f, CD24 and ALDH1 was evaluated by IHC 
in a series of 466 invasive human breast carcinomas. This figure represents a positive case for each of the 
markers analysed. CD44, CD49f and CD24 were evaluated according to the membranous stain, whereas 
ALDH1 presents a clear cytoplasmic stain. For the classification criteria of breast carcinomas see Chapter III. 
Materials and Methods (scale bar=150 µm). 
 
Classical 
prognostic factors 
Subtypes 
p Luminal A 
(n=302) 
Luminal B 
(n=41) 
HER2-OE 
(n=33) 
Basal-like 
(n=68) 
Unclassified 
(n=22) 
CD44 
Positive (n=237) 
Negative (n=226) 
Missing (n=3) 
 
147 (49.2%) 
152 (50.8%) 
 
 
17 (41.5%) 
24 (58.5%) 
 
 
12 (36.4%) 
21 (63.6%) 
 
 
56 (82.4%) 
12 (17.6%) 
 
 
5 (22.7%) 
17 (77.3%) 
 
<0.0001 
CD24 
Positive (n=53) 
Negative/Low 
(n=410) 
Missing (n=3) 
34 (11.4%) 
265 (88.6%) 
 
7 (17.1%) 
34 (82.9%) 
 
5 (15.2%) 
28 (84.8%) 
 
4 (5.9%) 
64 (94.1%) 
 
3 (13.6%) 
19 (86.4%) 
 
0.418 
CD49f 
Positive (n=49) 
Negative (n=378) 
Missing (n=39) 
 
11 (4.0%) 
263 (96.0%) 
 
 
6 (15.8%) 
32 (84.2%) 
 
 
2 (6.9%) 
27 (93.1%) 
 
 
27 (42.2%) 
37 (57.8%) 
 
 
3 (13.6%) 
19 (86.4%) 
 
<0.0001 
ALDH1 
Positive (n=33) 
Negative (n=433) 
Missing (n=3) 
 
12 (4.0%) 
287 (96.0%) 
 
 
4 (9.8%) 
37 (90.2%) 
 
 
4 (12.1%) 
29 (87.9%) 
 
 
13 (19.1%) 
55 (80.9%) 
 
 
0 (0%) 
22 (100%) 
 
<0.0001 
 
Table 3 – Association between the expression of P-cadherin, CD44, CD24, CD49f and ALDH1 and the major 
breast cancer molecular subtypes. There is a statistically significant association between positive expression 
for P-cadherin, CD44, CD49f and ALDH1 and the basal-like molecular subtype (chi-squared test). 
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CD44, CD49f and ALDH1 expression were significantly associated with the 
classification of the breast tumours into molecular subtypes (p<0.0001), whereas CD24 
expression was not (p=0.418) (Table 3). The majority of basal-like carcinomas were 
considered CD44+ (82.4% - 56/68) and CD49f+ (42,2% - 27/64) (Table 3). Furthermore, 
concerning ALDH1 cytoplasmic expression, 39.4% (13/33) of the cases were classified as 
basal-like carcinomas (Table 3). In addition, almost all basal-like tumours were CD24-/low 
(94.1% - 64/68) and, amongst the CD24+ cases, 64.2% (34/53) were luminal A (Table 3). 
 
 
 
 
Figure 13 – Graphical representation of the percentage of tumours positive for each of the CSC markers 
CD44, CD49f, ALDH1 and CD24 in a series of invasive breast cancer cases. Positivity was assessed by IHC 
as described in the Materials and Methods section. The Luminal A, Luminal B and Her-2 OE tumors were 
clustered together and compared to the basal-like and unclassified subgroups. 
 
To compare the expression of the stem cell markers in human carcinomas with the 
expression obtained for the breast cancer cell lines, the basal-like subgroup of breast 
tumours was put side by side against all the remaining luminal subgroups (luminal A + 
luminal B + HER-2 OE) and the unclassified group of breast tumours (Figure 13). Basal-
like carcinomas have a higher percentage of cases positive for CD44, CD49f and ALDH1, 
and a lower expression of CD24, in comparison with the remaining subgroups. These 
results are in accordance with the observations found in the breast cancer cell lines 
analysed. We showed that basal/epithelial cell lines expressed higher levels of the stem 
cell markers CD44 and CD49f, in comparison with the luminal cell lines (Figure 1). 
Furthermore, ALDH1 activity measured by the ALDEFLUOR assay was significantly 
increased in the basal/epithelial cells and nearly absent in luminal cell line group (with no 
HER-2 amplification) (Figure 7). Concerning CD24 expression, human breast carcinomas 
seem to resemble the basal/mesenchymal cells MDA-MB231, in which the expression of 
this stem cell marker was very low, compared with the remaining breast cancer cell lines. 
To explore the effect of the CSC phenotype CD44+CD24-/low on the clinical outcome 
and its prevalence in the molecular subtypes of breast cancer, our group evaluated the 
combined expression of the markers CD44/CD24 by double immunofluorescence staining 
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in 45 cases of the whole breast cancer series (i.e., corresponding to approximately 10% of 
all the cases present in the series). We considered a tumour with a CSC phenotype when 
the frequency of CD44+CD24-/low cells were more than 10%, as previously described in 
other studies (Abraham et al., 2005, Mylona et al., 2008).  
 
 
Subtypes 
Luminal A 
(100%) 
Luminal B 
(100%) 
Her-2 OE 
(100%) 
Basal-like 
(100%) 
Unclassified 
(100%) 
CD44+CD24-/low  
≥ 10% 43.0 41.4 27.3 76.5 18.2 
CD44+CD24-/low  
< 10% 57.0 58.6 72.8 23.5 81.8 
 p<0001, qui-square test 
 
Table 4 – Distribution of the CSC phenotype (CD44+CD24-/low > 10%) within human breast carcinoma 
subtypes present in our invasive breast cancer series. Basal-like breast cancers have the highest percentage 
of cases with more than 10% CD44+CD24-/low cells. 
 
Table 4 shows that the CSC phenotype (CD44+CD24-/low) was significantly 
associated with the breast cancer molecular subtype classifications (p<0.001). Most of the 
basal-like tumours were classified as CD44+CD24-/low > 10% (76.5%). Both luminal A and 
luminal B tumours presented similar levels of the CSC-phenotype (43.0% and 41.4%, 
respectively), and only 27.3% of the HER-2 OE tumours presented more than 10% 
CD44+CD24-/low cells. Univariate survival analysis (log-rank test) was performed for the 
four stem cell markers, namely CD44, CD49f, CD24 and ALDH1, as well as the combined 
expression of CD44/CD24.  CD24 expression showed a tendency for a better prognosis in 
Kaplan-Meier analysis (p=0.073, log-rank test), but CD44, CD49f and ALDH1 expression 
failed to reach statistically significant levels (log-rank test, p=0.272, p=0.447, p=0.511, 
respectively), meaning that these markers were not significant predictors of disease-free 
survival or overall survival in this series of breast carcinomas (data not shown).  
Interestingly, our series of breast tumours confirmed the results of other groups, 
showing that there was no association of the CSC phenotype CD44+CD24-/low with the 
overall survival of cancer patients (p>0.05, log-rank test) (Mylona et al., 2008). However, 
when we addressed the expression of CD44/CD24 pattern within the poor prognosis 
basal-like carcinomas, we found that tumours with a CSC phenotype (≥10% CD44+CD24-
/low cells) presented a trend towards a worse disease-free survival (log-rank test, p=0.065) 
(Figure 14). 
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Figure 14 – Kaplan-Meier survival curves representing the disease free survival (log rank test, p=0.065) and 
overall survival (log rank test, p=0.127) in the basal-like subtype of human carcinomas, according to the 
CD44/CD24 pattern of expression. 
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 3. Discussion 
 
One of the recent priorities in breast cancer research is the CSC 
identification/isolation, since it is well accepted that tumours are essentially driven by a 
cellular pool with stem-like properties, which are responsible for tumour invasiveness, 
heterogeneity, metastasis capacity, and therapy resistance (Reya et al., 2001). In this 
study, we analysed a series of breast cancer cell lines from distinct molecular subtypes for 
the expression of the breast CSC markers CD44, CD49f and CD24, as well as the activity 
of ALDH1 enzyme, and the survival of the cells in anchorage independent conditions 
(mammosphere assay). These results were compared with the ones obtained by the 
immunohistochemical membrane localization of the same panel CSC markers (CD44, 
CD49f and CD24, as well as the presence of intracellular ALDH1), in a large and well-
characterized series of invasive breast carcinomas.  
Regarding the characterization of the stem cell markers in cell lines, it is important to 
establish a comparison with similar studies described in the literature. Keller and 
collaborators have performed an extensive phenotypic characterization of stem cell 
surface markers in a panel of breast cancer cell lines which included some of the cell lines 
used in this study, namely in MCF7, T47D and BT-20 cells. Like in our study, the stem cell 
markers CD44, CD49f and CD24 were determined by flow cytometry (Keller et al., 2010). 
Concerning CD24 staining, the results observed in the cell lines are in accordance with 
the published literature. In fact, all cell lines that maintain an epithelial phenotype showed 
enrichment in CD24+ cells, whereas the mesenchymal cell lines BT-549 and MDA-MB-231 
sowed lower levels or absent expression by flow cytometry of this marker. CD24 is a 
luminal marker illustrating a clear stain in the luminal cell lines.  
Concerning the expression of the stem cell markers CD44 and CD49f, our study 
shows that in the selected panel of cell lines, there is a correlation between the above 
mentioned stem cell markers and the attributed subgroups: CD44 and CD49f were 
significantly more expressed in the aggressive basal epithelial cell lines. In contrast CD44 
and CD49f expression was lower in luminal cells, compared to the remaining subgroups. 
This result contrasts to the study by Keller et al, in which no correlation between CD44 or 
CD49f expression and the subgroups of cell lines was found. This discrepancy could be 
due to the fact that our study presents a slightly lower expression of the markers CD44 
and CD49f. Our study used a different set of fluorochromes to evaluate cell surface 
expression of these markers, possibly with different gating strategies. Moreover, the study 
performed by Keller et al. is not representative of our panel of cell lines, since it included 
only 3 out of the 8 cell lines used in this work (Keller et al., 2010). Notably, recent studies 
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have revealed despite CD44 being expressed on the majority of cells in both the basal 
and luminal lineages (Raouf et al., 2008), CD44 expression is lower in the luminal 
compartment (Chaffer et al., 2011, Mani et al., 2008) and in luminal cell lines (Sheridan et 
al., 2006). Our results for human breast invasive carcinomas show that the expression of 
the stem cell markers CD44 and CD49f were increased in the poor prognosis basal-like 
tumours. It has already been demonstrated that CD44+ cells show a mesenchymal stem 
cell-like profile, enriched for genes involved in cell motility, proliferation and angiogenesis 
(Shipitsin et al., 2007). CD49f stem cell properties have also been implicated in the 
aggressive behaviour of the human breast cancer cells, namely in the cell line MCF7/AZ 
(Cariati et al., 2008). Furthermore, despite our study showing no association of these 
biomarkers with disease outcome, other groups have shown that breast tumours positive 
for the stem cell marker CD44 have decreased patient survival (Shipitsin et al., 2007). In 
our series of primary carcinomas, CD24 membranous staining in breast tumours was not 
concordant with the previous literature data. Only a small percentage of tumours showed 
a clear cut membrane positivity. Distinct grading systems have been used to classify 
CD24 immunohistochemically (Fogel et al., 1999, Surowiak et al., 2006), and 
consequently, different percentages of CD24 expression have been observed in other 
series of invasive breast carcinomas. For example, Mylona et al. considered mainly 
membranous CD24 staining, whereas Honeth et al considered CD24 staining at the 
cytoplasm, possibly explaining why different conclusions were drawn by both studies 
(Honeth et al., 2008, Mylona et al., 2008). Indeed, cytoplasmic expression can reflect 
aberrant protein overexpression, with consequent disturbance of its membrane distribution 
and degradation in neoplastic cells (Bircan et al., 2006). Thus its significance to the most 
appropriate CD24 classification is still ambiguous and needs to be discussed further. 
Nevertheless, we found that CD24+ cases were enriched in luminal A + luminal B + HER-2 
OE tumours (39/53, 73.6%), while the majority of the basal-like tumours were classified as 
CD24-/low (64/68, 94.1%).  
The combinatorial evaluation of CD44/CD24 for the identification of CSC population 
in breast cancer cell lines was analysed by flow cytometry. The main phenotype found in 
the basal/mesenchymal cells (of which MDA-MB-231 cells are an example) was the CSC 
phenotype CD44+CD24-, whereas the remaining basal cell lines were positive for both 
markers, CD44+CD24+. In the basal/mesenchymal cells, the CSC phenotype reflects their 
metaplastic or claudin low features (Prat et al., 2010) and in the basal/epithelial cell lines, 
a more differentiated morphology, probably represents the basal-like human carcinomas. 
Noteworthy, in contrast to the results found in breast cell lines, the majority of basal-like 
tumours were significantly associated to the CSC phenotype CD44+CD24-/low, as shown by 
our study and others (Honeth et al., 2008, Park et al., 2010). These studies highlight the 
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biological heterogeneity of breast cancer and an enrichment of putative tumour-initiating 
cells in the aggressive basal-like tumour subtype.  
In spite of the classical CSC phenotype, the stem cell properties of the CD44+CD24+ 
population have also been addressed. These cells were shown to present tumourigenic 
ability, as well as to have a dynamic switch originating the CD44+CD24-/low cells (Meyer et 
al., 2009). It is therefore important to point out that, CD24 expression presents a dynamic 
regulation. Thus, CD44+CD24+ cells can readily give rise to CD44+CD24-/low cells and vice 
versa (Meyer et al., 2009). This may explain why the phenotype of the basal cell lines is 
not consistent with the phenotype found for human carcinomas, namely concerning CD24 
expression.  
Similarly, the analysis of the combination of markers CD49f/CD24 revealed that 
luminal cell lines are enriched in the phenotype CD49f-CD24+ (MCF-7/AZ, T47D and 
SkBr3), with the CD49f+CD24+ cells being the dominant population in basal/epithelial cell 
lines (BT-20 and MDA-MB-468). The phenotype of the basal epithelial cell lines thus 
reflects the cell of origin that has been proposed for this malignancy (Lim et al., 2009, 
Molyneux et al., 2010). Interestingly, the phenotype CD49f+CD24+ has also been 
associated with breast cancer stem cell features in BRCA1 deficient mice, presenting a 
high regeneration potential (Vassilopoulos et al., 2008). 
ALDH1 is an enzyme involved in retinoic acid synthesis and its activity is a 
biomarker of mammary luminal cells with stem/progenitor activity, constituting a predictor 
of poor clinical outcome in breast cancer (Eirew et al., 2011, Ginestier et al., 2007). The 
activity of this enzyme was nearly absent from our set of luminal cell lines. In contrast, the 
measured activity of ALDH1 enzyme was higher in basal cell lines, with the exception for 
MDA-MB-231, which showed undetectable ALDH1 activity, as already pointed out by 
Deng et al. (Deng et al., 2010). Furthermore, the ALDEFLUOR+ subpopulation was 
increased in the highly aggressive cell lines over-expressing the HER-2 oncogene, 
confirming the results of Korkaya and colleagues (Korkaya et al., 2008). In what concerns 
the immunohistochemical evaluation of human breast invasive carcinomas, we found that 
ALDH1 is expressed in 7.1% of all cases. Previous works also detected small 
percentages of ALDH1+ cases in invasive breast cancer, ranging from 4% to 19% (Deng 
et al., 2010, Morimoto et al., 2009, Park et al., 2010, Resetkova et al., 2010). Importantly, 
only the isoform ALDH1a1 was evaluated by IHC. Remarkably, the majority of the cases 
showing a predominant ALDH1-positive population were significantly associated with 
basal-like tumours but the survival rate of ALDH1-positive cases did not significantly 
correlate with poor clinical outcome, like stated in previous studies (Deng et al., 2010, 
Ginestier et al., 2007, Honeth et al., 2008). 
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The mammospheres formed from breast cancer cell lines show distinct 
morphologies that are not associated with molecular subtype. Furthermore, comparing the 
different methods of assessing the stem cell population in our series of breast cancer cell 
lines, we could not find an association between the size of the stem cell population 
measured by the mammosphere assay and the CSC phenotype CD44+CD24- or the 
cancer stem cell activity determined by the ALDEFLUOR assay.  
The identification of stem-like cells in breast cancer cell lines shows that the 
identified stem cell subpopulations differ according to the cell line analysed and the 
method used does not necessarily identify the same population of cells. For example, the 
highly metastatic MDA-MB-231 cells have the phenotypic profile of the CSC, being mainly 
CD44+CD24-/low, however, no ALDEFULOR+ population was identified for this cell line. 
Notably, this indicates that these sets of markers do not represent the same population. 
Another example is the HER-2 OE cell lines, SkBr3 and BT474, which showed 
predominance of the CD44-CD24+ luminal phenotype, but presented high ALDH activity. 
Thus, it seems that the different stem cell methods identify cells in different stages of 
differentiation. For each cell line a set of markers should be explored to better define a 
CSC phenotype. In certain contexts, a partial overlap of the various subpopulations 
defined by different methods may be possible. In fact, this has proven to enrich for the 
cancer stem cell population (Ginestier et al., 2007).  
Even though the stem-like features of the ALDEFLUOR + cells and the CD44+CD24-
/low cells are increasingly accepted, their location in the stem cell compartment hierarchy is 
still unclear. We believe that the ALDEFLUOR assay allows the identification of cells in a 
lower position of the mammary hierarchy, probably late progenitors with a proliferative 
epithelial phenotype. In contrast, the CD44+CD24-/low phenotype probably identifies the 
most primitive stem cell or an early progenitor stem cell of the mammary hierarchy, with 
unlimited self-renewal ability and very low proliferation, where ALDH1 is not active 
Alternatively, the CD44+CD24-/low phenotype may represent a progenitor-like cell, with a 
much more active proliferation rate. Stingl mentions that ‘the ESA+CD44+CD24-/low 
phenotype is remarkably similar to the human mammary repopulating unit and bipotent 
progenitor cell phenotype ESA+CD49f+MUC1-, since both CD44 and CD24 have a very 
similar distribution to CD49f and MUC1, respectively (Stingl, 2009)’. Figure 15 represents 
a model for the expression of the stem cell markers CD44, CD24, CD49f and ALDH1 
along the breast stem cell hierarchy and the possible association with breast cancer 
molecular subtypes and breast cancer cell lines. 
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Figure 15 – Expression of the stem cell markers CD44, CD24, CD49f and ALDH1 along the breast stem cell 
hierarchy and the possible association with breast cancer molecular subtypes and breast cancer cell lines. 
The phenotype CD44+CD24-/low represents the primitive stem cell and is probably the target of 
transformation for basal-like mesenchymal tumors (i.e., claudin low tumours). Basal-like epithelial tumours 
have a luminal progenitor origin with a putative expression of ALDH1, CD24 and CD49f. The targets of 
transformation of HER2-OE and Luminal breast cancers have not been clearly described. 
 
In summary, the described CD44+CD24-/low and the ALDH1+ stem-like phenotypes 
seem to identify CSCs with distinct levels of differentiation, being the former profile more 
related with triple carcinomas that most probably originate from the most primitive 
mammary stem cells, whereas the latter is a marker of basal-like and HER-2 OE tumours, 
putatively originated from luminal committed progenitors. With this hypothesis in mind, it 
seems that the paramount method and biomarkers that identify breast CSCs within the 
distinct molecular subtypes needs to be better explored, since it is pivotal to translate the 
CSC concept to the clinical practice. In the near future, the recognition of reliable markers 
to distinguish the CSC pool in each molecular subtype will be decisive for the 
development of specific target therapies. 
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 1. Introduction 
 
Several studies have shown that solid tumors may contain a small subpopulation of 
cancer cells that are tumorigenic and have the ability to self-renew and generate all the 
diverse cancer cells present within the tumor mass. This experimental evidence supports 
the cancer stem cell hypothesis which proposes that a hierarchy exists in the solid tumors 
comparable to the one found in normal tissue differentiation (Reya et al., 2001). In the 
breast, these cells are named breast cancer stem cells (CSC). Breast CSCs share 
important properties with mammary stem cells, namely the ability to proliferate and resist 
to radiation- and chemotherapy-induced cell death, allowing them to survive and to cause 
tumor recurrence (Li et al., 2008, Phillips et al., 2006). However, the identification of 
breast CSCs has been a hard task due to the current technical constraints and the high 
inter- and intra-tumor heterogeneity observed in breast cancer (Charafe-Jauffret et al., 
2009). Most authors make use of cell surface proteins, usually adhesion-related 
molecules, in an attempt to define a subpopulation of cells that represents the breast CSC 
population. In 2003, Michael Clarke’s group isolated a subset of breast cancer cells with 
the phenotype ESA+/CD44+/CD24-/low, which were able to self-renew and were highly 
tumorigenic at a low cell inoculum (Al-Hajj et al., 2003). Since then, several other 
phenotypes/markers to isolate breast CSCs have been described.  
For the basal-like breast cancer molecular subtype, in particular, which constitute 
10% of all breast cancer cases, few descriptions exist concerning the isolation of their 
breast CSCs. Meyer at al. isolated CD44+/CD49fhigh/CD133-2high cancer cells from ER-
negative patient tumors, which showed increased tumorigenic ability (Meyer et al., 2010). 
Wright et al. described the phenotype CD133+ as able to isolate CSCs from tumors 
developed in BRCA1-/- mice (Wright et al., 2008). Hwang-Verslues et al. characterized the 
CSC phenotype PROCR+/ESA+ for the human basal MDA-MB-231 breast cancer cell line 
(Hwang-Verslues et al., 2009). 
It was recently demonstrated that basal-like breast cancers have a molecular 
phenotype comparable to the luminal progenitor of the normal breast (Lim et al., 2009, 
Molyneux et al., 2010), which raised the hypothesis that markers of luminal progenitors 
would be good CSC markers for basal-like lesions. Additionally, it has been shown that 
inactivation of BRCA1 gene in the luminal layer of the normal breast originates breast 
carcinomas in mice that resemble basal-like carcinomas in humans (Molyneux et al., 
2010). In fact, BRCA1 is a major regulator of normal luminal maturation (Liu et al., 2008) 
and it is essential for the repression of a panel of genes which are typically expressed in 
basal-like carcinomas of the breast, such as the CDH3/P-cadherin gene (Gorski et al., 
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2009). These evidences suggest that P-cadherin can be an important CSC marker for this 
type of tumor lesions. 
P-cadherin, a classical type I adhesion molecule, is normally expressed in the 
myoepithelial/basal layer of the breast and is frequently overexpressed in basal-like breast 
carcinomas (Matos et al., 2005, Paredes et al., 2005, Paredes et al., 2002b). We have 
found that P-cadherin expression is linked to aggressive tumor behavior, increasing the 
production of MMPs by cancer cells to the extracellular matrix, as well as inducing cancer 
cell invasion, migration and motility, due to a mechanism involving alterations in the actin 
cytoskeleton and signaling through small GTPase-binding proteins (Ribeiro et al., 2010, 
Albergaria et al., 2011).  However, P-cadherin is also involved in homeostatic processes, 
such as cell differentiation, development, and embryogenesis, illustrating an indirect effect 
of this adhesion molecule in stem cell biology. P-cadherin deficient female mice present 
abnormal mammary gland morphology, showing premature differentiation of the breast 
and increased risk of developing pre-neoplastic lesions, such as alveolar hyperplasia and 
ductal dysplasia (Radice et al., 1997). In fact, P-cadherin seems to be important in the 
maintenance of an undifferentiated state in the malignant setting, as breast tumors with P-
cadherin expression show loss of cell polarity (Paredes et al., 2002b). The role of P-
cadherin in development and differentiation is also seen during embryonic histogenesis, 
since this cadherin is present in the extra-embryonic ectoderm and visceral endoderm, 
structures originating the placenta (Hirai et al., 1989a). P-cadherin also has a direct effect 
in normal stem cells, since it was identified as a stem cell surface marker in human 
embryonic stem cells (Kolle et al., 2009). Early hair progenitor cells were also isolated as 
P-cadherin+ (and K14+/α6-integrin (CD49f+) cells) (Rhee et al., 2006). Furthermore, the 
stem cell related transcription factors β-catenin, p63 and C/EBP-β were shown to induce 
P-cadherin promoter activation (Faraldo et al., 2007, Shimomura et al., 2008, Albergaria 
et al., 2010). Interestingly, in breast, P-cadherin is found in the cap cells, characteristic 
stem cells that are the precursors of myoepithelial cells (Daniel et al., 1995, Knudsen & 
Wheelock, 2005), and in the myoepithelial layer (Paredes et al., 2002a), eventually 
contributing to the suprabasal stem cell niche. 
Herein, we used human mammary cell lines (normal and malignant), as well as a 
series of invasive breast carcinomas, to provide evidence that P-cadherin expression is 
important in the cancer stem cell context, not only as a biomarker that better defines the 
basal-like breast cancer stem cell phenotype, but also as a protein with direct relevance in 
stem cell activity in this specific molecular subtype. 
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 2. Results 
 
Normal and tumorigenic breast cell lines, with a basal-like phenotype, are enriched 
for the expression of P-cadherin, as well as for the stem cell markers CD44, CD49f 
and show an increased ALDEFLUOR-positive subpopulation 
 
P-cadherin is normally expressed in the basal layer of the mammary epithelium 
(Paredes et al., 2002a) and is frequently up-regulated in basal-like breast carcinomas 
(Matos et al., 2005, Paredes et al., 2005, Paredes et al., 2007b, Paredes et al., 2002b, 
Paredes et al., 2002a). In order to study if this protein was associated with the expression 
of cancer stem cell markers in vitro, a panel of breast cancer cell lines was used. This 
series of cell lines comprised two main subgroups: the estrogen-receptor positive luminal 
cell lines (MCF-7/AZ and T47D) and the estrogen-receptor-negative basal-like cell lines 
(MDA-MB-468, BT-20, and BT-549) (Charafe-Jauffret et al., 2006, Neve et al., 2006). In 
order to demonstrate that this putative association was not restricted to cancer cells, a 
normal mammary cell line was also included in the study (MCF10A), which was previously 
described as harboring a basal gene expression signature (Charafe-Jauffret et al., 2006). 
In accordance to what is seen in human breast carcinomas (Matos et al., 2005, 
Paredes et al., 2007b, Paredes et al., 2002a), high/moderate cell surface expression of P-
cadherin (>50% of positive cells by FACS) was preferentially observed in basal-like cell 
lines, in contrast to luminal cell lines, which show lower levels of this protein (Figure 1A). 
The same association was observed for CD44 and CD49f, with increased cell surface 
expression of these markers in the basal-like phenotype (P-cadherin high/moderate cells), 
in contrast to the luminal phenotype (P-cadherin low cells) (Figure 1B). Other studies are 
in accordance with our data indicating that, in breast cell lines, luminal cells usually 
express lower levels of CD44 (Fillmore & Kuperwasser, 2008, Olsson et al., 2011, 
Sheridan et al., 2006) and CD49f (Neve et al., 2006, Yoon et al., 2001) in comparison with 
basal cells. Importantly, the later molecules are already well established as cancer stem 
cell markers of the basal phenotype (Meyer et al., 2010, Wright et al., 2008), as well as 
putative mammary gland stem cell biomarkers (Lim et al., 2009, Shackleton et al., 2006, 
Stingl et al., 2006). All the cell lines expressed high levels of CD24, independently of the 
level of P-cadherin expression. 
In addition to the cell surface markers, it was previously shown that normal and 
cancer human mammary epithelial cells with high aldehyde dehydrogenase (ALDH) 
enzyme activity have stem/progenitor properties (Ginestier et al., 2007). The analysis of 
ALDH activity in this panel of cell lines revealed that, the P-cadherinmod/high basal cells 
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showed a significant subpopulation with this putative stem cell profile (>15%), in contrast 
to P-cadherinlow luminal cells (Figure 1B). Again, these results are in accordance with 
other studies that have shown that basal cells have an increased ALDEFLUOR+ 
subpopulation, compared with the luminal ones (Ferlay et al., 2010, Marcato et al., 2011).  
FACS analysis of the ALDEFLUOR+ and ALDEFLUOR- cell compartments of cell 
lines from the two main groups, showed that there was an enrichment of P-cadherin 
expression in the ALDEFLUOR+ stem cell compartment, pointing for a direct association 
between these two markers. Interestingly, this association was only found in the basal-like 
group of cell lines, as shown in MDA-MB-468 (Figure 1C). In order to more clearly 
demonstrate the link between P-cadherin and the ALDEFLUOR+ subpopulation, we 
decided to perform transient inhibition of P-cadherin in the basal cells MDA-MB-468, BT-
20, BT-549 and MCF10A. Measurement of ALDH1 activity showed that the inhibition of P-
cadherin leads to a decrease in the number of ALDEFLUOR+ cells in all cell lines, being 
more significant in MCF10A and BT549 (in the cell line BT-549, the ALDEFLUOR+ 
subpopulation significantly decreased from 50.9% to 33.2%). These results clearly show 
an association between P-cadherin and the stem cell pool (Figure 1D). 
The inhibition of P-cadherin also clearly impacted in the expression of the stem cell 
marker CD49f. In all basal-like cell lines analyzed, P-cadherin knock-down was 
accompanied by a reduction of CD49f expression (Figure 1E). Expression of CD44 was 
also affected, namely the CD44v6 isoform, with a reduction found in the cell line BT-549 
after P-cadherin inhibition (Figure 1E). We also performed transient knock-down of CD44 
or CD49f and studied the impact of these stem cell markers on P-cadherin expression. 
Inhibition of CD44 caused a slight reduction of P-cadherin expression in the BT-549 cell 
line and inhibition of CD49f did not affect P-cadherin expression in the three basal cell 
lines (Figure 1E). 
___________________________________________ 
Figure 1 - FACS analysis of cell surface markers and ALDEFLUOR in breast cell lines. P-cadherin is highly 
expressed in mammary basal-like cell lines (A). In these cells expression of the stem cell markers CD44 and 
CD49f was found to be increased (Vs. luminal cells). Furthermore, the stem cell population, defined by the 
ALDEFLUOR assay, is also expanded in the basal-like cells (B). In addition, basal cells have an 
ALDEFLUOR-positive population enriched in P-cadherin expression (C). P-cadherin levels were measured by 
flow cytometry within the ALDEFLUOR+ and ALDEFLUOR- subpopulations (percentages of the ALDEFLUOR 
subpopulations are represented). The basal-like cell line MDA-MB-468 showed a stem cell population 
(ALDEFLUOR+) enriched in P-cadherin expression, whereas the same does not occur in the luminal cell line 
T47D. (D) ALDEFLUOR assay was performed after P-cadherin inhibition (siRNA P-cad) in the breast basal 
cell lines MCF10A, MDA-MB-468, BT-20 and BT-549 showing a decrease in the ALDEFLUOR+ fraction (for 
which BT-549 is shown as an example). (E) Using transient knock-down of P-cadherin in a panel of basal-like 
cell lines, the expression of the stem cell markers was evaluated by western-blot. Conversely, the impact on 
P-cadherin expression was evaluated after transient inhibition of the stem cell markers CD44 and CD49f. 
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P-cadherin expression is associated with the phenotype of the luminal progenitor 
from the normal breast differentiation hierarchy: CD49f+CD24+ 
 
Combinations of the markers CD44, CD24 and CD49f have been used in the 
literature in order to define subpopulations within cell lines or tissues that have stem or 
cancer stem cell properties (Cariati et al., 2008, Hutvagner & Zamore, 2002, Al-Hajj et al., 
2003, Keller et al., 2011, Keller et al., 2010, Mani et al., 2008, Raouf et al., 2008, Stingl et 
al., 2006). Specifically, in the cancer stem cell field, the phenotype CD44+CD24-/low is 
believed to exhibit CSC properties (Al-Hajj et al., 2003) and some authors also suggest 
that the CD44+CD24+ phenotype similarly harbors stem-like properties (Meyer et al., 2009, 
Rappa & Lorico, 2010). Importantly, CD44 expression in the normal human hierarchy is 
reported in both luminal and basal lineages by Visvader et al. (Visvader, 2009) and Raouf 
et al. (Raouf et al., 2008), possibly with a lower expression in the luminal compartment as 
seen in breast cell lines. Studies performed by Shipitsin et al. with cancerous and normal 
breast tissue, indicate that cells enriched for CD44 expression represent a more basal 
estrogen-receptor negative phenotype, with mammary epithelial progenitor-like 
properties(Shipitsin et al., 2007). Additionally, in the normal human breast, the luminal 
progenitor is reported to be CD49f+CD24+ (Molyneux et al., 2010, Lim et al., 2009, Stingl 
et al., 2006, Keller et al., 2010) (also EpCAM+MUC1+CD133+Thy1-CD10-) (Eirew et al., 
2008, Raouf et al., 2008, Stingl et al., 2001, Keller et al., 2011). 
In this work, cells were stained with a combination of target proteins, which include 
P-cadherin, CD44, CD24 and CD49f. Stringent cell sorting was applied to separate and 
analyze the cell subpopulations with stem-like properties described above within each of 
the breast cell lines, after gating for P-cadherin expression. Separation of the highest 20% 
P-cadherin (P-cadhigh) expressing cell subpopulation from the lowest 20% P-cadherin (P-
cadlow) expressing cell subpopulation revealed that, in all the cell lines studied, the P-
cadhigh cell subpopulation was enriched for the stem cell-associated markers CD44, CD49f 
and CD24, in comparison with the P-cadlow subpopulation, as shown in Figures 2A and 
Figure 3A. Conversely, when parental cells were separated into the four possible 
subpopulations by CD44/CD24 and CD49f/CD24 expression, the CD44+CD24+ and 
CD49f+CD24+ regions were the ones enriched for P-cadherin expression (Figure 2B and 
Figure 3B). 
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Figure 2 – FACS measurement of the combined expression of CD44/CD24 in a panel of luminal and basal 
breast cell lines. In all cell lines (MCF10A is represented as an example), P-cadherinhigh subpopulation (top 
20% expressing cells) expressed higher levels of CD24, CD44 and than P-cadherinlow subpopulation (lowest 
20% expressing cells) (A). Conversely, when analyzing the different quadrants defined by the stem cell 
markers CD44/CD24, P-cadherin expression was enriched in the CD44+/CD24+ subpopulation (B). * indicates 
≤ 1,5% of the total cell population. 
 
The population described by Al Hajj et al. as the cancer stem cell phenotype, 
CD44+CD24-/low, is decreased in the P-cadhigh fraction (0.20% Vs. 24.2% in the P-cadlow 
fraction, in the example shown in Figure 2A). However, the enrichment of the P-cadhigh 
fraction for the phenotype CD44+/CD24+ (from 50.9% in the P-cadlow to 99.6% in the P-
cadhigh) indicates that this adhesion molecule is associated with stem-like properties 
(Meyer et al., 2009, Rappa & Lorico, 2010). Furthermore, the P-cadhigh cells are also 
enriched in CD49f+/CD24+ cells (from 57.4% in the P-cadlow fraction to 99.9% in the P-
cadhigh) which is evocative of an association with the luminal progenitor profile of the 
breast (Molyneux et al., 2010, Lim et al., 2009, Keller et al., 2010).  
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Figure 3 – FACS measurement of the combined expression of CD49f/CD24 in a panel of luminal and basal 
breast cell lines. In all cell lines (MCF10A is represented as an example), P-cadherinhigh subpopulation (top 
20% expressing cells) expressed higher levels of CD24, CD44 and than P-cadherinlow subpopulation (lowest 
20% expressing cells) (A). Conversely, when analyzing the different quadrants defined by the stem cell 
markers CD49f/CD24, P-cadherin expression was higher in the CD49f+/CD24+ subpopulation In all cell lines 
indicated (except BT-20) (B). * indicates ≤ 1,5% of the total cell population.  
 
In human breast carcinomas, P-cadherin expression is associated with poor patient 
outcome, as well as with the expression of the stem cell markers CD44, CD49f and 
ALDH1 
 
The expression of P-cadherin and the breast stem cell markers CD44, CD24, CD49f 
and the isoform ALDH1 were analyzed by immunohistochemistry in a large series of 466 
invasive human breast carcinomas. This analysis was performed in order to validate in 
primary breast carcinomas the association of P-cadherin expression with the stem cell 
markers previously observed in vitro. P-cadherin membrane expression was found in 
24.5% of the cases (114/466), 63.2% of them were basal-like carcinomas (Table 1). CD44 
membrane staining was present in 51.2% (237/463) of the cases. CD49f membrane 
staining was positive in only 11.5% (49/427) of the invasive breast carcinomas. Regarding 
the membranous stain of CD24, the majority of the cases (88.6% - 410/463) were 
classified as negative/low, and only 11.4% (53/463) of the tumors had clear membrane 
staining. Concerning ALDH1 expression, a minority of cases (7.1% - 33/463) was 
classified as positive, showing a clear cytoplasmic expression in tumor cells.  
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Classical 
prognostic factors 
Subtypes 
p Luminal A 
(n=302) 
Luminal B 
(n=41) 
HER2-OE 
(n=33) 
Basal-like 
(n=68) 
Unclassified 
(n=22) 
P-cadherin 
Positive (n=114) 
Negative (n=352) 
Missing (n=0) 
 
42 (13.9%) 
260 (86.1%) 
 
 
14 (34.1%) 
27 (65.9%) 
 
 
15 (45.5%) 
18 (54.5%) 
 
 
43 (63.2%) 
25 (36.8%) 
 
 
0 (0%) 
22 (100%) 
 
<0.0001 
CD44 
Positive (n=237) 
Negative (n=226) 
Missing (n=3) 
 
147 (49.2%) 
152 (50.8%) 
 
 
17 (41.5%) 
24 (58.5%) 
 
 
12 (36.4%) 
21 (63.6%) 
 
 
56 (82.4%) 
12 (17.6%) 
 
 
5 (22.7%) 
17 (77.3%) 
 
<0.0001 
CD24 
Positive (n=53) 
Negative/Low 
(n=410) 
Missing (n=3) 
34 (11.4%) 
265 (88.6%) 
 
7 (17.1%) 
34 (82.9%) 
 
5 (15.2%) 
28 (84.8%) 
 
4 (5.9%) 
64 (94.1%) 
 
3 (13.6%) 
19 (86.4%) 
 
0.418 
CD49f 
Positive (n=49) 
Negative (n=378) 
Missing (n=39) 
 
11 (4.0%) 
263 (96.0%) 
 
 
6 (15.8%) 
32 (84.2%) 
 
 
2 (6.9%) 
27 (93.1%) 
 
 
27 (42.2%) 
37 (57.8%) 
 
 
3 (13.6%) 
19 (86.4%) 
 
<0.0001 
ALDH1 
Positive (n=33) 
Negative (n=433) 
Missing (n=3) 
 
12 (4.0%) 
287 (96.0%) 
 
 
4 (9.8%) 
37 (90.2%) 
 
 
4 (12.1%) 
29 (87.9%) 
 
 
13 (19.1%) 
55 (80.9%) 
 
 
0 (0%) 
22 (100%) 
 
<0.0001 
Table 1 – Association between the expression of P-cadherin, CD44, CD24, CD49f and ALDH1 and the major 
breast cancer molecular subtypes. There is a statistically significant association between positive expression 
for P-cadherin, CD44, CD49f and ALDH1 and the basal-like molecular subtype. 
 
Variable 
(n=466) 
P-cadherin+ 
(n=114, 100%) 
P-cadherin- 
(n=352, 100%) 
p value 
(Pearson chi-square) 
CD44+ (n=237) 
CD44- (n=226) 
Missing (n=3) 
72 (63.2%) 
42 (36.8%) 
 
165 (47.3%) 
184 (52.7%) 
 
0.003 
CD24+ (n=53) 
CD24-/low (n=410) 
Missing (n=3) 
14 (12.3%) 
100 (87.7%) 
 
39 (11.2%) 
310 (88.8%) 
 
0.747 
CD49f+ (n=49) 
CD49f- (n=378) 
Missing (n=39) 
29 (27.4%) 
77 (72.6%) 
 
20 (6.2%) 
301 (93.8%) 
 
<0.001 
ALDH1+ (n=33) 
ALDH1- (n=430) 
Missing (n=3) 
17 (14.9%) 
97 (85.1%) 
 
16 (4.6%) 
333 (95.4%) 
 
<0.001 
Table 2 – Association between P-cadherin expression and the expression of the stem cell markers CD44, 
CD24, CD49f and ALDH1, analyzed by immunohistochemistry in a series of 466 primary invasive breast 
carcinomas. P-cadherin positive cases are enriched in CD44, CD49f and ALDH1 expression (Vs. P-cadherin 
negative cases). No statistically significant association was seen between P-cadherin and CD24 expression. 
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Importantly, P-cadherin positive cases were significantly enriched for the stem cell 
markers CD44 (p=0.003), CD49f (p<0.001) and ALDH1 (p<0.0001) and no significant 
correlation was found between P-cadherin and CD24 expression (p=0.747) (Table 2). 
Further, the statistical analysis demonstrated that CD44, CD49f and ALDH1 expression 
were also significantly enriched in the basal-like carcinomas, in contrast to CD24 (Table 
1). 
Kaplan-Meier survival curves showed that P-cadherin positive tumors were 
significantly associated with poor overall survival (log-rank, p=0.023) (Figure 4A). 
Furthermore, when taken into account the classical prognostic markers tumor size, 
histological grade and node involvement, the expression of P-cadherin appeared as an 
independent factor, demonstrating the importance of this protein as a poor prognostic 
marker in breast cancer (HR=1.486, p= 0.037, by multivariate Cox analysis) (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Overall survival of patients with breast carcinomas (log-rank test), classified according to the 
expression of P-cadherin (A) and the combined expression of P-cadherin/CD44 (B), P-cadherin/CD24 (C) and 
P-cadherin/CD49f (D). Expression of CD44, CD24 or CD49f alone has no prognostic value (supplementary 
figure 2); however, when P-cadherin is combined with these markers, P-cadherin+/CD44+ and P-
cadherin+/CD24+ cases have a worst overall patient survival. 
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In contrast, the expression of the stem cell markers CD44, CD24, CD49f or ALDH1 
alone was not significantly associated with the clinical outcome (Figure 5). By multivariate 
Cox analysis, the expression of CD24 was the only significant stem cell marker influencing 
survival, in this case related to a better prognosis (HR=0.439, p= 0.014) (Table 3). 
Interestingly, however, when P-cadherin and CD24 were combined, the positive 
expression of both markers was highly associated with the worst patient overall survival 
(log rank, p=0.014) (Figure 4C), whereas tumors with a P-cadherin-CD24+ phenotype 
were associated with a good prognosis. The tumors with combined expression of P-
cadherin and CD44 were also associated with a worst patient overall survival (Figure 4B) 
(log-rank, p=0.047). Although a strong association between P-cadherin and CD49f 
expression was found, the combined expression of both these markers were not 
significantly associated with survival (log-rank, p=0.271) (Figure 4D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Overall survival and univariate analysis (log-rank test) of patients with breast carcinomas, 
according to the expression of CD44 (A), CD24 (B), CD49f (C) and ALDH1 (D). Expression of CD44, CD49f  
or ALDH1 alone do not show any prognostic value. However, although expression of CD24 alone has not 
reached significance, there is a tendency for CD24- cases to have a worse prognosis than CD24+ cases 
(p=0.073). 
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Variable 
Overall survival 
HR (95% CI) p 
P-cadherin 
(positive vs negative, ref) 1.486 (1.024-2.155) 0.037 
CD44 
(positive vs negative, ref) 1.012 (0.706-1.450) 0.949 
CD24 
(positive vs negative, ref) 0.439 (0.228-0.844) 0.014 
CD49f 
(positive vs negative, ref) 0.819 (0.455-1.474) 0.506 
ALDH1 
(positive vs negative, ref) 1.237 (0.536-2.856) 0.618 
 
Table 3 – Multivariate Cox proportional hazard analysis (for overall patient survival), with models including the 
classical prognostic factors in breast cancer (tumor size, nodal status and histological grade), for P-cadherin, 
CD44, CD24, CD49f and ALDH1 expression. P-cadherin expression appears as an independent factor of 
worse prognosis, whereas expression of CD24 is an independent factor of good breast cancer patient 
prognosis. 
 
 
P-cadherin expression confers increased self-renewal ability, improved cell growth 
in 3D cultures and radioresistance in breast cancer cell lines  
 
The previous in vitro and in vivo indications, showing that P-cadherin is associated 
with the expression of stem cell makers in breast cancer, led us to study the cellular 
effects mediated by the expression of P-cadherin, namely in stem cell activity. 
Stem cell activity can be measured by means of the mammosphere forming ability of a 
specific cell line/subpopulation. In different cell lines, the heterogeneous parental cell 
populations were separated by sorting according to P-cadherin levels of expression (high 
20% Vs. low 20%) and they were studied for stem cell activity. The estimated purity of the 
sorted fractions was on average 80-95%. A representative flow analysis of the isolated 
subpopulations is shown in Figure 6.  
We found that P-cadhigh cell fractions from basal-like cell lines showed a significant 
increased mammosphere forming efficiency (MFE) when compared with the P-cadlow cell 
fraction (Figure 7A). The MFE from the basal P-cadhigh fractions reached up to two times 
the levels of the negative fractions. This result was seen both in the basal tumorigenic 
cells, as well as in the normal MCF10A breast cell line, suggesting that P-cadherin 
contributes to the stem cell activity in both normal and malignant contexts. 
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Figure 6 – Sorting strategy of the Pcadhigh and  P-cadlow subpopulations using BD Influx or BD FACS Aria-II 
cell sorters. After sorting, the purity of sorted populations was checked (this diagram represents one sorting 
experiment performed for the cell line BT-549). 
 
We also studied the clonogenic capacity of P-cadherin positivity in a 3D proliferation 
permissive environment containing matrigel, a matrix resembling the basal lamina of the 
normal breast. Using the same sorting procedure, in the luminal MCF7/AZ and the basal 
BT-549 cells, we found that there was an increase in the number of 3D structures formed 
by the P-cadhigh cell subpopulation, compared to the P-cadlow subpopulation in the basal-
like cell line (Figure 7B). Furthermore, we found that the grape-like structures formed by 
P-cadhigh cells were bigger than the 3D structures formed by the P-cadlow subpopulation 
(95.8µm Vs. 50.1 µm, p=0.003, data not shown). The same does not hold true for luminal 
cells for both parameters analyzed. 
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Figure 7 – Mammosphere forming efficiency (MFE) was measured in the subpopulations isolated by FACS 
according to P-cadherin expression in a panel of human breast cell lines. The isolated subpopulations with 
higher amounts of P-cadherin (top 20% expressing cells), within the basal-like cell lines, displayed highest 
MFE (A); 3D cell cultures, in laminin-rich matrix (matrigel), revealed that the P-cadherinhigh subpopulation from 
the basal BT-549 cell line has increased clonogenic capacity, whereas the same result is not obtained with 
luminal cells (MCF7/AZ) (scale bar = 100 µm) (B). 
 
To verify the specific role of P-cadherin in stem cell activity, we used genetically 
manipulated cell lines, by in vitro transduction or silencing of P-cadherin. We showed that 
stable transduction of P-cadherin in MCF-7/AZ cells led to an increase of mammosphere 
formation (>25% of MFE) when compared to the mock cell line (Figure 8A and Figure 
8B). This difference in mammosphere formation persists for at least two passages (data 
not shown), suggesting a role of P-cadherin in mediating self-renewal or survival. 
Likewise, transient inhibition of P-cadherin expression by siRNA assays, showed that 
mammosphere forming ability was negatively affected, though not completely abrogated 
in most of the cell lines studied (Figure 8A and Figure 8C). These results indicate that P-
cadherin contributes to the stem cell activity of these cells. 
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Figure 8 – P-cadherin cDNA was stably transduced and over-expressed in the luminal cell line MCF7/AZ 
(MCF7/AZ.P-cad) or transiently silenced in the several basal cells lines (A). Measurement of stem cell activity 
by mammosphere forming efficiency (MFE) indicates a direct association between P-cadherin expression and 
this stem cell property (B and C); X-ray irradiation was administered to the normal cell line MCF10A (2Gy) or 
the indicated tumorigenic cells (4Gy) and mammosphere forming efficiency (MFE) was assessed. The 
decrease in the number of stem cells mediated by X-ray irradiation is potentiated after P-cadherin silencing in 
tumorigenic cells, but not in the normal MCF10A cell line (D). 
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The increase in clonogenic capacity in 3D mediated by P-cadherin, and the increase 
in stem cell activity measured by MFE, can be the result of either increased survival of 
cells in the particular conditions of these assays or/and due to alterations in the growth 
rate that affects proliferation/quiescence of the prospective P-cadhigh stem cells. In an 
attempt to understand if P-cadherin effects were mediated by changes in proliferative 
capacity, we evaluated the cell cycle profile in our cell lines, using Hoechst-33342 stain. 
Analysis of the cell cycle revealed that P-cadherin does not affect the subpopulations S 
and G2M (Figure 9). 
 
 
 
Figure 9 – Hoechst-33342 stain of the cell cycle profile in the basal cell lines MCF10A, BT-20 and BT-549 
revealed that inhibition of P-cadherin did not affect the proliferative phase of the cell cycle (G2M). 
 
One of the features attributed to breast cancer stem cells is the increased resistance 
to irradiation, which allows them to survive and persist in tissues after treatment, 
contributing to disease relapse. We investigated the effect of X-ray irradiation alone and in 
combination with P-cadherin inhibition on the stem cell activity measured by MFE. We 
found that inhibition of P-cadherin in the tumorigenic basal-like cell lines potentiated the 
effect of irradiation induced cell death, decreasing the number of mammospheres formed. 
This same effect was not observed in the normal breast cell line MCF10A, where 
irradiation treatment or P-cadherin silencing alone had a negative effect in MFE; however, 
when the two treatments were combined, no additive or synergistic effect was observed 
concerning stem cell activity (Figure 8D).  
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P-cadherin expression confers increased tumorigenic ability to breast cancer cells 
 
The indications given by in vitro functional assays, showing that P-cadherin 
expression has a role in the maintenance of stem cell properties and poor overall survival 
of breast cancer patients, led us to test if cancer cell populations enriched for P-cadherin 
have a higher capacity to promote tumour growth in nude mice. The tumorigenicity of the 
P-cadherin high and low subpopulations was addressed using the basal-like MDA-MB-468 
breast cancer cells, which were inoculated in different dilutions, and the results obtained 
are shown in Table 4. Interestingly, we could observe that cancer cells enriched for P-
cadherin expression have a higher capacity to promote tumor growth, since the number of 
tumors formed was higher in the P-cadhigh group, compared to the control group, in which 
the same number of parental cells was injected. Furthermore, tumours derived from the P-
cadhigh cells were larger in size than the tumours derived from the P-cadlow fraction: by 
week 6 of tumour growth the average size of the P-cadhigh tumors was 73.76 mm3 Vs. 
50.01 mm3 in the P-cadlow group, considering the animals in which 5x104 cells were 
injected (Figure 10A). 
 
Cell population 
Tumors / injection 
106 cells 105 cells 5x104 cells 
unsorted 4/4 2/4 2/4 
P-cad high  2/3 4/4 
P-cad low  0/3 2/4 
 
Table 4 – P-cadherin capacity to promote tumors was evaluated by xenografting P-cadhigh and P-cadlow  cells 
sorted from the basal-like MDA-MB-468 breast cancer cell line in the nude mouse model. The appearance of 
tumors, as well as the tumor mass volume was measured during time. 
 
The tumours formed had often a central core filled with a mucous substance (Figure 
10B). A pathologist will better explore the histopathologic features of the tumours derived 
from the MDA-MB-468 cell line in the future. Interestingly, all animals that developed a 
tumour had enlargement of the inguinal and peritoneal lymph nodes, indicating that there 
was regional involvement and raising the need to search for possible metastatic foci in 
distant sites.  
 
 - 118 - 
 
 
 
Figure 10 – Macroscopic evaluation of the tumours revealed that tumours derived from the 
xenotransplantation of P-cadhigh cells had increased size when compared with the tumours derived in the P-
cadlow group (A). Recruitment of blood vessels was clearly observed in all tumours and the interior of the 
tumours was often filled with a mucous substance (B). 
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 3. Discussion 
 
Increasing evidence supports that cancers are propagated by a small cell 
population, the CSCs, which originate both tumorigenic and non-tumorigenic cells and are 
responsible for tumor heterogeneity, therapy resistance and disease recurrence. The 
identification and analysis of CSCs is mandatory in carcinomas with high patient mortality 
rate, early relapses and lack of a targeted therapy. One of such poor-prognosis cancer is 
the basal-like subtype of breast cancer. 
Basal-like breast carcinomas include tumors that are characterized by an 
expression signature similar to that of the basal cells of the breast (Rakha & Reis-Filho, 
2009). However, features of the luminal gene expression profile are often also attributed 
to these cancers (Gusterson, 2009); therefore, basal-like breast carcinomas are often 
considered to have a mixed phenotype. More recently, the cell of origin for basal-like 
breast cancers was defined as the luminal progenitor cell from the normal breast (Lim et 
al., 2009, Molyneux et al., 2010), but the phenotype for the cancer stem cell has proven a 
tough task.  
In this work we established a positive association between P-cadherin, a basal 
marker, and the stem cell markers CD44, CD24 and CD49f in human breast cell lines 
(normal and cancer cells). We found that all the stem cell markers analysed (CD44, CD49f 
and CD24) segregated together with P-cadherin in the same subset of cells, suggesting 
that P-cadherin could be contributing to a stem-like aggressive phenotype in the breast. In 
accordance to this, the expression of all of these stem cell markers have been linked to 
the acquisition of a malignant phenotype or decreased patient survival (Baumann et al., 
2005, Cariati et al., 2008, Kristiansen et al., 2003, Marhaba & Zoller, 2004). Significantly, 
our study shows that breast cancer cases that express P-cadherin and CD44, or P-
cadherin and CD24, have the worst prognosis. Notably, P-cadherin could be an important 
regulator of stem cell markers in tumor cells, since when this adhesion molecule was 
knocked-down a reduction was found in the expression of CD49f and CD44v6. 
Based on these results, we believe that we got additional experimental evidence 
that P-cadherin can be classified as a stem cell marker in breast cancer. Although the 
simultaneous expression of all the three stem markers in the same cell was never clearly 
described, studies with CD49f and CD24 have shown that these markers combined in the 
same cell are able to identify cells with progenitor like properties in mammary epithelial 
cells in the mouse (Molyneux et al., 2010, Stingl et al., 2006) and in the human (Lim et al., 
2009, Keller et al., 2010). Specifically, Keller et al showed that the normal human breast 
tissue contains an epithelial subtype with the phenotype EpCAMhighCD49f+CD24+, 
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consistent with a definition of luminal progenitor cells, according to the characterization of 
lineage markers (Keller et al., 2010). CD44 has also been used in combination with CD24 
to show that the phenotype CD44+CD24+ identifies cells with stem-like properties, 
including tumourigenicity, in breast cell lines (Meyer et al., 2009, Rappa & Lorico, 2010) 
and in ER-negative human breast tumors (Meyer et al., 2010). In this last study Meyer et 
al also show that CD44posCD49fhigh cells are enriched for tumor initiating ability in ER-
negative breast cancers (Meyer et al., 2010). 
the association between the expression of P-cadherin and the phenotype 
CD49f+CD24+ in several cancer and normal cell lines supports the notion that P-cadherin 
could potentially be used together with other markers in the identification of the luminal 
progenitor of the normal breast. In fact, luminal progenitor cells have been described as 
the cell of origin for basal-like cancers (Lim et al., 2009, Molyneux et al., 2010) in which 
BRCA1 inactivation is a common feature and is considered to halt the maturation towards 
the luminal phenotype (Liu et al., 2008). This would explain the up-regulation of P-
cadherin found in basal-like cancers, since BRCA1 is a P-cadherin transcriptional 
repressor (Gorski et al., 2009). Notably, Sarrio at al recently reported that in a normal non-
tumorigenic human breast cell line with a basal-like profile the subpopulation defined as 
EpCAM+CD49f+ exhibits progenitor like properties and, interestingly, this subpopulation of 
cells specifically expressed P-cadherin (Sarrio et al., 2011). 
An enrichment of P-cadherin expression in cells that have the stem/progenitor 
phenotype CD44+CD24+ was also found in this study. Importantly, cells with the 
phenotype CD44+CD24+ have been described as having tumorigenic ability and represent 
a dynamic population which can originate the CSC phenotype (Meyer et al., 2009, Pece et 
al., 2010, Rappa & Lorico, 2010). In fact, Pece et al, showed that cells with cancer stem 
cell activity are CD24+ (Pece et al., 2010) and the phenotype CD44+CD24+, isolated from 
several human breast cancer cell lines, shows tumorigenic activity in murine xenograft 
models (Meyer et al., 2009). This indicates that targeting cells with the phenotype 
CD44+CD24+, which have increased P-cadherin expression, could help to eradicate the 
CSCs.  
Our data still show that P-cadherin is not a simple bystander present in the cells 
throughout the breast hierarchy, but it can also be a regulator of the stem cell function. 
First, we showed that P-cadherin has higher capacity in promoting tumor growth in nude 
mice. Second, we found that P-cadhigh cell lines have increased ALDH activity and that P-
cadherin expression is increased in the ALDEFLUOR+ subpopulation. Previous studies 
have shown that ALDH activity and expression is linked to increased stem cell activity, 
tumorigenicity and poor prognosis in breast carcinomas (Croker et al., 2009, Ginestier et 
al., 2007). Furthermore, P-cadherin gene expression manipulation (either by silencing with 
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siRNA or by P-cadherin/CDH3 overexpression), as well as separation of cell populations 
by sorting, showed that this adhesion molecule mediates stem cell activity and the self-
renewal of mammospheres in basal breast cell lines. The growth in 3D matrigel matrix 
was also increased in the P-cadhigh subpopulation relative to the P-cadlow subpopulation of 
basal-like breast cancer cells. It is still not clear whether the increase in clonogenic 
capacity in 3D mediated by P-cadherin, and the increase in stem cell activity measured by 
MFE, is the result of increased survival or alterations in the growth rate that affects 
proliferation/quiescence of the prospective P-cadhigh stem cells. Analysis of the cell cycle 
revealed that P-cadherin does not affect the subpopulations S and G2M (Figure 9). 
Importantly, the fact that cells with lower expression of P-cadherin still show some 
tumorigenic ability and a certain level of growth in anchorage independent conditions and 
in matrigel 3D cultures indicates that stem cell properties are still present in the P-
cadherin depleted fraction. Although P-cadherin does not seem to be an exclusive marker 
of CSCs, our results show that a further enrichment of the stem cell population could 
potentially be achieved by a combination of P-cadherin with other biomarkers. For basal-
like carcinomas, several studies have used combinations of the following biomarkers to 
define the CSC subpopulation: ESA, CD44, CD24, CD49f, CD133-2, PROCR and 
ALDEFLUOR(Al-Hajj et al., 2003, Croker et al., 2009, Hwang-Verslues et al., 2009, Meyer 
et al., 2010, Wright et al., 2008). Not surprisingly, expression of P-cadherin alone in 
invasive breast cancer confers bad prognosis and we observed that this marker is 
associated with the stem cell markers CD44, CD49f and ALDH1, and all these markers 
with the basal-like molecular subtype. The isolation of P-cadherin positive subpopulations 
within the CD44+ or within CD24+ fractions is of potential interest, since in our series of 
human breast carcinomas the tumors that exhibit P-cadherin+CD44+ or P-cadherin+CD24+ 
phenotype seem to be particularly aggressive. Interestingly, the phenotype P-
cadherin+CD44+CD49f+CD24+ could also support the isolation of progenitor cells from the 
normal breast, as mentioned above. 
Additionally, it is known that basal-like breast cancers are particularly aggressive 
because they resist to current therapeutic strategies, usually recurring in a short time 
frame. In particular, resistance to radiotherapy has been reported for breast cancer, and 
relapses often occur. Although poorly understood, this type of resistance could be 
mediated by several mechanisms controlling the survival and DNA repair mechanisms, 
allowing CSCs to survive and to give rise to a new tumor (Phillips et al., 2006). In this 
study, we show that, when given X-ray irradiation, the silencing of P-cadherin contributes 
to decreased survival of the stem cell population in the tumorigenic cells, but not in the 
normal. Hence, inhibition of P-cadherin could be an approach to increase sensitization of 
tumorigenic cells to radiotherapy, potentially allowing the reduction of the current doses of 
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radiation administered to the malignant tissue and causing less damage to the normal 
cells. 
 
In conclusion, we found, for the first time, that P-cadherin confers stem cell features 
to breast tumorigenic cells that could be linked to the aggressive behavior of basal-like 
breast cancers. We show that this molecule is associated with increased stem cell activity 
(tumorigenicity in athymic nude mice, mammosphere formation and growth in 3D matrix) 
in basal-like cell lines, but not in luminal cells. P-cadherin is associated with already 
described stem cell markers which define the luminal progenitor phenotype and which, in 
our series of primary invasive breast cancers, is associated with the shortest overall 
patient survival. We also found that inhibition of P-cadherin sensitizes cancer cells to X-
ray induced cell death. 
In the future, CSC therapies for the aggressive basal-like breast carcinomas can 
eventually involve the targeting of P-cadherin cell surface protein. In fact, phase-I clinical 
trials are underway, which will help to define if P-cadherin constitutes a good therapeutic 
target in breast cancer (Zhang et al., 2010). Importantly, our results show that anti-P-
cadherin treatment could improve radiation therapy in patients. 
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 1. Introduction 
 
Cadherin molecules have a major role in tumour progression. A significant example 
is the E-cadherin/CDH1 gene, for which a tumour suppressor function is clearly observed 
in the large majority of human carcinomas. In fact, one of the first steps in the metastatic 
cascade is the loss of E-cadherin expression by cancer cells. Mutations of the E-
cadherin/CDH1 gene are also involved in increased risk to develop certain types of breast 
and gastric cancers (Paredes et al., 2012). P-cadherin, on the other hand, has a tumour 
promoting effect in several solid tumours, including the pancreatic, prostate, colorectal 
and breast cancer (Albergaria et al., 2011, Hardy et al., 2002, Imai et al., 2008, Paredes et 
al., 2005, Taniuchi et al., 2005) (Paredes et al., 2012). Indeed, we have previously 
demonstrated that P-cadherin is a poor prognosis factor in mammary invasive ductal 
carcinomas and is associated with lack of differentiation and high grade carcinomas 
(Paredes et al., 2005, Paredes et al., 2002b). Its expression was found to be up-regulated 
in a particularly aggressive subtype of breast cancers, specifically in the basal-like 
subgroup (Matos et al., 2005, Paredes et al., 2005, Paredes et al., 2002a). In vitro studies 
from our group have shown that P-cadherin mediated aggressive behaviour in breast 
cancer involves increased cell invasion and motility (Paredes et al., 2004), increased 
production and activation of metalloproteinases (Ribeiro et al., 2010) and increased 
cancer stem/progenitor cell properties (Vieira et al., 2012).  
It is well known that the maintenance of the stem cell activity requires signalling 
mediated by the ECM and by ECM receptors, also known as integrins (Bissell & Hines, 
2011). Integrins are major signalling receptors that integrate external ECM signals 
controling the cell internal milieu. Conversely, they also signal from the inside of the cell to 
modulate the extracellular microenvironment. The basal/myoepithelial cells of the breast 
are in direct contact with the basement membrane which is composed of a complex 
mixture of ECM molecules that contribute to the survival and adhesion signalling of 
epithelial cells and to the maintenance of the stem cell niche within the normal breast. 
Interestingly, P-cadherin is expressed in the basal/myoepithelial cells and it was shown to 
be co-expressed with another adhesion molecule, the α6 integrin receptor (or CD49f), in a 
population of cells that mediate stem-like properties (Vieira et al., 2012).  
Alterations in the ECM or in integrin expression mediate major oncogenic effects in 
the initiation and progression of breast cancer (Bissell & Hines, 2011, Goss et al., 2008). 
For example, ECM remodelling and integrin activation assist in the malignant 
transformation of cells in the primary site, as well as in the activation of quiescent cells in 
distant metastatic sites, such as the bone, liver, lung and brain (Barkan et al., 2010b, 
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Pontier & Muller, 2009, Barkan et al., 2010a, Psaila & Lyden, 2009). In the normal breast, 
the basement membrane has a crucial role in limiting tumour progression, being 
composed mainly by collagen type-IV and laminin-332 (formerly termed laminin 5) 
(Tsuruta et al., 2008). In cancer, elevated expression of laminin in breast carcinomas is 
considered a poor prognosis factor (Tagliabue et al., 1998, Tsuruta et al., 2008). In fact, 
abnormal overexpression of laminin-332 is present in the migrating edge of the tumour 
mass and the expression of laminin receptors are believed to promote invasion of breast 
cancer cells (Kim et al., 2011, Tsuruta et al., 2008). Although several integrins recognize 
laminin substrates, the α6 integrins (α6β1 and α6β4) are the major receptors that 
contribute to breast cancer progression and have captured the interest of several cancer 
researchers (Mercurio et al., 2001, Soung et al., 2011). Thus, the role of the heterodimmer 
α6β4 in tumour progression has been extensively investigated. Aberrant activation of the 
α6β4 receptor is implicated in cell survival, migration and invasive potential (Shaw et al., 
1997, Bon et al., 2007, Mercurio et al., 2001, Soung et al., 2011). Interestingly, the 
expression of the β4 integrin subunit is associated with poor breast cancer patient 
prognosis (Lu et al., 2008, Tagliabue et al., 1998) and specifically with the basal-like 
molecular subtype (Lu et al., 2008). Although mice in which β4 integrin was inactivated in 
the mammary gland have a normal breast development (Klinowska et al., 2001), this 
integrin subunit was found to be crucial for breast cancer progression (Guo et al., 2006). 
Furthermore, overexpression of the α6 integrin subunit was found in invasive breast 
carcinomas correlating with decreased overall patient survival (Friedrichs et al., 1995), 
being an important breast stem cell marker in both mice and humans (Eirew et al., 2008, 
Stingl et al., 2001, Stingl et al., 2006, Villadsen et al., 2007). A major role has been also 
proposed for β1 integrin subunit in the normal development of the murine breast, 
regulating the ability of the stem cells to self-renew and properly differentiate (Taddei et 
al., 2008). This integrin molecule is also known as CD29 and it represents an important 
marker of normal murine stem cells (Shackleton et al., 2006). β1 integrin has also an 
important role in tumourigenesis, since the disruption of this integrin in the mammary 
gland of a transgenic mouse model completely blocked tumour formation driven by the 
polyomavirus middle T antigen (White et al., 2004). 
Thus, the crosstalk between cell-cell and cell-ECM adhesion complexes reflects a 
highly integrated network. Although often spatially distinct, integrin and cadherin 
adhesions activate many of the signalling pathways and elicit similar cellular functions that 
are part of a larger adhesive structure. In cancer, an association of cadherins and 
integrins can originate complexes that mediate important oncogenic responses, often 
through interaction with other transmembrane proteins, such as growth factor receptors. 
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Several reports  focus on the association of E-cadherin with integrin molecules (Canonici 
et al., 2008, Chartier et al., 2006, Chattopadhyay et al., 2003, Wang et al., 2004), but no 
interaction between P-cadherin and integrin molecules was ever described. P-cadherin 
role is well described in cell-cell interaction, however its role in the cell-ECM interaction is 
not known.  
The aim of this study was to reveal whether P-cadherin-induced stem cell features 
and invasive properties in breast cancer cells are dependent on ECM components and 
integrin receptors signalling. We used basal-like breast cancer cell lines and 
demonstrated that P-cadherin affects the adhesion of cells to different ECM substrates. 
Furthermore, we found that, mechanistically, the signalling pathway triggered by P-
cadherin in response to laminin is dependent, at least partially, on α6β4 integrin 
expression, and activates Src, FAK and AKT kinases in breast cancer cells. 
 - 128 - 
 2. Results 
 
P-cadherin dependent adhesion of breast cancer cells to ECM components 
 
The role of P-cadherin as a cell-cell adhesion molecule is well documented; 
however, its role in cell - ECM adhesion is unknown. In this study, the adhesion of cancer 
cells to several ECM components typically implicated in tumour progression was 
assessed. The cell lines tested were MDA-MB-468 and BT-20, which have a basal-like 
epithelial phenotype characterized by high expression of E-cadherin, negativity for 
hormone-receptors, lack of HER-2 amplification and high levels of basal markers, 
including EGFR amplification and high expression of P-cadherin (>80% P-cadherin 
positive). Transient knock-down of P-cadherin was performed by siRNA (60% inhibition in 
MDA-MB-468 and 82% inhibition in BT-20) and adhesion to collagen type-I, collagen type-
IV, laminin-332, vitronectin and fibronectin was measured by the crystal-violet assay    
(Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Adhesion of the breast cancer cell lines MDA-MB-468 and BT-20 to extracellular matrix (ECM) 
components is dependent on P-cadherin. (A) In the example shown, inhibition of P-cadherin expression in 
MDA-MB-468 cells decreased % adhesion to laminin-332, vitronectin and fibronectin (adhesion time = 20 
min). The same trend was observed for BT-20 cell line (adhesion time = 30 min). (B) Bright field images of 
MDA-MB-468 cells in the tissue culture plate coated with ECM substrates after the adhesion assay. Cells 
were fixed and the nuclei stained with crystal-violet. (Coll I – collagen I, Coll IV – collagen IV, Lam – laminin 
332, Vit – vitronectin, Fib – fibronectin, BSA – bovine serum albumin, negative control). 
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Both cell lines behaved similarly: control transfected cells preferentially adhered to 
collagen type-I and vitronectin (>90% adhesion), followed by a moderate adhesion to 
collagen type-IV, laminin-332 and fibronectin (50-70%). Adhesion of both cell lines to 
plastic was approximately 70% (Figure 1A). When P-cadherin was inhibited, adhesion to 
laminin-332, vitronectin and fibronectin was significantly reduced by about 20%, whereas 
adhesion to the collagen molecules (type I and IV) was not affected (Figure 1A and 1B). 
Adhesion to plastic was slightly reduced, although not significantly.  
 
 
P-cadherin regulates the expression of the laminin receptor α6β4 integrin in breast 
cancer cells 
 
Since P-cadherin interfered with the adhesion of cancer cells to laminin-332, 
vitronectin and fibronectin, we set out to investigate whether this was mediated by any 
alteration in the function or expression of integrins, the major receptor molecules that 
connect cells to the ECM and which are known to be directly implicated in cancer 
aggressiveness. Thus, we analysed the surface expression of β1, β4 and α6 integrins by 
flow cytometry. 
β1 integrin is a major component of most integrin heterodimers recognizing most 
ECM components, including laminin-332, vitronectin and fibronectin. α6 and β4 subunits 
bind exclusively to laminin and have important tumour promoting effects in breast cancer 
(Bon et al., 2007, Mercurio et al., 2001, Shaw et al., 1997, Soung et al., 2011). As shown 
in Figure 2, P-cadherin inhibition had no effect in the expression of β1 integrin. However 
P-cadherin knock-down caused a reduction in the cell surface expression of α6 and β4 
integrins in both cell lines MDA-MB-468 and BT-20, as evaluated by flow cytometry 
(Figure 2A). Furthermore, the expression of α6 and β4 subunits was also evaluated by 
immunofluorescence and immunoblot, confirming a decrease in the total amount of these 
integrins in breast cancer cells (Figure 2B and 2C). 
Interestingly, α6 and β4 form a heterodimer (also known as hemidesmosome, in 
normal cells) that recognizes the major component of the basement membrane, laminin-
332, for which we demonstrated that adhesion was impaired upon P-cadherin knock-down 
(Figure 1). 
 
 
 - 130 - 
Figure 2 – P-cadherin knock-down reduces integrin α6 and β4 expression in MDA-MB-468 and in BT-20 cells. 
Cell surface expression of P-cadherin and integrin molecules was analysed by Fluorescence Activated Cell 
analysis. The median intensity of integrins α6 and β4 stain was decreased upon P-cadherin knock-down. No 
effect was observed in integrin β1 expression. (A). Similarly, a decrease in integrin α6 and β4 was also found 
by Immunofluorescence (the cell line BT-20 is represented (scale bar=20µm) and similar results were 
obtained for MDA-MB-468 cell line) (B) and by Immunoblot (C).  
 
 
P-cadherin and the α6 integrin confer stem cell properties and invasive features to 
breast cancer cells  
 
Since P-cadherin expression shows an important effect on cell-ECM adhesion and 
clearly modifies integrin α6β4 expression in breast cancer cells, we set out to study if this 
integrin heterodimer was also implicated in important aggressive properties that have 
been previously ascribed to P-cadherin, namely, the invasive capacity and the cancer 
stem cell activity. Furthermore, to clarify the crosstalk between P-cadherin and α6β4 
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integrin, the effect of both α6 and β4 integrin subunits in the expression levels of P-
cadherin were also studied by immunoblot. 
Inhibition of α6β4 in breast cancer cells decreased the mammosphere forming 
efficiency (MFE), as well as the invasion capacity in the same magnitude as the inhibition 
of P-cadherin (Figure 3A and 3B). Importantly, α6 integrin inhibition alone showed the 
same impact in MFE and in the invasion potential as the inhibition of P-cadherin or the 
repression of the α6β4 heterodimer. However, inhibition of the β4 integrin subunit in 
breast cancer cells did not show a statistically significant impact in these functional 
properties (Figure 3A and 3B). These results indicate that P-cadherin downstream 
signalling effects could be primarily dependent on the integrin α6 subunit function. 
 
 
 
Figure 3 – Inhibition of α6β4 integrin decreased the stem cell activity in breast cancer cells to the same extent 
as inhibition of P-cadherin, measured by the mammosphere forming efficiency (MFE) (BT-20 cell line) (A). In 
the same way, the invasion capacity of these cells in matrigel was severely compromised when P-cadherin or 
α6β4 integrin were knocked-down (B). As P-cadherin clearly impacted in the expression of α6β4 heterodimer, 
these results indicated a possible association between both pathways; although the expression of the α6 and 
β4 subunits is decreased upon P-cadherin knock-down, the expression of P-cadherin is not affected after the 
inhibition of either α6 integrin or β4 integrin or both integrins at the same time (C).  
 
It is interesting to note that, while P-cadherin knock-down caused a reduction in α6 
and β4 integrin subunits, the opposite was not true (Figure 3C). The inhibition of α6 
and/or β4 integrins showed no effect in P-cadherin expression. Nonetheless, α6 integrin 
 - 132 - 
knock-down led to a decrease in the expression of its partner, the β4 integrin subunit, 
again raising the possibility that P-cadherin may in fact be controlling mainly the α6 
subunit expression which in turn controls the β4 subunit. In summary, only when the α6 
integrin subunit or the α6β4 integrin heterodimer were inhibited were the functional 
properties affected; the inhibition of β4 integrin subunit had no effect in MFE and invasion. 
 
 
P-cadherin overexpressing cells have increased adhesion to laminin as well as 
increased stem cell activity and these properties are dependent on α6β4 integrin 
expression 
 
The previous results raised the possibility that there could be a crosstalk between 
two adhesion molecules: P-cadherin and α6 integrin. Thus, to further explore the role of 
α6 integrin and its partner, β4 integrin, in the functional properties mediated by P-
cadherin, we analysed the cell-laminin adhesion capacity and the MFE of a breast cancer 
cell line constitutively overexpressing P-cadherin (MCF7/AZ.P-cad) and compared these 
properties with control cells, which have low levels of P-cadherin (MCF7/AZ.mock). P-
cadherin expression was accompanied by an increase in the expression of both the α6 
integrin subunit as well as the β4 integrin subunit (Figure 4A). Importantly, P-cadherin 
upregulation lead to an increase in the adhesion of MCF7/AZ.P-cad cells on top of a 
laminin coated surface (Figure 4B) and increased the stem cell activity of these cells, 
measured by the MFE (Figure 4C). These effects were mediated, at least partially, by 
α6β4 integrin expression, since this integrin heterodimer was increased in P-cadherin 
overexpressing cells (Figure 4C); when both integrin subunits were simultaneously 
knocked-down in MCF7/AZ.P-cad cells, these functional properties were significantly 
reduced (Figure 4). Once more, P-cadherin levels were not affected by α6β4 integrin 
knock down, indicating that these integrin molecules are most likely acting downstream of 
P-cadherin activation (Figure 4C).  
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Figure 4 – The increased adhesion to laminin and the increased stem cell activity observed in P-cadherin 
overexpressing cells is dependent on α6β4 integrin expression. MCF7/AZ cells overexpressing P-cadherin 
(MCF7/AZ.P-cad) presented increased capacity to adhere to laminin (adhesion time = 40 min) and increased 
mammosphere forming efficiency (MFE) (Vs. MCF7/AZ.mock cells) (A) and (B). These effects are 
accompanied by an increase in the expression of the integrin subunits α6 and β4. Inhibition of the α6β4 
integrin heterodimer in the P-cadherin overexpressing cells restored the levels of adhesion to the control 
levels, and strongly inhibited the MFE in these cells. P-cadherin expression was not affected by α6β4 integrin 
knock down (C). 
 
 
Integrin signalling in response to laminin-332 is dependent on P-cadherin 
expression 
 
The previous data established a cooperation between P-cadherin and α6β4 integrin 
regarding signalling. We therefore studied whether P-cadherin could affect the main 
signalling molecules downstream of the α6β4 integrin receptor in cancer cells grown on 
top of a laminin substrate. The activation of the integrin related kinases FAK and Src was 
studied by immunoblot after cell adhesion to this substrate. We found that P-cadherin 
inhibition in breast cancer cells reduced p-FAK Tyr397 and p-Src Tyr416 levels (Figure 
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5A). Notably, the p-FAK reduction was also detected by immunofluorescence in both cell 
lines studied (Figure 5B). Furthermore, activation of AKT was also affected, shown by the 
level of p-AKT Ser473 being reduced (Figure 5A). Altogether, these results indicate that 
FAK and Src activation in response to laminin is dependent on P-cadherin expression in 
breast cancer cells. Although lateral integrin-cadherin associations are known to occur 
(Canonici et al., 2008, Chattopadhyay et al., 2003, Weber et al., 2011), we were unable to 
demonstrate an interaction between P-cadherin and α6 or β4 by co-immunoprecipitation 
(data not shown). 
We also investigated if the cancer cell phenotype was affected in cells grown on top 
of ECM substrates. We analysed the cell actin microfilaments by phalloidin staining and 
visualized F-actin by fluorescence microscopy in breast cancer cells adhered to laminin 
coated coverslips (Figure 5B). We found that control cells (scrambled transfected) had 
more stress fibres and appeared more flattened than cancer cells with P-cadherin 
inhibition. The stress fibres provide the cytoskeletal tension which is required for focal 
adhesion formation in laminin, indicating a strong adhesion to the ECM substrate. Staining 
with an antibody for p-FAK Tyr397 allowed the identification of focal adhesions and sites 
of cell-to-cell contacts. Both focal adhesions and cell-cell contacts were decreased in P-
cadherin depleted cells (Figure 5B). In summary, P-cadherin has a role in eliciting cell 
shape changes associated with adhesion to the ECM. 
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Figure 5 – P-cadherin signalling in response to laminin is dependent on FAK and Src activation. Analysis of 
integrin downstream signaling molecules in breast cancer cell lines was performed after adhesion to laminin-
332 (20 min for MDA-MB-468 and 30 min for BT-20) (A); The number of stress fibers (F-actin was stained with 
phalloidin-rhodamine) and focal adhesions/contacts (stained with pFAK Tyr397 – Alexa 488) is reduced by P-
cadherin knockdown in MDAB-MB-468 cells grown on top of laminin. The same result was found for BT-20 
cell line (B). 
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 3. Discussion 
 
Cadherins are classically seen as molecules that make a major contribution for cell-
to-cell adhesion. Specifically in breast, P-cadherin expression is found in the myoepithelial 
cell layer, where it is thought to contribute to the self-organization of these cells as well as 
to cell-cell adhesion (Chanson et al., 2011). Notably, P-cadherin specific signalling 
pathways are far less well described compared to other classical adhesion molecules. 
Furthermore, the basal layer of the mammary epithelium is enriched in molecules involved 
in the adhesion of epithelial cells to the ECM, namely integrin molecules, such as α6β1 
and α6β4. In normal cells, the later heterodimer is known as hemidesmosome and it is the 
receptor for laminin, the major component of the basement membrane. 
In breast cancer, P-cadherin molecule appears upregulated in 30% of all breast 
cancer patients and it is associated with poor patient prognosis (Paredes et al., 2005, 
Turashvili et al., 2011). Importantly, cancer progression in the breast involves 
modifications of the normal ECM, as well as oncogenic activation of integrin signalling in 
both the primary, as well as in the metastatic site (Muschler & Streuli, 2011, Pontier & 
Muller, 2009). Here, we establish that P-cadherin is involved in the attachment of cells to 
ECM substrates, since silencing of P-cadherin expression rendered the cancer cells 
significantly less able to adhere to vitronectin, fibronectin and laminin. When integrins 
expression was investigated, we found that P-cadherin was necessary for the correct 
expression of the integrin subunits α6 and β4. Importantly, the recognition of laminin by 
cancer cells has significant tumour promoting effects. For example, laminin-332 induces 
motility in MCF-7 cell line (Carpenter et al., 2009). Furthermore, IHC analysis of laminin-
332 in human carcinomas in situ showed that this ECM substrate is located in the 
myoepithelium adjacent to preinvasive cells (Carpenter et al., 2009, Kim et al., 2011) that 
could potentially contribute to early steps of stromal invasion. The interface zone between 
the tumour cells and the stroma is enriched in laminin and in α6β4 integrin (Kim et al., 
2011). 
P-cadherin is a major player in inducing invasion and migration of breast cancer 
cells (Ribeiro et al., 2010). The signalling pathways that contribute to this aggressive 
behaviour are poorly understood, involving to some extent the activation of 
metalloproteinases and the consequent release of a pro-invasive P-cadherin fragment 
and/or the activation of small GTPases (Ribeiro et al., 2010, Taniuchi et al., 2005). 
Recently, we have shown that P-cadherin has been implicated in the maintenance of stem 
and progenitor properties in basal-like breast cancer cells, including the self-renewal 
capacity and the tumourigenic ability in nude mice (Vieira et al., 2012). We also found that 
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P-cadherin is co-expressed with α6 integrin in breast cancer cells (Vieira et al., 2012), a 
marker of the stem/progenitor phenotype present in the mouse and human breast (Eirew 
et al., 2008, Stingl et al., 2001, Stingl et al., 2006, Villadsen et al., 2007). In the present 
work, we explored further this association, showing that there is a crosstalk between both 
adhesion molecules. P-cadherin is acting upstream of a major signalling pathway that 
involves the activation of α6 integrin and its partner, the β4 subunit. As a consequence of 
the adhesion of cancer cells to laminin surface, the activation of the α6β4 heterodimer 
would lead to Src and FAK activation in a P-cadherin dependent manner. In fact, P-
cadherin knock-down reduces FAK and Src activation. Importantly, it has been reported 
that α6β4 integrin promotes survival and invasion by activating the PI3K/Akt pathway 
(Bachelder et al., 1999, Shaw et al., 1997) and, notably in our work, a reduction was also 
found in AKT activation in P-cadherin silenced cells.  
Interestingly, it was previously found that α6 integrin induces P-cadherin 
transcription (Deugnier et al., 1999), further supporting the idea that P-cadherin could 
cooperate with α6 integrin signalling. However, our work revealed that P-cadherin and α6 
integrin do not directly interact (by co-immunoprecipitation, data not shown). 
 β1 integrin is also a partner of α6 integrin subunit recognizing laminin, being also 
essential for the correct development of the mammary epithelium, and regulating the 
ability of the mammary stem cells to self-renew and differentiate properly (Taddei et al., 
2008). Despite not having found any alteration in the β1 integrin levels upon P-cadherin 
inhibition, we do not exclude the possibility that β1 integrin subunit is also implicated in the 
maintenance/acquisition of cancer stem cell and invasive properties, as this is the other 
major partner of α6 integrin, constituting an important laminin receptor.  
Additionally, although the cell shape was not severely affected by P-cadherin knock-
down and cells clearly maintained an epithelial phenotype, we found that the number of 
cell-to-cell contacts and the number or focal adhesions to laminin was clearly reduced 
upon P-cadherin inhibition. It is possible that α6β4 integrin and the implicated FAK/Src 
kinase activity may also be contributing to the stem/progenitor characteristics. It was 
shown that FAK deletion in the murine mammary gland suppressed tumourigenesis by 
decreasing the number of cancer stem cells (CD24+CD29+CD61+ and ALDEFLUOR+ 
populations) (Luo et al., 2009). Notably, FAK activation allows for the survival of cells in 
anchorage-independent conditions (Xu et al., 2000), which may explain why integrin 
knock-down, as well as P-cadherin knock-down, reduced survival of cells growing as 
suspension colonies in which the ECM is present within the mammosphere.  
Thus, the poor patient prognosis found in P-cadherin overexpressing breast cancer 
cases (Paredes et al., 2004) may be related, at least partially, to the fact that this cadherin 
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enables cells to respond to integrin signalling and promotes an oncogenic response. 
Importantly, strategies to inhibit P-cadherin could lead to a decrease in integrin activation 
and potentially oppose the oncogenic signalling mediated by laminin and its receptor. 
Since P-cadherin up-regulation is also found in in situ stage of breast cancer development 
(Paredes et al., 2002b), it is possible that it may already be contributing to the changes in 
integrin signalling in the early stages of breast cancer development.  
In conclusion, our results show that the cell-to-cell adhesion mediated by P-cadherin 
can modulate the expression or activity of another type of adhesions, in this case integrin 
adhesive contacts. P-cadherin and integrins have oncogenic signalling pathways that 
cooperate and cross-talk. This is particularly relevant because it helps to understand 
tumour cell-ECM interactions and the mechanisms by which ECM and ECM receptors 
regulate cancer progression.  
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 1. General Discussion 
 
The results described in this Doctoral Thesis highlight the importance of dissecting 
novel CSC biomarkers, with a focus in the basal-like subtype of breast carcinomas. Given 
the high heterogeneity of breast cancer and the fact that no universal phenotype for the 
CSC has been identified, new and better ways to isolate this important population of cells 
are needed. In this context, a putative new CSC biomarker, P-cadherin, is presented. P-
cadherin aggressive features were associated with CSC characteristics in basal-like 
breast carcinomas and a new signalling mechanism with implications in the stem cell 
niche signalling is presented. 
 
According to the hierarchical model of tumour progression (Bonnet & Dick, 1997, 
Reya et al., 2001), it is assumed that CSCs generate cells with aberrant and limited 
differentiation, which through mechanisms as yet unknown translate into the distinct 
breast cancer molecular subtypes. In this context, each molecular subtype is putatively 
composed of cancer cells with a different level of differentiation (Schmitt et al., 2012). 
First, in Chapter IV we established three different methods to characterize the stem 
cell properties present in human breast cancer cell lines: cell surface marker expression, 
the ALDEFLUOR assay and mammosphere formation. We showed that these methods 
identify different subpopulations of cells in our panel of breast cancer cell lines. We 
demonstrated that the expression of the stem cell markers CD44, CD49f and ALDH1 were 
increased in the basal/epithelial group of cell lines. Also, this subgroup of cells presented 
a CD44+CD24+ phenotype, as well as CD49f+CD24+ phenotype, indicating an association 
with the luminal progenitor of the normal breast, the cell-of-origin for basal-like breast 
carcinomas (Lim et al., 2009, Molyneux et al., 2010).  
Since it is pivotal to translate the CSC concept into the clinical practice, we also 
analysed the expression of stem cell markers in a series of human breast carcinomas by 
IHC. We demonstrated that of the five molecular subtypes, the basal-like subtype 
harbours the highest percentage of tumour cells with a CD44+CD24-/low and ALDH+ 
phenotype. This is corroborated by data published by Honeth and collaborators, who 
showed that the CD44+CD24−/low CSC phenotype is significantly associated with basal-like 
breast cancers in human patients and in particular with BRCA1-inherited cancers (Honeth 
et al., 2008). This was also confirmed in earlier studies using human breast cancer cell 
lines, which reported an enrichment of CD44+CD24-/low and CD44-CD24+ cell populations 
in basal-like and luminal molecular subtypes, respectively (Fillmore & Kuperwasser, 2008, 
Sheridan et al., 2006). In fact the CSC phenotype CD44+CD24-/low was present in our 
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panel of basal/mesenchymal cell lines, being associated to a highly invasive in vitro 
pattern. Even though CD44+CD24−/low cells and ALDH1+ cells are more frequently found in 
basal-like than in luminal tumours, we also noticed that ALDH1+ cells were also found in 
the HER2-OE subtype (Chapter IV). This may be because HER2-OE tumours present a 
stem-like transcriptional programme as a result of their specific transforming genetic 
alteration. In line with this notion, induced overexpression of HER2 in breast cancer cell 
lines increased the number of ALDEFLUOR-positive cells (Korkaya et al., 2008). Since 
the basal-like subtype of breast cancers has an increased CD44+CD24−/low CSC 
population in comparison with other molecular subtypes, it has been hypothesised that in 
these tumours, a differentiation block exists, as the majority of the cells constituting the 
bulk of the tumour do not display a differentiated phenotype (Charafe-Jauffret et al., 2006, 
Charafe-Jauffret et al., 2008, Shipitsin et al., 2007). The transformation of a basal-like 
mammary stem cell to a basal-like cancer cell may either be due to (a) LOH as a second 
hit in BRCA1 mutation carriers or (b) to the downregulation of BRCA1 expression in ER-
negative stem cells. This might result in the arrest of the luminal differentiation process, 
which fixes the cells in the undifferentiated phenotype of basal-like carcinomas with its 
unique expression of basal cytokeratins (K5/6) (Liu et al., 2008). It is important to refer 
that recently, a tumour initiating cell signature, derived from CD44+CD24−/low-sorted cells 
and mammospheres obtain from primary human breast tumours, was found to be 
exclusively enriched in a new molecular subtype referred to as claudin-low (Hennessy et 
al., 2009). This new molecular subtype is characterised by the low expression of genes 
involved in tight junctions and cell–cell adhesion, including claudins 3, 4 and 7, Occludin 
and E-cadherin and it also displays EMT features. These tumour characteristics reflect a 
low level of tumour differentiation and fit with the CSC and EMT phenotypes. 
Thus, our results show that the basal-like cancer subtype is enriched in several 
stem cell features, but the recognition of reliable markers to distinguish the breast CSC 
pool is still necessary and it will be decisive for the development of specific target 
therapies.  
 
Second, it is important to mention that, to date, there is no universal cell surface 
antigen, or combination of antigens, for the purification of the CSCs for each intrinsic 
breast cancer subtype. The identification of a CSC marker for the basal-like subtype of 
breast cancer is of particular importance, due to its high mortality rate, fast relapses and 
lack of target therapy (Rakha et al., 2009). Thus, in Chapter V, we explored the use of 
another cell surface protein to characterize the population of cells with stem cell properties 
in vivo and in vitro. We showed that P-cadherin is an adhesion molecule that may be a 
valuable biomarker, allowing the isolation and the study of CSCs in basal-like breast 
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cancers. The association of P-cadherin with the phenotypes CD24+CD44+ and 
CD24+CD49f+, as well as with the ALDEFLUOR+ subpopulation in breast cancer cells is 
highly suggestive that P-cadherin could be a marker of the luminal progenitor cell of the 
breast epithelial hierarchy. Figure 1 represents the hierarchy of the normal mammary 
gland, with a putative enrichment of P-cadherin expression in the luminal progenitor 
compartment. Furthermore, as already mentioned, this cell has been proposed as the cell-
of-origin for basal-like carcinomas (Lim et al., 2009, Molyneux et al., 2010), which are 
characterized by BRCA1 inactivation (Foulkes et al., 2003, Lakhani et al., 2005, Turner & 
Reis-Filho, 2006). In fact, BRCA1 is a transcriptional repressor of the CDH3/P-cadherin 
gene (Gorski et al., 2009), thus explaining the up-regulation of this protein in basal-like 
tumours and the association we found with the luminal progenitor cell. Further studies that 
include lineage tracing experiments and the use of additional sets of markers will clarify 
this hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Schematic representation of the hierarchy of the normal mammary gland. P-cadherin is putatively 
linked with BRCA1 mutation in basal-like breast tumours and with the CD44+CD49f+CD24+ phenotype. This 
phenotype encompasses the luminal progenitor compartment, which contains the cell-of-origin for basal-like 
breast cancers. 
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Furthermore, we showed that P-cadherin is not a simple bystander present in a 
subpopulation of cells, but it is in fact involved in basal-like breast CSC function. Cells 
enriched in P-cadherin expression exhibited increased self-renewal ability and were able 
to grow faster in complex 3D structures in clonal assays. Additionally, we showed that P-
cadherin was able to confer increased tumorigenic ability to cancer cells in 
xenotransplantation experiments using immune compromised mice. With these in vivo 
and in vitro experiments we proved that this adhesion molecule has the capacity to 
mediate the three hallmarks of CSCs.  
In the present work, we observed that P-cadherin enriched cells were more efficient 
to form mammospheres in both primary formation and in the secondary passage. We also  
showed that P-cadherin silencing reduced the mammosphere formation in the presence of 
X-ray irradiation, pointing to a role for this molecule in mediating radioresistance, another 
CSC property. In an attempt to understand the mechanisms behind the radioresistance, 
we have performed analysis of molecules involved in the DNA damage machinery. In fact, 
we have preliminary results that show that P-cadherin can interfere with the DNA repair 
machinery in non-irradiated cells: transient knock-down of P-cadherin in the basal cell 
lines MDA-MB-468, BT-20 and BT-549 caused an increase in the basal levels of activated 
Checkpoint kinase (Chk)1 and Chk2. This may indicate that cells without P-cadherin have 
increased basal levels of DNA damage which then leads to increased DNA repair 
mechanisms, therefore supporting the idea of P-cadherin in the resistance to DNA injury. 
Furthermore, Chk1 and Chk2 proteins have also been implicated in mediating cell death 
(de Lange et al., 2012, Ouyang et al., 2009, Wang et al., 2009, Sahu et al., 2009) and the 
observed activation of these proteins may support the role of P-cadherin in tumour cell 
survival. Still, more future studies need to be performed in order to unravel the 
mechanisms of radioresistance mediated by P-cadherin in breast cancer cells. 
Another major feature of cancer stem cells is their tumourigenic ability. P-cadherin 
enriched cells  (P-cadhigh), isolated from the basal cell line MDA-MB-468, could develop 
tumours in immune compromised mice which were higher in number and in size, 
compared to the P-cadherin depleted fraction (P-cadlow). The role of P-cadherin in the 
initiation and/or progression of breast cancer will be clarified in the future by assessing the 
tumourigenic ability of MDA-MB-468 cells stably expressing the shRNA for P-cadherin, 
under the control of a DOX inducible system. In fact, a CDH3 shRNA approach was used 
in a mouse metastatic breast cancer cell model (4T1) showing that the knock-down of P-
cadherin produced smaller tumours than the control cells, as well as lower numbers of 
metastatic foci in the lungs (preliminary results). Additionally, in the human BT20 cell line, 
the inhibition of P-cadherin using a siRNA strategy rendered the cells less tumourigenic 
(unpublished data).  
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In the third part of this work, we hypothesised that P-cadherin could have a role in 
the stem cell niche and in the response to the ECM. Thus, in Chapter VI, we dissected the 
molecular mechanisms that allow P-cadherin to induce cancer cell invasion and 
mammosphere formation. We showed that the self-renewal ability and the invasion 
capacity mediated by P-cadherin expression are, at least partially, dependent on 
α6 integrin expression. Furthermore, the self-renewal ability and the adhesion to laminin-
332 were shown to be dependent in α6β4 integrin expression in a P-cadherin 
overexpressing cellular system. The α6β4 integrin heterodimer constitutes a major laminin 
receptor. Interestingly, laminin expression is often upregulated in basal-like tumours 
(Rodriguez-Pinilla et al., 2007, Kwon et al., 2012), it is an indicator of poor prognosis 
(Molino et al., 2003) and its presence in the interface zone between the tumour and the 
stroma is thought to stimulate cancer cell migration (Kim et al., 2011). Thus, the cross-talk 
between P-cadherin and the α6β4 integrin receptor is indicative that P-cadherin has a role 
in the response of breast cells to ECM signals. In this signalling network, we believe that 
P-cadherin is acting upstream of the α6β4 integrin heterodimer. Specifically, P-cadherin is 
impacting on α6 integrin expression directly, which then leads to a decrease in the 
expression of β4 integrin. In fact, it is described that the knock down of α6 integrin in the 
breast leads to a decrease in the expression of its partner, β4 integrin (Klinowska et al., 
2001). Conversely, when β4 integrin is knocked-down specifically in the breast, the 
expression of α6 integrin is not affected, most likely because α6 integrin can bind to its 
other partner, β1 integrin (Klinowska et al., 2001, Klinowska et al., 1999). Actually, in our 
cell models, the inhibition of β4 integrin alone did not have any effect in the expression of 
either P-cadherin or α6 integrin and no effect was observed in the functional properties 
defined by the mammosphere assay and cell invasion. A schematic representation of the 
hypothetical signalling cooperation between the two adhesion molecules is represented in 
Figure 2. We do not exclude the possibility that P-cadherin may additionally be regulating 
α6β1 integrin function, despite the fact that no effect in β1 integrin subunit expression was 
seen upon P-cadherin knock-down. The signalling molecules activated in response to 
α6β4 engagement (adhesion to laminin-332) include the phosphorylation and the 
consequent activation of Fak, Src and AKT. Importantly, it is conceivable that this 
activation cooperates with another signalling network described for P-cadherin in which 
Src phosphorylates the p120ctn that binds to the juxtamembrane domain of P-cadherin. 
Activated p120ctn is dislocated to the cytoplasm, where it can subsequently recruit and 
modulate the activity of the small GTPases Rac1, Cdc42 and RhoA, which control the 
actin cytoskeleton dynamics (unpublished data and (Taniuchi et al., 2005)). Specifically, 
RhoA activation would be an interesting downstream molecule of the P-cadherin signalling 
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pathway, since we have observed that inhibiting P-cadherin expression affects stress fibre 
formation. The role of α6β4 integrin activation in stress fibres formation and small 
GTPases activation was not addressed yet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Crosstalk between P-cadherin and α6β4 integrin. These signalling molecules cooperate leading to 
the phosphorylation and activation of FAK, Src and AKT, mediating important aggressive cancer properties in 
vitro, such as cell invasion and stem cell activity (mammosphere forming efficiency).  
 
The relevance of P-cadherin in integrin signalling could be also attested by the fact 
that a subpopulation of cells depleted of P-cadherin expression had difficulties to grow in 
the 3D culture assays, as shown in Chapter V. This assay was performed with the cells 
growing on top of matrigel, which is a mixture of basement membrane ECM, being laminin 
a major constituent. The lack or the small size of multicellular structures formed in this 
assay indicated that P-cadlow cells had a decreased survival/growth. This observation is 
conceivably due to a lower integrin activity in these cells. However, the expression and 
activity of integrins was not yet assessed in this assay. 
 
The current standard therapy to manage breast cancer is based on targeting the 
bulk of tumour cells, reducing tumour size. However this approach often does not 
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eliminate CSCs, which eventually may lead to tumour recurrence (Figure 3). It is 
anticipated that CSC-targeted therapies, in combination with conventional therapies, will 
provide a more effective treatment strategy (Ablett et al., 2012). One of the potential ways 
to target breast CSCs is by the inhibition of the self-renewal signalling pathways thereby 
inducing differentiation or apoptosis and, as pointed out by our in vitro and in vivo assays, 
targeting the signalling axis P-cadherin/α6β4 integrin would allow a reduction in the stem 
cell activity of cancer cells. Thus, in the future, therapies directed at CSCs or the tumour 
microenvironment in the aggressive basal-like breast carcinomas can eventually involve 
the targeting of P-cadherin cell surface protein. Although the true clinical relevance of the 
CSC is yet to be revealed, there are tantalizing reports that the CSC can be selectively 
targeted without ablating normal stem cells. Interestingly, in 2008, Imai and collaborators 
have suggested CDH3/P-cadherin as a possible target for immunotherapy of pancreatic, 
gastric, and colorectal cancers, since it was identified as a novel tumour-associated 
antigen, meaning that was strongly expressed in tumour cells, but not in normal cells (Imai 
et al., 2008). Thus, since P-cadherin is not frequently expressed in adult tissues, an anti-
P-cadherin approach would be a valuable non-toxic therapy, as only malignant cells would 
be eliminated and the vital organs and normal tissues would not be critically affected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 - Inhibiting the signalling pathway P-cadherin/a6b4 integrin may be a valuable CSC therapeutic 
target. Standard therapies are based in the use of drugs that reduce tumour size. Typical chemo, radio and 
hormone therapy target the tumour bulk and leave the CSCs unaffected, that have intrinsic molecular 
mechanisms that allow therapy resistance and tumour relapse. 
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Recently, a novel and highly selective human monoclonal antibody against P-
cadherin (PF-03732010) was produced, demonstrating anti-tumour and anti-metastatic 
activity in a diverse panel of P-cadherin–overexpressing tumour models, without 
introducing any adverse secondary effects in mice (Zhang et al., 2010). This antibody 
failed to bind to the most closely target-related family members, including E-cadherin, N-
cadherin, and VE-cadherin. PF-03732010 also reduced lymph node metastases and 
lowered the levels of circulating tumour cells (CTC) in whole blood of P- cadherin+ tumour 
bearing mice. The anti-metastatic property of the antibody was remarkable, since it 
significantly inhibited tumour cell infiltration into the lungs. PF-03732010 still suppressed 
β-ctn, cyclin D1, vimentin, Bcl-2, Ki67 and survivin expression, and increased caspase-3 
expression (Zhang et al., 2010). In fact, in an attempt to reach the full potential for clinical 
development of the antibody, PF-03732010 has just completed a Phase I clinical trial 
development. The results from this first clinical trial will improve the knowledge of the 
antibody effective therapeutic dose; its toxicity and the pharmacokinetic and 
pharmacodynamic studies in humans. Preliminary reports provided by Pfizer 
(http://clinicaltrials.gov/ct2/show/results/NCT00557505) show that, in spite of the anti-
tumour effects of PF-03732010 were not clear, the participants did not experience toxicity, 
even for the maximum administrated a weekly dose of 15 mg/kg. 
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 2. Conclusions 
 
Considering our initial aims and the data presented and discussed herein we can 
conclude the following: 
 
1. The in vitro methods used to characterize stem cell properties identify cells 
in different stages of differentiation. 
 
2. The basal-like phenotype is enriched in the stem cell markers CD44, CD49f 
and ALDH1 expression/activity in both in vitro and in a series of invasive 
human breast carcinomas. Basal mesenchymal cell lines were associated 
with the CSC phenotype CD44+CD24-/low, whereas basal epithelial cell lines 
were associated with the CD44+CD24+ and CD49f+CD24+ phenotypes. 
 
3. The adhesion molecule P-cadherin is associated with increased stem cell 
activity in basal-like breast cancer cell lines, including the self-renewal 
capacity, growth in 3D matrix and the tumourigenicity in athymic nude mice. 
 
4. P-cadherin is associated with already described stem cell markers (CD44, 
CD49f and CD24), namely with the phenotypes CD44+CD24+ and 
CD49f+CD24+. 
 
5. P-cadherin inhibition sensitizes stem cells to X-ray-induced cell death. 
 
6. The aggressive phenotype induced by P-cadherin is dependent, at least 
partially, on α6β4 integrin activation. 
 
7. P-cadherin oncogenic signalling cascade involves α6β4 integrin 
engagement and the activation and phosphorylation of FAK, Src and AKT. 
 
In conclusion, this study contributed to identify P-cadherin as cancer stem cell 
marker. Moreover, it unravelled a new molecular mechanism and the associated CSC 
effects mediated by this protein. Importantly, our results show that anti-P-cadherin 
treatment could improve radiation therapy in patients. This work reinforced the importance 
of P-cadherin expression as a prognostic factor for breast cancer patients, and supports 
the development of new therapeutics to control aggressive carcinomas that express this 
cadherin molecule. 
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In this study, we described, for the first time, that P-cadherin mediates CSC 
properties linking several stem cell features to the aggressive behaviour of basal-like 
breast cancers. We also unravelled a novel oncogenic signalling pathway in which P-
cadherin and α6β4 integrin are closely involved, with a focus in the adhesion to the 
laminin substrate, the invasion capacity and mammosphere formation.  
In this context, many interesting questions and challenges remain to be elucidated. 
In order to clarify P-cadherin functional and clinical relevance, we aim to gather 
knowledge in future studies, addressing the following topics: 
 
1. We would like to clarify the role of P-cadherin as a marker of the luminal 
lineage in the normal breast hierarchy. Expanding this knowledge is of 
fundamental value and will enrich our notion of the physiology of the normal 
breast as well as breast cancer. P-cadherin will be combined with other 
markers already described in the literature to fractionate cell populations. 
 
2. Our work is lacking studies using primary human mammary epithelial cells 
from normal breast tissue, BRCA1 mutation carriers and basal-like breast 
tumours. This would help clarify the role of P-cadherin in the in vivo human 
setting. 
 
3. Another important aspect is to clarify the role of P-cadherin in the EMT 
progression. This is a process through which an epithelial cell can give rise 
to stem cells (Mani et al., 2008) and it may explain the plasticity observed in 
the hierarchy of breast differentiation. The role of EMT inducing agents (eg., 
microenvironmental factors, such as TGFβ) or the E-box transcriptional 
repressors Twist, Snail and Slug are very well described in the regulation of 
E-cadherin and N-cadherin, however, very little is known regarding P-
cadherin transcription. 
 
4. We described a major signalling pathway mediated by P-cadherin in cancer 
cells. This is of foremost importance if we are thinking of ways to target 
basal-like tumours, especially because no directed therapies exist for this 
entity of breast carcinomas. However, it is important to understand whether 
this signalling pathway is also present in normal mammary cells. If it is, 
does it mediate a tumour suppressive function or, on the other hand, was 
the P-cadherin/α6β4 integrin signalling selected during tumour progression? 
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5. To dissect the molecular mechanisms that explain P-cadherin mediated 
resistance to X-ray induced DNA damage is fundamental to comprehend 
therapy resistance and, ideally, to improve radiotherapy regimens.  
 
6. The optimization of a shRNA approach for the CDH3/P-cadherin gene, in a 
DOX inducible system, will provide a valuable cellular model to evaluate the 
role of P-cadherin in the origin and progression of basal-like breast cancer 
in vivo. 
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 1. Introduction  
 
Although the transient inhibition of P-cadherin is a quick way of effectively down-
regulating this molecule in in distinct cell models, allowing for the study of short term or 
immediate effects induced by P-cadherin silencing, this method of RNA interference 
(RNAi) does not allow for the study of cellular effects induced by prolonged P-cadherin 
inhibition in breast cell lines. Thus, studies regarding the stable inhibition of P-cadherin 
would be useful for both in vitro and in vivo studies. Furthermore, an inducible gene 
silencing system would allow to switch-on / switch-off gene expression which would give a 
broader perspective regarding the mechanisms of the tumourigenic role of P-cadherin, 
either in the initiation phase or in the progression of tumour growth. 
RNAi pathways are activated by various forms of double stranded RNAs (dsRNAs) 
that contain sequences which are homologous to the mRNA transcript of a target gene 
(Hammond et al., 2001, Hutvagner & Zamore, 2002, Sharp, 2001). It is known that short 
hairpin RNAs (shRNAs) adopt a stable stem-loop structure in solution, can be easily 
expressed from a cloned oligonucleotide template and are a convenient and reproducible 
means of activating RNAi in mammalian cell lines (Figure 1) (Brummelkamp et al., 2002, 
Paddison et al., 2002, Paul et al., 2002, Yu et al., 2002). 
To produce a stable human cancer cell line with inducible knock-down of CDH3/P-
cadherin, a shRNA vector was constructed based in the small interference RNA (siRNA) 
known-down sequence for this gene. The vector was derived from Knock-outTM Single 
Vector Inducible RNAi System (Clontech, Mountain View, CA). In comparison with the 
CDH3 siRNA oligos, this system constitutes a more versatile and more prolonged knock 
down of P-cadherin, with an inducible expression readily performed with doxycycline 
(DOX). The delivery method of this system is non-viral and plasmid-based. 
This system allows to quickly introduce and control the expression of functional 
shRNA molecules for the purpose of activating gene-specific RNAi. The tight on/off 
regulation and the coordinate inactivation of its target gene are provided by a tetracycline-
inducible system that responds to the presence of tetracycline, or its more stable 
derivative, DOX (Gossen et al., 1993, Gossen & Bujard, 1992, Gossen & Bujard, 1995). 
The system features two essential components combined on its pSingle-tTS-shRNA 
vector: 1) CMV promoter/enhancer-controlled expression of the tetracycline-controlled 
regulatory protein tTS (tetracycline-controlled transcriptional silencer) and 2) a 
tetracycline-inducible shRNA expression cassette. The tTS protein is a powerful 
transcriptional repressor created by fusing the Tet repressor protein (TetR) with a KRAB 
transcriptional silencing domain (Freundlieb et al., 1999, Witzgall et al., 1994, 
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Wiznerowicz & Trono, 2003). A tetracycline-inducible hybrid promotor was created by 
linking a modified Tet-responsive element from the tet operon (from TRE-Tight promoter) 
to a minimal U6 small nuclear RNA promoter (Kunkel & Pederson, 1989). 
 
 
Figure 1 – Mechanism of RNA interference. RNAi is activated by introducing a double stranded RNA, whose 
sequence is homologous to the target gene transcript. The exogenous dsRNA is digested into 21-23 
nucleotide small interfering RNAs (siRNAs), which bind a nuclease complex to form an RNA-induced silencing 
complex (RISC). The RISC then targets endogenous gene transcripts by base-pairing and cleaving the 
mRNA. Adapted from KnockoutTM Single Vector Inducible RNAi system User Manual. 
  
In the absence of the inducer, DOX, the tTS protein binds tightly to the tetO 
sequences within the tetracycline responsive element (TRE) and actively silences 
transcription of the shRNA from the downstream minimal U6 promoter (Figure 2). In this 
basal state, i.e., in the absence of induction, background expression of the shRNA is 
extremely low and prevents unwanted suppression of the target gene. When DOX is 
added to the culture medium, tTS dissociates from the TRE relieving transcriptional 
repression and permits the shRNA to be transcribed from the U6 promoter. Once 
derepressed, the human U6 Polymerase III promoter provides high level expression in 
many cell types (Kunkel & Pederson, 1989) and the accumulating shRNA transcripts 
initiate RNAi-mediated suppression of the target gene. 
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Figure 2 – The Knockout Single Vector Inducible RNAi system (Clontech, Mountain View, CA) uses a 
modified form of the tightly regulated, tetracycline-controlled gene expression system. In the absence of DOX, 
tTS binds to the tetO sequences within the TRE/U6 promoter and actively silences transcription of the shRNA. 
When DOX is added to the culture medium, tTS dissociates from the TRE, relieving transcriptional 
suppression and allowing high level transcription of the shRNA from the hybrid TRE/U6 promoter by 
Polymerase III in a highly dose dependent manner. Adapted from KnockoutTM Single Vector Inducible RNAi 
system User Manual. 
 
The pSingle-tTS-shRNA Vector Map is pictured in Figure 3. The shRNA sequence 
is under the control of the hybrid promoter TRE/thight-U6 that binds tTS or Polymerase III. 
The pSingle-tTS-shRNA vector also contains a bacterial origin of replication and the Ampr 
gene for propagation and selection in E. coli. it also contains the neomycinr gene for 
selection of stable transformants in mammalian cells. 
 
Figure 3 – pSingle-tTS-shRNA Vector Map. The pSingle-tTS-shRNA Vector expresses the tetracycline-
controlled transcriptional suppressor (tTS) under the control of the CMV promoter wich, in turn, controls 
expression of an shRNA sequence inserted in the shRNA cloning site. The tTS protein is a fusion of the Tet 
repressor protein (TetR) and the KRAB- AB silencing domain of the Kid-1 protein (SDKid-1), a powerful 
transcriptional suppressor. The shRNA sequence is under the control of the hybrid promoter TRE/thight-U6 
that binds tTS or Polymerase III. The pSingle-tTS-shRNA vector also contains a bacterial origin of replication 
and the Ampr gene for propagation and selection in E. coli; and the neomycinr gene for selection of stable 
transformants in mammalian cells. Adapted from KnockoutTM Single Vector Inducible RNAi system User 
Manual. 
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 2. Materials and methods 
 
The implementation of the Knockout pSingle-tTS-shRNA Vector was performed 
according to the steps listed below, essentially following the protocol provided by the 
manufacturer (Clontech, Mountain View, CA). 
 
Design and synthesis of the shRNA sequence 
The shRNA target sequence selection to clone in the pSingle Vector was based in 
the already known sequence used in our transient siRNA studies. This sequence 
recognizes a region near the 3’ of the CDH3/P-cadherin transcript message (exon 16) with 
high silencing efficiency. The shRNA oligonucleotide sequence included the 19-base 
target siRNA sequence, as shown in Figure 4. When selecting this target siRNA 
sequence we checked that it did not show significant homology to other genes and it did 
not contain a consecutive run of 3 or more thymidine (T) residues. The CG content was 
between 40% and 60%. This oligonucleotide sequence had minimal secondary structures, 
which could interfere with proper annealing. Since it is known that sequences that have at 
least 3 adenine or thymidine residues in positions 15-19 of the sequence appear to have 
increased knock-down activity, it was important to notice that our siRNA target sequence 
matched this requirement. 
The complementary oligonucleotides were synthesized using PAGE purification by 
Sigma-Aldrich (St. Louis, MO). The two sequences of oligonucleotides included a 5´- XhoI 
restriction site overhang and 5´- HindIII overhang, that enabled directional cloning of the 
annealed oligonucleotides into the XhoI/HindIII-digested pSingle Vector. Furthermore, a 9-
nucleotide hairpin loop sequence and a RNA Pol III terminator sequence, consisting of 6 
nucleotide poly(T) tract, were also designed and included in the shRNA sequence. A 
unique restriction site positioned immediately downstream of the terminator sequence was 
also included for restriction digest analysis in order to confirm the presence of the cloned 
insert (Figure 4). 
 
 
 
 
Figure 4 – shRNA sequence for CDH3/P-cadherin gene. Both complementary strands (upper strand and 
lower strands) were synthesized by Sigma-Aldrich. The hairpin loop sequence is one of the many functional 
loop sequences used to generate shRNAs. Termination is signalled using a poly(T) tract. The shRNA 
sequence includes a unique restriction site (MluI) that allows the confirmation of the cloned insert after the 
ligation and transformation reactions. XhoI (upper) and HindIII (lower) 5’ overhangs are necessary for 
directional cloning into the pSingle-tTS-shRNA vetor. 
XhoI 
siRNA CDH3 
Hairpin loop Terminator Mlu HindIII 
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The strategy was to establish the shRNA p-Single Vector in the breast cancer cell 
line MDA-MB-468. This cell line has a triple-negative phenotype (negative for HER-2, ER 
and PgR) and expresses high levels of P-cadherin, constituting an excellent model of 
human basal-like breast cancer in vitro. Furthermore, our previous experience in cloning 
revealed that this cell line is easily transfected using a non-viral delivery method. 
 
Annealing the single stranded oligonucleotides to form the double stranded 
Oligonucleotides 
Each oligonucleotide (top and lower strands) was resuspended in tris-EDTA buffer 
to a final concentration of 100 µM and then mixed to a 1:1 ratio. To form the double strand 
oligonucleotides, the following sequence of temperatures was applied to the mixture: 95ºC 
for 30 sec, 72ºC for 2 min, 37ºC for 2 min, 25ºC for 2 min. 
 
Cloning shRNA oligonucleotides into pSingle-tTS-shRNA vector 
1 ug of pSingle-tTS-shRNA vector (cat. Number 630933, Clonetech) was digested 
with XhoI and HindIII restriction enzymes (New England Biolabs, Hitchin, UK), with 1 U in 
endonuclease buffer NEB2 (New England Biolabs) containing 0.1 mg/ml BSA (New 
England Biolabs), during 1h ate 37ºC. After running the product of the endonuclease 
reaction in a 1% agarose gel, one band was observed at ~6900 bp. This band was cut out 
from the gel and the vector was extracted using QIAquick gel extraction kit (Qiagen, West 
Sussex, UK). 
  
Ligation reaction 
In order to ligate the annealed double stranded oligonucleotides into pSingle-tTS-
shRNA, 50 ng of the digested pSingle-tTS-shRNA vector DNA was mixed in a ligation 
reaction containing 0.5 mM annealed oligonucleotides, T4 DNA ligase (Roche, Burgess 
Hill, UK) and DNA ligase buffer (Roche). The ligase reaction mixture was incubated at 
room temperature for 3 hours. A control ligation was assembled using 1 µl nuclease-free 
water instead of the annealed oligos. 
 
Transformation of competent cells, identification of recombinant clones  
Fusion–Blue competent cells (Clontech, cat. No. 636700) are an E.coli K12 strain 
that provides high transformation efficiency. The strain carries recA and endA mutations 
that turn them into a good host for obtaining high yields of plasmid DNA. These competent 
E.coli cells were thawed on ice and transformed with 2 µL of the ligation reactions 
(previously diluted 1:5 to a final concentration of 10ng/µl), according to the protocol 
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supplied with the cells. Briefly, after adding the ligation reactions (one containing the 
CDH3 pSingle shRNA vector, and the other containing the empty vector) or water (control 
for transfection) to chilled test tubes containing 100 uL of E.coli cells, these were 
incubated on ice for 30 min and then heat shocked at 42ºC for 45 seconds. Next, 900 µL 
of S.O.C. medium (Invitrogen, cat. No.  15544-034) and the transfection mixture was 
shaken at 37ºC for 1 hour. Different volumes from each transformation (20-150 µL) were 
plated on LB agar + ampicillin plates (50 µg/ml) which were incubated overnight at 37 ºC. 
The control ligation reaction (water instead of plasmid) did not originate colonies; the 
ligation reaction performed with the pSingle-tTS-shRNA CDH3 vector and the one 
performed with the empty pSingle vector originated several colonies. Thus, well isolated 
colonies obtained from the ligation reaction were inoculated each into a small-scale liquid 
culture containing LB and ampicilin. Colonies grew overnight at 37ºC with shaking. 
Plasmid DNA minipreps were prepared from 4 ml of culture medium of each colony 
(Qiagen, West Sussex, UK) and the recombinant plasmids were identified by restriction 
analysis using the unique restriction site MluI within the shRNA oligonucleotide sequence. 
Briefly, 1 µL of the mini-prep DNA plasmid was digested with 1U of MluI and 1U of EcoRI 
restriction enzymes (New England Biolabs, Hitchin, UK) in endonuclease buffer NEB3 
(New England Biolabs) 1,5h at 37ºC. The product of the endonuclease reaction was run in 
a 2% agarose gel, as shown in Figure 5.  
According to the pattern of bands obtained after endonuclease digestion, we verified 
that all the selected clones (A-D) had the correct oligonucleotide insert. We selected one 
of the clones to continue our protocol and the insert was further verified by sequencing. 
Using a primer for the upper strand (TGTCGAGGTAGGCGTGTACGGT) and a primer for 
the lower strand (CCGCGCGTTGGCCGATTCAT). 
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A 
                  Clone A              Clone B             Clone C              Clone D            Empty vector 
                 ND     D              ND      D              ND    D               ND    D                ND    D 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 5 – (A) Verification of the presence of the insert after the ligation reaction. Four clones were selected 
after the ligation reaction and the transfection of competent cells (clones A-D). Control sample represent the 
ligation reaction product obtained without the oligonucleotide shRNA sequence (water), corresponding to the 
empty vector. N – no digestion; D – digestion with EcoRi + MluI. (B). The pattern of bands obtained after 
digestion in clone D is in agreement with the expected resulting bands. 
 
Preparation of DNA for transfection (maxi-prep) 
Once a positive clone was identified, a large-scale DNA prep of the recombinant 
pSingle-tTS-shRNA vector was performed. We performed a high purification Maxi-prep 
(Qiagen, West Sussex, UK) according to the manufacturer instructions. Briefly, 200 ml of 
LB broth was inoculated with 1 ml of a mini-prep cell culture of the selected clone. After 
overnight incubation at 37ºC with shaking, the culture was centrifuged and resuspended in 
lysis buffer. After adding the neutralizing buffer, the mixture was centrifuged and the 
supernatant applied to a QIAprep column. The column was washed and the DNA eluted. 
After DNA precipitation, the pellet was resuspendend in RNase-free water. 
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Transfection and selection of pSingle-tTS-shRNA CDH3 stable cell lines 
In order to transfect the breast cancer cell line MDA-MB-468, optimization 
experiments were performed to determine the optimal antibiotic (G418) concentration for 
the selection of stable clones. For this cell line, the optimal concentration of antibiotic was 
previously determined to be 0.5 mg/ml. This is the lowest concentration of G418 
(Invitrogen, cat. No. 10131-019) that begins to result in massive cell death in ~5 days and 
kills all the cells in two weeks. This determination was performed in the lab using the 
Sulforhodamine B colorimetric assay for cytotoxicity screening (Vichai & Kirtikara, 
2006Vichai & Kirtikara, 2006) that allowed the representation of a dose-response curve. 
We did not titrate the optimal concentration of DOX to use, as this was already 
established in our lab. This concentration was determined to be 1 µg/ml for the 
Doxycycline hyclate (Sigma-Aldrich, cat. No. D9891). 
The transfection method used was electroporation. An 8x106 cell suspension in PBS 
was mixed with 20 µg of plasmid in an electroporation cuvete kept on ice. A control 
electroporation tube was included (cells only). Using the Bio Rad Gene Pulser 
electroporator (Bio Rad, Hercules, CA), the optimal electroporation method was 800 V 
and 25 uF, with a time constant lower than 20 ms. After electroporation, cells were 
incubated 10 min on ice. Cells were then washed with 10 ml of complete medium (DMEM, 
10% FBS), centrifuged 1200 rpm 5 min, and resuspended in 4 ml of complete medium. In 
two 10 cm culture dish, 2 ml of electroporated cells were plated. Two days after 
electroporation, the selection medium was added to the dishes (DMEM with 10% FBS and 
0.5 mg/ml G418). The selection medium was replaced with fresh complete medium plus 
G418 every four days or more often if dead cells accumulated or if medium became 
depleted. After 3-5 weeks, isolated G418-resistant colonies begun to appear. Several 
colonies were observed (~5 colonies/ dish). The large healthy colonies were trypsinized 
using a cloning cylinder and transferred to individual wells.  
Although it is recommended that as many clones as possible be isolated following 
transfection, at the present time we could only isolate two clones (Figure 6). 
 
 
 
 
 
 
Figure 6 – Example of healthy colonies formed 1-2 months after transfection of pSingle-tTS-shRNA CDH3 in 
the MDA-MB-468 breast cancer cell line. Scale bar = 200 µm. 
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 3. Cell model characterization 
 
The clones that exhibit the highest overall shRNA expression (highest level of gene 
suppression) in the presence of DOX, and with little or no background suppression in the 
absence of DOX should be elected for propagation and further testing. However, up till 
now, we have obtained only one clone that has been amplified and screened for shRNA 
induction. This clone was routinely cultured in DMEM containing tetracyclin-free FBS 
(Clontech) plus 0.5 mg/ml G418 (Invitrogen). The commonly used FBS (EU approved 
from Lonza, Basel, Switzerland, or from Gibco, Paisley, UK) can contain residual 
tetracycline activity that could cause a small induction of the shRNA expression (leakage); 
so, in our initial studies we opted for a tetracycline free FBS. 
Cells were treated with DOX 1µg/ml (Sigma-Aldrich, St. Louis, MO), with medium 
renewal every three days, and protein lysates were obtained in different time points. 
Control cells were treated with water, the vehicle. P-cadherin protein expression was 
detected by western-blot using anti-P-cadherin antibody (BD Biosciences, Erembodegem, 
Belgium). Protein band quantification was performed using Image J 
(http://rsbweb.nih.gov/ij/). Results are presented in Figure 7. Western-blot analysis of this 
clone revealed that the efficiency of the knock-down after treatment with DOX was very 
low, with less than 20% inhibition. Further confirmation will be necessary using other gene 
screening methods, namely RT-PCR.  
 
 
Figure 7 – A stable clone derived from the cell line MDA-MB-468 containing the plasmid pSingle-tTS-shRNA 
CDH3 was screened for shRNA induction after treatment with 1 ug/ml doxycycline (DOX) for three (3d) and 
five days (5d). Western-blot was used to detect P-cadherin and the bands were quantified with Image J 
software. 
 
A functional assay was also used to check the efficiency of this knock-down method 
in this clone. The mammosphere assay was performed with a continuous administration of 
DOX every three days. Administration of DOX started three days before the 
mammosphere assay was performed and lasted for the whole 5 days of mammospheres 
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formation, with addition of DOX to the mammosphere medium. The mammosphere 
formation efficiency and the mammosphere phenotype is presented in Figure 8. 
 
A         B     
 
 
Figure 8 – (A) MFE is not affected by DOX treatment in this clone of MDA-MB-468 containing the plasmid 
pSingle-tTS-shRNA CDH3. (B) Mamospheres originated from DOX treated cells appeared to contain more 
loose spheres than the non-induced control cells. Scale bar = 250 µm. 
 
The MFE of MDA-MB-468 was not significantly affected by the addition of DOX 
during the experiment, even when DOX concentration was increased from 1 µg/ml to 10 
µg/ml (with no observable toxic effects). However, the grape-like shape of the 
mammospheres was affected by the induction procedure. DOX treatment lead to the 
formation of mammospheres with a less compact core and with less aggregation than the 
DOX untreated condition. It is difficult to say, at this point, whether this effect was caused 
by P-cadherin inhibition in the DOX treated cells and further experiments are needed. 
It is important to say that clonal variation in expression of both the tTS silencer and 
the shRNA construct is affected by the genomic integration site, therefore, the screening 
of more clones is needed. Furthermore, we could search for more shRNA sequences to 
find out which has the optimal gene silencing. 
In conclusion, although the protocol for the tetracycline-controlled system was 
established successfully in this cell line, more clones will need to be screened in order to 
find an optimal expressor.  
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Breast cancer stem cell markers CD44, CD24 and
ALDH1: expression distribution within intrinsic
molecular subtype
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ABSTRACT
Background and Aim The study of CD44/CD24 and
ALDH1 expression is the most accurate method to
identify cancer stem cells (CSC) from breast cancer
populations. However, the overlap between
CD44+CD24!/low and ALDH1high CSC phenotypes in
breast cancer seems to be very small, as well as their
distribution among intrinsic breast cancer subtypes. Due
to this discrepancy, it is imperative to improve the
understanding of breast CSC marker distribution.
Methods 466 invasive breast carcinomas and eight
breast cancer cell lines were analysed for the expression
of CD44, CD24 and ALDH1, to evaluate their distribution
among the distinct molecular subtypes.
Results Basal-like tumours (76.5%) contained the higher
percentage of cells with the CSC phenotype
CD44+CD24!/low (p<0.0001). From ALDH1-positive
cases, 39.4% were also basal-like tumours (p<0.0001).
The analysis of breast cancer cell lines indicated that
luminal cell lines are mainly enriched in a CD44!/
lowCD24+ cell population, basal/mesenchymal breast
cancer cell lines are enriched in the CD44+CD24!/low
phenotype, whereas the remaining basal/epithelial cell
lines are mainly positive for both markers. ALDH1 activity
was mainly found in HER-OE and basal/epithelial breast
cancer cell.
Conclusions CD44+CD24!/low and ALDH1+
phenotypes seem to identify CSC with distinct levels of
differentiation. It seems that the paramount method and
biomarkers that identify breast CSC within the distinct
molecular subtypes need to be better explored, because
it is pivotal to translate the CSC concept to clinical
practice. In the future, the recognition of reliable markers
to distinguish the CSC pool in each molecular subtype
will be decisive for the development of specific target
therapies.
Breast cancer is the most frequent cancer among
women,1 being a heterogeneous disease, with
distinct morphologies, metastatic behaviour and
therapeutic response. It is actually known that
variation in transcriptional programmes is the
major reason for biological diversity among human
breast cancers.2 In fact, global gene-expression
analyses have provided an appealing molecular
classiﬁcation for breast carcinomas, which is highly
associated with patients’ prognosis.2e5
The molecular classiﬁcation of breast cancer
established four major subtypes: the luminal A
and B, the HER2-overexpressing (HER2-OE) and
basal-like tumours.2e4 Luminal A is the most
prevalent subtype and is characterised by the
expression of oestrogen and progesterone receptors
(ER and PgR, respectively) in cancer cells, whereas
the luminal B subtype is characterised by ER and
PgR expression together with HER2 over-
expression and/or high rates of cell proliferation.
In contrast, HER2-OE tumours are negative for
hormonal receptors and overexpress HER2
protein, which is highly associated with gene
ampliﬁcation. Finally, within triple-negative
tumours, characterised by the absence of ER, PgR
and HER2 expression, the basal-like subtype still
constitutes a heterogeneous group of tumours,
expressing distinct basal markers. Actually, the
correct identiﬁcation of basal-like breast carci-
nomas is clinically relevant, because these are
highly associated with aggressive histological
features and poor patient survival, still lacking an
efﬁcient therapy.6e10
In the past decade, many treatments undergoing
clinical trials have been developed based on breast
cancer molecular proﬁles.11 However, one of the
most promising therapy targets came with the
identiﬁcation of a pool of cancer cells with stem
characteristicsdcancer stem cells (CSC). The CSC
model proposes that tumours, as normal tissues,
are organised in a cellular hierarchy, in which CSC
are the only cells with unlimited proliferation and
tumorigenic potential; therefore, being capable of
driving tumour growth, progression and metastasis
due to their stem cell-like characteristics: self-
renewal and differentiation.12 13 Recent evidence
has demonstrated that CSC are resistant to various
forms of therapies, including radio and chemo-
therapy.14e20 Based on these observations, the CSC
model became the foundation for new preventive
and therapeutic strategies in cancer.
In breast cancer, the ﬁrst report identifying and
isolating tumorigenic CSC from non-tumorigenic
cancer cells used the combined expression of two
cell surface markers: CD44+/CD24!/low.21e26
Interestingly, some studies revealed an enrichment
of the CD44+/CD24!/low and CD44!/CD24+ cell
populations in basal-like and luminal breast cancer
cell lines, respectively,27 28 CD44 being positively
associated with stem cell-like characteristics and
CD24 expression related to differentiated epithelial
features.29 These in-vitro data were later demon-
strated in primary breast carcinomas,30 but the
clinical and prognostic impact of these markers in
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breast cancer remains a controversial issue,25 31e33 demanding
additional efforts to ﬁnd other CSC markers that could better
predict breast cancer patient survival.
Using in-vitro and in-vivo experimental systems, Ginestier
et al34 demonstrated that normal and cancer human mammary
epithelial cells with increased aldehyde dehydrogenase activity
(ALDH) show stem/progenitor cell properties. Tumorigenic
ALDH1+ CSC are signiﬁcantly more resistant to platinum
treatments, are biologically aggressive, and their expression
tends to be associated with a poor patient prognosis.34e36
Interestingly, CD44+CD24!/low cells and ALDH1+ cells are
more frequently found in basal-like than in luminal tumours;
however, ALDH1+ cells are also commonly found in the HER2-
OE subtype.34 It was recently shown that ALDH1 breast CSC
marker can further divide the CD44+CD24!/low cell population
into fractions that are highly tumorigenic:
ALDH1+CD44+CD24!/low cells were able to generate tumours
from only 20 cells, whereas ALDH1!CD44+CD24!/low were not
tumorigenic in this same cell density.34 37
Based on this current knowledge, there is evidence to support
the idea that the use of CD44 and CD24 cell surface markers in
combination with ALDH1 activity is the most accurate method
to identify and isolate CSC-like cells within breast cancer
populations. However, the overlap between CD44+CD24!/low
and high ALDH1 expression in primary tumours is quite small
(approximately 1%).34 Due to this discrepancy, it is imperative
to improve CSC identiﬁcation into routine formalin-ﬁxed and
parafﬁn-embedded tissue samples.
In the present study, we analysed the expression of the main
established breast CSC markersdCD44, CD24 and ALDH1, in
a large series of invasive breast carcinomas, in order to evaluate
their distribution among the different molecular subtypes. In
addition, we investigated the correlation between the presence
of these markers and the clinicopathological features and patient
survival. Finally, these features were compared with the results
obtained with breast cancer cell lines from distinct molecular
subtypes, in which the different cancer cell populations,
expressing these CSC markers, were selected by ﬂow cytometry.
MATERIAL AND METHODS
Patient selection
A series of 466 primary and sporadic invasive breast carcinomas
was retrieved from the Pathology Department, Hospital Xeral-
Cíes, Vigo, Spain, diagnosed in 1978e1992. Patients’ ages ranged
from 28 to 92 years of age. The formalin-ﬁxed parafﬁn-
embedded histological sections were reviewed and the diagnoses
conﬁrmed. The tumours have been characterised for clinical
and pathological featuresdnamely age, tumour size, lymph
nodes status and histological grade (data summarised in
supplementary table S1, available online only). Patient follow-up
information was available for 455 cases, ranging from
a minimum of one to a maximum of 120 months after the
diagnosis. The disease-free survival (DFS) interval was deﬁned as
the time from the diagnosis to the date of breast-cancer-derived
relapse/metastasis, whereas overall survival (OS) was considered
as the number of months from the diagnosis to the disease-
related death. This study was conducted under the national
regulative law for the handling of biological specimens from
tumour banks, being the samples exclusively available for
research purposes in retrospective studies.
TMA construction and immunohistochemistry
Representative tumour areas were selected on haematoxylin and
eosin-stained sections and marked on parafﬁn blocks. At least
two tissue cores (0.6 mm in diameter) were obtained from each
selected specimen and deposited into a recipient parafﬁn block,
using a tissue microarray (TMA) workstation (Manual Tissue
Arrayer; Beecher Instruments, Inc. Sun Prairie, Wisconsin, USA).
The 12 TMA blocks were designed and constructed according to
rules previously described38 and non-neoplastic tissue cores were
included as controls.
In order to classify all breast cancer tumours molecularly, we
evaluated the expression of the most commonly used breast
cancer biomarkers,10 namely the hormonal receptors ER and
PgR, the proliferation marker Ki67, the tyrosine kinase receptors
HER2 and EGFR, the basal cytokeratins CK5 and CK14 and also
P-cadherin and vimentin basal markers. Immunohistochemistry
was performed in 3 mm sections. To study CSC markers in this
series, speciﬁc antibodies for CD44 (clone 156-3C11; Cell
Signaling Technology, Danvers, Massachusetts, USA), CD24
(clone Ab2-SN3b; Neomarkers, Fremont, California, USA) and
ALDH1 (clone EP1933Y; Abcam, Cambridge, Massachusetts,
USA) were assessed. The primary antibodies were detected using
a secondary antibody with horseradish peroxidase polymer
(Cytomation Envision System HRP; DAKO, Carpinteria, Cali-
fornia, USA), or a biotinylated goat anti-polyvalent as secondary
antibody, followed by the streptavidin-peroxidase complex
(Thermo Fisher Scientiﬁc, Fremont, California, USA), according
to the manufacturer ’s instructions. Both methods used diami-
nobenzidine as chromogen. Detailed conditions for each antibody
can be found in supplementary table S2 (available online only).
Immunohistochemical evaluation
The expression of the breast cancer biomarkers ER, PgR, HER2,
EGFR, CK5, CK14, P-cadherin and vimentin was evaluated
according to the grading systems already described.10 The
quantiﬁcation of cell proliferation by Ki67 expression was
measured using the publicly available web application software
ImunoRatio, as recently described by Tuominen et al,39 and
validated by a breast cancer pathologist. The cut-off value to
distinguish low from high proliferation tumours was 13.25% of
Ki67 nuclear staining. The Ki67 index was based on the study
published by Cheang and colleagues,40 in which its expression
was considered as a continuous variable and the cut point was
determined by the receiver operating characteristic method,
using gene expression proﬁle as the gold standard. These
immunohistochemical results were used to classify the tumours
in the different molecular breast cancer subtypes, namely in
luminal A, luminal B, HER2-OE and basal-like, according to
supplementary table S3 (available online only).
CD44 and CD24 staining were detected mainly at the
membrane of tumour cells and the scoring was considered as
follows: 0, 0e10% of positive tumour cells; 1+, 10e25% of
positive tumour cells; 2+, 25e50% of positive tumour cells; 3+,
more than 50% of positive tumour cells. Cytoplasmic staining
was not considered for any of these markers, in order to compare
these results with those obtained by ﬂow cytometry in cell lines,
which selects only cells expressing these markers at the cell
surface. For CD44, the cases classiﬁed as 0 were considered
negative, whereas 1+, 2+ and 3+ were established as positive
cases. For CD24, the cases were divided into negative/low
(!/low), when considered 0 or 1+, or in positive cases, when
classiﬁed as 2+ or 3+. Immunohistochemical staining of
ALDH1 was classiﬁed as positive when more than 1% of tumour
cells showed clear cytoplasmic positivity, as previously
described.34 36 Stromal expression of ALDH1 was also classiﬁed
in two categories: none/weak, or moderate/strong, as previously
described by Resetkova et al.41
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Immunofluorescence
To control the reliability of the CD44 and CD24 single staining
and evaluation, double staining immunoﬂuorescence with the
same primary antibodies was performed in 10% of all cases, not
only in TMA, but also in the whole tissue. Detection of the
primary antibody anti-CD44 was performed using a secondary
antibody goat anti-mouse IgG (H+L) conjugated with Alexa
Fluor 488 (Cell Signaling Technology, Inc.) and the detection of
the anti-CD24 was done using a secondary antibody goat anti-
mouse IgM (m chain) Alexa Fluor 594 (Cell Signaling
Technology, Inc.). The results from both techniques were
exactly the same.
Cell culture
Human breast cancer cell lines MCF-7/AZ, T47D, SkBr3, BT474,
BT-20, MDA-MB-468, BT-549 and MDA-MB-231 were obtained
from ATCC or from collections developed at Professor Mareel’s
laboratory (Laboratory of Experimental Cancerology, Ghent
University Hospital, Belgium). All cell lines were grown in
Dulbecco’s modiﬁed essential medium (Invitrogen, Carlsbad,
California, USA), supplemented with 10% fetal bovine serum
(Invitrogen) and with 1% antibiotic solution
(penicillinestreptomycin; Invitrogen), being routinely cultured
in a humidiﬁed atmosphere with 5% carbon dioxide and at
378C. These breast cancer cell lines were selected to be studied,
because they harbour distinct molecular proﬁles, as already
described42e44 (see supplementary table S4, available online
only).
Flow cytometry
Cells were washed twice with phosphate-buffered saline and
then harvested with versene/0.48 mM ethylenediammine
tetraacetic acid (Gibco, Invitrogen Ltd., Paisley, UK). Detached
cells were re-suspended in phosphate-buffered saline supple-
mented with 0.5% fetal bovine serum (13106 cells/50 ml).
Combinations of ﬂuorochrome-conjugated monoclonal anti-
bodies against human CD44 (FITC; cat. #555478) and CD24
(PE; cat. #555428) were obtained from BD Biosciences (San
Diego, California, USA). Primary antibodies or the respective
isotype controls (BD Biosciences) were added to the cell
suspension, as recommended by the manufacturer, and incu-
bated at 48C in the dark for 20 min. The labelled cells were
analysed on a FACS Calibur (BD Biosciences).
ALDEFLUOR assay
The ALDEFLUOR kit (Stem Cell Technologies, Grenoble,
France) was used to analyse the cell population with high ALDH
enzymatic activity, using a FACS Calibur (BD Biosciences),
according to the manufacturer ’s instructions. Brieﬂy, cells were
incubated in ALDEFLUOR assay buffer containing ALDH
substrate (1 mmol/l per 13106 cells). In each experiment,
a sample of cells was incubated, under identical conditions, with
50 mmol/l of diethylaminobenzaldehyde, a speciﬁc ALDH
inhibitor, as a negative control.
Statistical analysis
Association between the CD44/CD24 phenotype and ALDH1
pattern and the different molecular subtypes, the clinicopatho-
logical parameters or the different molecular markers were
assessed by Pearson correlation and c2 tests. Survival analyses
were estimated using the KaplaneMeier method and compared
using the log-rank test. Statistical analyses were carried out
using SPSS statistics V.17.0 software, and a signiﬁcance level of
5% was considered statistically signiﬁcant.
RESULTS
Tumour classification in breast cancer molecular subtypes
The series of invasive breast carcinomas was studied for the
expression of ER, PgR, HER2, Ki67, EGFR, CK5, P-cadherin,
CK14 and vimentin, in order to classify them in the different
immunohistochemical molecular subtypes. The results from the
different biomarkers are shown in supplementary table S5
(available online only). From the 466 invasive breast cancer cases,
64.8% (302/466) were luminal A, 8.8% (41/466) luminal B, 7.1%
(33/466) HER2-OE, 14.6% (68/466) basal-like tumours and 4.7%
(22/466) were unclassiﬁed tumours (ﬁgure 1A and supplemen-
tary table S1, available online only). As expected, the majority of
basal-like and HER2-OE tumours were grade III, highly prolif-
erative, with worse patient survival curves (ﬁgure 1B),
demonstrating the validity and power provided by this series of
invasive breast carcinomas.
Association between the expression of CD44, CD24 and ALDH1
with other breast cancer parameters
The expression of CD44, CD24 and ALDH1 was analysed in all
breast cancer cases and an example of the pattern of expression
of these three CSC markers is shown in supplementary ﬁgure 1
(available online only). Concerning CD44 membrane staining,
51.2% (237/463) of the cases were positive. In contrast, for
membrane CD24, the majority of the cases (88.7%, 411/463)
were classiﬁed as negative/low, and only 11.4% (53/463) of the
tumours had clear membrane staining. For ALDH1, a minority
of cases (7.1%, 33/464) was classiﬁed as positive, showing a clear
cytoplasmic expression in tumour cells. Moderate/strong
stromal staining for ALDH1 was also observed in 37.8% (176/
466) of the cases.
When CSC markers were associated with classic prognostic
factors, as well as with other biomarkers studied, CD44
expression was signiﬁcantly associated with lymph node
metastasis (p¼0.006), and with the expression of basal markers:
EGFR (p¼0.038), CK5 (p<0.0001), P-cadherin (p¼0.003), CK14
(p¼0.005) and vimentin (p<0.0001) (table 1). In contrast, any
signiﬁcant correlation between single CD24 expression and the
other parameters evaluated was found (table 1). Concerning
ALDH1 cytoplasmic expression, it was signiﬁcantly associated
with ER negativity (p¼0.003), and with basal marker expres-
sion, namely EGFR (p¼0.004), CK5 (p<0.0001), P-cadherin
(p<0.0001), CK14 (p<0.0001) and vimentin (p¼0.01); no asso-
ciation was found with HER2 overexpression. Concerning
classic prognostic factors, ALDH1 expression was signiﬁcantly
correlated with high grade tumours, as 78.8% (26/33) of the
positive cases were grade III (p¼0.003) (table 1). When CSC
markers were associated within themselves, a signiﬁcant asso-
ciation between CD24!/low tumours and ALDH1 expression
(p¼0.018) was found, 75.8% (25/33) of the ALDH1-positive
cases also being CD24!/low (data not shown). Concerning
stromal ALDH1 staining, no associations were found with the
several parameters evaluated. However, there was a signiﬁcant
association between CD24 positivity and moderate/strong
stromal ALDH1 expression (p¼0.018) (see supplementary table
S6, available online only).
CSC markers, breast cancer molecular subtypes and patient
survival
CD44 expression was signiﬁcantly associated with breast cancer
molecular subtype (p<0.0001), whereas CD24 was not
(p¼0.418) (table 1). The majority of basal-like carcinomas
(80.9%, 55/68) were considered CD44+, in contrast to what
was veriﬁed in others subtypes (table 1). In addition, almost all
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basal-like tumours were CD24!/low (94.1%, 64/68) and among
CD24+ cases 64.2% (34/53) were luminal A (table 1).
Concerning ALDH1 cytoplasmic expression, 39.4% (13/33) were
classiﬁed as basal-like carcinomas, this association being statis-
tically signiﬁcant (p<0.0001) (table 1). ALDH1 stromal staining
did not correlate with any molecular subtype (see supplemen-
tary table S6, available online only).
To explore the effect of the CSC phenotype CD44+CD24!/low
on the clinical outcome and its prevalence within the intrinsic
molecular subtypes, we decided to consider a tumour with CSC
phenotype when the frequency of CD44+CD24!/low cells were
more than 10%, as previously described in other studies.25 32 In
our series, 45.3% (209/461) of the tumours were considered
CD44+CD24!/low$10% and 54.7% (252/461) CD44+CD24!/low
<10%. The CSC phenotype CD44+CD24!/low was signiﬁcantly
increased in node-negative tumours (p<0.0001) and in tumours
expressing the basal markers CK5 (p<0.0001), P-cadherin
(p¼0.008), CK14 (p¼0.003) and vimentin (p<0.0001) (table 2).
Table 3 shows that the CD44/CD24 phenotype was also
signiﬁcantly associated with breast cancer molecular subtypes
(p<0.0001). Most of the basal-like tumours (76.5%, 52/68) were
classiﬁed as CD44+CD24!/low$10% (ﬁgure 2), independently of
ALDH1 expression. Luminal tumours showed a mixture
between the two CD44/CD24 phenotypes: 43.0% (127/295) of
luminal A tumours were CD44+CD24!/low$10% and 57.0%
(168/295) were CD44+CD24!/low<10%. Luminal B showed the
same CSC markers distribution (41.4% CD44+CD24!/low$10%
and 58.6% CD44!CD24!/low<10%).
Univariate survival analyses were performed for the three CSC
markers, namely CD44, CD24 and ALDH1, as well as for the
combined expression of CD44/CD24, and all failed to reach
statistically signiﬁcant levels, meaning that these markers were
not signiﬁcant predictors of DFS or OS (data not shown).
However, when we addressed the distribution of the CD44/
CD24 pattern within the poor prognosis basal-like carcinomas,
we found that tumours with more than 10% of the cells with the
CSC phenotype showed a trend to be associated with a worse
DFS (p¼0.065) and OS (p¼0.127) (ﬁgure 3). In accordance with
the KaplaneMeier survival curves, Cox univariate survival
analysis, within basal-like carcinomas, demonstrated a tendency
for tumours with more than 10% of CD44+CD24!/low
cells to present an increased risk of DFS, when compared with
tumours with less than 10% of CD44+CD24!/low cells. Never-
theless, multivariate analysis, with models including tumour
Figure 1 Breast tumour signature represented by immunohistochemistry array showing the protein expression of cancer stem cell markers (CD24,
CD44 and ALDH1) and classic prognostic factors (tumour size, histological grade and lymph node metastasis) in the series of 466 invasive breast
carcinomas analysed in this study (A); and disease-free survival and overall survival of the different molecular subtypes (B).
940 J Clin Pathol 2011;64:937e946. doi:10.1136/jcp.2011.090456
Original article
 group.bmj.com on June 18, 2012 - Published by jcp.bmj.comDownloaded from 
size, grade and lymph node involvement, showed that CD24/
CD44 was not an independent factor of the prediction of patient
DFS (data not shown).
CD44+CD24L/low phenotype and ALDH1 activity in breast
cancer cells
Flow cytometric analysis allows us to separate the cancer cell
populations according to different levels of the surface CSC
markers CD44 and CD24. As shown in ﬁgure 4AeC, luminal
(MCF-7/AZ and T47D) and HER2-OE (SkBr3 and BT474)
breast cancer cell lines are mainly constituted by cells with high
levels of CD24 and low levels of CD44, in accordance with an
epithelial luminal cell phenotype. In contrast, the basal/
epithelial cell lines BT-20 and MDA-MB-468 showed enrich-
ment in cell populations with high levels of both markers.
Basal/mesenchymal BT-549 and MDA-MB-231 cells show
a lower expression of CD24, reﬂecting their mesenchymal
phenotype.
The activity of ALDH1 enzyme was also evaluated in this
panel of breast cancer cells, using the ALDEFLUOR assay.
Figure 4C shows the percentage of the putative CSC fraction
obtained in the different cell lines. In this analysis, luminal
breast cancer cell lines showed the lowest percentage of
tumour cells with ALDH1 activity; in contrast, HER2-OE and
basal-like breast cancer cell lines showed increased levels of
ALDH1 activity; the exception was the MDA-MB-231 cell line,
in which we could not detect any ALDEFLUOR-positive
subpopulation.
Table 1 Associations between the expression of the breast cancer stem cell markers CD44, CD24 and ALDH1 and the classic breast cancer
prognostic factors, biological markers and molecular subtypes
CD44 CD24 ALDH1
n Positive Negative p Value n Positive Neg/low p Value n Positive Negative p Value
Tumour size 405 207 198 0.414 405 50 355 0.286 405 31 374 0.013
T1 <2 cm 100 49 51 100 13 87 101 1 100
T2 2e5 cm 242 121 121 242 33 209 241 23 218
T3 >5 cm 63 37 26 63 4 59 63 7 56
Lymph nodes 364 191 173 0.006 365 46 319 0.055 362 26 337 0.263
Positive 206 95 111 206 32 174 206 12 194
Negative 158 96 62 159 14 145 157 14 143
Histological grade 440 228 212 0.496 440 51 389 0.065 440 33 407 0.003
Grade I 81 42 39 80 4 76 81 1 80
Grade II 134 64 70 133 14 119 134 6 128
Grade III 225 122 103 227 33 194 225 26 199
ER 461 236 225 0.057 461 53 408 0.574 461 33 428 0.003
Positive 306 147 159 306 37 269 306 14 292
Negative 155 89 66 155 16 139 155 19 136
PgR 462 237 225 0.346 462 53 409 0.374 462 33 429 0.063
Positive 226 121 105 227 23 204 226 11 215
Negative 236 116 120 235 30 205 236 22 214
HER2 459 234 225 0.080 459 52 407 0.075 459 33 426 0.114
Positive 68 28 40 68 12 56 68 8 60
Negative 391 206 185 391 40 351 391 25 366
Ki67 442 228 214 0.988 443 53 390 0.754 441 33 408 0.181
High 29 15 14 29 4 25 29 4 25
Low 413 200 213 414 49 365 412 29 383
EGFR 463 237 226 0.038 463 53 410 0.741 463 33 430 0.004
Positive 22 16 6 22 3 19 22 5 17
Negative 441 221 220 441 50 391 441 28 413
CK5 462 237 225 <0.0001 463 53 410 0.546 462 33 429 <0.0001
Positive 66 52 14 66 9 57 66 12 54
Negative 396 185 211 397 44 353 396 21 375
P-cadherin 463 237 226 0.003 463 53 410 0.747 463 33 430 <0.0001
Positive 114 72 42 114 14 100 114 17 97
Negative 349 165 184 349 39 310 349 16 333
CK14 462 237 225 0.005 463 52 410 0.250 462 33 429 <0.0001
Positive 24 19 5 24 1 23 24 7 17
Negative 438 218 220 439 52 387 438 26 412
Vimentin 455 234 222 <0.0001 456 53 403 0.234 455 33 422 0.010
Positive 78 62 16 78 6 72 78 11 67
Negative 377 172 205 378 47 331 377 22 355
Molecular subtypes 464 237 226 <0.0001 463 53 410 0.418 463 33 430 <0.0001
Luminal A 299 147 152 299 34 265 299 12 287
Luminal B 41 17 24 41 7 34 41 4 37
HER2-OE 33 12 21 33 5 28 33 4 29
Basal-like 68 56 12 68 4 64 68 13 55
Unclassified 22 5 17 22 3 19 22 0 22
ER, oestrogen receptor; PgR, progesterone receptor.
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DISCUSSION
One of the recent priorities in breast cancer research is CSC
identiﬁcation/isolation, because it is well accepted that tumours
are essentially driven by a cellular pool with stem-like properties,
which are responsible for tumour invasiveness, heterogeneity,
metastasis capacity and therapy resistance.45 46 In this study, we
analysed the immunohistochemical membrane localisation of
the breast CSC markers CD44 and CD24, as well as the presence
of intracellular ALDH1, in a large and well characterised series of
invasive breast carcinomas. These results were compared with
those obtained by ﬂow cytometry in breast cancer cell lines from
distinct molecular subtypes, studying the same panel of CSC
markers.
As shown in ﬁgure 1, the CD44 CSC marker was commonly
expressed among primary breast carcinomas (51.2% of positive
cases), whereas expression of CD24 and ALDH1 was present in
a minority of cases (11.4% and 7.1%, respectively). When the
same CSC markers were studied in the selected breast cancer cell
lines, half of them expressed high levels of CD44. However, the
majority of the cell lines expressed increased amounts of
membrane CD24, as well as a high percentage of ALDEFLUOR-
positive cells.
Indeed, the results for CD44 were the most comparable
between tumours and cell lines, and the results obtained in
previous studies.29 This agreement is probably associated with
the speciﬁc and clear membrane staining observed for CD44.
CD44 was signiﬁcantly expressed in poor prognosis basal-like
tumours and aggressive basal-like cell lines, and was highly
associated with basal markers (EGFR, CK5, P-cadherin, CK14
and vimentin). It has already been demonstrated that CD44+
cells show a mesenchymal stem cell-like proﬁle, enriched for
genes involved in cell motility, proliferation and angiogenesis,
and its positivity has been associated with decreased patient
survival.33 CD44 expression was also inversely associated with
lymph node metastasis, as previously shown by Giatromanolaki
et al,47 probably because basal-like tumours usually also meta-
stasise via a haematogenic route.48 In addition, it has already
been shown that stem-like gene expression patterns, in lymph
node-negative primary breast tumours, correlate with shorter
distant metastasis-free survival.33 All these results reinforce the
prognostic relevance of this CSC marker and its possible use as
a therapeutic target.
Concerning CD24 membrane staining, the results were not
concordant between primary tumours and cell lines, or with
previous literature data. In tumours, only a small percentage of
the cases showed clear cut membrane positivity; however, with
the exception of MDA-MB-231, all cell lines showed CD24
positivity by ﬂow cytometry. Distinct grading systems have
been used to classify CD24 immunohistochemical results49 50
and, consequently, different percentages of CD24 expression
have been observed in other series of invasive breast carcinomas.
For example, Mylona et al32 considered mainly membrane CD24,
whereas Honeth et al30 considered CD24 staining at the
cytoplasm, possibly explaining why opposite conclusions were
drawn by both studies. Indeed, cytoplasmic expression can
reﬂect aberrant protein overexpression, with consequent
disturbance of its membrane distribution and degradation in
neoplastic cells;51 thus, its signiﬁcance to the most appropriate
CD24 classiﬁcation is still ambiguous, and needs to be
discussed further. Moreover, the extension of staining to
Table 2 Associations between the combined expression of CD44/
CD24 and the classic breast cancer prognostic factors and biomarkers
n
CD44+
CD24L/low<10%
CD44L
CD24L/low‡10 p Value
Tumour size 403 222 181 0.362
T1 <2 cm 100 54 46
T2 2e5 cm 240 138 102
T3 >5 cm 63 30 33
Lymph nodes 364 195 169 <0.0001
Positive 206 127 79
Negative 158 68 90
Histological grade 438 236 202 0.582
Grade I 80 40 40
Grade II 133 76 57
Grade III 225 120 105
ER 459 251 208 0.082
Positive 304 175 129
Negative 155 76 79
PgR 460 251 209 0.480
Positive 225 119 106
Negative 235 132 103
HER2 457 250 207 0.126
Positive 68 43 25
Negative 389 207 182
Ki67 441 241 200 0.657
High 29 17 12
Low 412 224 188
EGFR 461 252 209 0.184
Positive 22 9 13
Negative 439 243 196
CK5 461 252 209 <0.0001
Positive 66 22 44
Negative 395 230 165
P-cadherin 461 252 209 0.008
Positive 114 50 64
Negative 347 202 145
CK14 461 252 209 0.003
Positive 24 6 18
Negative 437 246 191
Vimentin 454 248 206 <0.0001
Positive 78 19 59
Negative 376 229 147
ALDH1 459 250 209 0.599
Positive 32 16 16
Negative 427 234 193
ER, oestrogen receptor; PgR, progesterone receptor.
Table 3 Associations between the combined expression of CD44/CD24/ALDH1 and the breast cancer molecular subtypes
Luminal A Luminal B HER2-OE Basal-like Unclassified
CD44+CD24!/low<10% ALDH1+ 9 (3.1%) 2 (4.9%) 2 (6.1%) 6 (8.8%) 0 (0%)
ALDH1! 159 (53.9%) 22 (53.7%) 22 (66.7%) 10 (14.7%) 18 (81.8%)
CD44+CD24!/low$10% ALDH1+ 6 (2.0%) 3 (7.3%) 2 (6.1%) 11 (16.2%) 0 (0%)
ALDH1! 121 (41.0%) 14 (34.1%) 7 (21.2%) 41 (60.3%) 4 (18.2%)
Total 295 (100%) 41 (100%) 33 (100%) 68 (100%) 22 (100%)
p#0.0001.
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consider a CD24-positive case is also diverse among these
studies:32 35 52 some have been categorising the CD24 marker
as CD24+ versus CD24!,29 30 35 whereas others compare
CD24!/low versus CD24+.25 32 These variables certainly affect
the results concerning breast CSC identiﬁcation in tumours
and, therefore, the prognostic value of this marker. Neverthe-
less, we found that CD24+ cases were enriched in luminal A
tumours (34/53, 64.2%), while the majority of the basal-like
tumours were classiﬁed as CD24!/low (64/68, 94.1%). Although
not statistically signiﬁcant, these results are in agreement with
previous studies addressing the fact that CD24+ cells are
related to more differentiated tissues or tumours, whereas
CD24!/low cells have stem or progenitor-like properties.29 30 33
This same trend was observed in cell lines, because those
maintaining an epithelial phenotype showed enrichment in
CD24+ cells, whereas the mesenchymal cell lines BT-549 and
MDA-MB-231 showed lower levels or no expression of CD24,
respectively.
The combinatorial evaluation of CD44/CD24 for the identi-
ﬁcation of the CSC population in breast cancer cell lines
mimicked in a way the results found in primary tumours. The
majority of basal-like tumours showed more than 10% of cells
expressing the CSC phenotype CD44+CD24!/low, which was
also the main phenotype found in the basal/mesenchymal
MDA-MB-231 breast cancer cell line. The remaining basal cell
lines were positive for both markers, which we believe are cancer
cells representative of basal-like tumours with higher levels of
differentiation (basal-like A, which maintain an epithelial
phenotype), whereas the MDA-MB-231 cells are representative
of the most poorly differentiated basal tumours (basal-like B),
showing a mesenchymal phenotype and CD24 negativity.53 This
hypothesis reinforces the idea that CSC marker expression
rather reﬂects the cell of origin of the different breast cancer
lesions. It has already been reported that luminal progenitors
(which are CD24+) are the most probable cell of origin of the
majority of basal-like carcinomas,54 explaining the positivity for
the CD24 marker in these basal-like breast cancer cell lines. It is
also important to point out that, as CD24 expression presents
a dynamic regulation, as recently demonstrated by Meyer et al,55
CD44+CD24+ cells can readily give rise to CD44+CD24!/low
Figure 2 Basal-like carcinoma showing CD44+CD24!/low$10% phenotype. Single-staining immunohistochemistry for CD44+ (A), CD24!/low (B) and
haematoxylineeosin (C); and double-staining immunofluorescence for CD44+ (D), CD24!/low (E) and merged image (F) (magnification 3200).
Figure 3 KaplaneMeier plots of
disease-free survival (DFS, p¼0.065)
and overall survival (OS, p¼0.127) in
the basal-like tumours defined
according to the CD44/CD24 pattern of
expression.
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cells and vice versa; therefore, the main phenotype seen in basal-
like tumour samples may be a consequence of CD24 loss of
expression during tumour progression, whereas the cell of origin
probably sustains its expression. In addition, it was also shown
that distant breast cancer metastasis are enriched with luminal
epithelial CD24+ cells, implying a phenotypic switch or a clonal
selection for cells with the CD24+ phenotype.33 56 As recent
studies have described that epithelial-to-mesenchymal transition
generates cells with CD44+CD24!/low stem-cell like character-
istics,57 a reversion of the process seems to occur in distant
metastasis.
Moreover, within basal-like tumours, a tendency towards
worse patient survival (DFS and OS) was demonstrated, when
carcinomas showed a predominant CD44+CD24!/low CSC
phenotype. Previous studies have already demonstrated an
association between basal-like carcinomas and the CSC
phenotype CD44+CD24!/low.27e30 These results highlight the
biological heterogeneity of breast cancer and an enrichment of
putative tumour-initiating cells in the aggressive basal-like
tumour subtype. Furthermore, it seems to reﬂect the fact that
whenever CSC markers are present in tumours, they probably
identify the tumour cell of origin more than cells harbouring
a higher selective advantage for tumour progression, because
highly aggressive HER2-overexpressing tumours did not show
an increased expression of these markers.
The breast CSC marker ALDH1 has been described as
a marker of both normal and malignant breast stem/progenitor
cells.34 36 58 ALDH1hi tumour cells form visibly larger colonies
and mammospheres, when compared with ALDH1low cells.36
Previous works also detected small percentages of ALDH1+ cases
in invasive breast cancer, ranging from 4% to 19%.29 35 36 41 59 In
our series, we found 7.1% of ALDH1 expression. Remarkably,
the majority of cases showing a predominant ALDH1-positive
population were signiﬁcantly associated with basal-like
tumours. Besides the low number of positive cases, ALDH1
expression was signiﬁcantly associated with high histological
Figure 4 (A) Percentages of the subpopulations defined by the combination of the stem cell markers CD44 and CD24 in a panel of breast cancer cell
lines representative of distinct molecular subtypes of the disease. Indicated is the mean6SEM of three independent experiments. (B) and (C)
Subpopulations defined by expression of the stem cell markers CD44-FITC and CD24-PE in a panel of breast cancer cell lines representative of distinct
molecular subtypes by flow cytometry. Isotype controls were performed (not shown). (D) Percentages of the ALDEFLUOR-positive subpopulation
defined by the ALDEFLUOR assay in a panel of breast cancer cell lines representative of distinct molecular subtypes of the disease. Plotted is the
mean6SEM of three independent experiments.
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grade but the survival rate of ALDH1-positive cases did not
signiﬁcantly correlate with poor clinical outcome, as stated in
previous studies.34 30 36
As veriﬁed in primary tumours, the measured activity of the
ALDH1 enzyme was also higher in basal-like cell lines, with the
exception of MDA-MB-231, which showed undetectable
ALDH1 activity, as already pointed out by Deng et al.36 Note-
worthy was the prevalence of the CD44+CD24!/low cell popu-
lation and the absent ALDEFLUOR-positive population in these
cells, indicating that these markers probably do not refer to the
same cell of origin that gives rise to the CSC compartment in
distinct breast tumours. Other examples are the HER2-OE
SkBr3 and BT474 breast cancer cell lines, which showed
predominance of the CD44!CD24+ luminal phenotype, but
presented with high levels of ALDH1.
In summary, the described CD44+CD24!/low and ALDH1+
stem-like phenotypes seem to identify CSC with distinct levels
of differentiation, the former proﬁle being more related to basal-
like carcinomas that most probably originate from the most
primitive mammary stem cells, whereas the latter is a marker of
basal-like and HER2-overexpressing tumours, putatively origi-
nating from luminal committed progenitors. With this
hypothesis in mind, it seems that the paramount method and
biomarkers that identify breast CSC within the distinct
molecular subtypes need to be better explored, because it is
pivotal to translate the CSC concept to clinical practice. In the
near future, the recognition of reliable markers to distinguish the
CSC pool in each molecular subtype will be decisive for the
development of speciﬁc target therapies.
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ABSTRACT
Although the luminal progenitor cell of the normal mam-
mary gland hierarchy has been proposed as the cell-of-ori-
gin for basal-like breast cancers, finding the cancer stem
cell (CSC) phenotype for this malignancy has proven a dif-
ficult task, mostly due to the lack of specific markers.
Recently, basal-like sporadic and familial cases of breast
cancer have been linked to BRCA1 gene inactivation,
which enables the upregulation of the target-repressed
CDH3/P-cadherin gene, an important biomarker of basal-
like breast carcinomas. Previously, we demonstrated that
P-cadherin overexpression can mediate aggressive behav-
ior in these tumors. Thus, our aim was to test whether
P-cadherin mediates stem cell properties in basal-like
breast carcinomas. Using a series of breast cancer cell
lines and primary tumors, we showed that P-cadherin was
directly associated with the expression of the breast stem
markers CD44, CD49f, and aldehyde dehydrogenase 1 in
the basal subtype. Moreover, cell population enriched for
P-cadherin expression comprised increased in vitro mam-
mosphere-forming efficiency and capacity to grow colonies
in three-dimensional cultures as well as greater tumorige-
nicity. Importantly, an association was found with stem-/
progenitor-like phenotypes of the breast, including the
luminal progenitor population, CD49f1CD241. Addition-
ally, P-cadherin expression conferred resistance to x-ray-
induced cell death, sustaining a role for this molecule in
another stem cell property. In summary, we demonstrated,
for the first time, that P-cadherin mediates stem cell prop-
erties, which could be explored in order to better define
the CSC phenotype of basal-like breast tumors and the
cell-of-origin of this malignancy. STEM CELLS 2012;30:854–
864
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INTRODUCTION
Several studies have shown that solid tumors may contain a
small subpopulation of cancer cells that are tumorigenic and
have the ability to self-renew and generate all the diverse cancer
cells present within the tumor mass. This experimental evidence
supports the cancer stem cell (CSC) hypothesis which proposes
that a hierarchy exists in the solid tumors comparable to the one
found in normal tissue differentiation [1]. In breast, these cells
are named breast CSCs. Breast CSCs share important properties
with mammary stem cells, namely the ability to proliferate and
resist to radiation- and chemotherapy-induced cell death,
allowing them to survive and to cause tumor recurrence [2, 3].
However, the identification of breast CSCs has been a hard task
due to the current technical constraints and the high intertumor
and intratumor heterogeneity observed in breast cancer [4].
Most authors make use of cell surface proteins, usually adhe-
sion-related molecules, in an attempt to define a subpopulation
of cells that represents the breast CSC population. In 2003, Mi-
chael Clarke’s group isolated a subset of breast cancer cells
with the phenotype ESAþ/CD44þ/CD24"/low, which were able
to self-renew and were highly tumorigenic at a low cell inocu-
lum [5]. Since then, several other phenotypes/markers to isolate
breast CSCs have been described.
For the basal-like breast cancer molecular subtype, in par-
ticular, which constitute 10% of all breast cancer cases, few
descriptions exist concerning the isolation of their breast CSCs.
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Meyer et al. isolated CD44þ/CD49fhigh/CD133-2high cancer
cells from estrogen-receptor (ER)-negative patient tumors,
which showed increased tumorigenic ability [6]. Wright et al.
described the phenotype CD133þ as able to isolate CSCs from
tumors developed in BRCA1"/" mice [7]. Hwang-Verslues
et al. characterized the CSC phenotype PROCRþ/ESAþ for the
human basal MDA-MB-231 breast cancer cell line [8].
It was recently demonstrated that basal-like breast cancers
have a molecular phenotype comparable to the luminal progeni-
tor of the normal breast [9, 10], which raised the hypothesis that
markers of luminal progenitors would be good CSC markers for
basal-like lesions. Additionally, it has been shown that inactiva-
tion of BRCA1 gene in the luminal layer of the normal breast
originates breast carcinomas in mice that resemble basal-like
carcinomas in humans [10]. In fact, BRCA1 is a major regulator
of normal luminal maturation [11] and it is essential for the
repression of a panel of genes that are typically expressed in ba-
sal-like carcinomas of the breast, such as the CDH3/P-cadherin
gene [12]. These evidences suggest that P-cadherin can be an
important CSC marker for this type of tumor lesions.
P-cadherin, a classic type I adhesion molecule, is normally
expressed in the myoepithelial/basal layer of the breast and is fre-
quently overexpressed in basal-like breast carcinomas [13–15].
We have found that P-cadherin expression is linked to aggressive
tumor behavior, increasing the production of metaloproteases
(MMPs) by cancer cells to the extracellular matrix as well as
inducing cancer cell invasion, migration, and motility, due to a
mechanism involving alterations in the actin cytoskeleton and
signaling through small guanosine triphosphatase (GTPase)-
binding proteins [16, 17]. However, P-cadherin is also involved
in homeostatic processes, such as cell differentiation, develop-
ment, and embryogenesis, illustrating an indirect effect of this
adhesion molecule in stem cell biology. P-cadherin deficient
female mice present abnormal mammary gland morphology,
showing premature differentiation of the breast and increased
risk of developing preneoplastic lesions, such as alveolar hyper-
plasia and ductal dysplasia [18]. In fact, P-cadherin seems to be
important in the maintenance of an undifferentiated state in the
malignant setting, as breast tumors with P-cadherin expression
show loss of cell polarity [15]. The role of P-cadherin in develop-
ment and differentiation is also seen during embryonic histogene-
sis, since this cadherin is present in the extraembryonic ectoderm
and visceral endoderm, structures originating the placenta [19].
P-cadherin also has a direct effect in normal stem cells, since it
was identified as a stem cell surface marker in human embryonic
stem cells [20]. Early hair progenitor cells were also isolated as
P-cadherinþ (and K14þ/a6-integrin [CD49fþ] cells) [21]. Fur-
thermore, the stem cell related transcription factors b-catenin,
p63, and C/EBP-b were shown to induce P-cadherin promoter
activation [22–24]. Interestingly, in breast, P-cadherin is found in
the cap cells, characteristic stem cells that are the precursors of
myoepithelial cells [25, 26], and in the myoepithelial layer [27],
eventually contributing to the suprabasal stem cell niche. Herein,
we used human mammary cell lines (normal and malignant) as
well as a series of invasive breast carcinomas to provide evidence
that P-cadherin expression is important in the CSC context not
only as a biomarker that better defines the basal-like breast CSC
phenotype but also as a protein with direct relevance in stem cell
activity in this specific molecular subtype.
MATERIALS AND METHODS
Cell Culture
Human breast cell lines T47D, MDA-MB-468, BT-20, BT-549,
and MCF-10A were obtained from ATCC (American Type
Culture Collection, Manassas, VA, www.atcc.org). The human
breast cancer cell line MCF-7/AZ was obtained from a collection
developed in the laboratory of Prof. Marc Mareel (Ghent Univer-
sity Hospital, Ghent, Belgium), which was genetically manipu-
lated to overexpress P-cadherin (MCF-7/AZ.Pcad). The control
cell line (MCF-7/AZ.mock) shows low P-cadherin levels, identi-
cal to the parental cell line [28]. MCF-10A cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM): F12, supple-
mented with 5% heat inactivated horse serum, 10 lg/ml insulin,
0.5 lg/ml hydrocortisone, 20 ng/ml epidermal growth factor
(EGF), and 100 ng/ml cholera toxin (Sigma-Aldrich, St Louis,
MO, www.sigmaaldrich.com). All the other cell lines were grown
in DMEM supplemented with 10% fetal bovine serum (FBS) and
with 1% antibiotic solution (penicillin–streptomycin) (Invitrogen,
Carlsbad, CA, www.invitrogen.com). All cell lines were routinely
cultured in a humidified atmosphere with 5% CO2 and at 37
#C.
Cells were used in experiments when reached 70%–80%
confluence.
Fluorescence-Activated Cell Sorting Analysis and
Sorting for P-Cadherin and for the Breast Stem
Markers CD44, CD24, and CD49f
Cells were harvested with versene/0.48 mM EDTA (Invitrogen).
Detached cells were washed with phosphate buffered saline
(PBS) supplemented with 0.5% FBS and resuspended in the stain
buffer (2 mM EDTA þ 0.5% bovine albumin in PBS). A single-
cell suspension was labeled by fluorescence-conjugated antibodies
at a concentration of 1–10 in stain buffer: fluorescein isothiocya-
nathe (FITC)-conjugated CD44, phycoerythrin (PE)-conjugated
CD24, and FITC-conjugated CD49f. These antibodies were
obtained from BD Biosciences (San Diego, CA, www.bdbioscien-
ces.com). P-cadherin monoclonal antibody APC-conjugated was
obtained from R&D (Minneapolis, MN, www.rndsystems.com)
and used at the same concentration as above. A live-dead stain
(Invitrogen) and the primary antibodies or the respective isotype
controls (BD Biosciences) were incubated at 4#C, in the dark, for
15 minutes. The labeled cells were then washed in the stain
buffer and analyzed on a LSR-II (BD Biosciences). In multicolor
experiments, fluorescent minus one samples were used to deter-
mine the gating strategy.
For the sorting experiments, the normal cell line MCF-10A,
two luminal cell lines, and two basal cell lines were selected and
subpopulations were sorted according to P-cadherin expression
(highest 20% expressing cells vs. lowest 20% expressing cells).
Briefly, cells were stained for P-cadherin (APC) and a live-dead
dye in stain buffer, as above. Cells were then passed through a
50 lm mesh to remove clumps and resuspended in stain buffer
prior to sorting. Cells were sorted using BD Influx or FACS
ARIA-II (BD Biosciences) and collected into 10% Hanks buf-
fered solution (Invitrogen). The purity of sorted population was
checked and the sorted population contained 80%–95% purified
cells. In addition, a further sample was also collected from cells
passed through the laser under pressure, but not sorted, to act as
a control for the effect of the pressure on the cells. No differen-
ces in cell behavior were detected.
Aldehyde Dehydrogenase Activity
Aldehyde dehydrogenase (ALDH) activity was assessed using the
ALDEFLUOR assay (Stem Cell Technologies, Grenoble, France,
www.stemcell.com). In brief, cells were incubated in ALDE-
FLUOR assay buffer containing ALDH substrate (1.5 lmol/l per
106 cells). In each experiment, a sample of cells was also incu-
bated with 15 lmol/l of diethylaminobenzaldehyde, a specific
ALDH inhibitor, to use as a negative control. P-cadherin mono-
clonal antibody (APC-conjugated; R&D) was incubated with the
sorted ALDEFLUOR positive and negative cells in assay buffer
for 20 minutes on ice. Incubation with the isotype antibody (BD
Biosciences) was used as a control. Cells were washed in assay
buffer and analyzed in the FACS analyzer LSR-II (BD
Biosciences).
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Tissue Microarray and Immunohistochemistry
A series of 466 primary invasive breast carcinomas were retrieved
from the files of the Department of Pathology, Hospital Xeral-Cı´es,
Vigo, Spain, which were diagnosed between 1978 and 1992. Breast
cancer patient follow-up information was available for 455 cases
ranging from 1 to 120 months after the diagnosis. Representative
tumor areas were carefully selected and at least two tissue cores
(0.6 mm in diameter) were deposited into a tissue microarray.
Immunohistochemistry was performed for P-cadherin (BD Bio-
sciences) (1/50, 60 minutes, RT) and the stem cell markers CD44
(clone 156-3C11; Cell Signaling Technology, Danvers, MA,
www.cellsignal.com) (1/100, 30 minutes, RT), CD24 (clone Ab2-
SN3b; Neomarkers, Fremont, CA) (1/100, 60 minutes, RT), CD49f
(HPA012696; Sigma-Aldrich, St. Louis, MO) (1/10, 120 minutes,
RT), and ALDH1 (clone EP1933Y; Abcam, Cambridge, UK,
www.abcam.com) (1/100, 60 minutes, RT).
High temperature (98#C) antigenic retrieval with Tris-EDTA
(P-cadherin) or citrate buffer (CD44, CD24, CD49f, and ALDH1)
was performed before primary antibody incubation. The primary
antibodies were detected using a secondary antibody with horse-
radish peroxidase polymer (Cytomation Envision System
HRP; DAKO, Carpinteria, CA, www.dako.com) using diamino-
benzidine as chromogen, according to the manufacturer’s instruc-
tions. This series of invasive breast carcinomas was previously
characterized in terms of patient and tumor parameters (Support-
ing Information Table S1) [29].
P-cadherin, CD44, CD24, and CD49f staining were detected
mainly at the membrane of tumor cells and the scoring was consid-
ered as follows: (0), 0%–10% of positive tumor cells; (1þ), 10%–
25% of positive tumor cells; (2þ), 25%–50% of positive tumor
cells; (3þ), >50% of positive tumor cells. For P-cadherin, CD44,
and CD49f, the cases which were classified as (0) were considered
negative, whereas (1þ), (2þ), and (3þ) were established as posi-
tive cases. For CD24, the cases were divided into negative/low ("/
low), when considered (0) or (1þ), or into positive cases when
classified as (2þ) or (3þ). Immunohistochemical staining of
ALDH1 was classified as positive when more than 1% of tumor
cells showed clear cytoplasmic positivity [30, 31]. Since the im-
munohistochemical result was not interpretable for some of these
markers, the statistical analyses were performed using only the
breast tumor cases with available data. This study was conducted
under the national regulative law for the usage of biological speci-
mens from tumor banks, where the samples are exclusively avail-
able for research purposes in the case of retrospective studies.
P-Cadherin and Stem Cell Markers Knockdown and
Immunoblot Analysis
P-cadherin (CDH3 gene) expression was silenced by a specific
siRNA, target sequence: AAGCCTCTTACCTGCCGTAAA. Inhi-
bition of P-cadherin was maintained for at least 72 hours after
cell transfection, confirmed by Western blot. Inhibition of the
expression of CD49f (ITGA6 gene), target sequence: CAGGGTA
ATAAACTTAGGTAA, and CD44 (CD44 gene), target sequence:
AACTCCATCTGTGCAGCAAAC, was also performed.
All transfections were carried out using HiPerFect transfec-
tion reagent (Qiagen, Hilden, Germany) in a final concentration
of 2 nM siRNA (Qiagen), according to manufacturer instructions.
A siRNA scrambled sequence was included as a control
(Qiagen).
Protein analysis was performed by Western blot using the fol-
lowing antibodies: anti-P-cadherin (BD Transduction, San Diego,
CA, www.bdbiosciences.com), anti-CD49f (HPA012696; Sigma-
Aldrich), anti-CD44 (Cell Signaling Technology, Danvers, MA),
anti-CD44v6 (VFF-7; Abcam, Cambridge, U.K.), and anti-a-tubu-
lin (DM1A; Sigma-Aldrich). Secondary antibodies were peroxi-
dase conjugated, from Santa Cruz Biotechnology (Heidelberg,
Germany, www.scbt.com) and detection was performed using the
Amersham Hyperfilm and Amersham ECL Detection substrate
(GE Healthcare, Chalfont St. Giles, U.K., www.gehealthcare.com).
Mammosphere Assay
Monolayer cells were enzymatically detached with 0.125% tryp-
sin-EDTA (Sigma, St. Louis, MO), manually disaggregated with
a 25-gauge needle to a single-cell suspension, and resuspended in
cold PBS. Cells were plated at 500 cm"2 in nonadherent culture
conditions, in flasks coated with 1.2% poly(2-hydroxyethylmetha-
crylate)/95% ethanol (Sigma). Cells were grown for 5 days, in
DMEM/F12 containing B27 supplement, 500 ng/ml hydrochorti-
sone, 40 ng/ml insulin, 20 ng/ml EGF, and maintained in a
humidified incubator at 37#C and 5% (vol/vol) CO2. Mammo-
sphere-forming efficiency (MFE) was calculated as the number of
mammospheres ($50 lm) formed, divided by the cell number
plated, being expressed as a percentage.
Three-Dimensional Cultures
The three-dimensional (3D) on-top method was used. Briefly, sin-
gle-cell suspensions were seeded at a density of 250 or 1,000
cells per well into eight-well glass chamber slides containing 50
ll of 100% growth factor-reduced matrigel per well (a biologi-
cally active matrix material resembling the mammalian cellular
basement membrane [BD Biosciences]). Cells were plated in
growth medium containing H14 medium (DMEM/F12 with insu-
lin 250 ng/ml, transferrin 10 lg/ml, sodium selenite 2.6 ng/ml,
estradiol 10"10 M, hydrocortisone 1.4 % 10"6 M, prolactin 5 lg/
ml, and EGF 10 ng/ml, according to Kenny et al. [32] with 5%
growth factor-reduced matrigel and 1% FBS).
Cells were incubated at 37#C, with replacement of the growth
medium containing 2% growth factor-reduced matrigel every 2–3
days, to allow 3D structures to form. The size and number of the
structures formed were assessed microscopically after 21 days.
Cell X-Ray Irradiation
Normal and cancer cells were plated in mammosphere culture
conditions and immediately irradiated with 2 Gy or 4 Gy, respec-
tively. Irradiations were performed using a 320 kV X-ray system
(Gulmay Medical Ltd., Camberley, U.K.). The machine was oper-
ated at 300 kV, 10 mA, with filtration fitted in the X-ray beam to
give a radiation quality of 2.3 mm Cu half-value layer. Samples
were positioned at a distance of 500 mm from the X-ray focus,
where the dose rate was determined to be 1.37 Gy/minute.
In Vivo Assessment of P-Cadherin Tumorigenic
Capacity
The basal-like cell line MDA-MB-468 was sorted according to P-
cadherin expression into two subpopulations: P-cadhigh and P-
cadlow fractions, as described above. The sorted cells were xeno-
transplanted at varying dilutions (106, 105, or 5 % 104 cells in
100 ll cell suspension) into the subcutaneous region, under the
mammary fat pad of 4–5-week-old female N:NIH(s)II:nu/nu nude
mice, using a 25-gauge needle. Mice were maintained and housed
at IPATIMUP Animal House, sited at the Medical Faculty of the
University of Porto, in a pathogen-free environment, under con-
trolled conditions of light and humidity. Animal experiments
were carried out in accordance with the European Guidelines for
the Care and Use of Laboratory Animals, directive 2010/63/UE.
Mice (four per group) were weighted, and tumor width and length
were measured with calipers every week. Tumor volume was
estimated by using the equation, V ¼ 0.5 % a % b2, where V is
volume, a is the length of the major axis of the tumor, and b is
the length of its minor axis. Mice were euthanized 3 months after
tumor cell inoculation.
Statistical Analysis
Mammosphere-forming ability and growth in 3D cultures (size
and number) were compared using two-tailed unpaired t test. Im-
munohistochemical associations between the molecular markers
were assessed by Pearson’s correlation and Chi-squared tests.
Survival curves were estimated by the Kaplan-Meier method and
compared using the log-rank test to assess significant differences
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for overall survival. A maximum cutoff value of 120 months (10
years) was considered. For multivariate survival analysis, Cox
regression models were fitted to estimate hazard ratios (HRs) and
the corresponding 95% confidence interval. Statistical analyses
were carried out using SPSS statistics 17.0 software (SPSS Inc.,
Chicago, IL), and a significant level of 5% was considered. Flow
cytometry data were analyzed with the Flowjo software package
(Treestar, Ashland, OR).
RESULTS
Normal and Tumorigenic Breast Cell Lines, with a
Basal-Like Phenotype, Are Enriched for the
Expression of P-Cadherin as well as for the Stem
Cell Markers CD44, CD49f and Show an Increased
ALDEFLUOR-Positive Subpopulation
P-cadherin is normally expressed in the basal layer of the
mammary epithelium [27] and is frequently upregulated in ba-
sal-like breast carcinomas [13–15, 27, 33]. In order to study
whether this protein was associated with the expression of
CSC markers in vitro, a panel of breast cancer cell lines was
used. This series of cell lines comprised two main subgroups:
the ER-positive luminal cell lines (MCF-7/AZ and -T47D)
and the ER-negative basal-like cell lines (MDA-MB-468, BT-
20, and BT-549) [34, 35]. In order to demonstrate that this
putative association was not restricted to cancer cells, a
normal mammary cell line was also included in the study
(MCF-10A), which was previously described as harboring a
basal gene expression signature [34].
In accordance to what is seen in human breast carcinomas
[13, 27, 33], high/moderate cell surface expression of P-cad-
herin (>50% of positive cells by fluorescence-activated cell
sorting [FACS]) was preferentially observed in basal-like cell
lines, in contrast to luminal cell lines, which show lower lev-
els of this protein (Fig. 1A). The same association was
observed for CD44 and CD49f, with increased cell surface
expression of these markers in the basal-like phenotype
(P-cadherin high/moderate cells), in contrast to the luminal
phenotype (P-cadherin low cells) (Fig. 1B). Other studies are
Figure 1. Fluorescence-activated cell sorting analysis of cell surface markers and ALDEFLUOR in breast cell lines. P-cadherin is highly
expressed in mammary basal-like cell lines (A). In these cells, expression of the stem cell markers CD44 and CD49f was found to be increased
(vs. luminal cells). Furthermore, the stem cell population, defined by the ALDEFLUOR assay, is also expanded in the basal-like cells (B). In
addition, basal cells have an ALDEFLUOR-positive population enriched in P-cadherin expression (C). P-cadherin levels were measured by flow
cytometry within the ALDEFLUORþ and ALDEFLUOR" subpopulations (percentages of the ALDEFLUOR subpopulations are represented).
The basal-like cell line MDA-MB-468 showed a stem cell population (ALDEFLUORþ) enriched in P-cadherin expression, whereas the same
does not occur in the luminal cell line T47D. (D): ALDEFLUOR assay was performed after P-cadherin inhibition (siRNA P-cad) in the breast ba-
sal cell lines MCF-10A, MDA-MB-468, BT-20, and BT-549 showing a decrease in the ALDEFLUORþ fraction (for which BT-549 is shown as
an example). (E): Using transient knockdown of P-cadherin in a panel of basal-like cell lines, the expression of the stem cell markers was eval-
uated by Western blot. Conversely, the impact on P-cadherin expression was evaluated after transient inhibition of the stem cell markers CD44
and CD49f. Abbreviation: FITC, fluorescein isothiocyanate; DEAB, diethyl amino benzaldehyde.
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in accordance with our data indicating that, in breast cell
lines, luminal cells usually express lower levels of CD44 [36–
38] and CD49f [35, 39] in comparison with basal cells.
Importantly, the later molecules are already well established
as CSC markers of the basal phenotype [6, 7] as well as puta-
tive mammary gland stem cell biomarkers [9, 40, 41]. All the
cell lines expressed high levels of CD24, independently of the
level of P-cadherin expression. In addition to the cell surface
markers, it was previously shown that normal and cancer
human mammary epithelial cells with high ALDH enzyme
activity have stem/progenitor properties [31]. The analysis of
ALDH activity in this panel of cell lines revealed that the
P-cadherinmod/high basal cells showed a significant subpopula-
tion with this putative stem cell profile (>15%), in contrast to
P-cadherinlow luminal cells (Fig. 1B). Again, these results are
in accordance with other studies that have shown that basal
cells have an increased ALDEFLUORþ subpopulation, com-
pared with the luminal ones [42, 43].
FACS analysis of the ALDEFLUORþ and ALDEFLUOR"
cell compartments of cell lines from the two main groups
showed that there was an enrichment of P-cadherin expression
in the ALDEFLUORþ stem cell compartment, pointing for a
direct association between these two markers. Interestingly,
this association was only found in the basal-like group of cell
lines, as shown in MDA-MB-468 (Fig. 1C). In order to more
clearly demonstrate the link between P-cadherin and the
ALDEFLUORþ subpopulation, we decided to perform transient
inhibition of P-cadherin in the basal cells MDA-MB-468, BT-
20, BT-549, and MCF-10A. Measurement of ALDH1 activity
showed that the inhibition of P-cadherin leads to a decrease in
the number of ALDEFLUORþ cells in all cell lines, being
more significant in MCF-10A and BT-549. In the cell line BT-
549, the ALDEFLUORþ subpopulation significantly decreased
from 50.9% to 33.2% (Fig. 1D). These results clearly show an
association between P-cadherin and the stem cell pool.
The inhibition of P-cadherin also clearly impacted in the
expression of the stem cell marker CD49f. In all basal-like
cell lines analyzed, P-cadherin knockdown was accompanied
by a reduction of CD49f expression (Fig. 1E). Expression of
CD44 was also affected, namely the CD44v6 isoform, with a
reduction found in the cell line BT-549 after P-cadherin inhi-
bition (Fig. 1E). We also performed transient knockdown of
CD44 or CD49f and studied the impact of these stem cell
markers on P-cadherin expression. Inhibition of CD44 caused
a slight reduction of P-cadherin expression in the BT-549 cell
line and inhibition of CD49f did not affect P-cadherin expres-
sion in the three basal cell lines (Fig. 1E).
P-Cadherin Expression Is Associated with the
Phenotype of the Luminal Progenitor from the
Normal Breast Differentiation Hierarchy:
CD49f1CD241
Combinations of the markers CD44, CD24, and CD49f have
been used in the literature in order to define subpopulations
within cell lines or tissues that have stem or CSC properties [5,
41, 44–49]. Specifically, in the CSC field, the phenotype
CD44þCD24"/low is believed to exhibit CSC properties [5] and
some authors also suggest that the CD44þCD24þ phenotype
similarly harbors stem-like properties [50, 51]. Importantly,
CD44 expression in the normal human hierarchy is reported in
both luminal and basal lineages by Visvader [52] and Raouf
et al. [49], with a lower expression in the luminal compartment
as seen in breast cell lines. Studies performed by Shipitsin et al.
with cancerous and normal breast tissue indicate that cells
enriched for CD44 expression represent a more basal ER-nega-
tive phenotype, with mammary epithelial progenitor-like proper-
ties [53]. Additionally, in the normal human breast, the luminal
progenitor is reported to be CD49fþCD24þ [9, 10, 41, 47] (also
EpCAMþMUC1þCD133þThy1"CD10") [46, 49, 54, 55].
In this work, cells were stained with a combination of tar-
get proteins, which include P-cadherin, CD44, CD24, and
CD49f. Stringent cell sorting was applied to separate and ana-
lyze the cell subpopulations with stem-like properties
described above within each of the breast cell lines, after gat-
ing for P-cadherin expression. Separation of the highest 20%
P-cadherin (P-cadhigh)-expressing cell subpopulation from the
lowest 20% P-cadherin (P-cadlow)-expressing cell subpopula-
tion revealed that, in all the cell lines studied, the P-cadhigh
cell subpopulation was enriched for the stem cell-associated
markers CD44, CD49f, and CD24, in comparison with the P-
cadlow subpopulation, as shown in Figure 2A, 2B. Conversely,
when parental cells were separated into the four possible sub-
populations by CD44/CD24 and CD49f/CD24 expression, the
CD44þCD24þ and CD49fþCD24þ cell subpopulations were
the ones enriched for P-cadherin expression (Fig. 2C and
Supporting Information Fig. S1).
The population described by Al Hajj et al. as the CSC phe-
notype, CD44þCD24"/low, is decreased in the P-cadhigh frac-
tion (0.20% vs. 24.2% in the P-cadlow fraction, in the example
shown in Fig. 2A). However, the enrichment of the P-cadhigh
fraction for the phenotype CD44þ/CD24þ (from 50.9% in the
P-cadlow to 99.6% in the P-cadhigh) indicates that this adhesion
molecule is associated with stem-like properties [50, 51]. Fur-
thermore, the P-cadhigh cells are also enriched in CD49fþ/
CD24þ cells (from 57.4% in the P-cadlow fraction to 99.9% in
the P-cadhigh), which are evocative of an association with the
luminal progenitor profile of the breast [9, 10, 47].
In Human Breast Carcinomas, P-Cadherin
Expression is Associated with Poor Patient Outcome
as well as with the Expression of the Stem Cell
Markers CD44, CD49f, and ALDH1
The expression of P-cadherin and the breast stem cell markers
CD44, CD24, CD49f, and the isoform ALDH1 was analyzed
by immunohistochemistry in a large series of 466 invasive
human breast carcinomas. This analysis was performed in
order to validate, in primary breast carcinomas, the associa-
tion of P-cadherin expression with the stem cell markers pre-
viously observed in vitro. P-cadherin membrane expression
was found in 24.5% of the cases (114/466), 63.2% of them
were basal-like carcinomas (Supporting Information Table
S2). CD44 membrane staining was present in 51.2% (237/
463) of the cases. CD49f membrane staining was positive in
only 11.5% (49/427) of the invasive breast carcinomas.
Regarding the membranous stain of CD24, the majority of the
cases (88.6%—410/463) were classified as negative/low, and
only 11.4% (53/463) of the tumors had clear membrane stain-
ing. Concerning ALDH1 expression, a minority of cases
(7.1%—33/463) were classified as positive, showing a clear
cytoplasmic expression in tumor cells. Importantly, P-cad-
herin-positive cases were significantly enriched for the stem
cell markers CD44 (p ¼ .003), CD49f (p < .001), and
ALDH1 (p < .0001), and no significant correlation was found
between P-cadherin and CD24 expression (p ¼ .747) (Table
1). Furthermore, the statistical analysis demonstrated that
CD44, CD49f, and ALDH1 expressions were also signifi-
cantly enriched in the basal-like carcinomas, in contrast to
CD24 (Supporting Information Table S2).
Kaplan-Meier survival curves showed that P-cadherin-pos-
itive tumors were significantly associated with poor overall
survival (log rank, p ¼ .023) (Fig. 3A). Furthermore, when
taken into account the classic prognostic markers tumor size,
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histological grade, and node involvement, the expression of
P-cadherin appeared as an independent factor, demonstrating
the importance of this protein as a poor prognostic marker in
breast cancer (HR ¼ 1.486, p ¼ .037, by multivariate Cox
analysis) (Supporting Information Table S3). In contrast, the
expression of the stem cell markers CD44, CD24, CD49f, or
ALDH1 alone was not significantly associated with the clini-
cal outcome (Supporting Information Fig. S2). By multivari-
ate Cox analysis, the expression of CD24 was the only signifi-
cant stem cell marker influencing survival, in this case related
to a better prognosis (HR ¼ 0.439, p ¼ .014) (Supporting In-
formation Table S3). Interestingly, however, when P-cadherin
and CD24 were combined, the positive expression of both
markers was highly associated with the worst patient overall
survival (log rank, p ¼ .014) (Fig. 3C), whereas tumors with
a P-cadherin"CD24þ phenotype were associated with a good
prognosis. The tumors with combined expression of P-cad-
herin and CD44 were also associated with a worst patient
Table 1. Association between P-cadherin expression and the expression of the stem cell markers CD44, CD24, CD49f, and ALDH1 analyzed
by immunohistochemistry in a series of 466 primary invasive breast carcinomas
Variable (n ¼ 466)
P-cadherinþ
(n ¼ 114, 100%)
P-cadherin"
(n ¼ 352, 100%)
p value
(Pearson chi-square)
CD44þ (n ¼ 237) 72 (63.2%) 165 (47.3%) .003
CD44" (n ¼ 226) 42 (36.8%) 184 (52.7%)
Missing (n ¼ 3)
CD24þ (n ¼ 53) 14 (12.3%) 39 (11.2%) .747
CD24"/low (n ¼ 410) 100 (87.7%) 310 (88.8%)
Missing (n ¼ 3)
CD49fþ (n ¼ 49) 29 (27.4%) 20 (6.2%) <.001
CD49f" (n ¼ 378) 77 (72.6%) 301 (93.8%)
Missing (n ¼ 39)
ALDH1þ (n ¼ 33) 17 (14.9%) 16 (4.6%) <.001
ALDH1" (n ¼ 430) 97 (85.1%) 333 (95.4%)
Missing (n ¼ 3)
P-cadherin-positive cases are enriched in CD44, CD49f, and ALDH1 expression (vs. P-cadherin-negative cases). No statistically significant
association was seen between P-cadherin and CD24 expression.
Abbreviation: ALDH1, aldehyde dehydrogenase 1.
p < .05 was considered significant.
Figure 2. Fluorescence-activated cell sorting measurement of the combined expression of CD44/CD24 and CD49f/CD24 in a panel of luminal
and basal breast cell lines. In all cell lines (MCF-10A is represented as an example), P-cadherinhigh subpopulation (top 20% expressing cells)
expressed higher levels of CD24, CD44, and CD49f than P-cadherinlow subpopulation (lowest 20% expressing cells) (A, B). Conversely, when
analyzing the different quadrants defined by the stem cell markers CD44/CD24, P-cadherin expression was enriched in the CD44þ/CD24þ subpo-
pulation (C). * indicates '1.5% of the total cell population.
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overall survival (Fig. 3B) (log rank, p ¼ .047). Although a
strong association between P-cadherin and CD49f expression
was found, the combined expression of both these markers
was not significantly associated with survival (log rank, p ¼
.271) (Fig. 3D).
P-Cadherin Expression Confers Increased
Self-Renewal Ability, Improved Cell Growth in 3D
Cultures, and Radioresistance in Breast Cancer
Cell Lines
The previous in vitro and in vivo indications, showing that P-
cadherin is associated with the expression of stem cell makers
in breast cancer, led us to study the cellular effects mediated
by the expression of P-cadherin, namely in stem cell activity.
Stem cell activity can be measured by means of the mam-
mosphere-forming ability of a specific cell line/subpopulation.
In different cell lines, the heterogeneous parental cell popula-
tion were separated by sorting according to P-cadherin levels
of expression (high 20% vs. low 20%) and they were studied
for stem cell activity. We found that P-cadhigh cell fractions
from basal-like cell lines showed a significant increased MFE
when compared with the P-cadlow cell fraction (Fig. 4A). The
MFE from the basal P-cadhigh fractions reached up to two
times the levels of the negative fractions. This result was seen
both in the basal tumorigenic cells as well as in the normal
MCF-10A breast cell line, suggesting that P-cadherin contrib-
utes to the stem cell activity in both normal and malignant
contexts.
We also studied the clonogenic capacity of P-cadherin
positivity in a 3D proliferation permissive environment con-
taining matrigel, a matrix resembling the basal lamina of the
normal breast. Using the same sorting procedure, in the lumi-
nal MCF-7/AZ and the basal BT-549 cells, we found that
there was an increase in the number of 3D structures formed
by the P-cadhigh cell subpopulation, compared with the P-
cadlow subpopulation in the basal-like cell line (Fig. 4B). Fur-
thermore, we found that the grape-like structures formed by
P-cadhigh cells were bigger than the 3D structures formed by
the P-cadlow subpopulation (95.8 lm vs. 50.1 lm, p ¼ .003,
data not shown). The same does not hold true for luminal
cells for both parameters analyzed.
To verify the specific role of P-cadherin in stem cell ac-
tivity, we used genetically manipulated cell lines, by in vitro
transduction or silencing of P-cadherin. We showed that sta-
ble transduction of P-cadherin in MCF-7/AZ cells led to an
increase of mammosphere formation (>25% of MFE) when
compared with the mock cell line (Fig. 5A, 5B). This differ-
ence in mammosphere formation persists for at least two pas-
sages (data not shown), suggesting a role of P-cadherin in
mediating self-renewal or survival. Likewise, transient inhibi-
tion of P-cadherin expression by siRNA assays showed that
mammosphere-forming ability was negatively affected,
although not completely abrogated in most of the cell lines
Figure 3. Overall survival of patients with breast carcinomas (log-rank test), classified according to the expression of P-cadherin (A) and the
combined expression of P-cadherin/CD44 (B), P-cadherin/CD24 (C), and P-cadherin/CD49f (D). Expression of CD44, CD24, or CD49f alone has
no prognostic value (Supporting Information Fig. S2); however, when P-cadherin is combined with these markers, P-cadherinþ/CD44þ and P-
cadherinþ/CD24þ cases have a worst overall patient survival.
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studied (Fig. 5A, 5C). These results indicate that P-cadherin
contributes to the stem cell activity of these cells.
One of the features attributed to breast CSCs is the
increased resistance to irradiation, which allows them to sur-
vive and persist in tissues after treatment, contributing to dis-
ease relapse. We investigated the effect of x-ray irradiation
alone and in combination with P-cadherin inhibition on the
stem cell activity measured by MFE. We found that inhibition
of P-cadherin in the tumorigenic basal-like cell lines potenti-
ated the effect of irradiation-induced cell death, decreasing
the number of mammospheres formed. This same effect was
not observed in the normal breast cell line MCF-10A, where
irradiation treatment or P-cadherin silencing alone had a nega-
tive effect in MFE; however, when the two treatments were
combined, no additive or synergistic effect was observed con-
cerning stem cell activity (Fig. 5D).
P-Cadherin Expression Confers Increased Tumori-
genic Ability to Breast Cancer Cells
The indications given by in vitro functional assays, showing
that P-cadherin expression has a role in the maintenance of
stem cell properties and poor overall survival of breast cancer
patients, led us to test whether cancer cell population enriched
for P-cadherin have a higher capacity to promote tumor
growth in nude mice. The tumorigenicity of the P-cadherin
high and low subpopulations was addressed using the basal-
like MDA-MB-468 breast cancer cells, which were inoculated
in different dilutions, and the results obtained are shown in
Table 2. Interestingly, we could observe that cancer cells
enriched for P-cadherin expression have a higher capacity to
promote tumor growth, since the number of tumors formed
was higher in the P-cadhigh group, compared with the control
group, in which the same number of parental cells was
injected. Furthermore, tumors derived from the P-cadhigh cells
were larger in size than the tumors derived from the P-cadlow
fraction.
DISCUSSION
Increasing evidence supports that cancers are propagated by a
small cell population, the CSCs, which originate both tumori-
genic and nontumorigenic cells and are responsible for tumor
heterogeneity, therapy resistance, and disease recurrence. The
identification and analysis of CSCs are mandatory in carcino-
mas with high patient mortality rate, early relapses, and lack
of a targeted therapy. One of such poor-prognosis cancer is
the basal-like subtype of breast cancer.
Basal-like breast carcinomas include tumors that are char-
acterized by an expression signature similar to that of the ba-
sal cells of the breast [56]. However, features of the luminal
gene expression profile are often also attributed to these can-
cers [57]; therefore, basal-like breast carcinomas are often
considered to have a mixed phenotype. More recently, the
cell-of-origin for basal-like breast cancers was defined as the
luminal progenitor cell from the normal breast hierarchy [9,
10], but the phenotype for the CSC has proven a tough task.
Thus, within this work, we established a positive associa-
tion between P-cadherin, a basal marker, and the stem cell
markers CD44, CD24, and CD49f in human breast cell lines.
Indeed, we found that all the stem cell markers analyzed seg-
regated with P-cadherin in the same subset of cells, suggest-
ing that this adhesion molecule could be contributing to a
stem-like aggressive phenotype in the breast. Accordingly, the
expression of all these markers has been previously linked to
Figure 4. MFE was measured in the subpopulations isolated by fluorescence-activated cell sorting according to P-cadherin expression in a
panel of human breast cell lines. The isolated subpopulations with higher amounts of P-cadherin (top 20% expressing cells), within the basal-like
cell lines, displayed highest MFE (A); 3D cell cultures, in laminin-rich matrix (matrigel), revealed that the P-cadherinhigh subpopulation from the
basal BT-549 cell line has increased clonogenic capacity, whereas the same result is not obtained with luminal cells (MCF-7/AZ) (scale bar ¼
100 lm) (B). Abbreviations: 3D, three dimension; MFE, mammosphere-forming efficiency.
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the acquisition of a malignant phenotype or to a decreased
breast cancer patient survival [44, 58, 59]. Significantly, our
study shows that breast cancer cases that express P-cadherin
and CD44, or P-cadherin and CD24, have the worst patient
prognosis. Additionally, P-cadherin could be an important
regulator of these stem cell markers in tumor cells, since
when this adhesion molecule was knocked down, a reduction
was found in the expression of CD49f and CD44v6.
Based on these results, we believe that we got experimen-
tal evidence that P-cadherin can be classified as a stem cell
marker in breast cancer. Although the simultaneous expres-
sion of all the three stem markers (CD44, CD24, and CD49f)
in the same cell was never clearly described, studies with
CD49f and CD24 have shown that these markers combined in
the same cell are able to identify cells with progenitor-like
properties in the mouse [10, 41] and human [9, 47] mammary
epithelial tissue. Specifically, Keller et al. showed that the
normal human breast tissue contains an epithelial subtype with
the phenotype EpCAMhighCD49fþCD24þ, consistent with a
definition of luminal progenitor cells, according to the charac-
terization of lineage markers [47]. Additionally, CD44 has also
been used in combination with CD24 to show that the pheno-
type CD44þCD24þ identifies cells with stem-like properties,
including tumorigenicity, in breast cell lines [50, 51] and in
ER-negative human breast tumors [6]. In this last study, Meyer
et al. also showed that CD44posCD49fhigh cells are enriched for
tumor-initiating ability in ER-negative breast cancers [6].
The association between the expression of P-cadherin and
the luminal progenitor phenotype CD49fþCD24þ in several
cancer and normal cell lines supports the notion that P-cad-
herin could potentially be used together with other markers in
the identification of the luminal progenitor of the normal
breast. In fact, luminal progenitor cells have been described
as the cell-of-origin for basal-like cancers [9, 10], in which
BRCA1 inactivation is a common feature and is considered to
halt the maturation toward the luminal phenotype [11]. This
would explain the upregulation of P-cadherin found in basal-
like cancers, since BRCA1 is a P-cadherin transcriptional
repressor [12]. Notably, Sarrio et al. recently reported that, in
a normal nontumorigenic human breast cell line with a basal-
like profile, the subpopulation defined as EpCAMþCD49fþ
exhibits progenitor-like properties and, interestingly, this sub-
population of cells specifically expressed P-cadherin [59].
An enrichment of P-cadherin expression in cells that have
the stem/progenitor phenotype CD44þCD24þ was also found
in this study. Importantly, cells with the phenotype
CD44þCD24þ have been described as having tumorigenic abil-
ity and represent a dynamic population that can originate the
CSC phenotype CD44þCD24"/low [50, 51, 60]. In fact, Pece
et al. showed that cells with CSC activity are CD24þ [60] and
that the phenotype CD44þCD24þ, isolated from several human
breast cancer cell lines, shows tumorigenic activity in murine
xenograft models [50]. This indicates that targeting cells with
the phenotype CD44þCD24þ, which have increased P-cadherin
expression, could help to eradicate CSCs.
Our data still show that P-cadherin is not a simple
bystander present in cells harboring a stem or progenitor phe-
notype, but it can also be a regulator of the stem cell func-
tion. First, we showed that high P-cadherin expression is asso-
ciated with an increased capacity of cancer cells to promote
tumor growth in nude mice. Second, we found that P-cadhigh
cell lines have increased ALDH activity and that P-cadherin
expression is increased in the ALDEFLUORþ subpopulation.
Previous studies have shown that ALDH activity and expres-
sion is linked to increased stem cell activity, tumorigenicity,
and poor prognosis in breast carcinomas [31, 61]. Further-
more, P-cadherin gene expression manipulation (either by
silencing with siRNA or by P-cadherin/CDH3 overexpres-
sion), as well as separation of cell population by sorting,
Figure 5. P-cadherin cDNA was stably transduced and overex-
pressed in the luminal cell line MCF-7/AZ (MCF-7/AZ.P-cad) or
transiently silenced in the several basal cells lines (A). Measurement
of stem cell activity by MFE indicates a direct association between P-
cadherin expression and this stem cell property (B, C); x-ray irradia-
tion was administered to the normal cell line MCF-10A (2 Gy) or the
indicated tumorigenic cells (4 Gy) and MFE was assessed. The
decrease in the number of stem cells mediated by x-ray irradiation is
potentiated after P-cadherin silencing in tumorigenic cells but not in
the normal MCF-10A cell line (D). Abbreviation: MFE, mammo-
sphere-forming efficiency.
Table 2. P-cadherin capacity to promote tumors was evaluated
by xenografting P-cadhigh and P-cadlow cells sorted from the
basal-like MDA-MB-468 breast cancer cell line in the nude
mouse model
Cell population
Tumors/injection
1 % 106 1 % 105 5 % 104
Unsorted 4/4 2/4 2/4
P-cadhigh 2/3 4/4
P-cadlow 0/3 2/4
The appearance of tumors as well as the tumor mass volume was
measured during time.
862 P-Cadherin Mediates Stem Cell Activity in Breast
showed that this adhesion molecule mediates stem cell activ-
ity and the self-renewal of mammospheres in basal breast cell
lines. The growth in 3D matrigel matrix was also increased in
the P-cadhigh subpopulation relative to the P-cadlow subpopula-
tion of basal-like breast cancer cells. It is still not clear
whether the increase in clonogenic capacity in 3D cultures
mediated by P-cadherin, and the increase in stem cell activity
measured by MFE, is the result of increased survival or alter-
ations in the growth rate that affects proliferation/quiescence
of the prospective P-cadhigh stem cells. Analysis of the cell
cycle revealed that P-cadherin does not affect the subpopula-
tions S and G2M (Supporting Information Fig. S4). Impor-
tantly, the fact that cells with lower expression of P-cadherin
still show some tumorigenic ability, as well as a certain level
of growth in anchorage-independent conditions and in matri-
gel 3D cultures, indicates that stem cell properties are still
present in the P-cadherin-depleted fraction. Although P-cad-
herin does not seem to be an exclusive marker of CSCs, our
results show that a further enrichment of the stem cell popula-
tion could potentially be achieved by a combination of P-cad-
herin with other biomarkers. For basal-like carcinomas, sev-
eral studies have used combinations of the following
biomarkers to define the CSC subpopulation: ESA, CD44,
CD24, CD49f, CD133-2, PROCR, and ALDEFLUOR [5–8,
61]. Not surprisingly, expression of P-cadherin alone in inva-
sive breast cancer confers bad prognosis, and we observed
that this marker is associated with the stem cell markers
CD44, CD49f, and ALDH1, and all these markers with the
basal-like molecular subtype. The isolation of P-cadherin-pos-
itive subpopulations within the CD44þ or within CD24þ frac-
tions is of potential interest, since in our series of human
breast carcinomas, the tumors that exhibit P-cadherinþCD44þ
or P-cadherinþCD24þ phenotype seem to be particularly
aggressive. Interestingly, the phenotype P-cadherinþ
CD44þCD49fþCD24þ could also support the isolation of pro-
genitor cells from the normal breast, as mentioned above.
Additionally, it is known that basal-like breast cancers
are particularly aggressive because they resist to current
therapeutic strategies, usually recurring in a short time
frame. In particular, resistance to radiotherapy has been
reported for breast cancer, and relapses often occur.
Although poorly understood, this type of resistance could be
mediated by several mechanisms controlling cell survival
and DNA repair mechanisms, allowing CSCs to survive and
to give rise to a new tumor [3]. In this study, we show that,
when given x-ray irradiation, the silencing of P-cadherin
contributes to decreased survival of the stem cell population
in the tumorigenic cells but not in the normal. Hence, inhibi-
tion of P-cadherin could be an approach to increase sensiti-
zation of tumorigenic cells to radiotherapy, potentially
allowing the reduction of the current doses of radiation
administered to the malignant tissue and causing less damage
to the normal cells.
CONCLUSIONS
We found, for the first time, that P-cadherin confers stem cell
features to breast tumorigenic cells that could be linked to the
aggressive behavior of basal-like breast cancers. We show
that this molecule is associated with increased stem cell activ-
ity (tumorigenicity in athymic nude mice, mammosphere for-
mation, and growth in 3D matrix) in basal-like cell lines but
not in luminal cells. P-cadherin is associated with already
described stem cell markers that define the luminal progenitor
phenotype and which, in our series of primary invasive breast
cancers, is associated with the shortest overall patient sur-
vival. We also found that inhibition of P-cadherin sensitizes
cancer cells to x-ray-induced cell death.
In the future, CSC therapies for the aggressive basal-like
breast carcinomas can eventually involve the targeting of P-
cadherin cell surface protein. In fact, phase-I clinical trials are
underway, which will help to define whether P-cadherin con-
stitutes a good therapeutic target in breast cancer [62]. Impor-
tantly, our results show that anti-P-cadherin treatment could
improve radiation therapy in patients.
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ABSTRACT  P-cadherin is a cell-cell adhesion molecule, whose expression is highly associated with 
undifferentiated cells in normal adult epithelial tissues, as well as with poorly differentiated carcino-
mas. Its expression has been already reported in human embryonic stem cells and it is presumed to 
be a marker of stem or progenitor cells of some epithelial tissues. In normal breast, P-cadherin has 
an essential role during ductal mammary branching, being expressed by the monolayer of epithelial 
cap cells at the end buds. In mature mammary tissue, its expression is restricted to the myoepithe-
lium; it has been postulated that it may also be present in early luminal progenitor cells. In breast 
cancer, P-cadherin is frequently overexpressed in high-grade tumours, being a well-established 
indicator of poor patient prognosis. It has been reported as an important inducer of cancer cell 
migration and invasion, with underlying molecular mechanisms involving the signalling mediated 
by its juxtamembrane domain, the secretion of matrix metalloproteases to the extracellular media, 
and the cleavage of a P-cadherin soluble form with pro-invasive activity. Intracellularly, this protein 
interferes with the endogenous cadherin/catenin complex, inducing p120-catenin delocalization 
to the cytoplasm, and the consequent activation of Rac1/Cdc42 and associated alterations in the 
actin cytoskeleton. Considering P-cadherin’s role in cancer cell invasion and metastasis formation, 
a humanized monoclonal antibody was recently produced to antagonize P-cadherin-associated sig-
nalling pathways, which is currently under Phase I clinical trials. In this review, the most important 
findings about the role of P-cadherin in normal breast development and cancer will be illustrated 
and discussed, with emphasis on the most recent data.
KEY WORDS: P-cadherin, CDH3 gene, mammary gland, breast cancer
Introduction
Classical cadherins constitute a family of molecules that mediate 
calcium-dependent cell-cell adhesion, localized to the adherens-
type junctions. The intracellular domains of cadherins bind directly 
to cytoplasmic catenins, which link them with the actin cytoskel-
eton, providing the molecular basis for stable cell interactions. 
The cadherin/catenin complex, as well as the signalling pathways 
controlled by this structure, represent a major regulatory mechanism 
WKDWJXLGHFHOOIDWHGHFLVLRQVWKURXJKLWVLQÁXHQFHRQFHOOJURZWK
differentiation, motility, and survival (Cavallaro and Dejana, 2011).
Classical cadherins include CDH1/E-cadherin (epithelial), 
CDH2/N-cadherin (neuronal), CDH3/P-cadherin (placental) and 
CDH4/R-cadherin (retinal), designated by their tissue distribution. 
E-cadherin is the predominant cadherin family member expressed in 
all epithelial tissues, being extremely important to the maintenance 
of the cell shape and polarity; in fact, it is well known that CDH1 
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binding domain; CDH, cadherin; C/EBP`, CCAAT/enhancer-binding protein 
`; CK, cytokeratin; CSC, cancer stem cell; CTC, circulating tumour cell; E-cad, 
E-cadherin; EC, epithelial cell; EEM, ectodermal dysplasia, ectrodactyly, and 
macular dystrophy; EGFR, epidermal growth factor receptor; ER, estrogen 
ZMKMX\WZ#-5<MXQ\PMTQIT\WUM[MVKPaUIT \ZIV[Q\QWV#./.:ÅJZWJTI[\OZW_\P
factor receptor; HDAC, histone deacetylase; HJMD, hypotrichosis with juvenile 
UIK]TIZLa[\ZWXPa#1*+QVÆIUUI\WZaJZMI[\KIVKMZ#25,R]`\IUMUJZIVMLW-
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XKI\MVQV#;0.5[XTQ\PIVLNWW\UITNWZUI\QWV#[8KIL[WT]JTM8KILPMZQV#
TEB, terminal end buds; TSA, trichostatin A.
acts as a tumour suppressor gene, negatively regulating the inva-
sion and metastasis of tumour cells in several malignancies (Yilmaz 
and Christofori, 2010). In contrast, N-cadherin is up-regulated 
in several cancers and contributes to an invasive phenotype by 
LQWHUDFWLQJZLWKÀEUREODVWJURZWKIDFWRUUHFHSWRU)*)5DQGLWV
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downstream signalling (Suyama et al., 2002).
P-cadherin is also often reported to correlate with increased 
tumour cell motility and invasiveness when overexpressed (Cheung 
et al., 2010, Paredes et al., 2004, Ribeiro et al., 2010, Taniuchi et 
al., 2005). Although the role of P-cadherin encoding gene (CDH3) 
in cancer is far less well characterized than the one attributed to 
CDH1, the opposite effects in mammary cancer are weird, since 
these molecules share more than 67% of homology (Hulpiau and 
van Roy, 2009). The CDH3JHQHKDUERXUVH[RQV)LJDQG
maps to chromosome 16q22.1, a region that contains a cluster of 
several cadherin genes, just 32 kilobases upstream of the gene 
encoding human E-cadherin (Bussemakers et al., 1994). The 
mature P-cadherin glycoprotein structure is similar to that of clas-
sical cadherins, comprising three distinct domains (extracellular, 
transmembrane and intracellular), in order to promote homotypic 
interactions. At the cell membrane, these create lateral dimers that 
act together in a zipper-like structure between neighbouring cells 
(Shapiro et al., 1995))LJ
The function and strength of P-cadherin-mediated adhesion 
depends on its dynamic association with catenins, which link the 
cadherin cytoplasmic tail to the actin cytoskeleton and facilitate 
clustering into the junctional structure, forming cadherin/catenin 
complexes. This tail comprises two main domains: the juxtamem-
brane domain (JMD), which has been suggested to play a critical 
role in cadherins stability at the cell membrane, and the catenin-
binding domain (CBD), which is known to be essential for cadherin 
function. The p120-catenin (p120ctn), ` -catenin (`ctn) and _-catenin 
(_ctn) are the major documented interaction partners that bind to 
cadherin intracellular domains and allow the binding to the actin 
cytoskeleton of the cell *UHHQ et al., 2010))LJ
P-cadherin upregulation was frequently observed in various 
malignant tumours, including breast, gastric, endometrial, colo-
rectal and pancreatic carcinomas, and is correlated with poor 
survival of breast cancer patients (Hardy et al., 2002, Imai et al., 
2008, Paredes et al., 2005, Stefansson et al., 2004, Taniuchi et 
al., 2005) ,QFRQWUDVWVLJQLÀFDQWO\ ORZ OHYHOVRI WKH3FDGKHULQ
gene expression were detected in a diverse panel of normal tis-
sues (Imai et al., 2008). Thus, disruption of P-cadherin signalling 
represents an intriguing opportunity for the development of novel 
targeted therapeutic agents in cancer.
P-cadherin role in epithelial cell differentiation
Classical cadherins play important roles in maintaining the 
structural integrity of epithelial tissues and are mainly involved 
in cell differentiation during embryogenesis. There are several 
indications in the literature that point to the relationship between 
cell adhesion molecules and stem cell features, not only as 
biomarkers that help to isolate and characterise stem cells, but 
also as important mediators of stem cell activity, via modulation 
of signalling pathways (Raymond et al., 2009). Regarding the 
classical cadherins, an important amount of data comes from the 
LGHQWLÀFDWLRQRI3FDGKHULQDVDPDUNHURIXQGLIIHUHQWLDWHGVWHP
or progenitor cells (Kendrick et al., 2008, Raymond et al., 2009). 
In a very recent study, it has been shown that CDH3 is one of 
the genes that encode a surface protein that identify the pluripotent 
population of human embryonic stem cells (Kolle et al., 2009). This 
expression is concomitant with the one of E-cadherin, which was 
Fig. 1. Schematic representation of the structural components of the P-cadherin adhesive junction. Lateral clustering of P-cadherin molecules 
is required to form stable cell-to-cell contacts in BT-20 breast cancer cells [immunofluorescence: P-cadherin (green), F-actin (red), DAPI (blue)]. In the 
intercellular space, P-cadherin extracellular domains interact with P-cadherin extracellular domains of adjacent cells to mediate cell adhesion. The intra-
cellular catenins bind to the cytoplasmic tail of P-cadherin. p120-catenin binds the cadherin tail at the juxtamembrane domain (JMD), whereas ` -catenin 
binds to the distal catenin binding domain (CBD). _-catenin associates with `-catenin and is directly linked to the actin cytoskeleton. The lower panel 
shows the genomic structure of CDH3/P-cadherin gene, which is constituted by 16 exons: the extracellular part of P-cadherin is encoded by 10 exons 
(exons 4-13), whereas the transmembrane and intracellular domains are determined only by the information included in the last 3 exons (exons 14-16).
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shown to be present even at the one cell stage of embryogenesis 
+\DÀO et al., 1980))LJ$,QIDFWPRXVHHPEU\RLPSODQWDWLRQLQWR
the uterine epithelium involves both E- and P-cadherin. The most 
dramatic expression of P-cadherin was observed in the placenta, 
both in the embryonic and maternal regions, hence the classical 
denomination of placental-cadherin. The expression of P-cadherin 
in the uterus began with the appearance of the decidua, into which 
the extraembryonic cells expressing P-cadherin of implanted em-
bryos invade to establish the embryo-maternal connection (Aplin 
et al., 2009, Nose and Takeichi, 1986)(DUO\UHSRUWVVSHFLÀHGORZ
expression in human placenta (Shimoyama et al., 1989), although 
P-cadherin is detectable where trophoblasts adjoin (cytotrophoblast-
cytotrophoblast and cytotrophoblast–syncytiotrophoblast) in the 
ÀUVW WULPHVWHUYLOOXVZLWKVRPH LPPXQRUHDFWLYLW\VWLOOGHWHFWDEOH
at term (Aplin et al., 2009))LJ$
In contrast, E-cadherin was found expressed only in the em-
bryonic region of placenta with a sharp boundary to the maternal 
region. These observations may suggest complementary roles of 
the two cadherins, such that P-cadherin is required for association 
of embryonic and maternal tissues during the late implantation 
stage, while E-cadherin is essential in preventing the embryonic 
tissues from mixing with the maternal tissues (Aplin et al., 2009, 
Nose and Takeichi, 1986))LJ$
It was also shown that E- and P-cadherins are both expressed 
in the ectoplacental cone, ectoderm, some endodermal tissues and 
nephric tubules, whereas both P- and N-cadherins are expressed 
in each cell of the lateral plate mesoderm, corneal endothelium, 
and pigmented retina (Nose and Takeichi, 1986))LJ$
Fig. 2. Schematic representation of P-cadherin expression during embryogenesis and mammary gland development. (A) Undifferentiated 
embryonic stem cells included in the morula, as well as in the inner mass of the blastocyst express E- and P-cadherin. During the blastocyst embryo 
implantation in the endometrial lining of the uterus, the trophectoderm differentiates into the cytotrophoblast and syncytiotrophoblast, which are key 
steps in placental development. There is an E-cadherin downregulation in the syncytiotrophoblast, which mainly expresses P-cadherin, while cells 
actively invade the uterine wall. Early in embryonic development, there is the formation of the neural tube, where a strip of specialized cells, forming 
the notochord, induces the cells of the ectoderm directly above it to become the primitive nervous system. Meanwhile, the ectoderm and endoderm 
continue to curve around and fuse beneath the embryo to create the body cavity, completing the transformation of the embryo from a flattened disk 
to a three–dimensional body. It is known that the ectoderm is E- and P-cadherin positive, which will give rise to the skin and its appendages. After cad-
herin switch, the neural tube becomes N-cadherin positive, as well as the somites. It was described that the notochord is N- and P-cadherin positive. 
(B) The ducts of the developing mammary gland are established, with their inner luminal epithelial cell layers (ECs) and outer myoepithelial cell layers 
(MECs), while the terminal end buds (TEB) move through the mammary fat pad. It is thought that cap cells at the tip of the TEB, which are P-cadherin 
positive, generate transit cells of the myoepithelial lineage on the outer side of the TEB (E- and P-cadehrin positive); at the same time, these cells also 
generate transit cells that form the central TEB mass, known as body cells, which will constitute the luminal epithelial lineage (E-cadherin positive). The 
ductal lumen is formed as body cells enter in apoptose and outer cells differentiate into luminal epithelial cells. Extracellular-matrix enzymes degrade 
the stroma in front of the TEB to enable it to move through the fat pad; however, it is unclear how the structures actually move through the gland. 
During lactation, secretory cells in the breast alveoli become P-cadherin positive at the cytoplasm, and secrete a soluble form of this protein (sP-cad) 
that is found in the milk.
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In adult tissues, the expression of P-cadherin is mainly found in 
the basal layer of several epithelial structures, such as skin, uterine 
cervix, prostate, and lung, contributing to the maintenance of the 
epithelial phenotype. The expression of cadherin molecules was 
extensively studied in mouse epidermis, in adulthood and during 
fetal development, where has been found that E-cadherin is ex-
pressed both in the basal and intermediate layers of epidermis, 
whereas P-cadherin is only expressed in the basal and prolifera-
tive layer (Pizarro et al., 1995))XUWKHUPRUHORVVRI(FDGKHULQ
plays an important role in bud formation and in the acquisition of 
an invasive behaviour, whereas P-cadherin becomes predominant 
expressed later in development, namely in the growing hair follicle 
and in the early progenitor cells from hair germs and small hair 
placodes )XMLWD et al., 1992, Rhee et al., 2006). Like hair follicles, 
sweat glands and mammary glands develop also from the same 
discrete accumulation of stem cells resting in the primitive epi-
dermis, the outermost cell layer of an embryo, and there is strong 
evidence that dynamic changes in the composition of adherens 
junctions are important for the development of skin appendages 
)XMLWD et al., 1992).
7KHÀQDOHYLGHQFHVKRZLQJWKHLPSRUWDQFHRI3FDGKHULQIRU
the architecture and development of epithelial tissues was dem-
onstrated by human genetic syndromes that are induced due to 
P-cadherin loss. CDH3 gene mutations have been shown to cause 
P-cadherin functional inactivation, leading to developmental defects 
associated with two inherited diseases in humans: 1) hypotrichosis 
with juvenile macular dystrophy (HJMD) and 2) ectodermal dys-
plasia, ectrodactyly, and macular dystrophy (EEM syndrome). The 
common features of both diseases are sparse hair and macular 
dystrophy of the retina, while only EEM syndrome shows the ad-
GLWLRQDOÀQGLQJRIVSOLWKDQGIRRWPDOIRUPDWLRQ6+)0(Kjaer et 
al., 2005, Sprecher et al., 2001). No defects were described for 
these conditions, concerning the human mammary development, 
or other epithelial bud structures. However, it is known that during 
bud patterning, a special arrangement occurs, where cells change 
their interaction with their neighbours and break their attachments 
to the extracellular matrix (ECM). Cells achieve this by activating 
VSHFLÀFWUDQVFULSWLRQDOSURJUDPV(Shimomura et al., 2008). 
P-cadherin role in normal breast development
Two members of the cadherin family are found to be expressed 
in the normal adult mature non-lactating mammary gland, usually 
at sites of cell-to-cell contact: E-cadherin is present in both luminal 
epithelial (ECs) and myoepithelial cells (MECs), whereas P-cadherin 
LVFRQÀQHGWRWKHP\RHSLWKHOLXP(Paredes et al., 2002). This type 
of cell localization is already found during mammary gland develop-
ment, since P-cadherin expression is only found in the precursor 
cells of the myoepithelial compartment, the cap cells of the ductal 
end buds, whereas luminal cells and body cells do not show any 
expression of P-cadherin and are typically E-cadherin positive 
(Daniel et al., 1995))LJ%
Besides the restricted expression of P-cadherin in the normal 
breast, this protein is extremely important to the establishment 
of the correct architecture of the tissue, as demonstrated by 
functional-blocking antibody experiments in vitro and in vivo. Daniel 
and collaborators exposed the end buds and mature mammary 
glands of 5 week-old virgin mice to slow-release plastic implants 
liberating a monoclonal antibody for P-cadherin. No effect in the 
luminal layer was found, but disruption of the basally located cap 
cell layer was clearly observed (Daniel et al., 1995). Also, more 
recently, Chanson et al., described that P-cadherin contributes 
VSHFLÀFDOO\ WR WKHRUJDQL]DWLRQRI WKHP\RHSLWKHOLDOFHOO OD\HURI
the breast, since when an antibody that blocks P-cadherin func-
tion was used in an in vitro self-organizing assay of the human 
mammary bilayer, the migration of MECs, occurring during normal 
sorting of both layers, was compromised (Chanson et al., 2011). 
These experiments indicate that selective expression of P-cadherin 
in the basal layer is necessary for the maintenance of mammary 
tissue integrity.
In fact, deletion of P-cadherin affects normal mammopoiesis, 
since the CDH3-null female mice exhibit precocious mammary 
gland differentiation in the virgin state, and breast hyperplasia 
and dysplasia with age (Radice et al., 1997). These observations 
in knockout animals indicate P-cadherin cell-cell interactions and 
signalling as regulatory determinants of the negative growth of 
the luminal epithelium, being important for the maintenance of an 
undifferentiated state of the normal mammary gland. 
Interestingly, the expression of this adhesion molecule is acti-
vated in human mammary luminal cells during late pregnancy and 
lactation (Soler et al., 2002). However, in these alveolar lactating 
cells, P-cadherin expression pattern is not restricted to the cell-cell 
borders, but shows a cytoplasmic staining, typical of a secreted 
protein. Indeed, in human milk, a soluble fragment of P-cadherin 
(sP-cad) with 80KDa was found to be present, corresponding to 
the extracellular domain of the molecule (Soler et al., 2002))LJ
2B). Recently, Mannello and collaborators showed that the high-
est concentration of sP-cad is detected in milk collected during 
WKHÀUVWWULPHVWHURIODFWDWLRQ(Mannello et al., 2008). Still, it is not 
clear which is the biological and physiological role attributed to 
this fragment in the normal function of the breast. Some authors 
suggest a role for sP-cad in alveolar differentiation during lacta-
tion, or in the immune response of the mother or the baby, or as a 
VLJQDOOLQJSURWHLQEHWZHHQHSLWKHOLDODQGP\RHSLWKHOLDOFHOOV)XUWKHU
studies are in progress to determine the sites of proteolysis of the 
V3FDGVHFUHWHGSURWHLQLQGLIIHUHQWERG\ÁXLGVZKHUHLWKDVEHHQ
previously described (such as milk, serum, semen, nipple aspirate 
ÁXLG1$)EUHDVWF\VWÁXLGDQGDPQLRWLFÁXLG(Mannello et al., 
2008, Soler et al., 2002).
Prognostic relevance of P-cadherin in breast cancer
As mentioned above, P-cadherin is expressed in normal breast 
MECs and in MECs associated with non-invasive breast prolif-
HUDWLRQVVKRZLQJQRVLJQLÀFDQWFURVVUHDFWLYLW\ZLWKOXPLQDO(&V
VWURPDOP\RÀEUREODVWVDQGEORRGYHVVHOV5HLV)LOKR et al., 2003). 
However, P-cadherin was described as being overexpressed in 
20% to 40% of invasive breast carcinomas, as well as in 25% of 
ductal carcinomas in situ (DCIS) (Paredes et al., 2007a, Paredes 
et al., 2007b, Paredes et al., 2002). Most important, several studies 
have reported P-cadherin as a marker of poor prognosis in breast 
FDQFHUVLQFH3FDGKHULQSRVLWLYHFDUFLQRPDVZHUHVLJQLÀFDQWO\
DVVRFLDWHGZLWKVKRUWWHUPRYHUDOODQGGLVHDVHVSHFLÀFVXUYLYDO
as well as with distant and loco-regional relapse-free interval 
*DPDOOR et al., 2001, Paredes et al., 2005, Peralta Soler et al., 
1999, Turashvili et al., 2011). 
P-cadherin expression has also been positively associated with 
high histological grade tumours, as well as with well-established 
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markers of poor prognosis, like Ki-67, epidermal growth factor 
UHFHSWRU(*)5F\WRNHUDWLQ&.YLPHQWLQSDQG+(5
expression and negatively associated with age at diagnosis, hor-
monal receptors (ER and PgR), and Bcl-2 expression. Interestingly, 
QRQHRIWKHVHUHSRUWVVKRZHGDVLJQLÀFDQWDVVRFLDWLRQZLWKWXPRXU
size and lymph node metastasis *DPDOOR et al., 2001, Paredes et 
al., 2005, Peralta Soler et al., 1999, Turashvili et al., 2011).
Besides the strong association between P-cadherin expression, 
poor patient prognosis and tumour aggressiveness, transgenic 
mice overexpressing CDH3/P-cadherin in the luminal epithelial 
layer of the mammary gland, under the control of the MMTV 
promoter, showed normal morphogenesis, architecture, lactation 
and involution, and no mammary tumours formed spontaneously 
(Radice et al., 2003). Nevertheless, Mannello et al., demonstrated 
DVLJQLÀFDQWLQFUHDVHGVKHGGLQJRIV3FDGLQ1$)VIURPZRPHQ
with breast cancer when compared with healthy subjects or with 
women with pre-cancer conditions, suggesting its possible release 
via proteolytic processing in cancer cells (Mannello et al., 2008). 
P-cadherin: marker of histological and molecular sub-
types in breast cancer
Besides the strong association between P-cadherin expres-
VLRQ DQGSRRU SDWLHQW SURJQRVLV QR VLJQLÀFDQW FRUUHODWLRQZDV
HYHUREVHUYHGEHWZHHQWKLVSURWHLQDQGDVSHFLÀFEUHDVWFDQFHU
histological type. The majority of positive P-cadherin tumours are 
invasive ductal carcinomas NOS, or carcinomas with metaplastic 
or medullary features (Paredes et al.  5HLV)LOKR et al., 
2003, Turashvili et al., 2011). The observation that metaplastic 
and medullary breast carcinomas are consistently immunoreac-
tive for P-cadherin supports a myoepithelial/basal transcriptomic 
programme for these lesions (Han et al., 1999, Jacquemier et al., 
2005). Han and coworkers reported P-cadherin expression in almost 
all studied cases of medullary, carcinosarcomas, and sarcomatoid 
metaplastic breast carcinomas (Han et al., 1999); in addition, all the 
metaplastic cases that we have studied were positive for at least 
one basal/myoepithelial marker, including P-cadherin 5HLV)LOKR et 
al., 2003). We also showed that P-cadherin expression, in canine 
PDOLJQDQWWXPRXUVZDVVLJQLÀFDQWO\UHODWHGWRVSLQGOHFHOOFDUFL-
noma, carcinosarcoma and osteosarcoma. In these lesions, both 
carcinomatous and sarcomatous components of carcinosarcoma 
expressed P-cadherin *DPD et al.*DPD et al., 2008). 
&RQFHUQLQJ PROHFXODU SURÀOLQJ FODVVLÀFDWLRQ DW OHDVW ÀYH
VXEW\SHVRI LQYDVLYHEUHDVWFDUFLQRPDZHUH LGHQWLÀHG/XPLQDO
A and B, Normal-like, HER2-overexpressing and Basal-like), ex-
hibiting distinct clinical prognostic behaviour (Perou et al., 2000). 
P-cadherin is one of the most important biomarkers to identify 
basal-like and HER2-overexpressing breast cancers (Arnes et 
al., 2005, Paredes et al., 2007b, Turashvili et al., 2011). Basal-like 
breast cancer expresses genes characteristic of basal epithelial 
cells, which include, besides P-cadherin, high-molecular weight 
basal cytokeratins (CK5/6, CK14, CK17), vimentin, _B-crystalline, 
FDYHROLQVDQG(*)5(Arnes et al., 2005). Until now, the most 
accepted criterion to identify basal-like breast carcinomas, by im-
munohistochemistry, is the triple negative phenotype along with 
&.DQGRU(*)5SRVLWLYLW\(Nielsen et al., 2004). However, we 
demonstrated that P-cadherin expression shows higher sensitivity 
to distinguish the basal phenotype of breast carcinomas, being a 
UHOLDEOHRSWLRQFRPSDUHGWRWKH´JROGVWDQGDUGµSDLU&.(*)5
(Sousa et al., 2010). Although this still need validation by gene 
H[SUHVVLRQSURÀOHVWKHVHUHVXOWVFDQLQWURGXFHWKHLGHDRIXVLQJ
P-cadherin as an additional option in the daily workup of breast 
pathology laboratories to identify basal-like breast cancers.
3FDGKHULQLVDOVRSURPLQHQWO\H[SUHVVHGLQLQÁDPPDWRU\EUHDVW
cancer (IBC), which is a distinct and aggressive form of locally-
advanced breast cancer, with high metastatic potential and high 
death rate. These tumours are characterized by frequent basal and 
HER2 phenotypes but, surprisingly, luminal IBC also express the 
basal marker P-cadherin (Ben Hamida et al., 2008)7KLVSURÀOH
VXJJHVWVDVSHFLÀFLW\WKDWQHHGVWREHIXUWKHULQYHVWLJDWHG
,QWHUHVWLQJO\WKHH[SUHVVLRQSURÀOLQJRIBRCA1GHÀFLHQWKHUHGL-
WDU\WXPRXUVKDVLGHQWLÀHGDSDWWHUQRIJHQHH[SUHVVLRQVLPLODU
to basal-like breast tumours (Palacios et al., 2003). Very recently, 
*RUVNL et al. showed that BRCA1 and c-Myc form a repressor 
FRPSOH[RQWKHSURPRWHUVRIVSHFLÀFEDVDOJHQHVLQFOXGLQJCDH3 
gene, and represent a potential mechanism to explain the observed 
overexpression of key basal markers in BRCA1-GHÀFLHQWWXPRXUV
*RUVNL et al., 2010). Actually, it has been shown that P-cadherin 
expression in breast carcinomas is strongly associated with the 
presence of BRCA1 mutations (Arnes et al., 2005).
P-cadherin role in adhesion, invasion and motility
Carcinomas progress by promotion of local invasion and distant 
metastasis. The acquisition of this invasive behaviour is one of 
WKHÀUVWVWHSVLQWKHPHWDVWDWLFSURFHVV7KRVHFDQFHUFHOOVRIWHQ
develop alterations in their shape, as well as in their attachment 
to other cells and to ECM. Therefore, cell-cell and cell-matrix in-
teractions play the most important role during tumour progression, 
since disruption of cell-cell adhesion during carcinogenesis is the 
basis for motility, invasion and metastasis of tumour cells (Yilmaz 
and Christofori, 2010).
P-cadherin has been detected as altered in various human 
tumours, but its effective role in the carcinogenesis process re-
mains discussible, since it behaves differently depending on the 
VWXGLHGWXPRXUFHOOPRGHODQGFRQWH[W)RULQVWDQFHLQDFRORUHFWDO
cancer cell line (HT-29), P-cadherin has been suggested to act as 
a pro-adhesive and anti-invasive/anti-migration molecule, exactly 
as E-cadherin (Van Marck et al., 2011). Also, in melanomas, P-
cadherin behaves as an invasion suppressor gene. Indeed, in highly 
invasive melanoma cell lines (that lack E-cadherin expression), 
P-cadherin overexpression was able to promote the formation of 
cell-cell contacts and counteract invasion (Van Marck et al., 2005). 
7KHDQWLLQYDVLYHHIIHFWRI3FDGKHULQZDVDOVRUHFHQWO\FRQÀUPHG
in in vivo experiments, showing that its expression is refractory to 
LQYDVLYHVLJQDOVLQGXFHGE\P\RÀEUREODVWV1HYHUWKHOHVVLWZDV
found a secreted truncated variant of P-cadherin in malignant mela-
nomas, which negatively regulates cell-cell adhesion and induces a 
more motile phenotype, thus playing an important role in migration 
and metastasis of melanoma cells (Bauer and Bosserhoff, 2006). 
On the other hand, in several other models, including breast 
cancer, P-cadherin behaves as an oncogene, and is often reported 
to correlate with increased tumour cell motility and invasiveness 
when aberrantly expressed (Cheung et al., 2010, Mandeville et 
al., 2008, Paredes et al., 2007a, Paredes et al., 2004, Taniuchi 
et al., 2005, Van Marck et al., 2011). Using in vitro breast cancer 
cell models, we found that overexpression of P-cadherin promotes 
single cell motility, directional cell migration, as well as invasion 
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capacity through the matrigel matrix (Ribeiro et al., 2010). This 
same migratory phenotype was observed in bladder, pancreatic 
and cholangiocarcinoma cancer cell lines (Baek et al., 2010, Man-
deville et al., 2008, Taniuchi et al., 2005, Van Marck et al., 2011). 
Curiously, we have noticed that P-cadherin is able to induce 
invasion only in cell systems which already express an endogenous 
and functional cadherin, like E-cadherin in breast cancer cells, 
or N-cadherin in HEK293T cells and PDAC pancreatic cancer 
cells (Paredes et al., 2004, Ribeiro et al., 2010, Taniuchi et al., 
2005). Based on this hypothesis, we have recently proved that 
P-cadherin is able to interact with E-cadherin in breast tumours 
and cancer cells, promoting cancer cell invasion by disrupting the 
interaction between E-cadherin and both p120ctn and ` ctn. In the 
absence of E-cadherin expression, in the same cancer model, P-
cadherin is able to suppress invasion by its strong interaction with 
catenins, surrogating the role of E-cadherin in cell-cell adhesion 
(unpublished data).
P-cadherin role in EMT and cadherin switch
Among the cadherin families, E-cadherin and N-cadherin are 
the most highly characterized subgroup of adhesion proteins. 
E-cadherin is ubiquitously expressed throughout most epithelial 
tissues and serves as a negative regulator to functionally block 
the `ctn signalling pathway and suppress tumour cell growth and 
invasion (Onder et al., 2008). However, numerous preclinical and 
clinical studies have shown that the loss of E-cadherin occurs 
concurrently with the upregulation of N-cadherin or other cadherin 
family members implicated in invasive growth, like P-cadherin or 
cadherin-11. This process, known as cadherin switching, has been 
reported to promote epithelial-to-mesenchymal transition (EMT) and 
leads to tumour cell invasion and metastasis (Thiery et al., 2009). 
Indeed, the switch from E- to N-cadherin is the one better known 
and reported by several studies. N-cadherin overexpression, via 
cadherin switching, was observed in various invasive cancer cell 
lines and tumours, namely from the esophagus, prostate, cervix, 
DQGRYDU\7KLVVSHFLÀFFDGKHULQVZLWFKOHDGVWRWKHLQKLELWLRQRI
cell-cell contacts and elicits active signals that support tumour-
cell migration, invasion, and metastatic dissemination (Thiery et 
al., 2009). 
The cadherin switch from E- to P-cadherin is a common event 
during embryo development; however, few reports describe it during 
tumour progression. Indeed, some invasive and aggressive epi-
thelial tumours, namely the local advanced IBC, and some highly 
metastatic breast cancer cells, as the 4T1 cell model, maintain 
E-cadherin expression at the cell membrane and show aberrant 
concomitant expression of P-cadherin (Ben Hamida et al., 2008, 
Lou et al., 2008). Nevertheless, there are some reports showing 
a switch from these two epithelial cadherins during tumour pro-
gression, namely in ovarian, endometrial and bladder carcinoma 
(Bryan et al., 2008, Patel et al., 2003, Stefansson et al., 2004). In 
DOOWKHVHVWXGLHV3FDGKHULQLQFUHDVHGH[SUHVVLRQVLJQLÀFDQWO\FRU-
related with decreased E-cadherin expression and, consequently, 
represented a key step in disease progression. However, it has 
been already shown that, in cholangiocarcinoma cells, the E- to 
P-cadherin switch does not induce EMT signalling, since does not 
affect the expression of mesenchymal markers, such as Snail 1 
DQGYLPHQWLQDQGÀEURQHFWLQ(Baek et al., 2010).
Recognized regulators of CDH3/P-cadherin transcription
Signalling pathways or other cellular mechanisms that are in-
volved in the regulation of cadherin-mediated adhesion are thought 
to underlie the dynamics of the adhesive interactions between cells. 
Fig. 3. Schematic representation of the described transcriptional regulators of CDH3 /P-cadherin promoter gene. It has been shown that 
`-catenin, p63 and C/EBP` are transcriptional activators of CDH3 promoter, inducing its expression at the mRNA and protein level. In contrast, 
estrogen receptor (ER), as well as the BRCA1/c-Myc/Sp1 complex, act as transcriptional repressors of CDH3 promoter gene.
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Although the evidence that the expression of cadherins can result 
from growth factors and from changes in the promoter regions of 
cadherins, data concerning CDH3 promoter regulation is still very 
limited. 
One of the most prominent demonstrations regarding the 
importance of a classical transcription factor in the regulation of 
cell adhesion programmes in epithelial cells was demonstrated 
by Carroll and collaborators. This study implicated p63, a p53-
family related transcription factor, as a key regulator of adhesion 
and survival in basal cells of the mammary gland. Importantly, the 
authors showed that p63 expression caused downregulation of cell 
adhesion-associated genes and detachment between mammary 
epithelial cells (Carroll et al., 2006). This involvement of p63 in cell 
DGKHVLRQPHFKDQLVPVZDVÀQDOO\OLQNHGZLWKCDH3 gene, when 
Shimomura and colleagues demonstrated that P-cadherin is a 
direct p63 transcriptional target and that this interplay has a crucial 
role in human limb bud and hair follicle development (Shimomura 
et al., 2008))LJ
)XUWKHUPRUHLWKDVEHHQVKRZQWKDW` ctn is also associated with 
CDH3 promoter activation and P-cadherin expression in basal mam-
mary epithelial cells. Down-regulation of endogenous `ctn levels 
inhibited CDH3 promoter activity, while activation of ` ctn signalling 
was correlated with up-regulation of P-cadherin expression in in 
vivo mammary gland mice models, eventually contributing to the 
establishment of the basal phenotype )DUDOGR et al., 2007))LJ
Recently, we still found that the CCAAT/enhancer-binding protein 
` (C/EBP`) transcription factor was able to activate CDH3 promoter 
in breast cancer cells. We showed that this novel activator of CDH3 
promoter activity exerts its activation preferably through its trun-
cated LIP isoform, being the abundance of Sp1 sites within CDH3 
promoter a feature which potentiate the C/EBP`-LIP activation role 
on CDH3 gene (Albergaria et al., 2010))LJ
Regulation of CDH3 gene has been also explored in terms of 
its transcriptional repression. In 2004, our group explored the link 
between ER-signalling and the regulation of P-cadherin expression 
in breast cancer cell lines, since we have already observed that 
breast tumours positive for P-cadherin expression were essentially 
(5QHJDWLYH:HYHULÀHGWKDW3FDGKHULQH[SUHVVLRQZDVLQGXFHG
by the pure anti-oestrogen ICI 182,780 and counteracted by 17`-
oestradiol. In fact, breast cancer cells treated with ICI 182,780 
VKRZHGDVLJQLÀFDQW LQFUHDVHRI3FDGKHULQP51$DQGSURWHLQ
levels in a time and dose dependent manner, establishing that the 
lack of ER-signalling is responsible for the increase of P-cadherin, 
therefore, categorizing CDH3 as an ER-repressed gene (Paredes 
et al., 2004))LJ9HU\UHFHQWO\LQRUGHUWRGHHSO\H[SORUHWKLV
antiestrogen-mediated mechanism, we described a cellular ad-
aptation process where ICI 182,780 is able to induce a chromatin 
structural remodelling, which lead to activation of CDH3 gene and 
overexpression of P-cadherin protein (Albergaria et al., 2010). Such 
genomic de-repression effect may contribute to an augmented 
invasive phenotype of ER-positive breast cancer cells. 
As a gene associated with the basal-like phenotype in breast 
cancer, CDH3/P-cadherin gene was recently described to be 
transcriptionally repressed by functional BRCA1 protein in breast 
cancer cell lines, at both mRNA and protein level. This same study 
also showed that, together with BRCA1, c-Myc form a repressor 
complex on the CDH3SURPRWHU )LJVXJJHVWLQJDSRWHQWLDO
mechanism to explain the observed overexpression of key basal 
PDUNHUVLQ%5&$GHÀFLHQWWXPRXUV*RUVNL et al., 2010). 
Epigenetic regulation of P-cadherin expression
Epigenetic regulation of CDH3/P-cadherin has been highly 
reported in the last few years, with greater emphasis in cancer 
PRGHOV 7KH HSLJHQHWLF GHUHJXODWLRQ RI 3FDGKHULQ ZDV ÀUVWO\
demonstrated by Sato et al., which LGHQWLÀHGCDH3 gene promoter 
to be aberrantly methylated in 20% of pancreatic cancers, but not 
in normal pancreatic epithelia (Sato et al., 2003). Similarly, CDH3 
gene was also shown to be silenced by methylation in melanoma 
cells (Tsutsumida et al., 2004). 
However, in 2005, we analysed P-cadherin promoter methyla-
tion in normal breast tissue, from which only epithelial cells were 
microdissected, and methylation of CDH3 gene promoter was 
found in the normal epithelial/luminal cell layer from all the speci-
mens analysed, which was associated with negative P-cadherin 
H[SUHVVLRQLQWKHVHFHOOV%XWLQFRQWUDVWWRZKDWKDVEHHQYHULÀHG
in E-cadherin control of expression by hypermethylation of its pro-
PRWHULQFDQFHURXUJURXSIRXQGDVLJQLÀFDQWFRUUHODWLRQEHWZHHQ
P-cadherin overexpression and CDH3 promoter hypomethylation. 
Using a large series of invasive breast carcinomas, we found that 
71% of P-cadherin-negative breast cancer cases were methylated 
for the CDH3 gene, whereas 65% of P-cadherin-positive cases 
were unmethylated (Paredes et al., 2005). 
Indeed, the genomic structure of the proximal CDH3 gene 
SURPRWHUVXFKDVWKHHQULFKPHQWLQ&S*LVODQGVDVZHOODVWKH
attributed DNA hypersensitive sites, suggests that it is likely to 
be regulated by epigenetic events, others than only methylation. 
In fact, we observed an up-regulation of CDH3 promoter activity 
and P-cadherin protein expression in cells treated with the histone 
deacetylases (HDAC) inhibitor Trichostatin A (TSA), showing that 
FKURPDWLQDFWLYDWLQJPRGLÀFDWLRQVDUHDOVRLPSRUWDQWLQWKHPRGX-
lation of this gene (Albergaria et al., 2010). Thus, if we previously 
described that overexpression of P-cadherin could result from a 
loss of promoter methylation, we have now evidences to assume 
that chromatin remodelling also play an important modulator role 
in CDH3 gene activity.
Reinforcing our results, CDH3 promoter was also found hypo-
methylated in colonic aberrant crypt foci, in colorectal cancer, and, 
occasionally, in the normal epithelium adjacent to cancer (Milicic et 
al., 2008). This hypomethylation pattern was associated with the 
LQGXFWLRQRI3FDGKHULQH[SUHVVLRQLQWKHQHRSODVWLFFRORQ)LQDOO\
demethylation of the CDH3 gene was recently detected in a large 
SHUFHQWDJHRI SULPDU\ JDVWULF FDUFLQRPDVDQGZDV VLJQLÀFDQWO\
associated with increasing TNM stage, suggesting that it is also a 
frequent event in gastric carcinomas (Kim et al., 2010). 
P-cadherin-downstream signalling pathways
Increasing evidences indicate that cadherins role in carcino-
genesis and tumour progression do not solely lie on their adhesive 
function, but also depend on their interaction with other molecules 
(such as cytoskeletal components, integrins, and growth-factor 
receptors, among others) and signalling pathways (Onder et al., 
2008). Therefore, the stabilization of the cadherin/catenin complex 
represents a major regulatory mechanism for oncogenic signalling 
pathways, that guide cell fate decisions through the modulation of 
VSHFLÀFJHQHVDWWKHWUDQVFULSWLRQDOOHYHODQGDVDFRQVHTXHQFH
regulation of several crucial cellular processes, as proliferation, 
survival, polarization, differentiation, shape and migration, which 
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in turn affect embryogenesis, tissue formation and pathogenic 
events, such as cancer. 
Although E-cadherin-induced signalling pathways have been 
extensively studied in cancer, little is known about the role of P-
cadherin (Paredes et al., 2004, Taniuchi et al., 2005, Van Marck et 
al., 2005). It is some kind expected that P-cadherin share common 
signalling pathways with other cadherins, due to its function as a 
cell-cell adhesion molecule; however, it is not known whether the 
pathways are triggered in the same way. 
Sarrió and collaborators analysed microarray gene expression 
of a breast cancer cell line (MDA-MB-231), negative for cadher-
ins, after expression of E- and P-cadherin. The data revealed 
that these molecules can activate signalling pathways leading to 
VLJQLÀFDQWFKDQJHVLQJHQHH[SUHVVLRQ$OWKRXJKWKHH[SUHVVLRQ
patterns induced by E- and P-cadherin showed more similarities 
WKDQGLIIHUHQFHVJHQHVZHUHGLIIHUHQWLDOO\PRGLÀHGE\WKHH[-
pression of either cadherin type. According to data bases, these 
genes belonged to a wide range of biological functions, including 
VLJQDOWUDQVGXFWLRQDQGJURZWKIDFWRUV9(*)&)*)5FHOOF\FOH
(CCNA2), cell adhesion and ECM (CDH4, COL12A1), or cytokines 
DQGLQÁDPPDWLRQ,/DPRQJRWKHUV(Sarrio et al., 2009). This 
indicates that, in addition to their role in cell adhesion, E-cadherin 
DQG3FDGKHULQKDYHDVLJQLÀFDQW LPSDFWRQ WKHRYHUDOOJHQHWLF
program of breast cancer cells. 
One of the molecules that have been several times referred has 
KDYLQJDVSHFLÀFUROHLQVLJQDOOLQJUHODWHGWR3FDGKHULQLVSFWQ
)LJ:HGHPRQVWUDWHGWKDWWKHSURLQYDVLYHDFWLYLW\RI3FDGKHULQ
requires the JMD of its cytoplasmic tail. Transfection of HEK293T 
cells with several mutants of P-cadherin showed that only the ones 
with altered JMD were not able to induce cell invasion in in vitro cell 
models (Paredes et al., 2004). Moreover, we observed that breast 
carcinomas co-expressing E- and P-cadherin were associated with 
p120ctn cytoplasmic localisation and poor patient survival (Paredes 
et al., 2008). Since then, several other reports have been exploring 
that pathway. Indeed, Taniuchi et al., showed that the induced cell 
migration by P-cadherin expression was due to activation of the Rho 
Fig. 4. Schematic representation of the signalling pathways regulated by P-cadherin expression. P-cadherin signals are transduced by many 
intracellular signalling pathways, which ultimately result in alterations of the cancer cells survival, as well as cell migration and invasion capacity. For 
simplicity, only some of the known interactions are depicted. It should be noted that the effect of P-cadherin on the overall gene expression program 
of cancer cells is highly dependent on the cellular type and the biological context.
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*73DVHV5DFDQG&GFWKURXJKDFFXPXODWLRQRISFWQLQWKH
cytoplasm in pancreatic cancer cell model (Taniuchi et al., 2005) 
)LJ9HU\UHFHQWO\3FDGKHULQKDVEHHQDOVRVKRZQWRFRRSHU-
ate with insulin-like growth factor-1 receptor to promote metastatic 
signalling of gonadotropin-releasing hormone in ovarian cancer via 
p120ctn (Cheung et al., 2010). These same authors had previously 
shown that this p120ctn signalling mediated by P-cadherin expres-
VLRQDOVROHDGWRLQFUHDVHGDFWLYLW\OHYHOVRI5DFDQG&GF)LJ
4). Still another study has shown that p120ctn and P-cadherin, but 
not E-cadherin, regulate cell motility and invasion of DU145 prostate 
cancer cells (Kumper and Ridley, 2010). 
Although binding of proteins to the JMD of P-cadherin has just 
been documented for p120ctn (Reynolds et al., 1996), other mol-
ecules, like Hakai and presenilin-1 (PS-1), have been reported to 
bind to the JMD of classical cadherins. This binding is established 
through a sequence adjacent to, or overlapping, the p120ctn-binding 
domain, thereby competing with p120ctn (Baki et al.)XMLWD 
et al., 2002)$OWKRXJKWKHVLJQLÀFDQFHRIWKHVHLQWHUDFWLRQVLVQRW
well known, we cannot exclude the possibility that disruption of the 
p120ctn–binding sequence may introduce conformational changes 
and/or uncouples the interaction of these or other proteins, which 
could explain our observations. Striking examples of this were 
shown for E-cadherin, where functional differences have been 
noted between larger and minimal deletions of the JMD, with even 
the minimal changes disrupting binding of multiple molecules (Baki 
et al., 2001).
Recently, it has been shown that the P-cadherin regulatory role in 
cell migration is also related with the expression of the non-muscle 
myosin II-B isoform, which is an ATP-dependent molecular motor 
SURWHLQWKDWFDQLQWHUDFWZLWKDQGFRQWUDFWÀODPHQWRXVDFWLQ)DFWLQ
(Jacobs et al., 2010))LJ7KHVHUHVXOWVLPSOLFDWHWKDWWKHUHLV
a coordinated cross-talk between adhesion molecules and cellular 
migration-related proteins.
More recently, the role of P-cadherin was investigated in oral 
squamous cancer cell model, where the authors used a cell line 
WKDWZDVGHÀFLHQWIRUFODVVLFDOFDGKHULQV$IWHU3FDGKHULQRYHU-
expression, cells gained an epithelial-like morphology, with Snail 
translocation to the cytoplasm. Analysing the signalling mechanism 
behind it, they found glycogen-synthase-kinase-3`*6.`) bound 
WR6QDLODVZHOODVDQLQFUHDVHLQDFWLYDWHG*6.` that phospho-
rylated Snail leading to its cytoplasmic translocation (Bauer et al., 
2009). These same authors also showed that Slit-2, a secreted 
ECM glycoprotein that acts as a molecular guidance cue in cellular 
migration, facilitates the interaction of P-cadherin with Robo-3, its 
receptor, and inhibits cell migration in oral squamous cell carcinoma 
cell line models (Bauer et al., 2011))LJ
In terms of breast cancer cell invasion, we found that the pres-
ence of P-cadherin, in an E-cadherin positive cellular background, 
is able to provoke the secretion of pro-invasive factors, such as 
MMP-1 and MMP-2, leading to P-cadherin ectodomain cleavage 
(sP-cad) which induces a pro-invasive activity by itself (Ribeiro 
et al., 2010)7KLVVWXG\FODULÀHGWKHPHFKDQLVPDVVRFLDWHGWR3
cadherin-induced cancer cell invasion. 
Different signalling pathways should be triggered in different cell 
models, in order to identify new interaction partners of P-cadherin, as 
well as to study whether the interaction of known partner molecules 
GLIIHUEHWZHHQFDGKHULQV)LQDOO\ LW LV LPSRUWDQW WRKLJKOLJKW WKDW
the effect of cadherins on the overall gene expression program of 
cancer cells is highly dependent on the cellular type and the biologi-
FDOFRQWH[W7KXV3FDGKHULQUHJXODWLRQRIVSHFLÀFWUDQVFULSWLRQDO
factors may depend on the activation of other signalling pathways, 
or on the presence of additional molecular alterations.
P-cadherin as a breast cancer stem cell marker
An increasing body of evidence supports the notion that cancers 
are propagated by a small population of cells present in the malignant 
tissue, that possess the ability to form a hierarchy similar to the 
one present in normal tissues (Visvader, 2011). These cancer stem 
cells (CSCs) are able to proliferate, originating more stem-like cells, 
to exhibit resistance to current therapies and to remain quiescent 
during long periods of time. However, it is still not clear whether 
the CSC originates from the normal stem cells of the tissue that 
deregulate their self-renewal ability, or from normal mature cells or 
progenitor cells that acquired stem cell characteristics (Visvader, 
2011) ,PSRUWDQWO\DWWHPSWVKDYHEHHQPDGH LQRUGHU WRÀQGD
universal phenotype for the breast cancer stem cell; but due to 
the high heterogeneity of this malignancy, it is not expected that a 
single CSC phenotype would apply to all breast cancers. 
7KH LGHQWLÀFDWLRQRIDFDQFHUVWHPFHOOPDUNHU IRUEDVDOOLNH
subtype of breast cancer is of particular importance, due to its 
high mortality rate, fast relapses and lack of target therapy (Rakha 
et al., 2009). Recently, it has been demonstrated that the luminal 
progenitor of normal breast hierarchy is the cell of origin for this 
malignancy, since the induction of a BRCA1 mutation in this cell 
was able to induce the formation of a tumour with basal phenotype 
(Lim et al., 2009, Molyneux et al., 2010). Since CDH3 gene is 
repressed by BRCA1, it is likely that P-cadherin could be a good 
FDQFHUVWHPFHOOPDUNHURIWKLVVSHFLÀFW\SHRIWXPRXUV,QIDFW
using a series of breast cancer cell lines, we found that P-cadherin 
enriched populations (by genetic manipulation or by sorting) were 
HQULFKHGIRUPDPPRVSKHUHIRUPLQJHIÀFLHQF\0)(DVZHOODV
for the expression of CD24, CD44 and CD49f, already described 
as CSC markers. When compared with luminal cell lines, basal-like 
FHOOOLQHVDOVRVKRZHGDJUHDWHU$/'()/825bright subpopulation 
and the P-cadherin positive subfraction of these cell lines was 
HQULFKHGLQVWHPFHOODFWLYLW\0)(DQG'JURZWKXQSXEOLVKHG
data). This observation linked P-cadherin expression with the 
luminal progenitor phenotype, which is CD44+CD24+CD49f+ (Lim 
et al., 2009). Importantly, it has been described that the phenotype 
CD44+CD24+ is tumorigenic (Meyer et al., 2009). Hence, the strat-
egy of directing therapies to the luminal progenitor phenotype, by 
VSHFLÀFDOO\WDUJHWLQJ3FDGKHULQFRXOGSRWHQWLDOO\KHOSWRHUDGLFDWH
the CSCs. Interestingly, P-cadherin also conferred resistance to 
X-ray induced DNA damage, supporting a role for this molecule in 
the maintenance of yet another CSC property (unpublished data). 
P-cadherin - potential therapeutic target in cancer
As clearly stated in this review, P-cadherin–mediated adhesion 
and the associated signalling pathways play diverse roles in the 
regulation of cancer cell survival, invasiveness and metastatic 
potential. Interestingly, in 2008, Imai and collaborators have sug-
gested CDH3/P-cadherin as a possible target for immunotherapy 
RISDQFUHDWLFJDVWULFDQGFRORUHFWDOFDQFHUVVLQFHLWZDVLGHQWLÀHG
as a novel tumour-associated antigen, meaning that was strongly 
expressed in tumour cells, but not in normal cells (Imai et al., 2008). 
Indeed, we have found that P-cadherin silencing, in breast cancer 
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FHOOVLQRFXODWHGLQQXGHPLFHZDVDEOHWRVLJQLÀFDQWO\LQKLELW in 
vivo tumour growth (unpublished data).
Recently, a novel and highly selective human monoclonal an-
WLERG\DJDLQVW3FDGKHULQ3)ZDVSURGXFHGGHPRQ-
strating anti-tumour and anti-metastatic activity in a diverse panel 
of P-cadherin–overexpressing tumour models, without introducing 
any adverse secondary effects in mice (Zhang et al., 2010). This 
antibody failed to bind to the most closely target-related family 
members, including E-cadherin, N-cadherin, and VE-cadherin. 
3)DOVRUHGXFHGO\PSKQRGHPHWDVWDVHVDQGORZHUHG
the levels of circulating tumour cells (CTC) in whole blood of P-
cadherin+ tumour bearing mice. The anti-metastatic property of 
WKHDQWLERG\ZDVUHPDUNDEOHVLQFHLWVLJQLÀFDQWO\LQKLELWHGWXPRXU
FHOOLQÀOWUDWLRQLQWRWKHOXQJV3)VWLOOVXSSUHVVHG`ctn, 
cyclin D1, Vimentin, Bcl-2, and survivin expression, decreased 
the Ki67 levels, and increased caspase-3 expression (Zhang et 
al., 2010))LJ
Taken together, these recent data highlight the critical role of 
P-cadherin signalling in regulating tumorigenesis and metastasis, 
especially because its inhibition leads to anti-tumour and anti-
metastatic effects in target-associated tumour models without any 
adverse indication. These observations provide the rationale and 
JXLGDQFHIRUWKHFOLQLFDOGHYHORSPHQWRI3)LQZKLFK
tumours with high P-cadherin expression will be essential criteria 
IRUSDWLHQWVHOHFWLRQ)XWXUHZRUNLVZDUUDQWHGWRVHHNDUHSURGXF-
LEOHPHWKRGWRTXDQWLI\3FDGKHULQLQKXPDQWXPRXUVDQGWRÀQGD
reasonable cut-off of expression related with therapeutic response, 
in an attempt to reach the full potential for clinical development 
RIWKHDQWLERG\3)LVFXUUHQWO\XQGHU3KDVH,FOLQLFDO
trial development.
Conclusions
Although this review is mainly focused on P-cadherin role as 
a poor prognostic factor, as well as a therapeutic target in breast 
cancer, its upregulation is also found in several other malignan-
cies, affecting organs such as pancreas, stomach, bladder and 
prostate, where it is also associated with an aggressive phenotype 
and poor prognosis. Thus, antagonizing P-cadherin represents a 
novel approach for anticancer therapy, by targeting tumours with 
high P-cadherin expression. Interestingly, P-cadherin silencing 
LQGXFHV VLJQLÀFDQW JURZWK LQKLELWLRQ LQ VHYHUDO WXPRXU PRGHOV
tested; however, this anti-proliferative activity was never observed 
in vitro (Zhang et al., 2010). This discrepancy suggests that fully 
functioning P-cadherin signalling may require the cell-cell and cell-
stroma crosstalk in intact tumour architecture during tumorigenesis 
and metastasis, a process that may not be recapitulated under in 
vitro conditions and that should be further studied in the future.
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Abstract The identification and characterization of cancer
stem cells might lead to more effective control of neoplastic
disease, by directing therapies to the most aggressive cells.
For that reason, the identification of cancer stem cells
(CSCs) in breast tumours is one of the priorities in breast
cancer research, which has resulted in many studies attempt-
ing to identify their presence based on the expression of
specific molecular markers. In this review, we describe the
main molecular markers that have been identified as being
able to recognise CSCs in breast carcinomas, the major
molecular pathways that regulate CSCs and their association
with the different molecular subtypes.
Keywords Breast cancer . Cancer stem cells . Stem cell
markers
Abbreviations
ALDH Aldehyde dehydrogenase
ATM Ataxia telangiectasia mutated gene
BCSC Breast cancer stem cell
Bmi-1 Polycomb group repressor protein
BRCA1 Breast cancer 1, early onset
CD24 Heat-stable antigen
CD29 β1-integrin
CD44 Receptor for hyaluronic acid
CD49f α6-integrin
CD61 β3-integrin
CD133 Prominin 1
CK5/6 Cytokeratin 5/6
CSC Cancer stem cell
DCIS Ductal carcinoma in situ
ECM Extracellular matrix
EMT Epithelial-to-mesenchymal transition
ER Estrogen receptor
ESA Epithelial-specific antigen
GPI Glycosylphosphatidylinositol
HER2 Human epidermal growth factor receptor 2
HER2-
OE
HER2 overexpressing molecular subtype
Ki67 Cellular proliferation marker
LOH Loss of heterozygosity
mRNA Messenger RNA
NOD/
SCID
Non-obese diabetic/severe combined immuno-
deficient mice
SP Side population
TIC Tumour-initiating cell
Introduction
Breast cancer is a heterogeneous disease consisting of a
growing number of biologically distinct subtypes. This
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heterogeneity is reflected by differences in hormone recep-
tor and human epidermal growth factor receptor 2 (HER2)
expression status, diverse histological subtypes, as well as
distinct biological behaviour, response to therapy and dis-
ease outcome [1]. This heterogeneity implies that in order to
plan for the optimally effective therapy of each breast cancer
subtype, it has become crucial to identify those cancer cells
in a tumour that drive disease progression. The prevailing
concept for many years was that the majority of the cells in a
tumour have the potential to extensively proliferate and
metastasize and should all be eliminated in order to effec-
tively treat the disease. However, recent studies have sug-
gested that the ability of tumours to proliferate, progress and
propagate relies on a limited subpopulation of cells with
stem cell-like properties, for which the term cancer stem
cells (CSCs) has become mainstream [2]. These cancer stem
cells share essential characteristics with normal adult stem
cells, such as the capacity to self-renew through asymmetric
cell division, producing one tumorigenic CSC and one non-
tumorigenic cancer cell destined for terminal differentiation.
This concept implies that cells in a cancer are hierarchically
organised in a manner very similar to cells in a normal
tissue: the progeny of a normal stem cell differentiates into
phenotypically diverse cells with limited proliferative po-
tential, and so, the progeny of CSCs also sustains genetic/
epigenetic alterations analogous to the differentiation of
normal cells, resulting in a population of phenotypically
diverse non-tumorigenic cancer cells that compose the bulk
of the tumour (Fig. 1a). These alterations are associated with
loss of tumorigenic capacity, implying that the vast majority
of cells in such carcinomas no longer contribute to disease
progression [3].
Cancer stem cell model: rediscovery of an old story
Stem cells are present in many different somatic tissues and
are important participants in their normal physiology. The
progenitor cell and the mature cell populations that derive
from it are organised in a hierarchical fashion, with the stem
cell residing at the apex of the differentiation pathway [2].
Stem cells have three distinctive properties: (a) self-renewal
(i.e. at cell division, one or both daughter cells retain the
same biological properties as the parental cell); (b) the
capacity to generate multiple cell lineages; and (c) the po-
tential for sustained proliferation. Indeed, the attribute of
self-renewal is especially notable because its subversion is
highly relevant to oncogenesis and malignancy [4, 5].
Therefore, malignant cells harbouring the three features that
define normal stem cells have been termed “cancer stem
cells” (Fig. 1a).
Even though, recently, the awareness of this concept in
cancer research has greatly expanded, it is not new. In 1855,
Rudolf Virchow proposed the embryonal rest hypothesis,
stating that cancer arises from the activation of “dominant”
cells present in mature tissues that are remaining embryonic
cells [6]. This theory, based on the morphological similari-
ties between developing foetal cells and some cancer cells,
was the first description of what we now call the CSC. Later,
in 1875, this theory was expanded by other pathologists
such as Julius Cohnheim, who proposed that misplacement
of stem cells during embryonic development could lead later
on in life to the development of tumours [7].
Back in 1937, Furth and Kahn established that engrafting
of a single cell from a mouse tumour could initiate a new
tumour in the recipient mouse [8]. The resulting tumours
typically showed the same morphologic heterogeneity as the
original tumour. Later, Kleinsmith and Pierce showed that
malignant teratocarcinomas contain highly tumorigenic cells
that, as single cells, have the capacity to differentiate into
multiple mature, non-tumorigenic cell types [9]. The con-
clusion was drawn that teratocarcinomas tend to follow the
pathways of development in embryonal tissues. To corrob-
orate the previous findings, the same authors showed by
radioactive pulse labelling of proliferating cells that these
occurred almost exclusively in undifferentiated areas. At
later time points, however, the DNA label appeared also in
well-differentiated areas, which had to be derived from
earlier labelled undifferentiated cells. These well-
differentiated cells did not form tumours when transplanted
into compatible recipients [10]. These results, among others,
led Pierce to formulate the following early definition of the
CSC concept [11]: “carcinomas are caricatures of tissue
renewal, in that they are composed of a mixture of malig-
nant stem cells”.
Finally, in 1994, the first human CSC, the leukaemia
stem cell, was identified in samples from patients with acute
myeloid leukaemia [12] and it was proposed that blocked
differentiation (“maturation arrest”) was responsible for
CSC proliferation and tumour growth [13]. Three years
later, Blair and collaborators as well as Bonnet and Dick
showed that only a small percentage of acute myeloid leu-
kaemia cells (0.002–1 %), which phenotypically resembled
hematopoietic stem cells, could transfer disease when trans-
planted into rodent recipients [14, 15]. These lines of evi-
dence supported the notion that many, if not all cancers,
depend on a small population of CSCs for their sustained
growth and expansion. Since then, several investigators
have documented the existence of CSCs in brain [16], breast
[17], prostate [18] and lung cancers [19], among others.
Breast cancer stem cell markers
Finding breast CSCs (BCSCs) has been an important goal
for many breast cancer researchers, who were trying to
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define a universal marker or combination of markers able to
specifically identify these cells in breast tumours and ulti-
mately isolate them. Reviewing the literature, it appears that
the most studied BCSC markers are the transmembrane
proteins CD44 and CD24. A subpopulation of tumour cells
that s t rongly express CD44 but not CD24 (the
CD44+CD24−/low phenotype) was identified as CSCs by
Al-Hajj and collaborators [5], and this was subsequently
confirmed by other authors. CD44 is a transmembrane gly-
coprotein, of which several isoforms exist, that normally
regulates cell–cell adhesion and cell–matrix interactions, as
well as cell migration. This glycoprotein binds mainly to
hyaluronic acid, as well as to collagen, fibronectin, laminin
and chondroitin sulphate—all important components of the
ECM. It also binds the cytokine osteopontin [20]. Members
of the CD44 family differ in their extracellular domain by
the insertion of variable regions through alternative splicing
[21]. The gene-encoding CD44 consists of 20 exons. In the
standard form (CD44s), 10 of the 20 exons are transcribed.
Multiple variant isoforms (CD44v1–v10) arise from alter-
native messenger RNA (mRNA) splicing of the other ten
exons [22]. In contrast to the standard form of CD44, which
is usually ubiquitously expressed on epithelial cells and
lymphocytes, CD44 variants exhibit tissue-specific expres-
sion. Some of these variants, in particular splice variant
CD44v6, are associated with aggressive tumour behaviour
Fig. 1 a Schematic representation of the cellular components of a
normal duct of the mammary gland. There is an outer layer of myoe-
pithelial cells (red) surrounding an inner layer of luminal epithelial
cells (blue). Stem cells of the normal mammary gland have two main
distinctive properties: self-renewal and the capacity to develop into
both lineages of fully breast-differentiated cells. Malignant cells har-
bouring the same features that define normal stem cells have been
termed cancer stem cells, which originate due to the accumulation of
genetic (or epigenetic) alterations that target the cellular components of
the breast. b The three major signalling pathways involved in the
maintenance of stem cell features in the breast cancer stem cell. The
Notch, Wnt and Hedgehog molecules are well-known mediators of
normal stem cell biology, which also mediate downstream effects in the
transcription profile of cancer stem cells. These effects include the
control of proliferation/self-renewal, survival, invasion and therapy
resistance. Cancer stem cell therapy may encompass the modulation
of these signalling pathways, which are over-activated in CSCs, with-
out affecting normal breast physiology
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in that their expression correlates with poor prognosis in a
variety of human malignancies including breast cancer [23].
CD24 is a small, heavily glycosylated mucin-type protein,
which is linked to the cell membrane via a GPI anchor. This
molecule is involved in the regulation of cell proliferation
and cell–cell interactions and it was shown to be expressed
by normal pre-B lymphocytes (which lose its expression
during the maturation into plasma cells), as well as in
various haematological malignancies and solid tumours of
some organs [24]. CD24 is the ligand of P-selectin and also
an adhesion receptor expressed on activated endothelial
cells and platelets, and this has led to the suggestion that it
might play an important role in the metastatic process [25,
26]. Using a combination of these two cell surface markers,
Al-Hajj and collaborators were the first to distinguish cancer
cells that were tumorigenic in immunocompromised (non-
obese diabetic/severe combined immunodeficient (NOD/
SCID)] mice from non-tumorigenic cells, in a small number
of breast tumours. In flow sorting experiments, they used
the ESA as an epithelial cell marker with CD44+/CD24−/low
as CSC marker combination, after eliminating the non-
epithelial cells that were stained for their lineage-specific
markers (hematopoietic and endothelial) [5]. Since then,
many more breast carcinomas have been reported to contain
a subpopulation of CD44+/CD24−/low cancer cells, which
are capable of generating tumours in the NOD/SCID mice,
even when implanted in very low numbers. In contrast,
other cancer cell populations fail to generate tumours, even
when implanted in high numbers. These reports therefore
established tumourigenicity and self-renewal potential of
these cells, in vitro and in vivo [27, 28].
Even though some clinical studies confirmed that CD44+/
CD24−/low-expressing tumours have a poor prognosis
[29–31], controversy remains concerning this issue [27,
32]. Shipitsin et al. demonstrated that genes specifically
expressed in CD44+ cells, among which many known stem
cell markers, identified carcinomas with poor patient surviv-
al [33], suggesting that CD44+ expression is prognostically
relevant and justifying its consideration as a new therapeutic
target for breast cancer. In contrast, Mylona et al. [32]
observed that breast cancers with the opposite CD44−/
CD24+ phenotype are associated with poor patient progno-
sis, in stark contrast with the CSC CD44+/CD24−/low phe-
notype. Furthermore, Abraham et al. failed to confirm that
the occurrence of CD44+/CD24−/low tumour cells in breast
cancer is associated with worse survival [27]. These contra-
dictory data demanded additional efforts to find other
markers that could complement the CSC markers CD44
and CD24, to arrive at an improved correlation with patient
survival.
Along these lines, a new marker proposed for the identi-
fication of BCSCs is aldehyde dehydrogenase 1 (ALDH1).
Ginestier et al. showed that normal human mammary
epithelial cells and breast cancer cells with high ALDH1
activity have stem/progenitor cell properties [34]. This find-
ing offered an important new potential molecular target for
the study of breast CSCs. It was subsequently found that
ALDH1+ cells (putative CSCs) are significantly more resis-
tant to platinum treatment and are biologically more aggres-
sive, and that ALDH1+ cancers are associated with poor
patient prognosis [34–36]. Unlike the CD44+CD24−/low
phenotype, the ALDH1+ phenotype consistently correlates
with worse clinical outcome and with certain histological
and clinical characteristics, such as high tumour grade,
HER2 positivity and Ki67 proliferation status [37]. In addi-
t ion, the ALDH1 marker can further divide the
CD44+CD24−/low cell population into fractions that are
highly tumorigenic: while as few as 20 xenografted
ALDH1+CD44+CD24−/low cells resulted in tumours, at this
cell density, ALDH1+CD44+CD24−/low cells were not tu-
morigenic [34, 38]. Taken together, this evidence supports
the notion that ALDH1−CD44+CD24−/low cells in a neoplas-
tic population represent CSC-like cells. However, the frac-
tion of ALDH1+ cells in the CD44+CD24−/low population in
primary tumours is quite small (1.16 %) [34].
Another candidate marker for the BCSC phenotype is
CD133, also known as Prominin-1 because of its location
on cell membrane protrusions. Although initially considered
a marker specific for haematopoietic stem cells, CD133
mRNA transcripts are also found in normal bone marrow
and in a variety of other tissues [39]. Furthermore, CD133 is
expressed in various solid tumours, including triple-negative
invasive breast carcinomas, but more restricted in expres-
sion in comparison with other previously mentioned CSC
markers, such as CD44 and ALDH1. In early-onset breast
cancer 1 (BRCA1)-associated breast cancer cell lines,
CD133+-sorted cells have CSC properties, including greater
colony-forming efficiency, higher proliferative activity and
higher tumourigenicity in NOD/SCID mice [40]. Moreover,
the expression of CD133 has been reported in the majority
of inflammatory breast cancers, as well as in triple-negative
tumours [41, 42].
Other markers, such as CD29 (β1-integrin), CD49f (α6-
integrin) and CD61 (β3-integrin), have been used for the
isolation of mammary CSCs. Vassilopoulos et al. [43] used
CD24/CD29 or CD24/CD49f to identify a subpopulation of
mammary tumour cells, while Vaillant et al. [44] found that
CD61 identifies a cell subpopulation highly enriched for
tumorigenic capacity in comparison with CD61-negative
cells.
Complementary to the use of biomarkers to identify or
isolate putative CSCs, by flow cytometry or immunolabel-
ing using CD44 and CD24 antibodies or ALDH1 activity
(using the ALDEFLUOR assay), functional assays have
been extensively used for this purpose (Fig. 2). One of these
methods is based on the capacity of purported stem cells to
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efflux a lipophilic fluorescent dye (Hoechst 33342), through
the same mechanism they use to expulse drugs and which
confers drug resistance. This dye excluding cell population
has been called “side population” (SP). This method was
initially described to isolate haematopoietic stem cells and
was subsequently applied to breast cancer cell lines [45].
However, unsolved issues with potential toxicity of this dye
for non-SP cells hinder the further application of this func-
tional assay for the identification of BCSC subpopulations.
Another important functional assay, used for breast epithe-
lial stem cells, is the mammosphere-forming assay, in which
mammary epithelial cells are cultured in a serum-free medi-
um on a surface to which they do not adhere and are thus
induced to form a three-dimensional cell cluster which is
called mammosphere (Fig. 2). Pointi et al. employed a
similar approach to derive mammospheres from human
breast cancers and found CSCs within the cancer cell-
derived mammospheres with the same phenotype as previ-
ously reported by Al-Hajj (CD44+CD24−/low) [46]. Since
then, several other markers associated with a stem cell
phenotype, such as components of the Notch and Wnt
signalling pathways, have been found overexpressed in
mammospheres from breast cancer cell lines [47].
Signalling pathways in breast cancer stem cells
Cancer stem cells share molecular markers with normal
stem cells, but in addition, they show aberrant activation
of self-renewal pathways, such as Wnt, Hedgehog and
Notch, also operative in normal stem cells. Normal human
mammary stem cells express high levels of the Notch-4
Fig. 2 Breast cancer stem cell identification and/or isolation rely in
several breast CSC biomarkers and methodologies, including flow
cytometry, in vivo tumorigenic models, mammospheres and histolog-
ical immunostaining. Flow cytometry allows the identification and
isolation of cancer cell subpopulations, using cell surface CSC
markers, such as CD44/CD24, and ALDH1 activity (ALDEFLUOR
assay). The mammosphere assay measures the survival of cancer cells
in anchorage-independent conditions and constitutes an indicator of in
vitro self-renewal capacity. Immunohistochemistry or immunofluores-
cence depend on the use of specific antibodies against breast CSC
markers (such as CD44 and CD24), in order to detect the CSC pheno-
type in fixed paraffin-embedded tissue samples. The tumourigenic
capability of CSCs subpopulations in immune-deficient mice allows
proving the cancer stem cell properties in vivo (author's original
images)
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receptor, which are assumed to play an activating role in the
stem cell compartment. Notch-4 and Notch-1 are involved
in normal development of the mammary gland and mutated
forms of these receptors are associated with the develop-
ment of mouse mammary tumours [48]. Aberrant activation
of Notch signalling is probably an early event in breast
cancer, since this has been found in ductal carcinoma in situ
(DCIS). High expression of Notch-1 in breast cancer is
associated with worse prognosis, and a gamma-secretase
inhibitor which blocks Notch signalling or a Notch-4-
neutralising antibody reduced mammosphere formation
from DCIS [48]. Notch-4 has been shown to be important
for the self-renewal of cancer stem cells, and in xenotrans-
plantation assays, it played an active role in tumour forma-
tion [49]. The Notch pathway activation and effects are
heterogeneous and depend on the cellular context and on
the in vivo model used. However, in both man and mice, the
Notch pathway stimulates differentiation of mammary stem
cells towards the luminal compartment. In man, this luminal
cell fate determination is mediated by Notch-3, whereas in
mice, Notch-1 seems to be more important [48, 50].
Stem cell self-renewal, maintenance and cell fate are also
controlled by Hedgehog signalling in different tissues. In the
mammary gland, strict regulation of the Hedgehog pathway
is required for normal development and alterations in
Hedgehog signalling cause defects during embryonic devel-
opment resulting in an abnormal mammary gland [51].
Hedgehog signalling is activated in CD44+CD24−/low hu-
man breast cancer stem cells [51], and stemness, measured
by mammosphere-forming capacity, is increased upon the
activation of this pathway [52]. Conversely, inhibition of
Hedgehog signalling results in a reduction of the number of
mammosphere-initiating cells and mammosphere size,
effects that are mediated by Bmi-1 [51], which suggests that
the Hedgehog pathway might provide new therapeutic
targets.
Elucidation of Wnt signalling is complex, given the fact
that there are 19 Wnt ligands, several Wnt receptors and
involvement of this signalling pathway in embryogenesis,
development, differentiation and proliferation. Inappropriate
Wnt/β-catenin signalling can result in deregulated self-
renewal. The activation of Wnt-1 causes expansion of the
mammary stem cell compartment and an aberrant popula-
tion of progenitor cells that have in vivo regenerative ability
[44, 53]. Since in the presence of inappropriate Wnt signal-
ling mammary glands express high levels of basal markers,
Wnt is thought to induce dedifferentiation of mammary cells
and confer a more stem-like phenotype. A role for Wnt
signalling in the development of breast cancers of the
basal-like subtype, and also the predictive capacity of Wnt
signalling for brain metastasis, has been reported and the
ligands Wnt5a/b have been identified as highly relevant for
this subtype of breast cancer [54].
In addition to these main pathways, represented in
Fig. 1b, many others have been implicated in the determi-
nation of breast stem cell fate. These pathways, when
deregulated in cancer, might present new therapeutic targets.
Molecules that interfere with these pathways should be
tested in vitro with regard to their effect on the CSC com-
partment, and when found effective, subsequently in in vivo
xenografted animal models of human cancer, before testing
in patient tumours.
Cancer stem cells in molecular subtypes of breast cancer
In breast cancer, it is assumed that CSCs generate cells with
aberrant and limited differentiation, which through mecha-
nisms as yet unknown translate into the distinct breast
cancer molecular subtypes. In this concept, each molecular
subtype putatively is composed of cancer cells with a dif-
ferent level of differentiation; CSCs being most prevalent in
the least differentiated molecular subtype (Fig. 3). Recently,
our group demonstrated that of the molecular subtypes, the
basal-like type harbours the highest percentage of tumour
cells with a CD44+CD24−/low and ALDH1+ cancer stem cell
phenotype [31]. This confirms earlier studies using breast
cancer cell lines, which reported enrichment of CD44+/
CD24−/low and CD44−/CD24+ cell populations in basal-
like and luminal molecular subtypes, respectively [55, 56];
Fig. 3 Representation of the putative association between breast can-
cer molecular subtypes and the expression pattern of breast CSC
biomarkers. In this hypothesis, each molecular subtype is enriched in
cancer cells with distinct levels of differentiation, being CSCs more
prevalent within the more undifferentiated molecular breast cancers,
such as claudin-low tumours. Basal-like tumours have a phenotype
close to the CSC phenotype but with an increase in the epithelial
phenotype. This subtype of breast cancer and the Her-2 overexpressing
molecular subtype have increased ALDH activity, a marker of the
luminal progenitor of the breast. Luminal A and luminal B carcinomas
present a mature differentiated cell profile, with the lowest expression
of mesenchymal markers and an epithelial CD24+ phenotype
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the CD44+ cells being more stem cell-like and CD24+ cells
more differentiated [37]. This is corroborated by data pub-
lished by Honeth and collaborators, who showed that the
CD44+/CD24−/low CSC phenotype is significantly associated
with basal-like breast cancers in human patients and in partic-
ular with BRCA1-inherited cancers [29]. However, ALDH1 is
not associated with a particular molecular subtype of breast
cancer [34, 35]. Even though CD44+CD24−/low cells and
ALDH1+ cells are more frequently found in basal-like than
in luminal tumours, ALDH1+ cells are also commonly found
in the HER2-overexpressing (HER2-OE) subtype [31]. This
difference between basal-like and HER2-OE tumours may be
due to a different cell-of-origin or to the induction of a stem-
like transcriptional programme as a result of specific trans-
forming genetic alterations (Fig. 3). In line with this notion,
induced overexpression of HER2 expression in breast cancer
cell lines increased the number of ALDEFLUOR-positive
cells [57].
Moreover, basal-like tumours with a predominantly
CD44+CD24−/low CSC phenotype show a tendency towards
worse prognosis, in agreement with earlier studies demon-
strating an association between basal-like carcinomas and
the CD44+CD24−/low CSC phenotype [29, 37, 55, 56].
These results contribute to our understanding of the mor-
phological and molecular heterogeneity of breast cancer.
Furthermore, they suggest that the CSC phenotype may
identify the cell-of-origin of the tumour, rather than the
unique population of responsible for tumour progression,
since the highly aggressive HER2-overexpressing tumours
do not show increased expression of these markers.
Since basal type breast cancers have an increased stem
cell-like population in comparison with other molecular
subtypes, it has been hypothesised that in these tumours, a
differentiation block exists, as the majority of the cells
constituting the bulk of the tumour do not display a differ-
entiated phenotype [51, 58]. The transformation of a basal-
like mammary stem cell to a basal-like cancer cell may
either be due to (a) LOH as a second hit in BRCA1 mutation
carriers or (b) to the downregulation of BRCA1 expression
in estrogen receptor (ER)-negative stem cells. This might
result in the arrest of the luminal differentiation process,
which fixes the cells in the undifferentiated phenotype of
basal-like carcinomas with its unique expression of basal
cytokeratins (CK5/6) [59]. Presumably, this goes along with
an increment of telomerase activity, since BRCA1 sup-
presses telomerase expression, and in DNA repair defects,
which generate inactivation or loss of the ataxia telangiec-
tasia mutated (ATM) gene and as a result increased genomic
instability, which may be the reason for the greater number
of genomic gains and losses in sporadic and familial basal-
like cancers [60].
Recently, a tumour-initiating cell (TIC) genomic signa-
ture, derived from CD44+/CD24−/low-sorted cells and
mammospheres obtained from primary human breast
tumours, was found to be exclusively enriched in a new
molecular subtype referred to as claudin-low [61]. This new
molecular subtype is characterised by the low expression of
genes involved in tight junctions and cell–cell adhesion,
including claudins 3, 4 and 7, Occludin and E-cadherin. It
also displays epithelial-to-mesenchymal transition (EMT)
features, such as high levels of expression of vimentin,
Snail-1, Snail-2, TWIST1, TWIST2, ZEB1 and ZEB2. In
addition, these tumours show low expression of luminal
genes, inconsistent basal gene expression, high expression
of lymphocyte and endothelial cell markers and lack of ER
expression, and they were all diagnosed as grade II or III
infiltrating ductal carcinomas. These tumour characteristics
reflect a low level of tumour differentiation and fit with the
CSC and EMT phenotypes [61].
Conclusion
The CSC model proposes that in tumours, like in nor-
mal tissues, a cellular hierarchy exists in which CSCs
are the only cells endowed with an unlimited potential
for proliferation and, as a consequence, capable of driv-
ing tumour growth and metastasis due to their stem cell-
like characteristics [51]. The presently available markers
that label cells with stem cell properties in tumours
should be further tested for specificity, and additional
markers, maybe in the form of specific gene signatures,
are needed to further define and potentially target the
CSC population of different breast cancer subtypes.
However, in the design of novel effective anti-BCSC therapy
strategies, the possibility that (a) marker expression is down-
regulated/silenced, (b) marker-negative BCSC cell clones
evolve from marker-positive cell clones and (c) different
BCSC subpopulations coexist in a single tumour or at differ-
ent metastatic sites should be taken into consideration. Prob-
ably, in the future, it will be necessary to use a panel of BCSC
markers, in order to effectively translate knowledge of CSCs
into breast cancer benefit.
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